
<html lang="en"     class="pb-page"  data-request-id="9a9f6ff5-168d-4d43-af50-7ba427e2c1b4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c00696;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia" /></meta><meta name="dc.Creator" content="Yue  Zhong" /></meta><meta name="dc.Creator" content="Run-Ze  Qiu" /></meta><meta name="dc.Creator" content="Shan-Liang  Sun" /></meta><meta name="dc.Creator" content="Chao  Zhao" /></meta><meta name="dc.Creator" content="Tian-Yuan  Fan" /></meta><meta name="dc.Creator" content="Min  Chen" /></meta><meta name="dc.Creator" content="Nian-Guang  Li" /></meta><meta name="dc.Creator" content="Zhi-Hao  Shi" /></meta><meta name="dc.Description" content="Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes. In re..." /></meta><meta name="Description" content="Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes. In re..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 13, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00696" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00696" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00696" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00696" /></link>
        
    
    

<title>Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00696" /></meta><meta property="og:title" content="Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0036.jpeg" /></meta><meta property="og:description" content="Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes. In recent years, increasing evidence have demonstrated that the activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new hope for AML therapy. In this review, we specifically highlighted FLT3 mediated JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR signaling. The structural properties and biological activities of representative FLT3 inhibitors reported from 2014 to the present were also summarized. In addition, the major challenges in the current advance of novel FLT3 inhibitors were further analyzed, with the aim to guide future drug discovery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00696"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00696">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00696&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00696&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00696&amp;href=/doi/10.1021/acs.jmedchem.0c00696" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12403-12428</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00643" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00748" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yue Zhong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yue Zhong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yue++Zhong">Yue Zhong</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Run-Ze Qiu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Run-Ze Qiu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Run-Ze++Qiu">Run-Ze Qiu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shan-Liang Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shan-Liang Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><span class="conrtib-corresp"><strong>*</strong>For S.-L.S: phone, +86-25-85811916; fax, +86-25-85811916; email, <a href="/cdn-cgi/l/email-protection#bbc8ced5c8d3d2dad5defb8a898d95d8d4d6"><span class="__cf_email__" data-cfemail="a9dadcc7dac1c0c8c7cce9989b9f87cac6c4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shan-Liang++Sun">Shan-Liang Sun</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7011-6146" title="Orcid link">http://orcid.org/0000-0001-7011-6146</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Zhao">Chao Zhao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tian-Yuan Fan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tian-Yuan Fan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tian-Yuan++Fan">Tian-Yuan Fan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Chen">Min Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nian-Guang Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nian-Guang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</div></div><span class="conrtib-corresp"><strong>*</strong>For N.-G.L.: phone, +86-25-85811916; fax, +86-25-85811916; email, <a href="/cdn-cgi/l/email-protection#deb2b7b0b7bfb0b9abbfb0b99eb0b4abbdb3f0bbbaabf0bdb0"><span class="__cf_email__" data-cfemail="d0bcb9beb9b1beb7a5b1beb790bebaa5b3bdfeb5b4a5feb3be">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nian-Guang++Li">Nian-Guang Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5793-6959" title="Orcid link">http://orcid.org/0000-0001-5793-6959</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zhi-Hao Shi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhi-Hao Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Organic Chemistry, China Pharmaceutical University, Nanjing 211198, China</div></div><span class="conrtib-corresp"><strong>*</strong>For Z.-H.X.: phone, +86-25-86185172; fax, +86-25-86185182; email, <a href="/cdn-cgi/l/email-protection#027171786a333431423334312c616d6f"><span class="__cf_email__" data-cfemail="d7a4a4adbfe6e1e497e6e1e4f9b4b8ba">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhi-Hao++Shi">Zhi-Hao Shi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6827-9533" title="Orcid link">http://orcid.org/0000-0002-6827-9533</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00696&amp;href=/doi/10.1021%2Facs.jmedchem.0c00696" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12403–12428</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 13, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 April 2020</li><li><span class="item_label"><b>Published</b> online</span>13 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12403%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYue%2BZhong%252C%2BRun-Ze%2BQiu%252C%2BShan-Liang%2BSun%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c00696%26title%3DSmall-Molecule%2BFms-like%2BTyrosine%2BKinase%2B3%2BInhibitors%253A%2BAn%2BAttractive%2Band%2BEfficient%2BMethod%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BMyeloid%2BLeukemia%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12428%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00696"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1979</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00696" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yue&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Run-Ze&quot;,&quot;last_name&quot;:&quot;Qiu&quot;},{&quot;first_name&quot;:&quot;Shan-Liang&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Tian-Yuan&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Nian-Guang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhi-Hao&quot;,&quot;last_name&quot;:&quot;Shi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12403-12428&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00696&quot;},&quot;abstract&quot;:&quot;Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes. In recent years, increasing evidence have demonstrated that the activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new hope for AML therapy. In this review, we specifically highlighted FLT3 mediated JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR signaling. The structural properties and biological activities of representative FLT3 inhibitors reported from 2014 to the present were also summarized. In addition, the major challenges in the current advance of novel FLT3 inhibitors were further analyzed, with the aim to guide future drug discovery.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00696&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00696" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00696&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00696" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00696&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00696" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00696&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00696&amp;href=/doi/10.1021/acs.jmedchem.0c00696" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00696" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00696" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (13 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26pmid%3D32659083%26genre%3Darticle%26aulast%3DZhong%26date%3D2020%26atitle%3DSmall-Molecule%2BFms-like%2BTyrosine%2BKinase%2B3%2BInhibitors%253A%2BAn%2BAttractive%2Band%2BEfficient%2BMethod%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BMyeloid%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0036.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes. In recent years, increasing evidence have demonstrated that the activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new hope for AML therapy. In this review, we specifically highlighted FLT3 mediated JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR signaling. The structural properties and biological activities of representative FLT3 inhibitors reported from 2014 to the present were also summarized. In addition, the major challenges in the current advance of novel FLT3 inhibitors were further analyzed, with the aim to guide future drug discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Acute myeloid leukemia (AML), which is the most common type of blood cancer, is a malignant clonal disorder in hematopoietic stem cells (HSCs) and characterized by abnormal proliferation or accumulation of immature cells in the bone marrow, peripheral blood, and other tissues.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Poorly differentiated progenitor cells can interfere with normal hematopoietic process, thus leading to severe infections, anemia, and hemorrhage.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It is estimated that five-year overall survival of patients diagnosed with AML is less than 50%, and the elderly account for over one-half in western countries. Moreover, the incidence of AML increases with age.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> In 2020, the American Cancer Society estimated that the number of new AML cases and deaths would up to 19 940 and 11 180, respectively, and AML accounted for the largest number of annual deaths due to leukemias in the United States.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, it remains certain that AML is a vital health concern to the societies worldwide. Recent genomic sequencing analysis has revealed that mutations in AML commonly occur in the Fms-like tyrosine kinase 3 (FLT3) gene, which has been consequently studied as a potential therapeutic target for AML.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  The Overview of FLT3</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FLT3, also called CD135, is a cytokine receptor which belongs to the class III receptor tyrosine kinase (RTK) family and plays an important role in the survival, proliferation, and differentiation of HSCs.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> FLT3 is highly homologous with c-Kit, c-Fms, and PDGFR, which are also included in the RTK family, with the structure composed of five immunoglobulin-like loops in the extracellular domain (ECD), a transmembrane domain (TMD), a juxtamembrane domain (JMD), 2 tyrosine kinase domains (TKD) separated by inserted domains, and an intracellular C-terminal domain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> FLT3 ligand (FL) stimulates the proliferation of early hematopoietic cells by activating FLT3, which synergizes well with many other colony stimulating factors and interleukins.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Without the FL, the JMD of FLT3 inhibits the formation and activation of FLT3 dimer under physiological conditions. However, the binding of FL to FLT3 results in receptor dimerization and then autophosphorylation of tyrosine residues in the intracellular domain, which activates a series of signalings through phosphorylating downstream protein substrates subsequently, including JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR pathways (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ribbon (a) and surface (b) diagrams for the crystal structure of FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>). The N-terminal kinase domain (purple), the C-terminal kinase domain (blue), the activation loop (green), and the JM domain (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rest, activation, and mutation of FLT3 in HSCs. FLT3, which is an essential receptor for the life process of HSCs, consists of extracellular N-terminal and ECD, transmembrane TMD, as well as intracellular JMD, two TKDs, and C-terminal domains. Without the ligand, JMD inhibits the formation of receptor dimerization, leaving FLT3 in a resting state. Under physiological conditions, the survival, proliferation, and differentiation of HSCs depend on the activation of FLT3, which is achieved by binding to its ligand FL. At this time, JMD rests, TKDs are activated, and FLT3 dimer ia formed, causing autophosphorylation of the tyrosine residue in the intracellular portion of the receptor. As a result, HSCs can grow, reproduce, and differentiate healthily via activated downstream signalings including JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR. However, when a mutation occurs, the dimer can be irreversibly formed even in the absence of FL, resulting in indefinitely activated downstream signalings, which is associated with the onset of AML.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Among patients newly diagnosed with AML, approximately 30% of them are identified with FLT3 mutations.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In 1996, Nakao et al. first found that internal tandem duplications of the FLT3 gene (FLT3-ITD) occurring in the form of a replicated sequence in the JMD accounted for 20–25% of AML cases, which was the most common form of FLT3 mutations and conferred a poor prognosis in patients.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Soon after, Yamamoto’s group observed point mutations in the activation loop of the second TKD in 7–10% of patients with AML, and mutations at position 835 of aspartic acid was the most common.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Both FLT3-ITD and TKD mutations can cause FL-independent FLT3 kinase activation and initiate downstream pathways, accordingly promoting cell proliferation and antiapoptosis, which further leads to AML. Point mutations in the JMD of FLT3 (FLT3-JM-PMs) are another type of FLT3 mutations, and it shows weaker conduction concerning lower autophosphorylation levels of the receptor and its downstream target STAT5 when compared with FLT3-ITD and FLT3-TKD mutations (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  FLT3-Mediated Downstream Signalings</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  JAK/STAT Signaling</h3><div class="NLM_p">The JAK/STAT signaling, which regulates the transcription of genes such as MYC, cyclin D1, survivin and BCL2, is essential for cell survival, proliferation, and differentiation.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The pathway serves as a signal transmitter for the cytokine receptor superfamily and is key to the formation of the blood and immune systems.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The JAK family consists of JAK1, JAK2, JAK3, and TYK2, which activate the STAT family, particularly STAT3 and STAT5.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As a major effector of JAK, the STAT family mediates cell growth, differentiation, apoptosis, transformation, and other basic cellular functions: STAT1 mediates the growth inhibition of IFN-γ by inducing cyclin-dependent kinase inhibitors, STAT5 mediates the proliferative effects of IL-3 and GM-CSF, and STAT3 mediates growth arrest conducted by IL-6 and IL-10 as well as GM-CSF and IL-3-induced proliferation.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Abnormal activation of the JAK/STAT pathway has been reported in a variety of disease states, particularly hematological malignancies.<a onclick="showRef(event, 'ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref20">(18,20)</a></div><div class="NLM_p">Autophosphorylation of tyrosine mediates the disorder of JAK/STAT signaling, then myeloid cells proliferate excessively in patients and abnormally up-regulated IL-6, GM-CSF, and TNF-α that activate JAK2 was observed, further stimulating the pathway. Suppression of JAK/STAT signaling can block cell proliferation and induce apoptosis and cell cycle arrest in AML cells.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In AML, FLT3 mutations with tyrosine autophosphorylation directly induce the constitutive activation of STAT5, particularly the phosphorylation of Y694, which is associated with poor survival rate.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In contrast, although mutations in JAK2 also cause the constitutive activation of STAT5 and the malignant transformation from myeloproliferative neoplasms (MPN) to AML, JAK2 in AML cells is wild type.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> JAK3 mutations are stably inherited in AML, which contribute to the autonomous proliferation of AML blast cells but mainly activate STAT1 and less activate STAT3/5, suggesting that FLT3 mutations are more dominant for the activation of STAT5 than JAK mutations in AML.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Apart from promotion of survival and proliferation, JAK/STAT signaling mediates drug resistance in AML cells, which may be related to the protective effect of bone marrow stromal cells on AML.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Inhibition of JAK1 or JAK2 not only hinders the growth of STAT5-mediated CD34<sup>+</sup>/CD38<sup>–</sup> chemotherapy-resistant AML lineage and induces apoptosis but also improves the resistance of AML cells to targeted drugs.<a onclick="showRef(event, 'ref17 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref24">(17,24)</a> With improved drug resistance via combined use of JAK inhibitors, FLT3 inhibitors can better exert the efficacy treating AML.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.2.  RAS/MAPK Signaling</h3><div class="NLM_p">The RAS/MAPK pathway contains core effectors such as RAS, RAF, MEK, ERK, RSK, and MAPK, governing cell proliferation, differentiation, adhesion, migration, apoptosis, and polarization.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> As a recognized oncogene, RAS includes three subtypes of NRAS, KRAS, and HRAS and can be activated by growth factors and cytokines via RTK signaling.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> FLT3 binds SOS through the SH3 domain of the adaptor protein GRB2, mediating the dissociation of GDP and the binding of GTP to RAS to activate the RAS/MAPK cascade.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> As a result of self-mutated RAS or mutations in FLT3, downstream effectors such as MAPK and PI3K are highly activated, leading to uncontrolled cell growth and differentiation, which are related to malignant progression of tumor.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a></div><div class="NLM_p last">In addition to stimulating abnormal growth and proliferation, the overactivation of RAS/MAPK signaling leads to the drug resistance. Autoactivated RAS via mutations in FLT3-ITD, FLT3-TKD, and RAS GTPase destroys DNA stability by inducing ROS, resulting in the resistance of AML cells to chemotherapeutic drugs.<a onclick="showRef(event, 'ref27 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref29">(27,29)</a> Even in FLT3 mutant AML cells treated with FLT3 inhibitors, excessive activation of MAPK caused by subclonal RAS mutations is found to resist the RAS inhibitory effect of FLT3 inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Inhibition of RAS/MAPK not only impedes proliferation of AML cells but also enhances the efficacy of other inhibitors, suggesting the importance of the combined inhibition of RAS and FLT3.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.3.  PI3K/AKT/mTOR Signaling</h3><div class="NLM_p">PI3K is a kinase with four isoforms, including p110α, p110β, and p110δ (class 1A) and p110γ (class 1B), which are ubiquitously expressed in cells and maintain cell growth and survival. As one of the most frequently signals involved in tumorigenesis and progression, PI3K can drive excessive activation of downstream proteins with its lipid product, PIP<sub>3</sub>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Although PI3K shows a low mutation rate in AML, the four isoforms have been found to be overexpressed in both AML cells and primary tissues.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The isoform p110δ is specifically enriched in leukocytes and is most closely related to PI3K activity and AML cell growth.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The protein kinase AKT and mTOR from the serine/threonine AGC family are the main downstream effectors of PI3K.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> PI3K stimulates the phosphorylation of threonine 308 of AKT by PDK1 via PIP3 and mTORC2 mediates the phosphorylation of serine 473 of AKT, leading to the complete activation of AKT and the downstream mTORC1, regulating autophagy, mRNA translation, and cell metabolism.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a></div><div class="NLM_p">In blast cells from AML patients, PI3K/AKT/mTOR signaling is frequently activated, especially constitutive mTORC1 activation, abnormally promoting cell proliferation and survival, which may be due to mutations involving FLT3, RAS and c-Kit.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Inhibition of the PI3K/AKT/mTOR pathway has pro-apoptotic and antiproliferative effects on AML cells with or without FLT3 mutations.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> Despite impeded proliferation of AML cells during inhibition of PI3K or mTORC1 alone in vitro, simultaneous inhibition of PI3K and mTOR may induce blast cell apoptosis because they are partially functionally independent, suggesting the importance of selectivity for the serine/threonine AGC family kinase.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Moreover, abnormal activation of the PI3K/AKT/mTOR signaling mediates the resistance of AML cells to chemotherapeutic drugs. Inhibition of this pathway enhances the cytotoxic effect of chemotherapeutic drugs on AML cells with decreased level of MDR1, which is one of the major drug-resistant proteins.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a></div><div class="NLM_p last">It is very important to know that the downstream signalings of FLT3 is responsible for the regular growth and survival of cells. When these signalings are overactivated, the myeloid cells proliferate and differentiate excessively, which triggers AML and promotes the drug resistance of AML cells, limiting the cytotoxic and pro-apoptotic effects of chemotherapy drugs. The sensitization and mutation of FLT3 is a significant cause of overactivation of these downstream pathways, which is widely repressed by FLT3 inhibitors through the attenuated phosphorylation of effectors such as STAT5, ERK, RSK, AKT, and MAPK, showing prominent efficacy in the treatment of AML.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">4.  Small-Molecule FLT3 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recently, FLT3, especially mutant FLT3, has been considered as an attractive and efficient target for the treatment of AML. In the joint efforts of many scientific researchers, a few small-molecule inhibitors targeting FLT3 have been intensively studied as potential therapeutic agents for AML, including <b>sunitinib</b>, <b>sorafenib</b>, <b>midostaurin</b>, <b>lestaurtinib</b>, <b>tandutinib</b>, <b>quizartinib</b>, <b>crenolanib</b>, <b>gilteritinib</b>, etc. (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These first-generation inhibitors lack specificity for FLT3 and perform antileukemia efficacy via inhibition of multiple RTKs. In contrast, second-generation FLT3 inhibitors are more selective and efficient, which have fewer toxicities related to off-target effects.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> On the basis of the binding site of the kinase, FLT3 inhibitors can be divided into three types. Type I inhibitors are ATP competitive inhibitors that can recognize the DFG-in (Asp-Phe-Gly, a conformational change with three residues) in active conformation of FLT3 and target the ATP binding site, while type II inhibitors can interact with the DFG-out inactive conformation and block the kinase activation via an additional hydrophobic binding domain adjacent to the ATP binding pocket.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Compared with type I inhibitors, those of type II generally possess higher selectivity because the hydrophobic region has less conservation than ATP binding site.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In addition, type III inhibitors bind to non-ATP binding site in an allosteric binding mode.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><b>Sunitinib</b>, <b>midostaurin</b>, <b>lestaurtinib</b>, <b>crenolanib</b>, and <b>gilteritinib</b> are type I inhibitors and display high affinity for the active conformation of the ATP binding region in FLT3. Owing to the high similarities of the ATP binding region between kinases, type I inhibitors generally appear to be multitargeting inhibitors. <b>Sorafenib</b> and <b>quizartinib</b> are classical type II inhibitors, which interact with the back pocket of the ATP binding region in an inactive conformation and make contacts with the side chains of amino acid residues, thereby increasing selectivity and inhibitory activities.<a onclick="showRef(event, 'ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61 ref62 ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61 ref62 ref63 ref64 ref65">(54−65)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Clinical Advances in Research and Development of FLT3 Inhibitors for AML Therapy<a onclick="showRef(event, 'ref65 ref66 ref67 ref68 ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67 ref68 ref69 ref70 ref71">(65−71)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0035.gif" alt="" id="gr35" /></img><div></div></div><div class="NLM_p">Because of the distinctiveness of inactive DFG-out conformations, it is hypothesized that type II inhibitors can be more selective than those of type I binding to standard active DFG-in conformations. However, <b>gilteritinib</b> being type I inhibitor displays higher selectivity than <b>sorafenib</b> being type II, which suggests that there is a large overlapping in selectivity between type I and type II inhibitors, and type II inhibitors does not have an absolute selectivity advantage over type I inhibitors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Actually, the DFG sequence of kinases is highly conserved, and the high selectivity of inhibitors may be completely manifested with the specific DFG-out conformation, which may explain why the type II inhibitors are less selective than the type I in some cases. Moreover, when FLT3 mutations occur (such as FLT3-ITD) and the mutation sites are outside the ATP binding domain, the interacting modes between the inhibitors and kinases are no longer suitable for evaluating selectivity due to altered protein conformations.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Therefore, understanding the interacting mode between inhibitors and kinases lays crucial foundation for the design of selective FLT3 inhibitors.</div><div class="NLM_p">In the following chapters, we mainly summarized the structural properties and biological activities of different FLT3 inhibitors that were reported from 2014 to the present, which could provide significant references for further research on novel and selective agents in the treatment of AML. The research on FLT3 inhibitors before 2014 could be seen in ref <a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a>. The FLT3 inhibitors discussed here can be generally categorized into six groups according to their basic chemical structures: indoles, aryl ureas, quinolines or isoquinolines, pyrimidines or fused pyrimidines, pyrazoles, and others.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.1.  Indole and Indolinone-Based Derivatives as FLT3 Inhibitors</h3><div class="NLM_p">Indole, which is one of the hot research structures in the field of anticancer drugs, is a common pharmacophore with extensive biological activities, and its derivatives display inhibitory effects on multiple protein kinases.<a onclick="showRef(event, 'ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref73 ref74 ref75">(73−75)</a> The scaffold of indole-based compounds is generally a fused ring composed of a six-membered aromatic ring and five-membered ring, the −NH– motif of which can interact with the hinge region of FLT3 to form hydrogen bonds. Thus, the design and synthesis of indole-based derivatives as FLT3 inhibitors illustrate a crucial research direction.</div><div class="NLM_p">In 2014, Donald’s group discovered indolocarbazole derivative as a novel and potent FLT3 inhibitor, and the results showed that the IC<sub>50</sub> value for <b>TTT-3002</b> are from 100 to 250 pM against FLT3 autophosphorylation in human FLT3-ITD mutant leukemia cell lines (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a).<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> The activity of <b>TTT-3002</b> has been proved against a wide range of FLT3 activating point mutations (including the most common D835 mutation), as well as a plenty of point mutations selected for in FLT3-ITD alleles that conferred resistance to other TKIs (including the F691L gatekeeper mutation). It was expected that <b>TTT-3002</b> could bind to FLT3 without making direct interactions with F691 residues which formed stable π–π stacking interactions with <b>quizartinib</b> (<b>AC220</b>), and thus mutations to Leu would lead to decreased TKI binding affinity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). Moreover, <b>TTT-3002</b> is cytotoxic to FLT3/ITD mutant cells extracted from AML patients, while less toxic to normal healthy HSCs. Subsequently, a unique and promising FLT3 inhibitor <b>Gö6976</b> (IC<sub>50</sub> = 0.7 nM) was reported by Akira et al., which also belongs to the series of indolocarbazole with a similar structural skeleton to staurosporine.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a><b>Gö6976</b> caused significant inhibition of the proliferation of human leukemia cells expressing FLT3-ITD, such as MV4-11 and MOLM13 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). This compound inhibited not only the autophosphorylation of FLT3 but also its downstream cascades STAT3/5, ERK1/2, and AKT. It is worth noting that <b>Gö6976</b> can down-regulate the antiapoptotic protein survivin and MCL-1 to enhance antiproliferative activity against leukemia cells. <b>EC-70124</b> is a potential dual inhibitor optimized from the approved multitarget FLT3 inhibitor <b>PKC412</b> and has strong suppression for both FLT3 and PIM, which are important therapeutic targets in AML (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a).<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a><b>EC-70124</b> showed potent inhibition of wild-type and mutant FLT3, especially ITD, with lower IC<sub>50</sub> for kinases than <b>PKC412</b>, and an increase in PIM selectivity made more desirable anti-AML functions in vitro than FLT3 single inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of indolocarbazole derivatives (a). Co-crystallized staurosporine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITQ">2ITQ</a>) was aligned with FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recent studies have demonstrated that dual inhibitors have been regarded as one of the effective agents against FLT3 mutant-associated AML.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> A series of acylureidoindolin-2-one derivatives was designed and synthesized as potential dual Aurora B/FLT3 inhibitors through ligand-based molecular engineering in Chen’s group.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Linker optimization of the (4-methoxyphenyl)ureido moiety in <b>Chen-2b</b> resulted in the (4-methoxybenzoyl)ureido moiety forming closed conformation in <b>Chen-32a</b>, which acted as a lead compound for modification of dual Aurora B/FLT3 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). The pyrrole ring bearing the 3′,5′-diCH<sub>3</sub> and long chain amine <i>N</i>-(2-(pyrrolidin-1-yl)ethyl) carboxamide improved Aurora B and FLT3 inhibitory activities, as well as the fluoro substituent enhanced the physicochemical properties, thus the most potent compound <b>Chen-54</b> was yielded with the IC<sub>50</sub> value of 0.4 nM and 0.5 nM against Aurora B and FLT3, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). The mesylate salt of <b>Chen-54</b> could markedly curb tumor growth and reduce the mortality of BALB/c nude mice subcutaneously transplanted with MOLM13 cells that deserved to be studied further.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structure and design strategy for target compound <b>Chen-54</b> (a), <b>Hu-10d</b> (b), and <b>Őrfi-20a</b> (c).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To develop FLT3 inhibitors with more potency and tolerability, in 2017, Hu’s group adopted the conventional bioisosterism strategy to change the carboxamide bond of the approved drug <b>sunitinib</b> into an amide-acyl bond. Three series of derivatives with amide-acyl bond were prepared and initially screened, and structure–activity relationship (SAR) studies showed that the heterocyclic alkane at the solvent interface remarkably improved the potency of inhibiting MV4-11 cell proliferation.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The most selective inhibitor <b>Hu-10d</b> exhibited excellent inhibitory activity against FLT3 (IC<sub>50</sub> = 5.3 nM) while apparently weaker inhibition of PDGFRα (IC<sub>50</sub> = 174.6 nM) and c-Kit (IC<sub>50</sub> = 227.0 nM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). Compared with wild-type, this compound is more sensitive to mutant FLT3 and pharmacokinetics data illustrated that its bioavailability was up to 59% in mice, which was greatly suitable for clinical research.</div><div class="NLM_p">It is noticeable that off-target effects extensively exist in multikinase inhibitors in the field of cancer treatment.<a onclick="showRef(event, 'ref84 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref84 ref85 ref86">(84−86)</a> To overcome such undesired side effects, 62 <b>sunitinib</b> derivatives containing amino acid substituents were designed, synthesized, and depicted based on targeted delivery strategies.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> In all of these prepared compounds, <b>Őrfi-20a</b>, bearing the amino acid moiety, displayed high affinity against FLT3-ITD mutant kinases, preferential cellular activity (MV4-11), and high log <i>D</i> at pH = 5.5, which was considered as a promising candidate to be conjugated with antibodies and peptides via its carboxyl group (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c).</div><div class="NLM_p"><b>H-89</b>, a well-known PKA inhibitor, possesses pharmacological activities against various kinases including S6K1, MSK1, and ROCK-II, and its analogues were used as lead compounds in several drug discoveries.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88,89)</a> On the basis of these, scientists from Leiden University employed topological SAR analysis and identified azaindole <b>van der Stelt-38</b> as a novel and efficient inhibitor of FLT3-ITD with better physicochemical properties (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Compound <b>van der Stelt-38</b> showed fairly strong inhibitory activity against FLT3 with a pIC<sub>50</sub> of 9.49, which was higher than the majority of kinase inhibitors derived from <b>H-89</b>. In addition, molecular docking studies indicated that <b>van der Stelt-38</b> had an alternative flipped binding mode to FLT3. The pyridine moiety of <b>H-89</b> analogue formed a hydrogen bond with the hinge region C694 and the adjacent phenyl engaged in a π-interaction with F691 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). The docking result of <b>van der Stelt-38</b> was consistent with the interacting mode of <b>H-89</b> analogue with an additional hydrogen bond interaction with C694, which may be the cause of the improved potency (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structure and design strategy for target compound <b>van der Stelt-38</b> (a). Predicted “flipped” binding mode of <b>H-89</b> analogue (b) and <b>van der Stelt-38</b> (c) in FLT3 crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). (b,c) Reproduced with permission from ref <a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a>. Copyright 2019 Elsevier</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the continuous development of computer programs permitting covalent molecular docking, covalent binding inhibitors have aroused intensive interest of the researchers.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Recently, <b>BSc5371</b>, an irreversible and selective FLT3 inhibitor, was discovered by Bensinger et al. through a virtual screening strategy that could overcome drug-resistant mutations of FLT3 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The virtual screening library was designed by adding chemically reactive groups to the reported reversible binding scaffolds, which targeted to the highly conserved Cys828 residue preceding the DFG motif. According to molecular dynamics simulation, the protein–ligand complex remained stable during the simulation. Further biological data exhibited that this irreversible compound was superior to the corresponding reversible scaffold in cytotoxicity and selectivity against FLT3-ITD leukemia cell lines.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structure, design strategy and covalent docking pose for target compound <b>Bsc5371</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.2.  Arylurea-Based Derivatives as FLT3 Inhibitors</h3><div class="NLM_p">The urea, a classical and functional group regularly applied to the rational drug design, plays prominent roles in modulating bioactivities and physicochemical properties of agents.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> It is commonly believed that the urea-like FLT3 inhibitors interact with tyrosine kinases in type II binding modes. The −NH– moiety of the urea can form hydrogen bonds with the allosteric site of protein kinases, and the inhibitory activity will be stronger when one side of the urea motif is substituted by a phenyl group or five-membered ring. Many FLT3 inhibitors with urea groups have been obtained in recent scientific studies.</div><div class="NLM_p">Considering that dual FLT3-Aurora A inhibitor was effective for FLT3 mutations including drug-resistant mutations, Hsu et al. selected an Aurora hit compound as a precursor to modify the side chain and the framework upon computer-guided drug design. A series of hybrids were presented, and the strongest inhibitory activity toward FLT3 and Aurora-A was displayed by <b>Hsieh-39</b> (IC<sub>50</sub> = 67 and 15 nM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> It was observed that the core of the inhibitor bound to Cys694 and the terminal heterocyclic urea group functioned with Lys644 and Asp829 through four critical hydrogen bonds. Western blot analysis further confirmed the inhibition of compound <b>Hsieh-39</b> against phospho-FLT3 and phospho-Aurora kinase A, which was consistent with the enzyme-based assays.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structure and design strategy for target compound <b>Hsieh-39</b> (a) and <b>Schmidt-12a</b> (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By an in silico rational drug-design approach, Schmidt’s group designed a multiple set of bisarylurea derivatives starting from the fragment-sized FLT3 inhibitor <b>AG1295</b>.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Substitution of the <b>AG1295</b> scaffold with bisarylureas occupying the DFG pocket contributed to the emergence of potential FLT3 inhibitors, and the most active compounds showed IC<sub>50</sub> values of 71 and 32 nM. Consecutively, a zebrafish embryo phenotype assay, which was internationally regarded as a main model in toxicological and pharmacological research, indicated that compound <b>Schmidt-12a</b> was noncytotoxic up to concentrations of 20 μM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b).</div><div class="NLM_p">Clinical data suggest that secondary mutations conferring resistance are a major obstacle in the current advances of FLT3 inhibitors, which have forced researchers to develop new inhibitors with activity against drug-resistant FLT3-ITD mutations. In 2015, Jiaang’s group modified the structure of previously reported pyrazole derivatives and a novel class of 5-phenyl-thiazol-2-ylamine compounds with a missing hydrogen-bond donor in the pyrazole ring were described, which were multitargeted FLT3 inhibitors with better bioavailability.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Among such potent compounds, the urea derivative <b>Jiaang-7h</b> was efficient both in vitro and in vivo against AML cell lines (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). More importantly, <b>Jiaang-7h</b> appeared to be highly active against clinically relevant FLT3-ITD mutations, especially in the residue of D835Y/V, and exhibited strong anti-AML efficacy in the drug resistant (FLT3-ITD/D835Y) xenograft model. Therefore, it is indicative that compound <b>Jiaang-7h</b> could be a promising agent for clinical drug resistant therapy against AML.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structure and design strategy for target compound <b>Jiaang-7h</b> (a), <b>Yu-16i</b> (b), and <b>Yang-19</b> (c).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>AC220</b>, a second-generation selective FLT3 inhibitor approved in Japan, is one of the most potential clinical candidates for relapsed and refractory AML. To develop novel second-generation FLT3 inhibitors, Yu’s group designed a series of novel <i>N</i>-(5-(tertbutyl)isoxazol-3-yl)-<i>N</i>′-phenylurea derivatives through the isosterism principle derived from <b>AC220</b>.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> SAR analysis demonstrated that an electron-rich fused ring at the phenyl was able to improve the antiproliferative activity as well as FLT3 inhibitory potency, and the introduction of substituents at C7 position were the most beneficial (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b, compound <b>Yu-16i</b>). At the same year, a highly selective FLT3 inhibitor <b>Yang-19</b> was discovered by Yang’s group through the cell-based screening strategy (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> They concentrated on two regions of the hit compound <b>Yang-1</b>, the 3′/4′-position substituent of phenyl ring (ring A) and the 3-position substituent of imidazo[2,1-<i>b</i>]thiazole, thus obtaining <b>Yang-19</b> sharing the similar urea motif with the hybrid <b>Yu-16i</b>. Further biological studies illustrated that both compound <b>Yu-16i</b> and <b>Yang-19</b> could lower the level of phospho-FLT3, induce apoptosis, and block the proliferation of MV4-11 cell.</div><div class="NLM_p">In Ge’s laboratory, much effort has been devoted to searching for novel and potent FLT3 inhibitors against both FLT3-ITD and a second mutation. Through a series of screening assays in vitro, it was found that <b>MZH29</b> possessed therapeutic effects on FLT3-ITD mutant AML, especially for FLT3-D835H/Y/V, FLT3-K663Q, and FLT3-ITD/F691L (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Docking studies initially revealed the possible action mechanism of <b>MZH29</b> against the known F691L mutation, namely forming hydrogen bonds at residues K614, E661, C694, and D829 in the docked <b>MZH29</b> and FLT3/F691L model (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b,c). The stable combined conformation may explain the almost unchanged activities of <b>MZH29</b> against the F691L mutation. Besides, the researchers observed remarkable tumor regression and prolonged survival with less toxicity in a mouse model of AML.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structure of compound <b>MZH29</b> (a), molecular docking of <b>MZH29</b> with FLT3 in an inactive conformation (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (b), and hydrogen bonds formed with K614, E661, C694, and D829 residues (c).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Enlightened by favorable clinical efficacy of multitarget TKIs for cancer treatment, our group designed and synthesized two series of diaryl-ureas with novel isoxazol[3,4-<i>b</i>] pyridine-3-amino-structure through the bioisosterism strategy based on the lead compound <b>Linifanib</b> (ABT-869, Abbott), which was an oral active multitarget RTK inhibitor of KDR (VEGFR2), PDGFR-β, and CSF-1R.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Preliminary biological evaluations indicated that compound <b>Li-S21</b> was a superb inhibitor against FLT3, KDR, and PDGFR-β (IC<sub>50</sub> = 4, 3, and 8 nM, respectively), as well as various cancer cell lines (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>a). Molecular docking analysis demonstrated that the nitrogen atom and oxygen atom in the isoxazole ring formed two hydrogen bonds with Cys694, the amino group interacts with Glu692, and the urea part formed hydrogen bonds with Asp829 and Glu661, respectively (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>b). Altogether, these data provide a blueprint for the development of novel and efficacious FLT3 inhibitors toward relapsed and refractory AML. Relevant investigation is currently underway in our laboratory.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure and design strategy for compound <b>Li-S21</b> (a). Molecular docking for target compound <b>Li-S21</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a>. Copyright 2018 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fluorine has been known as magic substituents, whose introduction could improve the potency as well as drug-like properties of the drug molecules.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Lately, He’s group designed a group of hiazolidin-4-one urea analogues based on their previous obtained compound <b>He-9a</b>, and SAR analysis disclosed that introduction of fluorine on phenyl group caused a moderate boost in anticancer activity.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Compound <b>He-17b</b> proved to be a potent dual inhibitor that displayed inhibitory activity against FLT3 (IC<sub>50</sub> = 8.6 nM) and VEGFR2 (IC<sub>50</sub> = 18.7 nM) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a). The molecular modeling results showed that compound <b>He-17b</b> adopted a type II binding mode with the FLT3 kinase and the urea moiety formed two hydrogen bonds with the residue Asp698 and additional arene–H interactions increased the binding affinity (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structure and design strategy for target compound <b>He-17b</b> (a). Molecular docking for compound <b>He-17b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.3.  Quinoline or Isoquinoline-Based Derivatives as FLT3 Inhibitors</h3><div class="NLM_p">The series of compounds with quinoline or isoquinoline motif is another common type of FLT3 inhibitors in drug design, as the nitrogen atom on the skeleton is bound to the hinge region. Studies have suggested that the position of the ring nitrogen on the isoquinoline or quinoline and the substitution mode of the benzene ring were of great significance for FLT3 inhibition.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">To search for proper anti-AML agents with high selectivity, two quinolinone analogues, <b>KR65367</b> and <b>KR65370</b>, were subjected to FLT3, Met, Ron, EGFR, and other homologous kinase for activity filter by Korean researchers (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Interestingly, the <b>KR</b> compounds performed excellent inhibitory effects on FLT3, but little inhibition toward other tested kinases, which suggested both two compounds retaining high selectivity. The compounds <b>KR65367</b> and <b>KR65370</b> also displayed cytotoxicity against MV4-11 cells and induced cell apoptosis in flow cytometric assays. Additionally, it was notable that the decrease in p-STAT5 level by <b>KR</b> compounds was consistent with growth inhibition in MV4-11 cells.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structure of compounds <b>KR65367</b> and <b>KR65370</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2017, scientists from Purdue University established a drug discovery protocol called “azo-click-it/staple-it”, which first used the facile azo coupling to make compound libraries and then replaced the problematic azo group with a more stable unit after the discovery of a potential hit compound.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> After confirming that the azo molecule <b>HSW630-1</b> possessed superior FLT3 inhibition profile, alkene or alkyne linker was applied to optimize the labile azo moiety, thus forming the representative hybrid <b>HSM1651</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Intriguingly, the stable <b>HSW630-1</b> derivative acted analogously to the azo lead compound, which could inhibit FLT3 kinase and the proliferation of FLT3-driven AML cells. However, multiple amidine drugs are generally not taken orally, and therefore this group decided to carry out further structural optimization for oral bioavailability.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Detailed SAR studies disclosed that the substitution mode and property of benzamide determined the inhibitory activities of corresponding compound against FLT3 and related cell lines, which contributed to the identification of 3-amino and 1-aminoisoquinoline benzamides <b>HSN286</b> as potential FLT3 and Src kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Unfortunately, <b>HSN286</b> suffered from poor drug-like properties and weak activities against AML harboring secondary FLT3 mutations, which constituted drawbacks for further drug development. With the aim to eliminate these limitations, lately, researchers introduced the essential nitrogen and a magic fluorine moiety into drugs to develop the second-generation alkynyl aminoisoquinoline and alkynyl aminonaphthyridine compounds with reduced log <i>P</i> values and enhanced activities against TKI resistant FLT3-ITD cell lines (including the D835Y and F691L mutations) as well as efficacy in in vivo mice studies.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The best result was observed for <b>HSN431</b> that suppressed FLT3 and downstream targets like Src at low nanomolar concentrations (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structure and design strategy for compound <b>HSW630-1</b>, <b>HSW1651</b>, <b>HSN286</b>, and <b>HSN431</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because the semicarbazide fragment participated in the interaction with FLT3 kinase through the presence of hydrogen bonds (Asp829 and Glu661) and the critical roles of phenyl-1,2,3-triazole skeleton in the regulation of tumor genesis, recently, Xu et al. employed semicarbazide as the linker between 4-((6,7-dimethoxyquinoline-4-yl) oxy)aniline scaffold and 1,2,3-triazole to generate novel target compounds as promising FLT3 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>a).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Activities screening against HL-60 and MV4-11 cell lines in vitro indicated that the series I compounds with the semicarbazide fraction held more potency than the positive control <b>cabozantinib</b>. Compounds <b>Liu-12c</b> and <b>Liu-12g</b> showed remarkable enzymatic inhibitory activities toward FLT3, with IC<sub>50</sub> values of 312 and 384 nM, respectively. By analyzing the docking model, the target compound <b>Liu-12c</b> formed hydrogen bonds with Asp829, Glu661, and Cys694. In addition, a π–π stacked interaction between 1,2,3-triazole with His809 and a π-−σ interaction between terminal benzene ring with Leu802 were also observed (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>b).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structure and design strategy for compound <b>Liu-12c</b> and <b>Liu-12g</b> (a). The molecular docking of compound <b>Liu-12c</b> to FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (b). , Reproduced with permission from ref <a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">4.4.  Pyrimidine or Fused Pyrimidine-Based Derivatives as FLT3 Inhibitors</h3><div class="NLM_p">The pyrimidine or fused-pyrimidine derivatives are generally considered to be fundamental for the development of novel and specific FLT3 inhibitors because the pyrimidine core is essential for achieving optimal activities and outstanding drug-like properties. Molecular docking indicated that nitrogen atoms on the pyrimidine moiety could form classical hydrogen bonds with Cys694 in the hinge region.</div><div class="NLM_p">In 2014, Han’s group designed, synthesized, and evaluated thienopyrimidine derivatives biologically for the purpose of seeking out prominent IKKβ inhibitors through modification on the thienopyrimidine core and the known IKKβ inhibitor, <b>SPC-839</b>. They replaced the quinazoline with thienopyrimidine as the scaffold and diversified its functional groups, introducing alkyl, substituted aromatic, and heterocyclic groups at positions 2, 4, and 5 of the thienopyrimidine scaffold. However, the resulting thienopyrimidine analogues appeared to target another different kinase, FLT3, instead of IKKβ.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Among these analogues, compound <b>Han-13i</b> was the most active one, manifesting good inhibitory profile against FLT3 and AML related cells harboring either wild-type or mutants (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>a). Subsequently, this group reported another class of thieno[2,3-<i>d</i>]pyrimidine derivatives based on the previous research, which led to the discovery of compound <b>Han-17a</b>, bearing relatively short and simple substituents at the C6 position of thieno[2,3-<i>d</i>]pyrimidine with great potency (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>a).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Although compounds <b>Han-13i</b> and <b>Han-17a</b> were deemed as efficacious FLT3 inhibitors in the synthesized hybrids, their metabolic stability in human and rat liver microsomes was poor. Hence, further structure modification at the 6-position was carried out for the identification of potent FLT3 inhibitors with increased metabolic stability. Compound <b>Han-16d</b>, possessing a 4-(2-methylaminoethoxy) phenyl group at the C-6, displayed effective inhibition against FLT3 kinase and several leukemia cell lines with relatively high metabolic stability (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>a).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure and design strategy for compound <b>Han-13i</b>, <b>Han-17a</b>, <b>Han-16d</b>, and <b>Han-13b</b> (a). The chemical structure for compound <b>G-749</b> (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Nevertheless, low water solubility was an obstacle to the development of compound <b>Han-16d</b> as a potential FLT3 inhibitor for AML chemotherapy, which urged researchers to conduct further structural optimization on the thieno[2,3-<i>d</i>]pyrimidine scaffold. In an attempt to develop novel derivatives with improved solubility of compound <b>Han-16d</b> while retaining its advantageous activity and microsomal stability, 19 compounds were synthesized through the manner of fixing diverse moieties at the thieno[2,3-<i>d</i>]pyrimidine scaffold.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> This approach afforded compound <b>Han-13b</b>, which possessed a thiazole moiety at the C2 position and a methyl group at the C6 position, exhibiting better antiproliferative activity and moderate microsomal stability, especially increased solubility (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>a).</div><div class="NLM_p">The compounds of the <b>Han</b>-series were thienopyrimidine-based analogues with great potency against FLT3 and discovered accidentally through structural modifications of the classical IKKβ inhibitor, <b>SPC-839</b>. This series of compounds contained highly reactive Michael acceptors, which could form irreversible interactions with the cysteine residue of targeted proteins through Michael addition reactions. Compared with traditional reversible inhibitors, the irreversible binding inhibitors could avoid the defects of relatively low selectivity, no long-lasting efficacy and drug resistance. However, once the off-target occurs, the toxicity and side effects are quite serious.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p"><b>G-749</b>, a novel small-molecule FLT3 inhibitor against FLT3, FLT3-ITD, FLT3-D835Y, FLT3-ITD/F691L, and FLT3-ITD/N676D was obtained using a structure-based drug design approach and proved to exert sustained inhibitory effects on FLT3 phosphorylation and downstream signals in cellular assays (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>b).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It maintained strong antileukemia activities in bone marrow blasts of AML patients, including those with little or only slight responses to drugs like <b>AC220</b> and <b>PKC412</b>. Oral administration of <b>G-749</b> could result in apparent tumor regression and increased life span in mouse models. Altogether, <b>G-749</b> was expected to become a potent next-generation FLT3 inhibitor for the treatment of patients with relapsed and refractory AML, harboring multiple ITD or TKD mutations.</div><div class="NLM_p">Potential dual inhibitors of FLT3 and CDKs may offer tremendous benefits for antileukemia efficiencies by adjusting the two essential targets simultaneously because, apart from FLT3 hyperactivation, the upregulation of the CDKs in AML could also bring about dysregulation of cancer cells.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Encouragingly, Amgen Inc. designed various FLT3 and CDK4 dual inhibitors to address the major issues associated with lead compound <b>Amgen-1</b>:CYP3A4 inhibition, suboptima selectivity, and poor oral bioavailability through combining traditional and novel structure-based drug strategies (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>a).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> The nanomolar and orally bioavailable FLT3 and CDK4 dual inhibitor <b>AMG 925</b> (IC<sub>50</sub> = 1 and 3 nM, respectively) was identified as a type I kinase inhibitor, which tended to interact with the active DFG-in conformations and retained inhibition against several key FLT3 mutants (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>b). <b>AMG 925</b> apparently inhibited the tumor growth in xenograft mouse models without significant body weight loss, and its antitumor activity was closely related to the downregulation of FLT3 and Rb phosphorylation in vivo.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Besides, it was well tolerated toward FLT3-D835Y mutants that were resistant to the agent like <b>sorafenib</b> and <b>AC220</b>, which was expected to yield longer lasting efficacy in clinic.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure and design strategy for compound <b>AMG 925</b> (a). DFG-in kinase with <b>AMG 925</b> model with type I binding homology mode (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, Lu’s group conjugated a pyrimidine-fused heterocycle at the position 4 of pyrazole to obtain novel active pharmacophores based on the hit compound <b>Lu-26</b>, which were expected to be potent dual inhibitors targeting FLT3 and CDKs.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The attachment of a fused heterocycle bearing a pyrimidine or pyridine structure to pyrazole is proved to be the most important factor in determining the efficiency toward FLT3 and CDKs while optimizing the hydrophilic region did not make a great difference to the potency of the compounds (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>a). Among variously synthetic 1<i>H</i>-pyrazole-3-carboxamide derivatives, compound <b>FN-1501</b> showed appreciable inhibitory activities with IC<sub>50</sub> values of 0.27 nM against FLT3 and 2.47 nM against CDK2. The nanomolar kinase inhibition and excellent antiproliferative activities against MV4-11 cells (IC<sub>50</sub> = 0.008 μM) were in line with the reduced phosphorylation of retinoblastoma, FLT3, ERK, AKT, and STAT5, and the generation of cell apoptosis. As is shown in molecular docking studies, the pyrazole-3-carboxamide skeleton of <b>FN-1501</b> formed hydrogen bonds (Glu81 and Leu83) with the hinge region of CDK2 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>b). <b>FN-1501</b> bound to FLT3 in a similar manner to the interacting mode of CDK2 with the core forming hydrogen bonds (Glu692 and Cys694) in the hinge region of FLT3. The 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine group of <b>FN-1501</b> occupied the hydrophobic pocket, and the <i>N</i>-methylpiperazine group extended into the solvent accessible region (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>c). Both in vitro and in vivo studies revealed that <b>FN-1501</b> possessed highly efficacy and great safety, which was in phase I clinical trials in the United States and China as an antileukemia treatment.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structure and design strategy for compound FN-1501 (a). FN-1501 docked into CDK2 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>) (b).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> FN-1501 docked into a homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (c).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Convincing data suggest abnormal expressed Mer tyrosine kinase in 80–100% AML patients, and the joint inhibition of FLT3 and Mer may be an effective therapeutic strategy.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> To address the solubility and PK properties of the Mer inhibitor <b>UNC1062</b> while retaining its activity and kinome profile, medicinal chemists replaced the N2 nitrogen with a carbon on the pyrazole ring and <b>UNC1666</b> was obtained with better solubility (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). However, the structure of <b>UNC1666</b> needed to be further optimization to solve the PK limitations such as high clearance. Subsequently, researchers removed the sulfonamide linker and made other minor changes in the corresponding positions of <b>UNC1666</b>. As a result, <b>UNC2025</b> was synthesized and revealed excellent PK characteristics: low clearance, longer half-life, and high oral exposure. <b>UNC2025</b> is a potential and orally bioavailable Mer/FLT3 dual inhibitor (IC<sub>50</sub> = 0.8 and 0.74 nM, respectively), with highly selectivity that is approximately 20-fold higher than that of Axl and Tyro3.<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> Additionally, administrating <b>UNC2025</b> orally could significantly prevent the proliferation of cancer cells in acute leukemia mice models.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure and design strategy for compound <b>UNC1666</b> and <b>UNC2025</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Liu’s group from High Magnetic Field Laboratory of the Chinese Academy of Science has long been committed to developing novel FLT3 inhibitors for the treatment of AML. On the basis of the chemical structure of <b>Ibrutinib</b>, a type I BTK kinase inhibitor that was shown to selectively target FLT3-ITD in mutant FLT3-positive AML, they applied rational drug design approach and detailed SAR analysis to further enhance the FLT3 kinase potency and selectivity of this series of compounds (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>a).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Considering no appropriate cysteine residues could be used to form covalent bonds in the FLT3 kinase as in BTK kinase, researchers saturated the double bond and a selective type I inhibitor <b>CHMFL-FLT3-122</b> docked into the FLT3 DFG-in conformation was obtained, which held the impressive potential to inhibit the proliferation of FLT3-ITD positive AML cell lines and avoided dual inhibition of FLT3/c-Kit induced myelosuppression toxicity.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structure and design strategy for compound <b>CHMFL-FLT3-122</b> and <b>CHMFL-FLT3-213</b> (a). <b>CHMFL-FLT3-213</b> docked into the homology model of DFG-out conformation of FLT3-F691L mutant (site mutation from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, <b>CHMFL-FLT3-122</b> could not overcome the drug resistance caused by the secondary mutations in the FLT3 kinase domain, e.g., ITD-F691L, which is located at the “gatekeeper” area in FLT3. Researchers further explored its parental structure and introduced a proper type II binding unit urea at the R<sub>2</sub> moiety to break limitations of the core pharmacophore as a type I FLT3 kinase inhibitor through the structure-guided drug design methodology. Because the R1 moiety was directed to the solvent exposed region and more hydrophilic groups would be favorable, O-linked morpholine was added, thus leading to the discovery of <b>CHMFL-FLT3-213</b>, a potent type II FLT3 kinase inhibitor which displayed potential in vitro and in vivo inhibitory effects against FLT3-ITD and numerous mutations including gatekeeper FLT3-ITD-F691L, FLT3-ITD-D835Y, and FLT3-D835Y/H/V (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>a).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> In the F691L mutant binding model, hydrogen bonds formed by the urea part turned the benzene ring away from the position, which created enough space to accommodate the Leu691 residue (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>b). This may explain why <b>CHMFL-FLT3-213</b> maintain high activities against the F691L mutation.</div><div class="NLM_p">Continually, a promising phenoxypyrimidine skeleton-based type II FLT3-ITD mutant selective inhibitor <b>CHMFL-FLT3-335</b> has been developed by a hybrid binding fragment approach based on the structure of <b>AZD2932</b> and <b>sorafenib</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>a).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><b>CHMFL-FLT3-335</b> exhibited distinct inhibitory activities against different ITD mutations ranging from 30 to 80 nM and possessed good selectivity over FLT3 wt and c-Kit kinase (up to 8-fold and 300-fold, respectively). The docking model illustrated that <b>CHMFL-FLT3-335</b> formed hydrogen bonds with Cys694, Asp829, and Glu661, respectively, and the benzene ring of the linker moiety generated edge-to-face π–π stacking interactions with Phe691 and Phe830 in the FLT3 kinase (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>b). In the hydrophobic pocket, the tail moiety trifluoromethylaniline formed more preferred interactions in FLT3 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>c) than in c-KIT (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>d) because the residues Met664 and Met665 in FLT3 are changed with Val643 and Leu644 in c-KIT, which caused the size of the hydrophobic pocket in FLT3 more suitable for <b>CHMFL-FLT3-335</b> than in c-KIT. This may also be responsible for the high selectivity of <b>CHMFL-FLT3-335</b> against FLT3 and c-KIT.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structure and design strategy for compound <b>CHMFL-FLT3-335</b> (a). The binding mode of <b>CHMFL-FLT3-335</b> with FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Solid surface view of the hydrophobic pocket formed by residues Met664 and Met665 in FLT3 (c).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Solid surface view of the hydrophobic pocket formed by residues Val643 and Leu644 in c-KIT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) (d).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To overcome the poor selectivity of FLT3 versus c-Kit (only 0.9-fold) and relatively low bioavailability of <b>CHMFL-FLT3-213</b>, in 2019, Chen’s group replaced the pyrazolo[3,4-<i>d</i>]pyrimidine with pyrrolo[2,3-<i>d</i>]pyrimidine as the core scaffold and altered the position of the urea-linked benzene ring and ethylmorpholine, as well as simplifying related critical functional groups (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>a).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Among these pyrimidine analogues, <b>Chen-9u</b> showed significant inhibition against FLT3 kinase and FLT3-ITD positive cancer cells, especially gained efficacy toward FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to <b>AC220</b>. As is demonstrated in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>b, the fused pyrimidine core and urea linkage formed hydrogen bonds with the Cys694, Glu692, Glu661, and Asp829 residues, respectively, and π–π stacking was observed between the linker phenyl with Phe691 and Phe830 residues. Meanwhile, <i>tert</i>-butyl substituted isoxazole occupied the hydrophobic pocket (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>b). Importantly, <b>Chen-9u</b> exhibited more than 40-fold selectivity for FLT3 (IC<sub>50</sub> = 7 nM) versus c-Kit (IC<sub>50</sub> > 300 nM), which might decrease myelosuppression toxicity. The pyrimidine derivative could suppress the phosphorylation of FLT3 and downstream signalings, along with induce cell cycle G0/G1 arrest and apoptosis in the dose-dependent manner.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structure and design strategy for compound <b>Chen-9u</b> (a). Docking model with the FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2016, Li’s group transformed previously reported irreversible EGFR inhibitors into potential FLT3 inhibitors and introduced the premium pteridin-7(8<i>H</i>)-one core as a member of the FLT3 inhibitor family (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>a).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> The 4-methylpiperazinyl moiety could improve the enzymatic and cellular activities of the compound by generating a hydrogen bond interaction with Asn701. Conversion of the electrophile group acrylamide into an amino group resulted in an increase in FLT3 inhibition and selectivity against FLT3 over EGFR due to the hydrogen bond interaction between the amino group and Asp698. Additionally, introduction a methy group further stabilized the hydrogen bond interaction between the 4-methylpiperazinyl moiety and Asn701 and an intramolecular π–π stacking interaction (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>b). The most promising pteridin-7(8<i>H</i>)-one derivative <b>Li-31</b> possessed single-digit nanomolar FLT3 inhibition and subnanomolar activities toward drug resistant FLT3 mutations. It also demonstrated highly selectivity against FLT3-ITD mutations related MV4-11 and MOLM13 cell lines when compared with other leukemia and solid tumor cell lines.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structure and design strategy for compound <b>Li-31</b> (a). Compound <b>Li-31</b> docked into the active site of the FLT3 homology model (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the lead compound <b>Guy-1</b>, Guy’s group expanded a range of compounds and conducted detailed SAR analysis with respect to the inhibition of FLT3 and MV4-11 cellular proliferation.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> As a result, compound <b>Guy-5e</b> was identified, which not only displayed great inhibitory activities toward FLT3 and MV4-11 cell lines but also maintained favorable efficiency in MOLM13 cell lines harboring FLT3-ITD and drug resistant TKD mutations. The pyrimidine nitrogens and nitrogen linker atoms played crucial roles in MV4-11 cellular activity. Incorporating a 3-pyridinylphenyl group and a small aliphatic substituent to the pyrimidine scaffold offered a balance of potency, solubility, and permeability (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>a). Nevertheless, compound <b>Guy-5e</b> still required further structure optimization for its inferior metabolic stability and high clearance in pharmacokinetic studies.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structure and design strategy for compound <b>Guy-5e</b> (a) and <b>Wang-16a</b> (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As one of the MAPK-activated protein kinases, Mnk2 attaches great significance to the tumor formation and the cooperative blockade of Mnk2 and FLT3 may contribute to the antileukemia therapy, particularly drug resistance after FLT3 inhibition. Upon the <i>N</i>-(2,4-dimethoxyphenyl)-pyrimidin-2-amine scaffold, Sarah et al. evaluated a series of FLT3 and Mnks dual inhibitors through replacing the thiazole ring at C4 of the lead compound <b>Wang-11</b> with an indole, where its 1-NH might be memetic of the C2-NH of thiazole (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>b).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a><i>N</i>-Phenylpyrimidin-2-amine derivative <b>Wang-16a</b> was a potent Mnk2 and FLT3 dual inhibitor with the <i>K</i><sub>i</sub> values of 0.11 and 0.34 μM, respectively, which induced G1 phase cell cycle arrest and apoptosis in MV4-11 cell lines dose dependently. Noteworthily, the dual inhibition against Mnk2 and FLT3 cumulatively functioned through down-regulating the expression of antiapoptotic protein Mcl-1.</div><div class="NLM_p">In 2018, a new set of 2,6,9-trisubstituted purine derivatives were presented through replacing the 6-benzylaminopurine core of previously reported nanomolar CDK inhibitors with a 6-anilinopurine. The lead compound <b>Krystof-7d</b> exhibited single-digit nanomolar activity in biological assays and higher selectivity in AML cell lines harboring FLT3-ITD mutants than in other cancer cell lines (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>a).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Molecular docking studies suggest a type I binding mode for compound <b>Krystof-7d</b> and that the amino group of aniline and the adjacent nitrogen atom in the pyrimidine ring formed classic hydrogen bonds with Cys694 backbone in the hinge region, the cyclopentyl moiety formed a hydrophobic interaction with hydrophobic residues including the gatekeeper Phe691, and the 4-amino group in the 1,4-diaminocyclohexyl section could be protonated to generate a salt bridge with Asp829 (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>b).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structure and design strategy for compound <b>Krystof-7d</b> (a). <b>Krystof-7d</b> docked into a homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because JAK2/FLT3 dual inhibitors could exert impacts on JAK2/STATs signaling and the phosphorylation of FLT3 kinase, Li et al. evaluated the pharmacophores of <b>momelotinib</b> and <b>tandutinib</b> and utilized hybridization strategy to afford varieties of 4-piperazinyl-2-aminopyrimidine derivatives as potent dual inhibitors for JAK2 and FLT3 (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>a).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Representative promising compound <b>Zhao-14j</b> was the most potent pyrimidine-based inhibitor against JAK2 and FLT3 in the screened library, which caused cell cycle G1/S phase arrest and apoptosis dose-dependently in flow cytometry analysis. The binding mode of <b>Zhao-14j</b> in the FLT3 kinase was further elucidated, as shown in <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>b, the NH portion of 2-aminopyrimidine and the oxygen atom of acetophenone moiety formed hydrogen bonds with Cys695 and Asp829, respectively, and the morpholine group was fully entered the solvent exposed region. The “B” phenyl ring formed a π–π stacked interaction with Tyr696, while the “A” phenyl ring was tightly installed through two edge-to-face π–π stacked interactions with Phe691 and Phe830.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure and design strategy for compound <b>Zhao-14j</b> (a). <b>Zhao-14j</b> docked into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b). Reproduced with permission from ref <a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, compound <b>Chen-18e</b> was the optimal 4-substituent pyrimidine-2-amine pharmacophore derived from the hit compound <b>Pacritinib</b> to append JAK2 and FLT3 inhibition with IC<sub>50</sub> values of 0.7 and 4 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>a).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Besides, compound <b>Chen-18e</b> possessed highly selectivity over other JAK isoforms and 100 representative kinases. Orally administrating <b>Chen-18e</b> in 60 mg/kg, the TGI (tumor growth inhibition) in MV4-11 and SET-2 xenograft models was up to 93% and 85%, respectively. Furthermore, it demonstrated fantastic drug-like properties, such as outstanding bioavailability (<i>F</i> = 58%), appropriate half-life time (<i>T</i><sub>1/2</sub> = 4.1 h), reasonable metabolic stability, and weak CYP3A4 inhibition, which could be a promising drug for the treatment of AML and MPNs. To better clarify how <b>Chen-18e</b> interacted with JAK2 and FLT3, molecular docking was operated. As expected, <b>Chen-18e</b> formed essential hydrogen bonds with the amino acid residues Asp939 and Leu932 in the JAK2 kinase, and a salt bridge interaction was generated between the methylamine of piperidine and the Asp939 residues (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>b). Correspondingly, <b>Chen-18e</b> interacted with the FLT3 kinase by means of engendering hydrogen bonds with Met665 and Asp829, while cation−π stacking interactions occurred between the benzene ring of <b>Chen-18e</b> and Phe830 (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>c).</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structure and design strategy for compound <b>Chen-18e</b> (a). Molecular docking of <b>Chen-18e</b> to the JAK2 protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>) (b).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Molecular docking of <b>Chen-18e</b> to the FLT3 protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (c).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">4.5.  Pyrazole-Based Derivatives as FLT3 Inhibitors</h3><div class="NLM_p">Because of the broad spectrum of pharmacological activities, heterocyclic compounds containing pyrazole derived molecules have been thought as remarkable structural skeletons in the development of anticancer agents. Numerous structural optimizations of the pyrazole motif have been carried out to investigate its characteristics and biological potential.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a><b>G-11</b>, a synthesized pyrazole derivative, was found to cause selective cytotoxicity and induce differentiation in the acute myeloid leukemia HL-60 cells (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>a).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> It was suggested that <b>G-11</b> induced HL-60 cells to differentiate into monocytes/macrophages and granulocytes both in a dose and time dependent manner. The inhibitory effect of the <b>G-11</b>, even on mutant FLT3, was detected through two human AML cell lines of MV4-11 and MOLM-13, which were known to bear ITD mutations in FLT3, resulting in constitutively activation. Molecular docking studies clearly demonstrated the hydrogen bonding interactions of <b>G-11</b> to Leu616, Asp698, Cys694, and Cys828 binding sites, as well as hydrophobic and π-stacking interactions involving Phe691 and Ile674, and Met665 residues (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>b).</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structure for compound <b>G-11</b> (a). <b>G-11</b> docked into an inactive homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) (b). The chemical structure and design strategy for compound <b>Nagano-26</b> (c). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a>. Copyright 2016 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Soon after, Hirofumi et al. rationally designed and synthesized 27 pyrazole derivatives through fragment-based screening followed by systematic structure optimization of a nonselective kinase inhibiting fragment (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>c).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> This methodology seemed reasonable because the most promising molecule, compound <b>Nagano-26</b>, displayed nanomolar activity against FLT3 (IC<sub>50</sub> = 10 nM) and an even better selectivity profile over a panel of 50 kinases. It was also confirmed that the pyrazole derivative <b>Nagano-26</b> efficiently suppressed the proliferation of MV4-11 cell lines with FLT3-ITD mutations, reduced the phosphorylation of FLT3, and induced apoptosis in a dose-dependent manner.</div><div class="NLM_p">Beginning with the lead compound <b>LT-106-175</b>, a multitargeting kinase inhibitor against CDKs and FLT3, Lu’s lab adopted the structure-guided drug design strategy to synthesize a quantity of 1<i>H</i>-pyrazole-3-carboxamide analogues for the purpose of increasing the FLT3 inhibitory potency, as well as its selectivity.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The methyl substitution at position 2 of pyrimidine maintained the balance between selectivity and cell potency, while the piperazine ring was the ideal hydrophilic group, thus forming compound <b>Lu-44</b>. Subsequently, compound <b>Lu-50</b> was obtained through replacing the thiophene in <b>Lu-44</b> with a cyclopentane ring (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>a). To better understand the binding mode of <b>Lu-50</b>, molecular docking analysis was further performed. The pyrazole ring formed hydrogen bonds with Glu692 and Cys694 in the hinge region, and the piperazine ring formed a hydrogen bond with Asn701 in the hydrophilic pocket. Moreover, the 2-methyl group made beneficial van der Waals interactions with the gatekeeper residue Phe691 around the back pocket, which further explained why the introduction of methyl is the crucial factor to increase the selectivity against FLT3 (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>b). Preliminary mechanism study indicated that the inhibitory effects of compound <b>Lu-44</b> was associated with FLT3 mediated signal pathways and the enhanced metabolic stability of compound <b>Lu-44</b> (<i>t</i><sub>1/2</sub> = 147 min) was also observed in the human liver microsomes assay.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structure and design strategy for compound <b>Lu-50</b> (a). <b>Lu-50</b> docked into a homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a>. Copyright 2018 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequently, a novel type I FLT3 inhibitor, <b>LT-180-0712</b>, was discovered by means of virtual screening an in-house molecule database, which was expected to overcome the existed kinase selectivity and drug resistance.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> The developed compound <b>LT-180-0712</b> showed strong inhibitory activities against FLT3 and multiple FLT3 mutants, including FLT3-ITD, FLT3-TKD, and the simultaneous FLT3-ITD/TKD mutations, with IC<sub>50</sub> or <i>K</i><sub>d</sub> values in the nanomolar ranges. Importantly, this hybrid exhibited high FLT3 selectivity over other kinases. However, the cellular activity of compound <b>LT-180-0712</b> against MV4-11 cell line was moderate (IC<sub>50</sub> = 917 nM), and Lu’s group continued to seek novel selective FLT3-ITD inhibitors with improved cell efficacy upon structure- and property-based optimization (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>a).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> The representative compound <b>Lu-46</b> possessing a pyrazole amine scaffold, with the most potential cellular activity, displayed potential inhibitory activities and high selectivity against both FLT3-ITD and AML cells harboring FLT3-ITD. Notably, this compound was also efficacious for concurrent FLT3-ITD/TKD mutant kinases and transformed BaF3 cells. As is illustrated in <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>b, the amino and pyrazole moiety formed hydrogen bonds with the residue Cys694 and Glu692, respectively. The π–cation and π–π interactions were also generated for compound <b>Lu-46</b> with Lys614 and Phe691, as well as an unfavorable tight interaction emerged between the pyrazole moiety and backbone NH of Cys694 (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>b). Moreover, stable metabolism and significant tumor growth inhibition were observed for compound <b>Lu-46</b> in MV4-11 xenograft model, while little weight loss and no obvious toxicity to the viscera of treated mice.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Chemical structure and design strategy for compound <b>LT-180-0712</b> and <b>Lu-46</b> (a). <b>Lu-46</b> docked into a homology model of FLT3 (based on multiple templates, PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P2H">2P2H</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UX0">4UX0</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHX">3RHX</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FGK">1FGK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN">4WUN</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JS2">3JS2</a>.) (b) (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.6.  Other Structure-Based Derivatives as FLT3 Inhibitors</h3><div class="NLM_p">One of the favorable advantages among irreversible inhibitors is their long resident time within the interacting site of the target protein so that prolonged duration of drug action can be obtained. In 2014, Chai’s group designed and synthesized a series of ring-opened resorcylic acid lactone derivatives, which contained a highly reactive Michael acceptor (acrylamide, vinylsulfonamide, or maleimide) and could covalently bind to cysteine residues of the FLT3 kinase.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Compound <b>Chai-2</b>, <b>Chai-6</b>, and <b>Chai-15</b> are novel unsaturated inhibitors, which formed hydrogen bonds between the hydroxyl group on the benzene ring with the hinge region of FLT3 (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>). When attaching N-containing aliphatic heterocycles and unsaturated groups into the parental structure, the activity of the inhibitors could be enhanced. The most representative compound <b>Chai-15</b>, as an irreversible inhibitor of FLT3, had good inhibitory activities against FLT3-WT, FLT3-D835Y, and FLT3-ITD, with the IC<sub>50</sub> values of 0.15, 0.94, and 0.98 μM, respectively.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Chemical structure for compound <b>Chai-2</b>, <b>Chai-6</b>, and <b>Chai-15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Multitargeting inhibitors that simultaneously inhibit HDAC, FLT3, and JAK2 could exert synergistic cytotoxic effects against cell lines harboring JAK2<sup>V617F</sup> mutation and FLT3-ITD mutation, which might be a promising combination therapy for the treatment of AML.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> After thoroughly understanding the structural properties of HDAC, FLT3, and JAK2 inhibitors, macrocycle-based target compounds were constructed by combining crucial parts of template compounds <b>SAHA</b>, <b>SB1317</b>, and <b>Pacritinib</b> (<b>SB1518</b>) (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> The structural characteristics of a classic HDAC inhibitor should cover a zinc binding group, a linker, a cap, and a unit connecting the linker and cap. The macrocyclic moiety of <b>SB1317</b> and <b>SB1518</b> are proper cap groups for HDAC inhibition, while the unit Y were critical for HDAC and FLT3 inhibition instead of JAK2. Particularly, the HDAC inhibition was enhanced when the unit Y was a methylene group. The suitable carbon chain length appeared to be five or six and the hydroxamic acid at one end of the carbon chain could make some contacts with residues of FLT3 and JAK2. Thus, the novel multitargeting macroclic compound <b>Yu-32</b> was obtained. In vitro enzymatic assays initially demonstrated that <b>Yu-32</b> displayed potent HDAC, FLT3, and JAK2 inhibition (IC<sub>50</sub> = 87, 87, and 686 nM, respectively), while further cellular assays emphasized <b>Yu-32</b> was more cytotoxic to MV4-11 bearing FLT3-ITD mutation and HEL cells bearing JAK2<sup>V617F</sup> mutation (GI<sub>50</sub> = 0.27 and 0.34 μM, respectively). Therefore, <b>Yu-32</b> showed great potential for AML patients with FLT3-ITD or JAK2<sup>V617F</sup> positive, which deserved to be further investigated.</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Chemical structure and design strategy for compound <b>Yu-32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the hypothesis, an assumed binding pattern between <b>AC220</b> and the FLT3 kinase, Liu et al. designed de novo efficacious aminopyridine-based hinge binding scaffolds.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> They simplified the hinge binding region of <b>AC220</b> with the monocyclic amino heteroaryl group to offer required H-bond donor–acceptor arrays and extracted the proximal N–H of the urea linker with a methylene as only one of the urea N–Hs generated hydrogen bond binding with the αC-helix. Gratifyingly, substitution the <i>t</i>-butyl group with a trifluoromethylcyclopropane at the isoxazole moiety preserved the high cellular potency and selectivity. What’s more, incorporating the sulfones on the amino group with the 2-F substituent in the central phenyl ring resulted in a series of highly effective compounds with minimal CYP time-dependent inhibition (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>). As a result, compound <b>Liu-6s</b> was presented, which appeared to show the best response in FLT3-ITD mediated MV4-11 xenograft tumor model and was chosen for exploratory toxicology experiments.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Chemical structure and design strategy for compound <b>Liu-6s</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inspired by the hit compound <b>LT-793-323</b> with the IC<sub>50</sub> value of 500 nM against FLT3-ITD and the structure-based molecular design strategy, Lu’s group designed and synthesized a line of FLT3 inhibitors in accordance with the structurally new benzo[<i>d</i>]oxazole-2-amine framework.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Introducing appropriate substituents on the benzoxazole moiety could make crucial intermolecular interactions with the unoccupied ribose binding area of FLT3 binding sites, while small hydrophobic groups on the benzene linker might tend to remain interactions with the hydrophobic side chains of its surrounding residues. Among all these compounds, compound <b>Lu-T24</b> was the most potent FLT3 inhibitor, which displayed favorable inhibition against both FLT3-ITD kinase (IC<sub>50</sub> = 0.41 nM) and MV4-11 cell line (IC<sub>50</sub> = 0.037 μM) (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>a). The molecular dynamics (MD) method was then employed to study the binding mode of compound <b>Lu-T24</b> with the DFG-in FLT3 exactly, and the resulting complex was simulated by a 20 ns molecular dynamic run. Besides, <b>Lu-T24</b> was docked to the DFG-out conformation of FLT3, which was similar to the interacting mode in the DFG-in FLT3 with an extra π–π interaction existed between Phe830 and the carbamoyl substituted phenyl ring (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>b).</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Chemical structure and design strategy for compound <b>Lu-T24</b> (a). Interacting mode of <b>Lu-T24</b> with DFG-out conformation of FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b). (b) Reproduced with the permission from ref <a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a>. Copyright 2020 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">5.  Summary and Future Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">AML is one of the most aggressive and difficult-to-treat blood cancers and efficient therapeutic schedules are very limited, with only approximately 28% of patients surviving five years or more. FLT3, a class III RTK, is the most commonly mutant gene in AML and plays an essential role in the survival, growth, and development of hematopoietic and nonhematopoietic cells. Thus, the development of FLT3 inhibitors is of great necessity for AML therapy, and small-molecule inhibitors targeting FLT3 have become a research hotspot in the field of AML treatment, which has obtained many exciting achievements. So far, there are numerous small-molecule FLT3 inhibitors available or in clinical practice, such as <b>midostaurin</b>, <b>sunitinib</b>, <b>quizartinib</b>, <b>gilteritinib</b>, and so on. However, there have been some defects existed among these inhibitors, such as low selectivity caused by multitargets, drug-resistant secondary mutations and some other side effects, which have brought tremendous challenges for developing novel FLT3 inhibitors.<a onclick="showRef(event, 'ref46 ref71'); return false;" href="javascript:void(0);" class="ref ref46 ref71">(46,71)</a></div><div class="NLM_p">The secondary drug-resistant mutations in the tyrosine kinase domain have constituted an obstacle to the clinical application of TKIs. Drug resistance can be addressed through developing type II inhibitors that bind to unconservative and inactive kinase regions and utilizing the allosteric sites adjacent to the ATP binding pockets.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Resistant mutations such as FLT3-ITD/TKD conferred poor prognosis and higher recurrent rates after being treated with FLT3 inhibitors. Hence, overcoming FLT3 mutations is a potential drug design strategy for AML treatment. For example, according to the existed π–π stacking between the benzene ring in the aromatic urea of <b>AC220</b> and the Phe691, Shah’s group replaced the structure of phenylisoxazourea with pyridine and the linker urea with methylamine to solve <b>AC220</b> induced gatekeeper F691L mutation, and <b>pexidartinib</b> was obtained (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>a).<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Because the binding pattern of <b>pexidartinib</b> is independent of the interaction with the gatekeeper, <b>pexidartinib</b> maintains efficiency against the F691L mutation and is now in phase III clinical trial, which brings great guidance to the structural optimization of novel FLT3 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>b).</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Chemical structure for <b>Pexidartinib</b> (a). The binding mode of <b>Pexidartinib</b> is minimally affected by F691L (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H">4R7H</a>) (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although single-target medicines can inhibit their targets in clinic, drug resistance will occur within a few months after the initial treatment. Combination therapy that suppresses multiple signalings is currently one of the most effective strategies to overcome drug resistance. Nevertheless, drug–drug interactions, complex pharmacokinetic characteristics, and poor patient compliance can reduce clinical efficacy and safety.<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145,146)</a> More and more researchers tend to study multitarget drugs to address the limited efficacy, resistance, and toxicity, related to many single-target or combination-based therapies.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Potential FLT3 dual inhibitors are formed through the coinhibition of FLT3 and another vital target simultaneously (such as PIM, CDKs, Mer, JAK2, Mnks, etc.) to block downstream signal transduction, thereby solving drug resistance and safety.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a><b>Gilteritinib</b> (<b>ASP2215</b>, <b>Xospata</b>), an efficient dual inhibitor against FLT3 and AXL, has been approved by FDA for adults with relapsed and/or refractory AML with FLT3 mutations in 2018. The evaluation criteria of dual inhibitors are becoming more and more reasonable and mature, with in-depth studies of the mechanism of targeted drugs and the accumulation of clinical data.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><div class="NLM_p">To date, covalently irreversible binding TKIs have made important contributions in the field of cancer treatment due to increased target residence time, higher selectivity, and more durable responses over classical reversibly binding inhibitors, while enhanced toxicity of off-targets are additional risks.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The covalent inhibitors, also known as irreversible inhibitors, form covalent bonds with cysteines or other nucleophilic residues in the ATP binding pocket to exert biological functions. <b>Ibrutinib</b> is the first-generation BTK inhibitor and approved by FDA for MCL and CLL in 2013 and 2014, respectively.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Its unsaturated acrylamide group forms a covalent bond with the cysteine residue (Cys481) in the ATP binding pocket of BTK to irreversibly inhibit BTK, thereby effectively preventing tumor from migrating from B cell to lymph tissue adapted to tumor growth environment. <b>FF-10101</b> is a novel irreversible FLT3 inhibitor and displays excellent efficacy against AML cells with FLT3 mutations including <b>quizartinib</b>-resistant activation loop mutations through forming a covalent bond to the Cys695 residue.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The specific binding of <b>FF-10101</b> to FLT3 makes it highly selective and kinase inhibitory, and it is currently in phase II. Owing to the significant clinical benefits of covalent irreversible inhibitors and the vulnerability of FLT3 treatment to drug resistance, irreversible binding FLT3 inhibitors may build confidence for overcoming drug-resistant mutations.</div><div class="NLM_p last">Small-molecule TKIs targeting FLT3 have become an attractive and effective method for the treatment of various malignant tumors. To address drug resistance caused by FLT3 mutations, multitarget FLT3 inhibitors have become the main research direction, and the emergence of irreversible FLT3 inhibitors also provides new ideas for the development of novel FLT3 inhibitors. It is believed that with the deepening research on the molecular expression mechanism of AML, more and more FLT3 inhibitors with excellent activity, high selectivity, and favorable pharmacokinetic characteristics will be gradually developed to provide more possibilities for AML with targeted therapy.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00696" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shan-Liang Sun</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7011-6146" title="Orcid link">http://orcid.org/0000-0001-7011-6146</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f083859e839899919e95b0c1c2c6de939f9d"><span class="__cf_email__" data-cfemail="285b5d465b404149464d68191a1e064b4745">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nian-Guang Li</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5793-6959" title="Orcid link">http://orcid.org/0000-0001-5793-6959</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6dadfd8dfd7d8d1c3d7d8d1f6d8dcc3d5db98d3d2c398d5d8"><span class="__cf_email__" data-cfemail="deb2b7b0b7bfb0b9abbfb0b99eb0b4abbdb3f0bbbaabf0bdb0">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhi-Hao Shi</span> - <span class="hlFld-Affiliation affiliation">Department
of Organic Chemistry, China Pharmaceutical
University, Nanjing 211198, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6827-9533" title="Orcid link">http://orcid.org/0000-0002-6827-9533</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cdbebeb7a5fcfbfe8dfcfbfee3aea2a0"><span class="__cf_email__" data-cfemail="6112121b09505752215057524f020e0c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue Zhong</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Run-Ze Qiu</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Zhao</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tian-Yuan Fan</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Chen</span> - <span class="hlFld-Affiliation affiliation">National
and Local Collaborative Engineering Center of Chinese Medicinal Resources
Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization,
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Yue Zhong</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2848-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yue Zhong</b> received her Bachelor’s degree from Nanjing University of Chinese Medicine in 2018. Currently, she studies for a Master’s degree under the supervision of Professor Nian-Guang Li at Nanjing University of Chinese Medicine. Her Master’s research mainly concentrates on the design, synthesis, and biological evaluations of small-molecule FLT3 inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Run-Ze Qiu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2853-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Run-Ze Qiu</b> received his Bachelor’s and Master’s degrees from Nanjing University of Chinese Medicine in 2016 and 2019, respectively. At present, he is engaged in clinical research at the phase I clinical research center of Nanjing First Hospital. His research mainly focuses on the molecular mechanism of antitumor drugs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Shan-Liang Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2858-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shan-Liang Sun</b> performed his Ph.D. research at Vrije Universiteit Amsterdam on computational prediction of structural protein–ligand interactions, under the supervision of Dr. Chris de Graaf, Prof. Dr. Iwan de Esch, and Prof. Dr. Rob Leurs (2014–2019). Shan-Liang Sun obtained his B. Sc. degree in Information Management and Information System (2006–2010) and his M.Sc. degree in Medicinal Chemistry at China Pharmaceutical University. During his Master’s, he worked on the discovery of Polo-like kinase 1 (PLK1) inhibitors under the supervision of Prof. Dr. Tao Lu (2010–2013). In 2020, Shan-Liang Sun was appointed senior lecturer in the Division Medicinal Chemistry at Nanjing University of Chinese Medicine. In his project, computational techniques are combined with medicinal chemistry approaches to develop novel small-molecule ligands for kinases, especially Fms-like tyrosine kinase-3 (FLT3).</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Chao Zhao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2863-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chao Zhao</b> obtained his Bachelor’s degree from Xiangnan University in 2018. He is currently a postgraduate student at Nanjing University of Chinese Medicine under the supervision of Professor Nian-Guang Li. His research mainly focused on the biological screenings of the FLT3 inhibitors.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Tian-Yuan Fan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2868-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tian-Yuan Fan</b> received his Bachelor’s degree from Hubei University of Traditional Chinese Medicine in 2017. Currently, he is pursuing his Master’s degree under the supervision of Professor Nian-Guang Li at Nanjing University of Chinese Medicine. His research mainly focuses on the synthesis of reversible FLT3 kinase inhibitors.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Min Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2873-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Min Chen</b> received his Bachelor’s degree from Nanjing University of Chinese Medicine in 2019. He is currently a postgraduate student at Nanjing University of Chinese Medicine under the supervision of Professor Nian-Guang Li. His master’s study mainly focuses on the synthesis of covalent and irreversible FLT3 inhibitors based on computer-aided drug design.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Nian-Guang Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2878-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nian-Guang Li</b> obtained his Ph.D. degree (major medicinal chemistry, supervisor Professor Qidong You) from China Pharmaceutical University in 2007. He became a senior lecturer at Nanjing University of Chinese Medicine in 2007 and was promoted to an associate professor three years later. From 2012 to 2013, he was engaged in organic synthesis research in Professor E. J. Corey’s group at Harvard University as a visiting scholar. He was appointed as a professor of medicinal chemistry in 2016. His research interests mainly focus on the identification of small molecules that target FLT3 for acute myeloid leukemia.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Zhi-Hao Shi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=BIO-d7e2883-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhi-Hao Shi</b> obtained her Ph.D. degree (major medicinal chemistry, supervisor Professor Yunyang Wei) from Nanjing University of Science and Technology in 2007. She became a senior lecturer at China Pharmaceutical University in 2007 and was promoted to an associate professor in 2015. From 2015 to 2016, she was engaged in organic synthesis research in professor Mark Lautens’ group at the University of Toronto as a visiting scholar. Her research interests mainly focus on the design and synthesis of small molecule inhibitors that target tyrosine receptor kinase for cancer.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was financially supported by National Natural Science Foundation of China (81973171), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX20_1561, SJCX20_0533), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, Project Funded by the Flagship Major Development of Jiangsu Higher Education Institutions (PPZY2015A070), Key Laboratory of Therapeutic Material of Chinese Medicine, Jiangsu Province, and State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">Fms-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">HSC</td><td class="NLM_def"><p class="first last">hematopoietic stem cell</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor</p></td></tr><tr><td class="NLM_term">ECD</td><td class="NLM_def"><p class="first last">extracellular domain</p></td></tr><tr><td class="NLM_term">TMD</td><td class="NLM_def"><p class="first last">transmembrane domain</p></td></tr><tr><td class="NLM_term">JMD</td><td class="NLM_def"><p class="first last">juxtamembrane domain</p></td></tr><tr><td class="NLM_term">TKD</td><td class="NLM_def"><p class="first last">tyrosine kinase domain</p></td></tr><tr><td class="NLM_term">FL</td><td class="NLM_def"><p class="first last">FLT3 ligand</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplication</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte-macrophage colony stimulating factor</p></td></tr><tr><td class="NLM_term">MPN</td><td class="NLM_def"><p class="first last">myeloproliferative neoplasm</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">NRAS</td><td class="NLM_def"><p class="first last">neuroblastoma RAS</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">Kirsten RAS</p></td></tr><tr><td class="NLM_term">HRAS</td><td class="NLM_def"><p class="first last">Harvey RAS</p></td></tr><tr><td class="NLM_term">PIP3</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PDK1</td><td class="NLM_def"><p class="first last">3-phosphoinositide dependent kinase 1</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">PMDA</td><td class="NLM_def"><p class="first last">Pharmaceuticals and Medical Devices Agency</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">protein kinase</p></td></tr><tr><td class="NLM_term">PIM</td><td class="NLM_def"><p class="first last">proviral integration site for Moloney murine leukemia virus</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">CSF-1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">IKKβ</td><td class="NLM_def"><p class="first last">IκB kinase β</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">Mnk</td><td class="NLM_def"><p class="first last">MAP kinase-interacting kinase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 150 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisdorf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1406184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1056%2FNEJMra1406184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26376137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1136-1152&author=H.+D%C3%B6hnerauthor=D.+J.+Weisdorfauthor=C.+D.+Bloomfield&title=Acute+myeloid+leukemia&doi=10.1056%2FNEJMra1406184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia</span></div><div class="casAuthors">Dohner Hartmut; Weisdorf Daniel J; Bloomfield Clara D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1136-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7_lmkXqa4eckU0YCbOU3EfW6udTcc2eb3QE0WsuSusrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D&md5=a22a9f8b7b0e31e1084d2e76281bb35a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1406184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1406184%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DWeisdorf%26aufirst%3DD.%2BJ.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1136%26epage%3D1152%26doi%3D10.1056%2FNEJMra1406184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Short, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytting, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukaemia</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31041-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS0140-6736%2818%2931041-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30078459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=593-606&author=N.+J.+Shortauthor=M.+E.+Ryttingauthor=J.+E.+Cortes&title=Acute+myeloid+leukaemia&doi=10.1016%2FS0140-6736%2818%2931041-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukaemia</span></div><div class="casAuthors">Short Nicholas J; Rytting Michael E; Cortes Jorge E</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10147</span>),
    <span class="NLM_cas:pages">593-606</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia.  However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval.  In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies.  Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease.  Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-2ehJOMY27yA3UY9EwTNrfW6udTcc2eb3QE0WsuSusrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D&md5=212ad7a55f4f9e1e1d90f2e265987f3c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931041-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931041-9%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DN.%2BJ.%26aulast%3DRytting%26aufirst%3DM.%2BE.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DAcute%2520myeloid%2520leukaemia%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D593%26epage%3D606%26doi%3D10.1016%2FS0140-6736%2818%2931041-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prada-Arismendy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arroyave, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röthlisberger, S.</span></span> <span> </span><span class="NLM_article-title">Molecular biomarkers in acute myeloid leukemia</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.blre.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27639498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVylu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=63-76&author=J.+Prada-Arismendyauthor=J.+C.+Arroyaveauthor=S.+R%C3%B6thlisberger&title=Molecular+biomarkers+in+acute+myeloid+leukemia&doi=10.1016%2Fj.blre.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biomarkers in acute myeloid leukemia</span></div><div class="casAuthors">Prada-Arismendy, Jeanette; Arroyave, Johanna C.; Rothlisberger, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-76</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common acute leukemia in adults.  The pathophysiol. of this disease is just beginning to be understood at the cellular and mol. level, and currently cytogenetic markers are the most important for risk stratification and treatment of AML patients.  However, with the advent of new technologies, the detection of other mol. markers such as point mutations and characterization of epigenetic and proteomic profiles, have begun to play an important role in how the disease is approached.  Recent evidence shows that the identification of new AML biomarkers contributes to a better understanding of the mol. basis of the disease, is significantly useful in screening, diagnosis, prognosis and monitoring of AML, as well as the possibility of predicting each individual's response to treatment.  This review summarizes the most relevant mol. (genetic, epigenetic, and protein) biomarkers assocd. with acute myeloid leukemia and discusses their clin. importance in terms of risk prediction, diagnosis and prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFTaiBaPaanLVg90H21EOLACvtfcHk0lhMDTxPML4p4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVylu7jL&md5=34a5288290d85a69b4ac348d15c43009</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DPrada-Arismendy%26aufirst%3DJ.%26aulast%3DArroyave%26aufirst%3DJ.%2BC.%26aulast%3DR%25C3%25B6thlisberger%26aufirst%3DS.%26atitle%3DMolecular%2520biomarkers%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Rev.%26date%3D2017%26volume%3D31%26spage%3D63%26epage%3D76%26doi%3D10.1016%2Fj.blre.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maness, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shami, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogba, N.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology</span>. <i>J. Natl. Compr. Cancer Network</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.6004/jnccn.2017.0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.6004%2Fjnccn.2017.0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28687581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=926-957&author=M.+R.+O%E2%80%99Donnellauthor=M.+S.+Tallmanauthor=C.+N.+Abboudauthor=J.+K.+Altmanauthor=F.+R.+Appelbaumauthor=D.+A.+Arberauthor=V.+Bhattauthor=D.+Bixbyauthor=W.+Blumauthor=S.+E.+Coutreauthor=M.+De+Limaauthor=A.+T.+Fathiauthor=M.+Fiorellaauthor=J.+M.+Foranauthor=S.+D.+Goreauthor=A.+C.+Hallauthor=P.+Kropfauthor=J.+Lancetauthor=L.+J.+Manessauthor=G.+Marcucciauthor=M.+G.+Martinauthor=J.+O.+Mooreauthor=R.+Olinauthor=D.+Pekerauthor=D.+A.+Pollyeaauthor=K.+Pratzauthor=F.+Ravandiauthor=P.+J.+Shamiauthor=R.+M.+Stoneauthor=S.+A.+Stricklandauthor=E.+S.+Wangauthor=M.+Wieduwiltauthor=K.+Gregoryauthor=N.+Ogba&title=Acute+myeloid+leukemia%2C+version+3.2017%2C+NCCN+clinical+practice+guidelines+in+oncology&doi=10.6004%2Fjnccn.2017.0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology</span></div><div class="casAuthors">O'Donnell Margaret R; Tallman Martin S; Abboud Camille N; Altman Jessica K; Appelbaum Frederick R; Arber Daniel A; Bhatt Vijaya; Bixby Dale; Blum William; Coutre Steven E; De Lima Marcos; Fathi Amir T; Fiorella Melanie; Foran James M; Gore Steven D; Hall Aric C; Kropf Patricia; Lancet Jeffrey; Maness Lori J; Marcucci Guido; Martin Michael G; Moore Joseph O; Olin Rebecca; Peker Deniz; Pollyea Daniel A; Pratz Keith; Ravandi Farhad; Shami Paul J; Stone Richard M; Strickland Stephen A; Wang Eunice S; Wieduwilt Matthew; Gregory Kristina; Ogba Ndiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network : JNCCN</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-957</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.  This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2aszz8ssiQXl8icjszYl0fW6udTcc2eaL9VPMT4SKxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D&md5=6d087e673a8e9556532bdede9151f2e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.6004%2Fjnccn.2017.0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6004%252Fjnccn.2017.0116%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BR.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DAbboud%26aufirst%3DC.%2BN.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DBhatt%26aufirst%3DV.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DDe%2BLima%26aufirst%3DM.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DFiorella%26aufirst%3DM.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DHall%26aufirst%3DA.%2BC.%26aulast%3DKropf%26aufirst%3DP.%26aulast%3DLancet%26aufirst%3DJ.%26aulast%3DManess%26aufirst%3DL.%2BJ.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%2BG.%26aulast%3DMoore%26aufirst%3DJ.%2BO.%26aulast%3DOlin%26aufirst%3DR.%26aulast%3DPeker%26aufirst%3DD.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DPratz%26aufirst%3DK.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DShami%26aufirst%3DP.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DWieduwilt%26aufirst%3DM.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DOgba%26aufirst%3DN.%26atitle%3DAcute%2520myeloid%2520leukemia%252C%2520version%25203.2017%252C%2520NCCN%2520clinical%2520practice%2520guidelines%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2017%26volume%3D15%26spage%3D926%26epage%3D957%26doi%3D10.6004%2Fjnccn.2017.0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2020</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3322%2Fcaac.21590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31912902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3Mbns1emug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2020&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2020&doi=10.3322%2Fcaac.21590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2020</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence.  Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data (through 2017) were collected by the National Center for Health Statistics.  In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States.  The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted.  This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer.  In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017.  Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined.  Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013.  It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men.  In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOzlnUMKF5EwlCcfExbvbfW6udTcc2eaL9VPMT4SKxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mbns1emug%253D%253D&md5=a54b884bbc3c3f592921026db34b29db</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21590%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202020%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2020%26volume%3D70%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papaemmanuil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Loo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martincorena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greaves, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. J.</span></span> <span> </span><span class="NLM_article-title">Genomic classification and prognosis in acute myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">2209</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1516192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1056%2FNEJMoa1516192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27276561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1aisbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=2209-2221&author=E.+Papaemmanuilauthor=M.+Gerstungauthor=L.+Bullingerauthor=V.+I.+Gaidzikauthor=P.+Paschkaauthor=N.+D.+Robertsauthor=N.+E.+Potterauthor=M.+Heuserauthor=F.+Tholauthor=N.+Bolliauthor=G.+Gundemauthor=P.+Van+Looauthor=I.+Martincorenaauthor=P.+Ganlyauthor=L.+Mudieauthor=S.+McLarenauthor=S.+O%E2%80%99Mearaauthor=K.+Raineauthor=D.+R.+Jonesauthor=J.+W.+Teagueauthor=A.+P.+Butlerauthor=M.+F.+Greavesauthor=A.+Ganserauthor=K.+D%C3%B6hnerauthor=R.+F.+Schlenkauthor=H.+D%C3%B6hnerauthor=P.+J.+Campbell&title=Genomic+classification+and+prognosis+in+acute+myeloid+leukemia&doi=10.1056%2FNEJMoa1516192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic classification and prognosis in acute myeloid leukemia</span></div><div class="casAuthors">Papaemmanuil, Elli; Gerstung, Moritz; Bullinger, Lars; Gaidzik, Verena I.; Paschka, Peter; Roberts, Nicola D.; Potter, Nicola E.; Heuser, Michael; Thol, Felicitas; Bolli, Niccolo; Gundem, Gunes; Van Loo, Peter; Martincorena, Inigo; Ganly, Peter; Mudie, Laura; McLaren, Stuart; O'Meara, Sarah; Raine, Keiran; Jones, David R.; Teague, Jon W.; Butler, Adam P.; Greaves, Mel F.; Ganser, Arnold; Dohner, Konstanze; Schlenk, Richard F.; Dohner, Hartmut; Campbell, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2209-2221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML).  Our next challenge is to understand how this genetic diversity defines the pathophysiol. of AML and informs clin. practice. methods We enrolled a total of 1540 patients in three prospective trials of intensive therapy.  Combining driver mutations in 111 cancer genes with cytogenetic and clin. data, we defined AML genomic subgroups and their relevance to clin. outcomes.  Results: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients.  Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clin. outcomes.  In addn. to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2R172 mutations (in 1%).  Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome.  In addn. to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival.  The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations.  Such gene-gene interactions were esp. pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis.  These predictions require validation in prospective clin. trials. conclusions The driver landscape in AML reveals distinct mol. subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVvMgDMgsgpLVg90H21EOLACvtfcHk0lg-bZynGjB4Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1aisbbK&md5=848f1c0d24f22b2178d93eac75609301</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1516192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1516192%26sid%3Dliteratum%253Aachs%26aulast%3DPapaemmanuil%26aufirst%3DE.%26aulast%3DGerstung%26aufirst%3DM.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DN.%2BD.%26aulast%3DPotter%26aufirst%3DN.%2BE.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DBolli%26aufirst%3DN.%26aulast%3DGundem%26aufirst%3DG.%26aulast%3DVan%2BLoo%26aufirst%3DP.%26aulast%3DMartincorena%26aufirst%3DI.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DMudie%26aufirst%3DL.%26aulast%3DMcLaren%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DS.%26aulast%3DRaine%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DTeague%26aufirst%3DJ.%2BW.%26aulast%3DButler%26aufirst%3DA.%2BP.%26aulast%3DGreaves%26aufirst%3DM.%2BF.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26atitle%3DGenomic%2520classification%2520and%2520prognosis%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D2209%26epage%3D2221%26doi%3D10.1056%2FNEJMoa1516192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0357-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fs41375-018-0357-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30651634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=299-312&author=N.+Daverauthor=R.+F.+Schlenkauthor=N.+H.+Russellauthor=M.+J.+Levis&title=Targeting+FLT3+mutations+in+AML%3A+review+of+current+knowledge+and+evidence&doi=10.1038%2Fs41375-018-0357-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span></div><div class="casAuthors">Daver, Naval; Schlenk, Richard F.; Russell, Nigel H.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets.  Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approx. 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approx. 25% of all AML cases).  FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML.  The prognostic value of a FLT3 mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approx. 7-10% of all cases), is uncertain.  Accumulating evidence demonstrates that FLT3 mutational status evolves throughout the disease continuum.  This so-called clonal evolution, together with the identification of FLT3-ITD as a neg. prognostic marker, serves to highlight the importance of FLT3-ITD testing at diagnosis and again at relapse.  Earlier identification of FLT3 mutations will help provide a better understanding of the patient's disease and enable targeted treatment that may help patients achieve longer and more durable remissions.  First-generation FLT3 inhibitors developed for clin. use are broad-spectrum, multikinase inhibitors; however, next-generation FLT3 inhibitors are more specific, more potent, and have fewer toxicities assocd. with off-target effects.  Primary and secondary acquired resistance to FLT3 inhibitors remains a challenge and provides a rationale for combining FLT3 inhibitors with other therapies, both conventional and investigational.  This review focuses on the pathol. and prognostic role of FLT3 mutations in AML, clin. classification of the disease, recent progress with next-generation FLT3 inhibitors, and mechanisms of resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjK_p2nZ_9j7Vg90H21EOLACvtfcHk0lg-bZynGjB4Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI&md5=25ea007d2f7b670aaddeb02866f15c69</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0357-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0357-9%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520FLT3%2520mutations%2520in%2520AML%253A%2520review%2520of%2520current%2520knowledge%2520and%2520evidence%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D299%26epage%3D312%26doi%3D10.1038%2Fs41375-018-0357-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span> <span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazakiauthor=H.+Akiyamaauthor=K.+Saitoauthor=M.+Nishimuraauthor=T.+Motojiauthor=K.+Shinagawaauthor=A.+Takeshitaauthor=H.+Saitoauthor=R.+Uedaauthor=R.+Ohnoauthor=T.+Naoe&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0lit4TZBovTxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DMotoji%26aufirst%3DT.%26aulast%3DShinagawa%26aufirst%3DK.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DOhno%26aufirst%3DR.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsapogas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolink, A.</span></span> <span> </span><span class="NLM_article-title">The cytokine Flt3-ligand in normal and malignant hematopoiesis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1115</span>, <span class="refDoi"> DOI: 10.3390/ijms18061115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3390%2Fijms18061115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOjt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1115&author=P.+Tsapogasauthor=C.+J.+Mooneyauthor=G.+Brownauthor=A.+Rolink&title=The+cytokine+Flt3-ligand+in+normal+and+malignant+hematopoiesis&doi=10.3390%2Fijms18061115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine Flt3-ligand in normal and malignant hematopoiesis</span></div><div class="casAuthors">Tsapogas, Panagiotis; Mooney, Ciaran James; Brown, Geoffrey; Rolink, Antonius</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1115/1-1115/23</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The cytokine Fms-like tyrosine kinase 3 ligand (FL) is an important regulator of hematopoiesis.  Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages.  Activating mutations of Flt3 are frequently found in acute myeloid leukemia (AML) patients and assocd. with a poor clin. prognosis.  In the present review we provide an overview of our current knowledge on the role of FL in the generation of blood cell lineages.  We examine recent studies on Flt3 expression by hematopoietic stem cells and its potential instructive action at early stages of hematopoiesis.  In addn., we review current findings on the role of mutated FLT3 in leukemia and the development of FLT3 inhibitors for therapeutic use to treat AML.  The importance of mouse models in elucidating the role of Flt3-ligand in normal and malignant hematopoiesis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZAD7KNkGLsLVg90H21EOLACvtfcHk0lit4TZBovTxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOjt7zN&md5=30f9d6538ba9b7ec92d75353a384f270</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fijms18061115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18061115%26sid%3Dliteratum%253Aachs%26aulast%3DTsapogas%26aufirst%3DP.%26aulast%3DMooney%26aufirst%3DC.%2BJ.%26aulast%3DBrown%26aufirst%3DG.%26aulast%3DRolink%26aufirst%3DA.%26atitle%3DThe%2520cytokine%2520Flt3-ligand%2520in%2520normal%2520and%2520malignant%2520hematopoiesis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1115%26doi%3D10.3390%2Fijms18061115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstraete, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandriessche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Januar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elegheert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shkumatov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desfosses, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Craenenbroeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svergun, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutsche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savvides, S. N.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-01-329532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2011-01-329532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=21389326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=60-68&author=K.+Verstraeteauthor=G.+Vandriesscheauthor=M.+Januarauthor=J.+Elegheertauthor=A.+V.+Shkumatovauthor=A.+Desfossesauthor=K.+Van+Craenenbroeckauthor=D.+I.+Svergunauthor=I.+Gutscheauthor=B.+Vergauwenauthor=S.+N.+Savvides&title=Structural+insights+into+the+extracellular+assembly+of+the+hematopoietic+Flt3+signaling+complex&doi=10.1182%2Fblood-2011-01-329532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex</span></div><div class="casAuthors">Verstraete, Kenneth; Vandriessche, Gonzalez; Januar, Mariska; Elegheert, Jonathan; Shkumatov, Alexander V.; Desfosses, Ambroise; Van Craenenbroeck, Kathleen; Svergun, Dmitri I.; Gutsche, Irina; Vergauwen, Bjorn; Savvides, Savvas N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-68</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The class III receptor tyrosine kinase (RTKIII) Fms-like tyrosine kinase receptor 3 (Flt3) and its cytokine ligand (FL) play central roles in hematopoiesis and the immune system, by establishing signaling cascades crucial for the development and homeostasis of hematopoietic progenitors and antigen-presenting dendritic cells.  However, Flt3 is also one of the most frequently mutated receptors in hematol. malignancies and is currently a major prognostic factor and clin. target for acute myeloid leukemia.  Here, we report the structural basis for the Flt3 ligand-receptor complex and unveil an unanticipated extracellular assembly unlike any other RTKIII/V complex characterized to date.  FL induces dimerization of Flt3 via a remarkably compact binding epitope localized at the tip of extracellular domain 3 of Flt3, and it invokes a ternary complex devoid of homeotypic receptor interactions.  Comparisons of Flt3 with homologous receptors and available mutagenesis data for FL have allowed us to rationalize the unique features of the Flt3 extracellular assembly.  Furthermore, thermodn. dissection of complex formation points to a pronounced enthalpically driven binding event coupled to an entropic penalty.  Together, our data suggest that the high-affinity Flt3:FL complex is driven in part by a single preformed binding epitope on FL reminiscent of a "lock-and-key" binding mode, thereby setting the stage for antagonist design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF8FAW5sscnbVg90H21EOLACvtfcHk0lh5xcki7NnQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSnt70%253D&md5=ae5624cf7885929c65436fe7524cc42d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-01-329532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-01-329532%26sid%3Dliteratum%253Aachs%26aulast%3DVerstraete%26aufirst%3DK.%26aulast%3DVandriessche%26aufirst%3DG.%26aulast%3DJanuar%26aufirst%3DM.%26aulast%3DElegheert%26aufirst%3DJ.%26aulast%3DShkumatov%26aufirst%3DA.%2BV.%26aulast%3DDesfosses%26aufirst%3DA.%26aulast%3DVan%2BCraenenbroeck%26aufirst%3DK.%26aulast%3DSvergun%26aufirst%3DD.%2BI.%26aulast%3DGutsche%26aufirst%3DI.%26aulast%3DVergauwen%26aufirst%3DB.%26aulast%3DSavvides%26aufirst%3DS.%2BN.%26atitle%3DStructural%2520insights%2520into%2520the%2520extracellular%2520assembly%2520of%2520the%2520hematopoietic%2520Flt3%2520signaling%2520complex%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D60%26epage%3D68%26doi%3D10.1182%2Fblood-2011-01-329532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faerman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span> <span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(03)00505-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain&doi=10.1016%2FS1097-2765%2803%2900505-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lh5xcki7NnQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178%26doi%3D10.1016%2FS1097-2765%2803%2900505-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">STAT signaling in the pathogenesis and treatment of myeloid malignancies</span>. <i>JAKSTAT.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.4161/jkst.20006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.4161%2Fjkst.20006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24058751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt1yjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=55-64&author=M.+Bar-Natanauthor=E.+A.+Nelsonauthor=M.+Xiangauthor=D.+A.+Frank&title=STAT+signaling+in+the+pathogenesis+and+treatment+of+myeloid+malignancies&doi=10.4161%2Fjkst.20006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">STAT signaling in the pathogenesis and treatment of myeloid malignancies</span></div><div class="casAuthors">Bar-Natan Michal; Nelson Erik A; Xiang Michael; Frank David A</div><div class="citationInfo"><span class="NLM_cas:title">JAK-STAT</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">55-64</span>
        ISSN:<span class="NLM_cas:issn">2162-3988</span>.
    </div><div class="casAbstract">STAT transcription factors play a critical role in mediating the effects of cytokines on myeloid cells.  As STAT target genes control key processes such as survival, proliferation and self-renewal, it is not surprising that constitutive activation of STATs, particularly STAT3 and STAT5, are common events in many myeloid tumors.  STATs are activated both by mutant tyrosine kinases as well as other pathogenic events, and continued activation of STATs is common in the setting of resistance to kinase inhibitors.  Thus, the targeting of STATs, alone or in combination with other drugs, will likely have increasing importance for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4U-tZwxXjRaNc3HjJRoFAfW6udTcc2eZr1B9dylR-V7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt1yjug%253D%253D&md5=e6bda357c68734bfd953780733bf918f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4161%2Fjkst.20006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.20006%26sid%3Dliteratum%253Aachs%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DSTAT%2520signaling%2520in%2520the%2520pathogenesis%2520and%2520treatment%2520of%2520myeloid%2520malignancies%26jtitle%3DJAKSTAT.%26date%3D2012%26volume%3D1%26spage%3D55%26epage%3D64%26doi%3D10.4161%2Fjkst.20006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamborini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virdis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsenigo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stacchiotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotti, S.</span></span> <span> </span><span class="NLM_article-title">Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1093/neuonc/noq003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1093%2Fneuonc%2Fnoq003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=20164240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFSlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=776-789&author=E.+Tamboriniauthor=E.+Virdisauthor=T.+Negriauthor=M.+Orsenigoauthor=S.+Brichauthor=E.+Concaauthor=A.+Gronchiauthor=S.+Stacchiottiauthor=G.+Manentiauthor=P.+G.+Casaliauthor=M.+A.+Pierottiauthor=S.+Pilotti&title=Analysis+of+receptor+tyrosine+kinases+%28RTKs%29+and+downstream+pathways+in+chordomas&doi=10.1093%2Fneuonc%2Fnoq003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas</span></div><div class="casAuthors">Tamborini, Elena; Virdis, Emanuela; Negri, Tiziana; Orsenigo, Marta; Brich, Silvia; Conca, Elena; Gronchi, Alessandro; Stacchiotti, Silvia; Manenti, Giacomo; Casali, Paolo G.; Pierotti, Marco A.; Pilotti, Silvana</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">776-789</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a no. of patients.  The aim of this study was to identify the possible presence of other activated RTKs and their downstream signaling effectors.  Cryopreserved material from 22 naive sporadic chordomas was investigated for the presence of activated RTKs and their cognate ligands and downstream signaling effectors by means of human phospho-RTK antibody arrays, Western blotting, and mol. anal.; immunohistochem. and fluorescence in situ hybridization were used to analyze the corresponding formalin-fixed and paraffin-embedded samples.  We detected activated PDGFRB, FLT3, and colony stimulating factor 1 receptor (CSF1R) of the PDGFR family and highly phosphorylated EGFR, HER2/neu, and (to a lesser extent) HER4 of the EGFR family.  The detection of PDGFRB/PDGFB confirmed our previous data.  The presence of activated EGFR was paralleled by the finding of high levels of epidermal growth factor (EGF) and transforming growth factor α (TGFα) and PDGFB co-expression and PDGFRB co-immunopptn.  Of the downstream effectors, the PI3K/AKT and RAS/MAPK pathways were both activated, thus leading to the phosphorylation of mammalian target of rapamycin (mTOR) and 4E-BP1 among the regulators involved in translational control.  Taken together, our results (i) provide a rationale for tailored treatments targeting upstream activated receptors, including the PDGFR and EGFR families; (ii) support the idea that a combination of upstream antagonists and mTOR inhibitors enhances the control of tumor growth; and (iii) indicate that the 4E-BP1/eIF4E pathway is a major regulator of protein synthesis in chordoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOgC0XrB2e1rVg90H21EOLACvtfcHk0ljE1lZ4xYIUrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFSlt7s%253D&md5=ad5f408f200ab2aa9b2a58b7288815e9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnoq003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnoq003%26sid%3Dliteratum%253Aachs%26aulast%3DTamborini%26aufirst%3DE.%26aulast%3DVirdis%26aufirst%3DE.%26aulast%3DNegri%26aufirst%3DT.%26aulast%3DOrsenigo%26aufirst%3DM.%26aulast%3DBrich%26aufirst%3DS.%26aulast%3DConca%26aufirst%3DE.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DStacchiotti%26aufirst%3DS.%26aulast%3DManenti%26aufirst%3DG.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DPilotti%26aufirst%3DS.%26atitle%3DAnalysis%2520of%2520receptor%2520tyrosine%2520kinases%2520%2528RTKs%2529%2520and%2520downstream%2520pathways%2520in%2520chordomas%26jtitle%3DNeuro%2520Oncol.%26date%3D2010%26volume%3D12%26spage%3D776%26epage%3D789%26doi%3D10.1093%2Fneuonc%2Fnoq003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönnstrand, L.</span></span> <span> </span><span class="NLM_article-title">FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1433</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1152/physrev.00029.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1152%2Fphysrev.00029.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31066629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGlurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2019&pages=1433-1466&author=J.+U.+Kaziauthor=L.+R%C3%B6nnstrand&title=FMS-like+tyrosine+kinase+3%2FFLT3%3A+from+basic+science+to+clinical+implications&doi=10.1152%2Fphysrev.00029.2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications</span></div><div class="casAuthors">Kazi, Julhash U.; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1433-1466</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">1522-1210</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is expressed almost exclusively in the hematopoietic compartment.  Its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity.  Activation of FLT3 leads to its autophosphorylation and initiation of several signal transduction cascades.  Signaling is initiated by the recruitment of signal transduction mols. to activated FLT3 through binding to specific phosphorylated tyrosine residues in the intracellular region of FLT3.  Activation of FLT3 mediates cell survival, cell proliferation, and differentiation of hematopoietic progenitor cells.  It acts in synergy with several other cytokines to promote its biol. effects.  Deregulated FLT3 activity has been implicated in several diseases, most prominently in acute myeloid leukemia where around one-third of patients carry an activating mutant of FLT3 which drives the disease and is correlated with poor prognosis.  Overactivity of FLT3 has also been implicated in autoimmune diseases, such as rheumatoid arthritis.  The observation that gain-of-function mutations of FLT3 can promote leukemogenesis has stimulated the development of inhibitors that target this receptor.  Many of these are in clin. trials, and some have been approved for clin. use.  However, problems with acquired resistance to these inhibitors are common and, furthermore, only a fraction of patients respond to these selective treatments.  This review provides a summary of our current knowledge regarding structural and functional aspects of FLT3 signaling, both under normal and pathol. conditions, and discusses challenges for the future regarding the use of targeted inhibition of these pathways for the treatment of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfuVERCf3VnLVg90H21EOLACvtfcHk0lh8WWxwcaJYDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGlurrE&md5=ed99d5ecf4de02acb8196801e4e66e6a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00029.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00029.2018%26sid%3Dliteratum%253Aachs%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26atitle%3DFMS-like%2520tyrosine%2520kinase%25203%252FFLT3%253A%2520from%2520basic%2520science%2520to%2520clinical%2520implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2019%26volume%3D99%26spage%3D1433%26epage%3D1466%26doi%3D10.1152%2Fphysrev.00029.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, S.</span></span> <span> </span><span class="NLM_article-title">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+flt3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2eZY7O11XtiTmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520flt3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrintseva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vempati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnittger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwart, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfner, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span> <span> </span><span class="NLM_article-title">Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3700</span>– <span class="NLM_lpage">3707</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-06-2596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2005-06-2596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16410449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3700-3707&author=C.+Reindlauthor=K.+Bagrintsevaauthor=S.+Vempatiauthor=S.+Schnittgerauthor=J.+W.+Ellwartauthor=K.+Wenigauthor=K.+P.+Hopfnerauthor=W.+Hiddemannauthor=K.+Spiekermann&title=Point+mutations+in+the+juxtamembrane+domain+of+FLT3+define+a+new+class+of+activating+mutations+in+AML&doi=10.1182%2Fblood-2005-06-2596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML</span></div><div class="casAuthors">Reindl, Carola; Bagrintseva, Ksenia; Vempati, Sridhar; Schnittger, Susanne; Ellwart, Joachim W.; Wenig, Katja; Hopfner, Karl-Peter; Hiddemann, Wolfgang; Spiekermann, Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3700-3707</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In acute myeloid leukemia (AML), two clusters of activating mutations are known in the FMS-like tyrosine kinase-3 (FLT3) gene: FLT3-internal tandem duplications (FLT3-ITDs) in the juxtamembrane (JM) domain in 20% to 25% of patients, and FLT3 point mutations in the tyrosine-kinase domain (FLT3-TKD) in 7% to 10% of patients, resp.  Here, we have characterized a new class of activating point mutations (PMs) that cluster in a 16-amino acid stretch of the juxtamembrane domain of FLT3 (FLT3-JM-PMs).  Expression of 4 FLT3-JM-PMs in interleukin-3 (IL-3)-dependent Ba/F3 cells led to factor-independent growth, hyperresponsiveness to FLT3 ligand, and resistance to apoptotic cell death.  FLT3-JM-PM receptors were autophosphorylated and showed a higher constitutive dimerization rate compared with the FLT3-wild-type (WT) receptor.  As a mol. mechanism, we could show activation of STAT5 and up-regulation of Bcl-x(L) by all FLT3-JM-PMs.  The FLT3 inhibitor PKC412 abrogated the factor-independent growth of FLT3-JM-PM-expressing cells.  Compared with FLT3-ITD and FLT3-TKD mutants, the FLT3-JM-PMs showed a weaker transforming potential related to lower autophosphorylation of the receptor and its downstream target STAT5.  Mapping of the FLT3-JM-PMs on the crystal structure of FLT3 showed that these mutations reduce the stability of the autoinhibitory JM domain, and provides a structural basis for the transforming capacity of this new class of gain-of-function mutations of FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXOXwmMIS-7Vg90H21EOLACvtfcHk0ljSAYKIO9auUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7w%253D&md5=1ce45965aa65d75fb434eec4c09eb3bf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-06-2596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-06-2596%26sid%3Dliteratum%253Aachs%26aulast%3DReindl%26aufirst%3DC.%26aulast%3DBagrintseva%26aufirst%3DK.%26aulast%3DVempati%26aufirst%3DS.%26aulast%3DSchnittger%26aufirst%3DS.%26aulast%3DEllwart%26aufirst%3DJ.%2BW.%26aulast%3DWenig%26aufirst%3DK.%26aulast%3DHopfner%26aufirst%3DK.%2BP.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DSpiekermann%26aufirst%3DK.%26atitle%3DPoint%2520mutations%2520in%2520the%2520juxtamembrane%2520domain%2520of%2520FLT3%2520define%2520a%2520new%2520class%2520of%2520activating%2520mutations%2520in%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3700%26epage%3D3707%26doi%3D10.1182%2Fblood-2005-06-2596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-12-2087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23209034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=327-335&author=H.+J.+Leeauthor=N.+Daverauthor=H.+M.+Kantarjianauthor=S.+Verstovsekauthor=F.+Ravandi&title=The+role+of+JAK+pathway+dysregulation+in+the+pathogenesis+and+treatment+of+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-12-2087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Lee, Hun Ju; Daver, Naval; Kantarjian, Hagop M.; Verstovsek, Srdan; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-335</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase 2 (JAK2) V617F mutation has improved our understanding of the pathophysiol. of myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.  Before discovery of the JAK2 V617F mutation, there were no specific targeted therapies for patients with myeloproliferative neoplasms.  More recently, several small-mol. inhibitors have been developed that have shown therapeutic potential in the clin. setting.  There is evidence that the JAK2 pathway is dysregulated in some acute myeloid leukemias and may also represent a novel therapeutic target in this disease.  In this review, we describe the preclin., clin., and pathophysiol. evidence for using JAK inhibitors in the treatment of acute myeloid leukemias.  Clin Cancer Res; 19(2); 327-35. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVJg_eZ3d87Vg90H21EOLACvtfcHk0ljSAYKIO9auUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CgtL8%253D&md5=be1e8c2c096a02b0c331263f2e2b6911</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2087%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DThe%2520role%2520of%2520JAK%2520pathway%2520dysregulation%2520in%2520the%2520pathogenesis%2520and%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D327%26epage%3D335%26doi%3D10.1158%2F1078-0432.CCR-12-2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0lixX9abFEji1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eghtedar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faderl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">4614</span>– <span class="NLM_lpage">4618</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-12-400051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2011-12-400051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22422826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVKhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=4614-4618&author=A.+Eghtedarauthor=S.+Verstovsekauthor=Z.+Estrovauthor=J.+Burgerauthor=J.+Cortesauthor=C.+Bivinsauthor=S.+Faderlauthor=A.+Ferrajoliauthor=G.+Borthakurauthor=S.+Georgeauthor=P.+A.+Scherleauthor=R.+C.+Newtonauthor=H.+M.+Kantarjianauthor=F.+Ravandi&title=Phase+2+study+of+the+JAK+kinase+inhibitor+ruxolitinib+in+patients+with+refractory+leukemias%2C+including+postmyeloproliferative+neoplasm+acute+myeloid+leukemia&doi=10.1182%2Fblood-2011-12-400051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia</span></div><div class="casAuthors">Eghtedar, Alireza; Verstovsek, Srdan; Estrov, Zeev; Burger, Jan; Cortes, Jorge; Bivins, Carol; Faderl, Stefan; Ferrajoli, Alessandra; Borthakur, Gautam; George, Solly; Scherle, Peggy A.; Newton, Robert C.; Kantarjian, Hagop M.; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4614-4618</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias.  Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 wk (1 cycle).  Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression.  Dose escalation to 50 mg twice daily was permitted in patients demonstrating a benefit.  Thirty-eight patients, with a median age of 69 years (range, 45-88), were treated.  The median no. of prior therapies was 2 (range, 1-6).  Twelve patients had JAK2V617F mutation.  Patients received a median of 2 cycles of therapy (range, 1-22).  Three of 18 patients with postmyeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) showed a significant response; 2 achieved complete remission (CR) and one achieved a CR with insufficient recovery of blood counts (CRi).  The responding patients with palpable spleens also had significant redns. in spleen size.  Overall, ruxolitinib was very well tolerated with only 4 patients having grade 3 or higher toxicity.  Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtWHaQZwqMqLVg90H21EOLACvtfcHk0lixX9abFEji1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVKhur4%253D&md5=e87c29333ee00b38ff6b33ae9f7fe8e3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-12-400051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-12-400051%26sid%3Dliteratum%253Aachs%26aulast%3DEghtedar%26aufirst%3DA.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DBurger%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DBivins%26aufirst%3DC.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DPhase%25202%2520study%2520of%2520the%2520JAK%2520kinase%2520inhibitor%2520ruxolitinib%2520in%2520patients%2520with%2520refractory%2520leukemias%252C%2520including%2520postmyeloproliferative%2520neoplasm%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D4614%26epage%3D4618%26doi%3D10.1182%2Fblood-2011-12-400051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1933</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-12-0284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23406773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1933-1940&author=A.+Quint%C3%A1s-Cardamaauthor=S.+Verstovsek&title=Molecular+pathways%3A+Jak%2FSTAT+pathway%3A+mutations%2C+inhibitors%2C+and+resistance&doi=10.1158%2F1078-0432.CCR-12-0284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1933-1940</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease states, including inflammatory conditions, hematol. malignancies, and solid tumors.  For instance, a large proportion of patients with myeloproliferative neoplasms (MPN) carry the acquired gain-of-function JAK2 V617F somatic mutation.  This knowledge has dramatically improved our understanding of the pathogenesis of MPNs and has facilitated the development of therapeutics capable of suppressing the constitutive activation of the JAK/STAT pathway, now recognized as a common underlying biol. abnormality in MPNs.  Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematol. malignancies.  A series of agents with different specificities against different members of the JAK family of proteins is currently undergoing evaluation in clin. trials for patients with MPNs, lymphoma, and solid tumors such as breast or pancreatic cancer.  Despite the significant clin. activity exhibited by these agents in myelofibrosis, some patients fail to respond or progress during JAK kinase inhibitor therapy.  Recent reports have shed light into the mechanisms of resistance to JAK inhibitor therapy.  Several approaches hold promise to overcome such resistance.  Clin Cancer Res; 19(8); 1933-40. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyMnvN-07bLVg90H21EOLACvtfcHk0liFt5vK43eg2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjs78%253D&md5=27cc6d84279e644740e82aa8a073eba6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0284%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DMolecular%2520pathways%253A%2520Jak%252FSTAT%2520pathway%253A%2520mutations%252C%2520inhibitors%252C%2520and%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D1933%26epage%3D1940%26doi%3D10.1158%2F1078-0432.CCR-12-0284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmukhaiah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu Rao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madkaikar, M.</span></span> <span> </span><span class="NLM_article-title">Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1111/ejh.12592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fejh.12592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26010294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVSmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=309-317&author=S.+Gargauthor=C.+Shanmukhaiahauthor=S.+Maratheauthor=P.+Mishraauthor=V.+Babu+Raoauthor=K.+Ghoshauthor=M.+Madkaikar&title=Differential+antigen+expression+and+aberrant+signaling+via+PI3%2FAKT%2C+MAP%2FERK%2C+JAK%2FSTAT%2C+and+Wnt%2F%CE%B2+catenin+pathways+in+Lin-%2FCD38-%2FCD34%2B+cells+in+acute+myeloid+leukemia&doi=10.1111%2Fejh.12592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia</span></div><div class="casAuthors">Garg, Swati; Shanmukhaiah, Chandrakala; Marathe, Supreet; Mishra, Prashant; Babu Rao, Vunditi; Ghosh, Kanjaksha; Madkaikar, Manisha</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-317</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Acute myeloid leukemia is often called as stem cell disease that presents with treatment failure and poor disease outcome.  Leukemic stem cells in acute myeloid leukemia (AML) are enriched in Lineage-/CD38-/CD34+ compartment of CD34-pos. AML.  Many markers important for stem cell biol. have been reported for their assocn. with leukemic stem cell population, but what remains clin. most important is a rapid identification of prognostic information.  In this study, we evaluated four signal transduction pathways and thirteen markers on Lin-/CD38-/CD34+ population in AML.  Expressions were compared in different AML subtypes, survival, and treatment outcome groups.  We obsd. that markers important in homing, cell quiescence, and signal propagation such as CD44, CD96, CD90, WT-1, CD123 and CD25 were most significantly differentially expressed on Lin-/CD38-/CD34+ population in AML from their normal counterparts (P < 0.05, Mann-Whitney).  Constitutive activation of phospho ERK, AKT, and STAT5 in these cells was assocd. with poor outcome.  Also, an increased frequency of putative leukemic stem cell population shows neg. impact on treatment outcome and overall survival, suggesting that initial evaluation of AML samples for pLSC frequency and constitutively activated signaling pathway can provide prognostic and therapeutic information at the time of diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw7QmEWUz6p7Vg90H21EOLACvtfcHk0liFt5vK43eg2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVSmtr8%253D&md5=c39930bbd4f671beb89e7a52a04dad09</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fejh.12592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.12592%26sid%3Dliteratum%253Aachs%26aulast%3DGarg%26aufirst%3DS.%26aulast%3DShanmukhaiah%26aufirst%3DC.%26aulast%3DMarathe%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DBabu%2BRao%26aufirst%3DV.%26aulast%3DGhosh%26aufirst%3DK.%26aulast%3DMadkaikar%26aufirst%3DM.%26atitle%3DDifferential%2520antigen%2520expression%2520and%2520aberrant%2520signaling%2520via%2520PI3%252FAKT%252C%2520MAP%252FERK%252C%2520JAK%252FSTAT%252C%2520and%2520Wnt%252F%25CE%25B2%2520catenin%2520pathways%2520in%2520Lin-%252FCD38-%252FCD34%252B%2520cells%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2016%26volume%3D96%26spage%3D309%26epage%3D317%26doi%3D10.1111%2Fejh.12592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biethahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, F.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of STAT transcription factors in acute myelogenous leukemia</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1034/j.1600-0609.2001.t01-1-00385.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1034%2Fj.1600-0609.2001.t01-1-00385.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=11722592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos12ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2001&pages=63-71&author=K.+Spiekermannauthor=S.+Biethahnauthor=S.+Wildeauthor=W.+Hiddemannauthor=F.+Alves&title=Constitutive+activation+of+STAT+transcription+factors+in+acute+myelogenous+leukemia&doi=10.1034%2Fj.1600-0609.2001.t01-1-00385.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of STAT transcription factors in acute myelogenous leukemia</span></div><div class="casAuthors">Spiekermann, K.; Biethahn, S.; Wilde, S.; Hiddemann, W.; Alves, F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-71</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Hematopoietic growth factors (HGF) are essential for proliferation and differentiation of hematopoietic precursors and activate a distinct set of JAK-STAT (Janus kinases-signal transducers and activators of transcription) proteins.  Previous results from the authors' group have shown a strong expression of JAK-STAT proteins in primary acute myelogenous leukemia (AML) blasts and AML cell lines.  Here, the authors asked whether a constitutive activation of the JAK-STAT pathway might be involved in the pathogenesis of AML.  The authors could demonstrate a constitutive activation of STAT1, 3 and 5 by immunopptn. of the tyrosine phosphorylated proteins in different human AML cell lines.  Three patterns of STAT activation were found: (I) activation of only STAT1, (II) activation of STAT1 in combination with STAT3, and (III) activation of STAT1, 3 and 5.  Furthermore, STAT1 and 3 formed stable heterodimers only in cell lines with constitutive STAT3 activation.  In all cell lines analyzed, tyrosine phosphorylation of the four known Janus kinases could not be detected, although JAK1 was stably assocd. with STAT3.  To further analyze whether a constitutive activation of tyrosine kinases might contribute to the autonomous growth of AML blasts, inhibitor studies were performed.  The tyrphostin AG490, an inhibitor of the JAK-STAT pathway, but not A1, an inactive tyrphostin induced a time- and dose-dependent growth arrest without overt morphol. signs of differentiation in AML cell lines.  These results show that STAT transcription factors are constitutively activated in human AML cell lines and might contribute to the autonomous proliferation of AML blasts.  Inhibition of this pathway might be of interest for the establishment of more specific antileukemic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq23_sXX8Ss7rVg90H21EOLACvtfcHk0liFt5vK43eg2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos12ksrc%253D&md5=89865bf7cb7cf7cbc61acf75d6b1e646</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0609.2001.t01-1-00385.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0609.2001.t01-1-00385.x%26sid%3Dliteratum%253Aachs%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBiethahn%26aufirst%3DS.%26aulast%3DWilde%26aufirst%3DS.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DAlves%26aufirst%3DF.%26atitle%3DConstitutive%2520activation%2520of%2520STAT%2520transcription%2520factors%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2001%26volume%3D67%26spage%3D63%26epage%3D71%26doi%3D10.1034%2Fj.1600-0609.2001.t01-1-00385.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karjalainen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemovska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javarappa, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bychkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayoral Safont, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porkka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioniemi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckman, C. A.</span></span> <span> </span><span class="NLM_article-title">JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-02-699363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2016-02-699363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28619982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSku7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=789-802&author=R.+Karjalainenauthor=T.+Pemovskaauthor=M.+Popaauthor=M.+Liuauthor=K.+K.+Javarappaauthor=M.+M.+Majumderauthor=B.+Yadavauthor=D.+Tamboreroauthor=J.+Tangauthor=D.+Bychkovauthor=M.+Kontroauthor=A.+Parsonsauthor=M.+Suvelaauthor=M.+Mayoral+Safontauthor=K.+Porkkaauthor=T.+Aittokallioauthor=O.+Kallioniemiauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=K.+Wennerbergauthor=J.+Knowlesauthor=C.+A.+Heckman&title=JAK1%2F2+and+BCL2+inhibitors+synergize+to+counteract+bone+marrow+stromal+cell-induced+protection+of+AML&doi=10.1182%2Fblood-2016-02-699363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML</span></div><div class="casAuthors">Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir M.; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Safont, Mireia Mayoral; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjoern T.; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">789-802</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The bone marrow (BM) provides a protective microenvironment to support the survival of leukemic cells and influence their response to therapeutic agents.  In acute myeloid leukemia (AML), the high rate of relapse may in part be a result of the inability of current treatment to effectively overcome the protective influence of the BM niche.  To better understand the effect of the BM microenvironment on drug responses in AML, we conducted a comprehensive evaluation of 304 inhibitors, including approved and investigational agents, comparing ex vivo responses of primary AML cells in BM stroma-derived and std. culture conditions.  In the stroma-based conditions, the AML patient cells exhibited significantly reduced sensitivity to 12% of the tested compds., including topoisomerase II, B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), and many tyrosine kinase inhibitors (TKIs).  The loss of TKI sensitivity was most pronounced in patient samples harboring FLT3 or PDGFRB alterations.  In contrast, the stroma-derived conditions enhanced sensitivity to Janus kinase (JAK) inhibitors.  Increased cell viability and resistance to specific drug classes in the BM stroma-derived conditions was a result of activation of alternative signaling pathways mediated by factors secreted by BM stromal cells and involved a switch from BCL2 to BCLXL-dependent cell survival.  Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model.  These findings highlight the potential of JAK inhibitors to counteract stroma-induced resistance to BCL2 inhibitors in AML. (Blood. 2017;130(6):789-802).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWKjMWNILYfrVg90H21EOLACvtfcHk0lipeqQdDqQd1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSku7bJ&md5=a43567040357a235c85cf4878f5579c7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-02-699363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-02-699363%26sid%3Dliteratum%253Aachs%26aulast%3DKarjalainen%26aufirst%3DR.%26aulast%3DPemovska%26aufirst%3DT.%26aulast%3DPopa%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DJavarappa%26aufirst%3DK.%2BK.%26aulast%3DMajumder%26aufirst%3DM.%2BM.%26aulast%3DYadav%26aufirst%3DB.%26aulast%3DTamborero%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DBychkov%26aufirst%3DD.%26aulast%3DKontro%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DA.%26aulast%3DSuvela%26aufirst%3DM.%26aulast%3DMayoral%2BSafont%26aufirst%3DM.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DAittokallio%26aufirst%3DT.%26aulast%3DKallioniemi%26aufirst%3DO.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DKnowles%26aufirst%3DJ.%26aulast%3DHeckman%26aufirst%3DC.%2BA.%26atitle%3DJAK1%252F2%2520and%2520BCL2%2520inhibitors%2520synergize%2520to%2520counteract%2520bone%2520marrow%2520stromal%2520cell-induced%2520protection%2520of%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D789%26epage%3D802%26doi%3D10.1182%2Fblood-2016-02-699363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobumoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2015.219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26260387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2296-2306&author=C.+Nishiokaauthor=T.+Ikezoeauthor=A.+Takeuchiauthor=A.+Nobumotoauthor=M.+Tsudaauthor=A.+Yokoyama&title=The+novel+function+of+CD82+and+its+impact+on+BCL2L12+via+AKT%2FSTAT5+signal+pathway+in+acute+myelogenous+leukemia+cells&doi=10.1038%2Fleu.2015.219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells</span></div><div class="casAuthors">Nishioka, C.; Ikezoe, T.; Takeuchi, A.; Nobumoto, A.; Tsuda, M.; Yokoyama, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2296-2306</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The aim of this study was to explore the biol. functions of a tetraspanin family protein CD82 expressed aberrantly in chemotherapy-resistant CD34+/CD38- acute myelogenous leukemia (AML) cells.  Microarray anal. of patient-isolated CD34+/CD38- AML cells revealed that the levels of anti-apoptotic protein BCL2L12 were downregulated after CD82 depletion by specific short hairpin RNA (shRNA).  Western blot anal. indicated that BCL2L12 was aberrantly expressed in patient-isolated AML cells and AML cell lines.  Furthermore, CD82 blockade by a specific antibody downregulated BCL2L12 in parallel with dephosphorylation of signal transducer and activator of transcription 5 (STAT5) and AKT, whereas pharmacol. inhibition of STAT5 and AKT activation decreased BCL2L12 expression in leukemia cells.  In addn., shRNA-mediated downregulation of BCL2L12 increased the levels of cleaved caspase-3 and suppressed proliferation of leukemia cells, impairing their engraftment in immunodeficient mice.  Taken together, our results indicate that CD82 regulated BCL2L12 expression via STAT5A and AKT signaling and stimulated proliferation and engrafting of leukemia cells, suggesting that CD82 and BCL2L12 may be promising therapeutic targets in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2TqXgTM7Ig7Vg90H21EOLACvtfcHk0ljanYcdfQpWjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtbnL&md5=a329ddb1d1cce22509dbba37f7ec87a7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.219%26sid%3Dliteratum%253Aachs%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DA.%26aulast%3DNobumoto%26aufirst%3DA.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DThe%2520novel%2520function%2520of%2520CD82%2520and%2520its%2520impact%2520on%2520BCL2L12%2520via%2520AKT%252FSTAT5%2520signal%2520pathway%2520in%2520acute%2520myelogenous%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D2296%26epage%3D2306%26doi%3D10.1038%2Fleu.2015.219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Naggar, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.645805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1517%2F14728222.2011.645805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22239440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Wktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=103-119&author=L.+Santarpiaauthor=S.+M.+Lippmanauthor=A.+K.+El-Naggar&title=Targeting+the+MAPK-RAS-RAF+signaling+pathway+in+cancer+therapy&doi=10.1517%2F14728222.2011.645805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy</span></div><div class="casAuthors">Santarpia, Libero; Lippman, Scott M.; El-Naggar, Adel K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-119</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The MAPK pathway comprises several key signaling components and phosphorylation events that play a role in tumorigenesis.  These activated kinases transmit extracellular signals that regulate cell growth, differentiation, proliferation, apoptosis and migration functions.  Alteration of the RAS-RAF-MEK-ERK-MAPK (RAS-MAPK) pathway has been reported in human cancer as a result of abnormal activation of receptor tyrosine kinases or gain-of-function mutations mainly in the RAS or RAF genes.  These pathways are considered potential therapeutic targets for cancer treatment.  Recently, several small-mol. inhibitors targeting this pathway have been developed and are currently being tested in clin. trials.Areas covered: The biol. role of the RAS-MAPK pathway, the consequence of its disregulation and the development of small-mol. inhibitors.  The rationale for targeting the RAS-MAPK pathway and the application and the results of various inhibitory mols. as anticancer agents in clin. trials.Expert opinion: Inhibitors of MEK and particularly of RAF kinases have shown effectiveness in clin. trials with manageable side effects.  RAS and BRAF genes need to be analyzed for mutations as markers of response to treatments and to avoid paradoxical effects.  Further characterization of the RAS-MAPK mol. mechanisms regulation in malignant cells or underlying the acquired resistance to RAF inhibitors will facilitate development of novel combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFz0Tl-yNlE7Vg90H21EOLACvtfcHk0ljanYcdfQpWjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Wktw%253D%253D&md5=67be09e29593e670071e8a94d8630012</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.645805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.645805%26sid%3Dliteratum%253Aachs%26aulast%3DSantarpia%26aufirst%3DL.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DEl-Naggar%26aufirst%3DA.%2BK.%26atitle%3DTargeting%2520the%2520MAPK-RAS-RAF%2520signaling%2520pathway%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26spage%3D103%26epage%3D119%26doi%3D10.1517%2F14728222.2011.645805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grafone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storti, S.</span></span> <span> </span><span class="NLM_article-title">An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment</span>. <i>Oncol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">8</span> <span class="refDoi"> DOI: 10.4081/oncol.2012.e8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.4081%2Foncol.2012.e8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&author=T.+Grafoneauthor=M.+Palmisanoauthor=C.+Nicciauthor=S.+Storti&title=An+overview+on+the+role+of+FLT3-tyrosine+kinase+receptor+in+acute+myeloid+leukemia%3A+biology+and+treatment&doi=10.4081%2Foncol.2012.e8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4081%2Foncol.2012.e8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4081%252Foncol.2012.e8%26sid%3Dliteratum%253Aachs%26aulast%3DGrafone%26aufirst%3DT.%26aulast%3DPalmisano%26aufirst%3DM.%26aulast%3DNicci%26aufirst%3DC.%26aulast%3DStorti%26aufirst%3DS.%26atitle%3DAn%2520overview%2520on%2520the%2520role%2520of%2520FLT3-tyrosine%2520kinase%2520receptor%2520in%2520acute%2520myeloid%2520leukemia%253A%2520biology%2520and%2520treatment%26jtitle%3DOncol.%2520Rev.%26date%3D2012%26volume%3D6%26doi%3D10.4081%2Foncol.2012.e8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sillar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germon, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeIuliis, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dun, M. D.</span></span> <span> </span><span class="NLM_article-title">The role of reactive oxygen species in acute myeloid leukaemia</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6003</span>, <span class="refDoi"> DOI: 10.3390/ijms20236003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3390%2Fijms20236003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFahsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=6003&author=J.+R.+Sillarauthor=Z.+P.+Germonauthor=G.+N.+DeIuliisauthor=M.+D.+Dun&title=The+role+of+reactive+oxygen+species+in+acute+myeloid+leukaemia&doi=10.3390%2Fijms20236003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The role of reactive oxygen species in acute myeloid leukaemia</span></div><div class="casAuthors">Sillar, Jonathan R.; Germon, Zacary P.; De Iuliis, Geoffry N.; Dun, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6003</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is an aggressive haematol. malignancy with a poor overall survival.  Reactive oxygen species (ROS) have been shown to be elevated in a wide range of cancers including AML.  While previously thought to be mere byproducts of cellular metab., it is now clear that ROS modulate the function of signalling proteins through oxidn. of crit. cysteine residues.  In this way, ROS have been shown to regulate normal haematopoiesis as well as promote leukaemogenesis in AML.  In addn., ROS promote genomic instability by damaging DNA, which promotes chemotherapy resistance.  The source of ROS in AML appears to be derived from members of the "NOX family" of NADPH oxidases.  Most studies link NOX-derived ROS to activating mutations in the Fms-like tyrosine kinase 3 (FLT3) and Ras-related C3 botulinum toxin substrate (Ras).  Targeting ROS through either ROS induction or ROS inhibition provides a novel therapeutic target in AML.  In this review, we summarise the role of ROS in normal haematopoiesis and in AML.We also explore the current treatments that modulate ROS levels in AML and discuss emerging drug targets based on pre-clin. work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpltnRR-iWAZrVg90H21EOLACvtfcHk0lhqhTGRrZWxkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFahsrvP&md5=792daf3dfa2709f4406de8f422a11916</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fijms20236003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20236003%26sid%3Dliteratum%253Aachs%26aulast%3DSillar%26aufirst%3DJ.%2BR.%26aulast%3DGermon%26aufirst%3DZ.%2BP.%26aulast%3DDeIuliis%26aufirst%3DG.%2BN.%26aulast%3DDun%26aufirst%3DM.%2BD.%26atitle%3DThe%2520role%2520of%2520reactive%2520oxygen%2520species%2520in%2520acute%2520myeloid%2520leukaemia%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D6003%26doi%3D10.3390%2Fijms20236003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4186</span>– <span class="NLM_lpage">4192</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-13-3270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24895460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4186-4192&author=D.+B.+Johnsonauthor=K.+S.+Smalleyauthor=J.+A.+Sosman&title=Molecular+pathways%3A+targeting+NRAS+in+melanoma+and+acute+myelogenous+leukemia&doi=10.1158%2F1078-0432.CCR-13-3270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia</span></div><div class="casAuthors">Johnson, Douglas B.; Smalley, Keiran S. M.; Sosman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4186-4192</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Successful targeting of specific oncogenic "driver" mutations with small-mol. inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years.  The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be an elusive target.  Activating mutations in RAS induce mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase-AKT pathway signaling and drive malignant progression in up to 30% of cancers.  Oncogenic NRAS mutations occur in several cancer types, notably melanoma, acute myelogenous leukemia (AML), and less commonly, colon adenocarcinoma, thyroid carcinoma, and other hematol. malignancies.  Although NRAS-mutant tumors have been recalcitrant to targeted therapeutic strategies historically, newer agents targeting MAP/ERK kinase 1 (MEK1)/2 have recently shown signs of clin. efficacy as monotherapy.  Combination strategies of MEK inhibitors with other targeted agents have strong preclin. support and are being evaluated in clin. trials.  This review discusses the recent preclin. and clin. studies about the role of NRAS in cancer, with a focus on melanoma and AML.  Clin Cancer Res; 20(16); 4186-92. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHb9TN00_uU7Vg90H21EOLACvtfcHk0lhqhTGRrZWxkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK&md5=4656a7aa671cfa3989c09d93f4d60226</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3270%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520NRAS%2520in%2520melanoma%2520and%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D4186%26epage%3D4192%26doi%3D10.1158%2F1078-0432.CCR-13-3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatangelo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roshal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marteyn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnoud, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaemmanuil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakurta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-04-779447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2017-04-779447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28588019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSku77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=732-741&author=M.+D.+Amatangeloauthor=L.+Quekauthor=A.+Shihauthor=E.+M.+Steinauthor=M.+Roshalauthor=M.+D.+Davidauthor=B.+Marteynauthor=N.+R.+Farnoudauthor=S.+de+Bottonauthor=O.+A.+Bernardauthor=B.+Wuauthor=K.+E.+Yenauthor=M.+S.+Tallmanauthor=E.+Papaemmanuilauthor=V.+Penard-Lacroniqueauthor=A.+Thakurtaauthor=P.+Vyasauthor=R.+L.+Levine&title=Enasidenib+induces+acute+myeloid+leukemia+cell+differentiation+to+promote+clinical+response&doi=10.1182%2Fblood-2017-04-779447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response</span></div><div class="casAuthors">Amatangelo, Michael D.; Quek, Lynn; Shih, Alan; Stein, Eytan M.; Roshal, Mikhail; David, Muriel D.; Marteyn, Benoit; Farnoud, Noushin Rahnamay; de Botton, Stephane; Bernard, Olivier A.; Wu, Bin; Yen, Katharine E.; Tallman, Martin S.; Papaemmanuil, Elli; Penard-Lacronique, Virginie; Thakurta, Anjan; Vyas, Paresh; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">732-741</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML).  In preclin. models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block.  Single-agent enasidenib (AG-221/CC- 90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a phase 1 trial.  However, its mechanism of action and biomarkers assocd. with response remain unclear.  Here, we measured 2-HG, mIDH2 allele burden, and co-occurring somatic mutations in sequential patient samples from the clin. trial and correlated these with clin. response.  Furthermore, we used flow cytometry to assess inhibition of mIDH2 on hematopoietic differentiation.  We obsd. potent 2-HG suppression in both R140 and R172 mIDH2 AML subtypes, with different kinetics, which preceded clin. response.  Suppression of 2-HG alone did not predict response, because most nonresponding patients also exhibited 2-HG suppression.  Complete remission (CR) with persistence of mIDH2 and normalization of hematopoietic stem and progenitor compartments with emergence of functional mIDH2 neutrophils were obsd.  In a subset of CR patients, mIDH2 allele burden was reduced and remained undetectable with response.  Co-occurring mutations in NRAS and other MAPK pathway effectors were enriched in nonresponding patients, consistent with RAS signaling contributing to primary therapeutic resistance.  Together, these data support differentiation as the main mechanism of enasidenib efficacy in relapsed/refractory AML patients and provide insight into resistance mechanisms to inform future mechanism-based combination treatment studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCbUXE9c5Uc7Vg90H21EOLACvtfcHk0liOAbJIH6_WFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSku77F&md5=9ed74a28d17125b405156f8fa1600438</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-04-779447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-04-779447%26sid%3Dliteratum%253Aachs%26aulast%3DAmatangelo%26aufirst%3DM.%2BD.%26aulast%3DQuek%26aufirst%3DL.%26aulast%3DShih%26aufirst%3DA.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DRoshal%26aufirst%3DM.%26aulast%3DDavid%26aufirst%3DM.%2BD.%26aulast%3DMarteyn%26aufirst%3DB.%26aulast%3DFarnoud%26aufirst%3DN.%2BR.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DBernard%26aufirst%3DO.%2BA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DPapaemmanuil%26aufirst%3DE.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DThakurta%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DEnasidenib%2520induces%2520acute%2520myeloid%2520leukemia%2520cell%2520differentiation%2520to%2520promote%2520clinical%2520response%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D732%26epage%3D741%26doi%3D10.1182%2Fblood-2017-04-779447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canaani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissette, J. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastburn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durruthy-Durruthy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asthana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFilippis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peretz, C. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGary, L. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deihimi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span> <span> </span><span class="NLM_article-title">Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-1453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F2159-8290.CD-18-1453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31088841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1050-1063&author=C.+M.+McMahonauthor=T.+Ferngauthor=J.+Canaaniauthor=E.+S.+Wangauthor=J.+J.+D.+Morrissetteauthor=D.+J.+Eastburnauthor=M.+Pellegrinoauthor=R.+Durruthy-Durruthyauthor=C.+D.+Wattauthor=S.+Asthanaauthor=E.+A.+Lasaterauthor=R.+DeFilippisauthor=C.+A.+C.+Peretzauthor=L.+H.+F.+McGaryauthor=S.+Deihimiauthor=A.+C.+Loganauthor=S.+M.+Lugerauthor=N.+P.+Shahauthor=M.+Carrollauthor=C.+C.+Smithauthor=A.+E.+Perl&title=Clonal+selection+with+RAS+pathway+activation+mediates+secondary+clinical+resistance+to+selective+FLT3+inhibition+in+acute+myeloid+leukemia&doi=10.1158%2F2159-8290.CD-18-1453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia</span></div><div class="casAuthors">McMahon, Christine M.; Ferng, Timothy; Canaani, Jonathan; Wang, Eunice S.; Morrissette, Jennifer J. D.; Eastburn, Dennis J.; Pellegrino, Maurizio; Durruthy-Durruthy, Robert; Watt, Christopher D.; Asthana, Saurabh; Lasater, Elisabeth A.; DeFilippis, RosaAnna; Peretz, Cheryl A. C.; McGary, Lisa H. F.; Deihimi, Safoora; Logan, Aaron C.; Luger, Selina M.; Shah, Neil P.; Carroll, Martin; Smith, Catherine C.; Perl, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1050-1063</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clin. efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).  In this context, however, gilteritinib is not curative, and response duration is limited by the development of secondary resistance.  To evaluate resistance mechanisms, we analyzed baseline and progression samples from patients treated on clin. trials of gilteritinib.  Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in NRAS or KRAS.  Less frequently, secondary FLT3-F691L gatekeeper mutations or BCR-ABL1 fusions were identified at progression.  Single-cell targeted DNA sequencing revealed diverse patterns of clonal selection and evolution in response to FLT3 inhibition, including the emergence of RAS mutations in FLT3-mutated subclones, the expansion of alternative wild-type FLT3 subclones, or both patterns simultaneously.  These data illustrate dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5DKxLElhPrVg90H21EOLACvtfcHk0liOAbJIH6_WFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs77F&md5=229d18816b0cc7b69e14f0dc64a43af9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1453%26sid%3Dliteratum%253Aachs%26aulast%3DMcMahon%26aufirst%3DC.%2BM.%26aulast%3DFerng%26aufirst%3DT.%26aulast%3DCanaani%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DMorrissette%26aufirst%3DJ.%2BJ.%2BD.%26aulast%3DEastburn%26aufirst%3DD.%2BJ.%26aulast%3DPellegrino%26aufirst%3DM.%26aulast%3DDurruthy-Durruthy%26aufirst%3DR.%26aulast%3DWatt%26aufirst%3DC.%2BD.%26aulast%3DAsthana%26aufirst%3DS.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DDeFilippis%26aufirst%3DR.%26aulast%3DPeretz%26aufirst%3DC.%2BA.%2BC.%26aulast%3DMcGary%26aufirst%3DL.%2BH.%2BF.%26aulast%3DDeihimi%26aufirst%3DS.%26aulast%3DLogan%26aufirst%3DA.%2BC.%26aulast%3DLuger%26aufirst%3DS.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26atitle%3DClonal%2520selection%2520with%2520RAS%2520pathway%2520activation%2520mediates%2520secondary%2520clinical%2520resistance%2520to%2520selective%2520FLT3%2520inhibition%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D1050%26epage%3D1063%26doi%3D10.1158%2F2159-8290.CD-18-1453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of MEK inhibition in Nras-mutant AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3947</span>– <span class="NLM_lpage">3955</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-574582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2014-05-574582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25361812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFegsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3947-3955&author=M.+R.+Burgessauthor=E.+Hwangauthor=A.+J.+Firestoneauthor=T.+Huangauthor=J.+Xuauthor=J.+Zuberauthor=N.+Bohinauthor=T.+Wenauthor=S.+C.+Koganauthor=K.+M.+Haigisauthor=D.+Sampathauthor=S.+Loweauthor=K.+Shannonauthor=Q.+Li&title=Preclinical+efficacy+of+MEK+inhibition+in+Nras-mutant+AML&doi=10.1182%2Fblood-2014-05-574582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of MEK inhibition in Nras-mutant AML</span></div><div class="casAuthors">Burgess, Michael R.; Hwang, Eugene; Firestone, Ari J.; Huang, Tannie; Xu, Jin; Zuber, Johannes; Bohin, Natacha; Wen, Tiffany; Kogan, Scott C.; Haigis, Kevin M.; Sampath, Deepak; Lowe, Scott; Shannon, Kevin; Li, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3947-3955</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Oncogenic NRAS mutations are highly prevalent in acute myeloid leukemia (AML).  Genetic anal. supports the hypothesis that NRAS mutations cooperate with antecedent mol. lesions in leukemogenesis, but have limited independent prognostic significance.  Using short hairpin RNA-mediated knockdown in human cell lines and primary mouse leukemias, we show that AML cells with NRAS/Nras mutations are dependent on continued oncogene expression in vitro and in vivo.  Using the Mx1-Cre transgene to inactivate a conditional mutant Nras allele, we analyzed hematopoiesis and hematopoietic stem and progenitor cells (HSPCs) under normal and stressed conditions and found that HSPCs lacking Nras expression are functionally equiv. to normal HSPCs in the adult mouse.  Treating recipient mice transplanted with primary NrasG12D AMLs with 2 potent allosteric mitogen-activated protein kinase kinase (MEK) inhibitors (PD0325901 or trametinib/GlaxoSmithKline 1120212) significantly prolonged survival and reduced proliferation but did not induce apoptosis, promote differentiation, or drive clonal evolution.  The phosphatidylinositol 3-kinase inhibitor GDC-0941 was ineffective as a single agent and did not augment the activity of PD0325901.  All mice ultimately succumbed to progressive leukemia.  Together, these data validate oncogenic N-Ras signaling as a therapeutic target in AML and support testing combination regimens that include MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0a5noXfVE7Vg90H21EOLACvtfcHk0liOAbJIH6_WFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFegsw%253D%253D&md5=cc33710e7207b1f4d934b0588051a70c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-574582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-574582%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DM.%2BR.%26aulast%3DHwang%26aufirst%3DE.%26aulast%3DFirestone%26aufirst%3DA.%2BJ.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DBohin%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DT.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DHaigis%26aufirst%3DK.%2BM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLowe%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DPreclinical%2520efficacy%2520of%2520MEK%2520inhibition%2520in%2520Nras-mutant%2520AML%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3947%26epage%3D3955%26doi%3D10.1182%2Fblood-2014-05-574582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5483</span>– <span class="NLM_lpage">5495</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-14-0902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25186968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5483-5495&author=E.+Weisbergauthor=A.+Nonamiauthor=Z.+Chenauthor=E.+Nelsonauthor=Y.+Chenauthor=F.+Liuauthor=H.+Choauthor=J.+Zhangauthor=M.+Sattlerauthor=C.+Mitsiadesauthor=K.+K.+Wongauthor=Q.+Liuauthor=N.+S.+Grayauthor=J.+D.+Griffin&title=Upregulation+of+IGF1R+by+mutant+RAS+in+leukemia+and+potentiation+of+RAS+signaling+inhibitors+by+small-molecule+inhibition+of+IGF1R&doi=10.1158%2F1078-0432.CCR-14-0902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R</span></div><div class="casAuthors">Weisberg, Ellen; Nonami, Atsushi; Chen, Zhao; Nelson, Erik; Chen, Yongfei; Liu, Feiyang; Cho, HaeYeon; Zhang, Jianming; Sattler, Martin; Mitsiades, Constantine; Wong, Kwok-Kin; Liu, Qingsong; Gray, Nathanael S.; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5483-5495</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activating mutations in the RAS oncogene occur frequently in human leukemias.  Direct targeting of RAS has proven to be challenging, although targeting of downstream RAS mediators, such as MEK, is currently being tested clin.  Given the complexity of RAS signaling, it is likely that combinations of targeted agents will be more effective than single agents.  Exptl. Design: A chem. screen using RAS-dependent leukemia cells was developed to identify compds. with unanticipated activity in the presence of an MEK inhibitor and led to identification of inhibitors of IGF1R.  Results were validated using cell-based proliferation, apoptosis, cell-cycle, and gene knockdown assays; immunopptn. and immunoblotting; and a noninvasive in vivo bioluminescence model of acute myeloid leukemia (AML).  Results: Mechanistically, IGF1R protein expression/activity was substantially increased in mutant RAS-expressing cells, and suppression of RAS led to decreases in IGF1R.  Synergy between MEK and IGF1R inhibitors correlated with induction of apoptosis, inhibition of cell-cycle progression, and decreased phospho-S6 and phospho-4E-BP1.  In vivo, NSG mice tail veins injected with OCI-AML3-luc+ cells showed significantly lower tumor burden following 1 wk of daily oral administration of 50 mg/kg NVP-AEW541 (IGF1R inhibitor) combined with 25 mg/kg AZD6244 (MEK inhibitor), as compared with mice treated with either agent alone.  Drug combination effects obsd. in cell-based assays were generalized to addnl. mutant RAS-pos. neoplasms.  Conclusions: The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clin. investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.  Clin Cancer Res; 20(21); 5483-95. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob8U93Vz-F3rVg90H21EOLACvtfcHk0lhAiaaURGef9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7vP&md5=9ce5a77cd145f6b351b1a319b4e88525</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0902%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DUpregulation%2520of%2520IGF1R%2520by%2520mutant%2520RAS%2520in%2520leukemia%2520and%2520potentiation%2520of%2520RAS%2520signaling%2520inhibitors%2520by%2520small-molecule%2520inhibition%2520of%2520IGF1R%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5483%26epage%3D5495%26doi%3D10.1158%2F1078-0432.CCR-14-0902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lien, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dibble, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span> <span> </span><span class="NLM_article-title">PI3K signaling in cancer: beyond AKT</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2017.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ceb.2017.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28343126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVCksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=62-71&author=E.+C.+Lienauthor=C.+C.+Dibbleauthor=A.+Toker&title=PI3K+signaling+in+cancer%3A+beyond+AKT&doi=10.1016%2Fj.ceb.2017.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K signaling in cancer: beyond AKT</span></div><div class="casAuthors">Lien, Evan C.; Dibble, Christian C.; Toker, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently altered pathways in human cancer and has a crit. role in driving tumor initiation and progression.  Although PI3K and its lipid product phosphatidylinositol-3,4,5-trisphosphate (PIP3) have been shown to activate multiple downstream signaling proteins, the vast majority of studies have focused on the protein kinase AKT as the dominant effector of PI3K signaling.  However, recent studies have demonstrated many contexts under which other PIP3-dependent signaling proteins critically contribute to cancer progression, illustrating the importance of understanding AKT-independent signaling downstream of PI3K.  Here, we highlight three PI3K-dependent, but AKT-independent, signaling branches that have recently been shown to have important roles in promoting phenotypes assocd. with malignancy.  First, the PDK1-mTORC2-SGK axis can substitute for AKT in survival, migration, and growth signaling and has emerged as a major mechanism of resistance to PI3K and AKT inhibitors.  Second, Rac signaling mediates the reorganization of the actin cytoskeleton to regulate cancer cell migration, invasion, and metab.  Finally, the TEC family kinase BTK has a crit. role in B cell function and malignancy and represents a recent example of an effective therapeutic target in cancer.  These mechanisms highlight how understanding PI3K-dependent, but AKT-independent, signaling mechanisms that drive cancer progression will be crucial for the development of novel and more effective approaches for targeting the PI3K pathway for therapeutic benefit in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFeOU2VGjLLVg90H21EOLACvtfcHk0lhAiaaURGef9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVCksbk%253D&md5=c9d37af3723a15bc37f079fa5a2d7d11</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2017.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2017.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DLien%26aufirst%3DE.%2BC.%26aulast%3DDibble%26aufirst%3DC.%2BC.%26aulast%3DToker%26aufirst%3DA.%26atitle%3DPI3K%2520signaling%2520in%2520cancer%253A%2520beyond%2520AKT%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2017%26volume%3D45%26spage%3D62%26epage%3D71%26doi%3D10.1016%2Fj.ceb.2017.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piddock, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rushworth, S. A.</span></span> <span> </span><span class="NLM_article-title">The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3390/cancers9040029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3390%2Fcancers9040029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=29&author=R.+E.+Piddockauthor=K.+M.+Bowlesauthor=S.+A.+Rushworth&title=The+role+of+PI3K+isoforms+in+regulating+bone+marrow+microenvironment+signaling+focusing+on+acute+myeloid+leukemia+and+multiple+myeloma&doi=10.3390%2Fcancers9040029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma</span></div><div class="casAuthors">Piddock, Rachel E.; Bowles, Kristian M.; Rushworth, Stuart A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">29/1-29/15</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Despite the development of novel treatments in the past 15 years, many blood cancers still remain ultimately fatal and difficult to treat, particularly acute myeloid leukemia (AML) and multiple myeloma (MM).  While significant progress has been made characterizing small-scale genetic mutations and larger-scale chromosomal translocations that contribute to the development of various blood cancers, less is understood about the complex microenvironment of the bone marrow (BM), which is known to be a key player in the pathogenesis of chronic lymphocytic leukemia (CLL), AML and MM.  This niche acts as a sanctuary for the cancerous cells, protecting them from chemotherapeutics and encouraging clonal cell survival.  It does this by upregulating a plethora of signalling cascades within the malignant cell, with the phosphatidylinositol-3-kinase (PI3K) pathway taking a crit. role.  This review will focus on how the PI3K pathway influences disease progression and the individualised role of the PI3K subunits.  We will also summarise the current clin. trials for PI3K inhibitors and how these trials impact the treatment of blood cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDmyAJz9HSLVg90H21EOLACvtfcHk0lhAiaaURGef9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKiurrJ&md5=d89e1ba98d8d00c26eca00e4fd55da1c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Fcancers9040029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers9040029%26sid%3Dliteratum%253Aachs%26aulast%3DPiddock%26aufirst%3DR.%2BE.%26aulast%3DBowles%26aufirst%3DK.%2BM.%26aulast%3DRushworth%26aufirst%3DS.%2BA.%26atitle%3DThe%2520role%2520of%2520PI3K%2520isoforms%2520in%2520regulating%2520bone%2520marrow%2520microenvironment%2520signaling%2520focusing%2520on%2520acute%2520myeloid%2520leukemia%2520and%2520multiple%2520myeloma%26jtitle%3DCancers%26date%3D2017%26volume%3D9%26spage%3D29%26doi%3D10.3390%2Fcancers9040029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillet-Lefebvre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span> <span> </span><span class="NLM_article-title">Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia</span>. <i>Haematologica.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.3324/haematol.2009.013797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3324%2Fhaematol.2009.013797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=19951971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yrsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=819-828&author=S.+Parkauthor=N.+Chapuisauthor=J.+Tamburiniauthor=V.+Bardetauthor=P.+Cornillet-Lefebvreauthor=L.+Willemsauthor=A.+Greenauthor=P.+Mayeuxauthor=C.+Lacombeauthor=D.+Bouscary&title=Role+of+the+PI3K%2FAKT+and+mTOR+signaling+pathways+in+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2009.013797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia</span></div><div class="casAuthors">Park, Sophie; Chapuis, Nicolas; Tamburini, Jerome; Bardet, Valerie; Cornillet-Lefebvre, Pascale; Willems, Lise; Green, Alexa; Mayeux, Patrick; Lacombe, Catherine; Bouscary, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">819-828</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">A review.  The PI3K/AKT and mTOR signaling pathways are activated in acute myeloid leukemia, including in the more immature leukemic populations.  Constitutive PI3K activation is detectable in 50% of acute myeloid leukemia samples whereas mTORC1 is activated in all cases of this disease.  In leukemic cells, the PI3K activity relates to the expression of the p110δ isoform of class IA PI3K.  Constitutive PI3K activation is the result of autocrine IGF-1/IGF-1R signaling in 70% of acute myeloid leukemia samples but specific inhibition of this pathway does not induce apoptosis.  Specific inhibition of PI3K/AKT or mTORC1 alone in vitro has antileukemic effects which are essentially exerted via the suppression of proliferation.  However, as mTORC1 activation is independent of PI3K/AKT in acute myeloid leukemia, dual PI3K and mTOR inhibitors may induce apoptosis in blast cells.  Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.  Recent data also indicate that mTORC1 does not control protein translation in acute myeloid leukemia.  These results open the way for the design of direct inhibitors of protein synthesis as novel acute myeloid leukemia therapies and also for the development of second generation mTOR inhibitors (the TORKinhibs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK4wSopw8w1LVg90H21EOLACvtfcHk0lgzjY01wRrL-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yrsbzI&md5=51c773df2df0849e64c92e1c62187cb1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2009.013797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2009.013797%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DChapuis%26aufirst%3DN.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DBardet%26aufirst%3DV.%26aulast%3DCornillet-Lefebvre%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DL.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DBouscary%26aufirst%3DD.%26atitle%3DRole%2520of%2520the%2520PI3K%252FAKT%2520and%2520mTOR%2520signaling%2520pathways%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica.%26date%3D2010%26volume%3D95%26spage%3D819%26epage%3D828%26doi%3D10.3324%2Fhaematol.2009.013797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puliafito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primo, L.</span></span> <span> </span><span class="NLM_article-title">PDK1: at the crossroad of cancer signaling pathways</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2017.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.semcancer.2017.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28473254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlWkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=27-35&author=P.+A.+Gagliardiauthor=A.+Puliafitoauthor=L.+Primo&title=PDK1%3A+at+the+crossroad+of+cancer+signaling+pathways&doi=10.1016%2Fj.semcancer.2017.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">PDK1: At the crossroad of cancer signaling pathways</span></div><div class="casAuthors">Gagliardi, Paolo Armando; Puliafito, Alberto; Primo, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rational target therapy of cancer would benefit from the identification of new targets that can be easily inhibited by small mols.  An increasing amt. of evidence hints at 3-phosphoinositide dependent protein kinase-1 (PDK1 or PDPK1) as an intriguing and underexplored target for cancer therapy.  Several reports show that PDK1 expression is dysregulated in multiple cancer types.  Furthermore PDK1 is implicated in signaling pathways frequently altered in cancer, such as PI3K/Akt, Ras/MAPK and Myc.  PDK1 targeting has been proven to be effective in exptl. models harboring alterations of these pathways.  In this paper we review PDK1 main biochem. mechanisms, its alterations in cancer and interactions with relevant cancer pathways.  A potential role of PDK1 in tumor microenvironment is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSy7NtdFtBrVg90H21EOLACvtfcHk0lgzjY01wRrL-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlWkur8%253D&md5=4d84028328442049486f410708038eb4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2017.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2017.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DGagliardi%26aufirst%3DP.%2BA.%26aulast%3DPuliafito%26aufirst%3DA.%26aulast%3DPrimo%26aufirst%3DL.%26atitle%3DPDK1%253A%2520at%2520the%2520crossroad%2520of%2520cancer%2520signaling%2520pathways%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2018%26volume%3D48%26spage%3D27%26epage%3D35%26doi%3D10.1016%2Fj.semcancer.2017.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, M. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmawardhane, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Rac and Cdc42 GTPases in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3101</span>– <span class="NLM_lpage">3111</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F0008-5472.CAN-18-0619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29858187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFeqs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3101-3111&author=M.+D.+M.+Maldonadoauthor=S.+Dharmawardhane&title=Targeting+Rac+and+Cdc42+GTPases+in+cancer&doi=10.1158%2F0008-5472.CAN-18-0619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Rac and Cdc42 GTPases in Cancer</span></div><div class="casAuthors">Maldonado, Maria del Mar; Dharmawardhane, Suranganie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3101-3111</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rac and Cdc42 are small GTPases that have been linked to multiple human cancers and are implicated in epithelial to mesenchymal transition, cell-cycle progression, migration/invasion, tumor growth, angiogenesis, and oncogenic transformation.  With the exception of the P29S driver mutation in melanoma, Rac and Cdc42 are not generally mutated in cancer, but are overexpressed (gene amplification and mRNA upregulation) or hyperactivated.  Rac and Cdc42 are hyperactivated via signaling through oncogenic cell surface receptors, such as growth factor receptors, which converge on the guanine nucleotide exchange factors that regulate their GDP/GTP exchange.  Hence, targeting Rac and Cdc42 represents a promising strategy for precise cancer therapy, as well as for inhibition of bypass signaling that promotes resistance to cell surface receptor-targeted therapies.  Therefore, an understanding of the regulatory mechanisms of these pivotal signaling intermediates is key for the development of effective inhibitors.  In this review, we focus on the role of Rac and Cdc42 in cancer and summarize the regulatory mechanisms, inhibitory efficacy, and the anticancer potential of Rac- and Cdc42-targeting agents.  Cancer Res; 78(12); 3101-11. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSDjwGurIUPrVg90H21EOLACvtfcHk0lgzjY01wRrL-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFeqs7bN&md5=d4fbd989476469bed0a8e9a1960a9d15</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0619%26sid%3Dliteratum%253Aachs%26aulast%3DMaldonado%26aufirst%3DM.%2BD.%2BM.%26aulast%3DDharmawardhane%26aufirst%3DS.%26atitle%3DTargeting%2520Rac%2520and%2520Cdc42%2520GTPases%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3101%26epage%3D3111%26doi%3D10.1158%2F0008-5472.CAN-18-0619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujobert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylbersztejn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palama, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnais, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevier-Gobeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraisse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeissat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Récher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, N.</span></span> <span> </span><span class="NLM_article-title">High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2326</span>– <span class="NLM_lpage">2335</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2017.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28280275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=2326-2335&author=L.+Poulainauthor=P.+Sujobertauthor=F.+Zylbersztejnauthor=S.+Barreauauthor=L.+Stuaniauthor=M.+Lambertauthor=T.+L.+Palamaauthor=V.+Chesnaisauthor=R.+Birsenauthor=F.+Vergezauthor=T.+Fargeauthor=C.+Chenevier-Gobeauxauthor=M.+Fraisseauthor=F.+Bouillaudauthor=C.+Debeissatauthor=O.+Heraultauthor=C.+R%C3%A9cherauthor=C.+Lacombeauthor=M.+Fontenayauthor=P.+Mayeuxauthor=T.+T.+Macielauthor=J.+C.+Portaisauthor=J.+E.+Sarryauthor=J.+Tamburiniauthor=D.+Bouscaryauthor=N.+Chapuis&title=High+mTORC1+activity+drives+glycolysis+addiction+and+sensitivity+to+G6PD+inhibition+in+acute+myeloid+leukemia+cells&doi=10.1038%2Fleu.2017.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells</span></div><div class="casAuthors">Poulain, L.; Sujobert, P.; Zylbersztejn, F.; Barreau, S.; Stuani, L.; Lambert, M.; Palama, T. L.; Chesnais, V.; Birsen, R.; Vergez, F.; Farge, T.; Chenevier-Gobeaux, C.; Fraisse, M.; Bouillaud, F.; Debeissat, C.; Herault, O.; Recher, C.; Lacombe, C.; Fontenay, M.; Mayeux, P.; Maciel, T. T.; Portais, J.-C.; Sarry, J.-E.; Tamburini, J.; Bouscary, D.; Chapuis, N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2326-2335</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities.  Here we decipher the interplay between mTORC1 activity and glucose metab. in acute myeloid leukemia (AML).  We show that mTORC1 signaling that is constantly overactivated in AML cells promotes glycolysis and leads to glucose addiction.  The level of mTORC1 activity dets. the sensitivity of AML cells to glycolysis inhibition as switch-off mTORC1 activity leads to glucose-independent cell survival that is sustained by an increase in mitochondrial oxidative phosphorylation.  Metabolic anal. identified the pentose phosphate pathway (PPP) as an important pro-survival pathway for glucose metab. in AML cells with high mTORC1 activity and provided a clear rational for targeting glucose-6-phosphate dehydrogenase (G6PD) in AML.  Indeed, our anal. of the cancer genome atlas AML database pinpointed G6PD as a new biomarker in AML, as its overexpression correlated with an adverse prognosis in this cohort.  Targeting the PPP using the G6PD inhibitor 6-aminonicotinamide induces in vitro and in vivo cytotoxicity against AML cells and synergistically sensitizes leukemic cells to chemotherapy.  Our results demonstrate that high mTORC1 activity creates a specific vulnerability to G6PD inhibition that may work as a new AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAc8A3CaBnhrVg90H21EOLACvtfcHk0ljCftuuG7wAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWlu7c%253D&md5=53fb2baa221e40b32b1170c59ebc6354</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.81%26sid%3Dliteratum%253Aachs%26aulast%3DPoulain%26aufirst%3DL.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DZylbersztejn%26aufirst%3DF.%26aulast%3DBarreau%26aufirst%3DS.%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DLambert%26aufirst%3DM.%26aulast%3DPalama%26aufirst%3DT.%2BL.%26aulast%3DChesnais%26aufirst%3DV.%26aulast%3DBirsen%26aufirst%3DR.%26aulast%3DVergez%26aufirst%3DF.%26aulast%3DFarge%26aufirst%3DT.%26aulast%3DChenevier-Gobeaux%26aufirst%3DC.%26aulast%3DFraisse%26aufirst%3DM.%26aulast%3DBouillaud%26aufirst%3DF.%26aulast%3DDebeissat%26aufirst%3DC.%26aulast%3DHerault%26aufirst%3DO.%26aulast%3DR%25C3%25A9cher%26aufirst%3DC.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DFontenay%26aufirst%3DM.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DMaciel%26aufirst%3DT.%2BT.%26aulast%3DPortais%26aufirst%3DJ.%2BC.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DBouscary%26aufirst%3DD.%26aulast%3DChapuis%26aufirst%3DN.%26atitle%3DHigh%2520mTORC1%2520activity%2520drives%2520glycolysis%2520addiction%2520and%2520sensitivity%2520to%2520G6PD%2520inhibition%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D2326%26epage%3D2335%26doi%3D10.1038%2Fleu.2017.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyåkern, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tazzari, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, L.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fsj.leu.2404245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16642045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVylsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=911-928&author=A.+M.+Martelliauthor=M.+Ny%C3%A5kernauthor=G.+Tabelliniauthor=R.+Bortulauthor=P.+L.+Tazzariauthor=C.+Evangelistiauthor=L.+Cocco&title=Phosphoinositide+3-kinase%2FAkt+signaling+pathway+and+its+therapeutical+implications+for+human+acute+myeloid+leukemia&doi=10.1038%2Fsj.leu.2404245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia</span></div><div class="casAuthors">Martelli, A. M.; Nyakern, M.; Tabellini, G.; Bortul, R.; Tazzari, P. L.; Evangelisti, C.; Cocco, L.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">911-928</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is crucial to many aspects of cell growth, survival and apoptosis, and its constitutive activation has been implicated in the both the pathogenesis and the progression of a wide variety of neoplasias.  Hence, this pathway is an attractive target for the development of novel anticancer strategies.  Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells.  Upregulation of the PI3K/Akt network in AML may be due to several reasons, including FLT3, Ras or c-Kit mutations.  Small mols. designed to selectively target key components of this signal transduction cascade induce apoptosis and/or markedly increase conventional drug sensitivity of AML blasts in vitro.  Thus, inhibitory mols. are currently being developed for clin. use either as single agents or in combination with conventional therapies.  However, the PI3K/Akt pathway is important for many physiol. cellular functions and, in particular, for insulin signaling, so that its blockade in vivo might cause severe systemic side effects.  In this review, we summarize the existing knowledge about PI3K/Akt signaling in AML cells and we examine the rationale for targeting this fundamental signal transduction network by means of selective pharmacol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQE0BlR7fW2LVg90H21EOLACvtfcHk0ljCftuuG7wAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVylsr4%253D&md5=6a52e13e1818e1f81b43c8444fdfb877</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404245%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DNy%25C3%25A5kern%26aufirst%3DM.%26aulast%3DTabellini%26aufirst%3DG.%26aulast%3DBortul%26aufirst%3DR.%26aulast%3DTazzari%26aufirst%3DP.%2BL.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DCocco%26aufirst%3DL.%26atitle%3DPhosphoinositide%25203-kinase%252FAkt%2520signaling%2520pathway%2520and%2520its%2520therapeutical%2520implications%2520for%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D911%26epage%3D928%26doi%3D10.1038%2Fsj.leu.2404245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertacchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mediani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capitani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahjahani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saki, N.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K/AKT/mTOR network for treatment of leukemia</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2337</span>– <span class="NLM_lpage">2347</span>, <span class="refDoi"> DOI: 10.1007/s00018-015-1867-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1007%2Fs00018-015-1867-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25712020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlGjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=2337-2347&author=J.+Bertacchiniauthor=N.+Heidariauthor=L.+Medianiauthor=S.+Capitaniauthor=M.+Shahjahaniauthor=A.+Ahmadzadehauthor=N.+Saki&title=Targeting+PI3K%2FAKT%2FmTOR+network+for+treatment+of+leukemia&doi=10.1007%2Fs00018-015-1867-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K/AKT/mTOR network for treatment of leukemia</span></div><div class="casAuthors">Bertacchini, Jessika; Heidari, Nazanin; Mediani, Laura; Capitani, Silvano; Shahjahani, Mohammad; Ahmadzadeh, Ahmad; Saki, Najmaldin</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2337-2347</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Objective: Increased activity of PI3K/AKT/mTOR pathway has been obsd. in a huge no. of malignancies.  This pathway can function as a prosurvival factor in leukemia stem cells and early committed leukemic precursors and its inhibition is regarded as a therapeutic approach.  Accordingly, the aim of this review is to evaluate the PI3K/Akt/mTOR inhibitors used in leukemia models.  Discussion: Inhibition of the PI3K/AKT/mTOR pathway has been reported to have beneficial therapeutic effects in leukemias, both in vitro in leukemia cell lines and in vivo in animal models.  Overall, the use of dual PI3K/mTOR inhibitor, dual Akt/RTK inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor and dual PI3K/PDK1 inhibitor in CML, AML, APL, CLL, B-ALL and T-ALL has a better therapeutic effect than conventional treatments.  Conclusions: Targeting the PI3K/Akt/mTOR pathway may have pro-apoptotic and antiproliferative effects on hematol. malignancies.  Furthermore, modulation of miRNA can be used as a novel therapeutic approach to regulate the PI3K/Akt/mTOR pathway.  However, both aspects require further clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1oIfnyXtpfLVg90H21EOLACvtfcHk0ljCftuuG7wAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlGjtr4%253D&md5=a0fa035a0fd7a43eed71861f10f19cb5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-1867-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-1867-5%26sid%3Dliteratum%253Aachs%26aulast%3DBertacchini%26aufirst%3DJ.%26aulast%3DHeidari%26aufirst%3DN.%26aulast%3DMediani%26aufirst%3DL.%26aulast%3DCapitani%26aufirst%3DS.%26aulast%3DShahjahani%26aufirst%3DM.%26aulast%3DAhmadzadeh%26aufirst%3DA.%26aulast%3DSaki%26aufirst%3DN.%26atitle%3DTargeting%2520PI3K%252FAKT%252FmTOR%2520network%2520for%2520treatment%2520of%2520leukemia%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26spage%3D2337%26epage%3D2347%26doi%3D10.1007%2Fs00018-015-1867-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herschbein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liesveld, J. L.</span></span> <span> </span><span class="NLM_article-title">Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2017.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.blre.2017.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29276026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVaktL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=235-248&author=L.+Herschbeinauthor=J.+L.+Liesveld&title=Dueling+for+dual+inhibition%3A+Means+to+enhance+effectiveness+of+PI3K%2FAkt%2FmTOR+inhibitors+in+AML&doi=10.1016%2Fj.blre.2017.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML</span></div><div class="casAuthors">Herschbein, Lauren; Liesveld, Jane L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-248</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway is amplified in 60-80% of patients with acute myelogenous leukemia (AML).  Since this complex pathway is crucial to cell functions such as growth, proliferation, and survival, inhibition of this pathway would be postulated to inhibit leukemia initiation and propagation.  Inhibition of the mTORC1 pathway has met with limited success in AML due to multiple resistance mechanisms including direct insensitivity of the mTORC1 complex, feedback activation of the PI3k/Akt signaling network, insulin growth factor-1 (IGF-1) activation of PI3K, and others.  This review explores the role of mTOR inhibition in AML, mechanisms of resistance, and means to improve outcomes through use of dual mTORC1/2 inhibitors or dual TORC/PI3K inhibitors.  How these inhibitors interface with currently available therapies in AML will require addnl. preclin. expts. and conduct of well-designed clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQWul_8qSZULVg90H21EOLACvtfcHk0ljOXFgOxY0-WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVaktL%252FK&md5=8a078e7eac1f44d0751edc4b496c095b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2017.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2017.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DHerschbein%26aufirst%3DL.%26aulast%3DLiesveld%26aufirst%3DJ.%2BL.%26atitle%3DDueling%2520for%2520dual%2520inhibition%253A%2520Means%2520to%2520enhance%2520effectiveness%2520of%2520PI3K%252FAkt%252FmTOR%2520inhibitors%2520in%2520AML%26jtitle%3DBlood%2520Rev.%26date%3D2018%26volume%3D32%26spage%3D235%26epage%3D248%26doi%3D10.1016%2Fj.blre.2017.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umezawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the STAT5/Pim kinase axis enhances cytotoxic effects of proteasome inhibitors on FLT3-ITD-positive AML cells by cooperatively inhibiting the mTORC1/4EBP1/S6K/Mcl-1 pathway</span>. <i>Transl Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.tranon.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30472492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3crksVSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=336-349&author=A.+Nogamiauthor=K.+Okadaauthor=S.+Ishidaauthor=H.+Akiyamaauthor=Y.+Umezawaauthor=O.+Miura&title=Inhibition+of+the+STAT5%2FPim+kinase+axis+enhances+cytotoxic+effects+of+proteasome+inhibitors+on+FLT3-ITD-positive+AML+cells+by+cooperatively+inhibiting+the+mTORC1%2F4EBP1%2FS6K%2FMcl-1+pathway&doi=10.1016%2Fj.tranon.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway</span></div><div class="casAuthors">Nogami Ayako; Okada Keigo; Ishida Shinya; Akiyama Hiroki; Umezawa Yoshihiro; Miura Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">336-349</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">FLT3-ITD and FLT3-TKD are the most frequent tyrosine kinase mutations in acute myeloid leukemia (AML), with the former conferring a poor prognosis.  We have recently revealed that FLT3-ITD confers resistance to the PI3K/AKT pathway inhibitors by protecting the mTORC1/4EBP1/Mcl-1 pathway through Pim kinases induced by STAT5 activation in AML.  The proteasome inhibitor bortezomib has recently been reported as a promising agent for treatment of AML.  Here, we show that the proteasome inhibitor bortezomib as well as carfilzomib induces apoptosis through the intrinsic pathway more conspicuously in cells transformed by FLT3-TKD than FLT3-ITD.  Mechanistically, bortezomib upregulated the stress-regulated protein REDD1 and induced downregulation of the mTORC1 pathway more distinctively in cells transformed by FLT3-TKD than FLT-ITD, while overexpression of Pim-1 partly prevented this downregulation and apoptosis in FLT3-TKD-transformed cells.  Genetic enhancement of the REDD1 induction or pharmacological inhibition of STAT5, Pim kinases, mTORC1, or S6K by specific inhibitors, such as pimozide, AZD1208, PIM447, rapamycin, and PF-4708671, accelerated the downregulation of mTORC1/Mcl-1 pathway to enhance bortezomib-induced apoptosis in FLT3-ITD-expressing cells, including primary AML cells, while overexpression of Mcl-1 prevented induction of apoptosis.  Thus, FLT3-ITD confers a resistance to the proteasome inhibitors on AML cells by protecting the mTORC1/Mcl-1 pathway through the STAT5/Pim axis, and inhibition of these signaling events remarkably enhances the therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCptdMoKFKJ1WTCLT8lX9SfW6udTcc2eZgE6FYcpvEQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crksVSluw%253D%253D&md5=131a28b46d5e8c27672fb534524d831a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DNogami%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DIshida%26aufirst%3DS.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DUmezawa%26aufirst%3DY.%26aulast%3DMiura%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520the%2520STAT5%252FPim%2520kinase%2520axis%2520enhances%2520cytotoxic%2520effects%2520of%2520proteasome%2520inhibitors%2520on%2520FLT3-ITD-positive%2520AML%2520cells%2520by%2520cooperatively%2520inhibiting%2520the%2520mTORC1%252F4EBP1%252FS6K%252FMcl-1%2520pathway%26jtitle%3DTransl%2520Oncol.%26date%3D2019%26volume%3D12%26spage%3D336%26epage%3D349%26doi%3D10.1016%2Fj.tranon.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindblad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallon-Christersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levander, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietras, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span> <span> </span><span class="NLM_article-title">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">5119</span>– <span class="NLM_lpage">5131</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fonc.2016.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26999641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=5119-5131&author=O.+Lindbladauthor=E.+Corderoauthor=A.+Puissantauthor=L.+Macaulayauthor=A.+Ramosauthor=N.+N.+Kabirauthor=J.+Sunauthor=J.+Vallon-Christerssonauthor=K.+Haraldssonauthor=M.+T.+Hemannauthor=%C3%85.+Borgauthor=F.+Levanderauthor=K.+Stegmaierauthor=K.+Pietrasauthor=L.+R%C3%B6nnstrandauthor=J.+U.+Kazi&title=Aberrant+activation+of+the+PI3K%2FmTOR+pathway+promotes+resistance+to+sorafenib+in+AML&doi=10.1038%2Fonc.2016.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span></div><div class="casAuthors">Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N. N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M. T.; Borg, Aa; Levander, F.; Stegmaier, K.; Pietras, K.; Roennstrand, L.; Kazi, J. U.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5119-5131</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient.  To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib.  Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors.  Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells.  Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent.  Gene expression anal. of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array anal.  Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines.  Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model.  Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfp1049FgsbVg90H21EOLACvtfcHk0ljOXFgOxY0-WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D&md5=94a7570e240d12c506af0850819c77d9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.41%26sid%3Dliteratum%253Aachs%26aulast%3DLindblad%26aufirst%3DO.%26aulast%3DCordero%26aufirst%3DE.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DMacaulay%26aufirst%3DL.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3DKabir%26aufirst%3DN.%2BN.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DVallon-Christersson%26aufirst%3DJ.%26aulast%3DHaraldsson%26aufirst%3DK.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DBorg%26aufirst%3D%25C3%2585.%26aulast%3DLevander%26aufirst%3DF.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26atitle%3DAberrant%2520activation%2520of%2520the%2520PI3K%252FmTOR%2520pathway%2520promotes%2520resistance%2520to%2520sorafenib%2520in%2520AML%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D5119%26epage%3D5131%26doi%3D10.1038%2Fonc.2016.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertacchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Avella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Accordi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barozzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forghieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luppi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najmaldin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosravi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmiroli, S.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.jbior.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29576448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslKls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=2-9&author=J.+Bertacchiniauthor=C.+Frassonauthor=F.+Chiariniauthor=D.+D%E2%80%99Avellaauthor=B.+Accordiauthor=L.+Anselmiauthor=P.+Barozziauthor=F.+Forghieriauthor=M.+Luppiauthor=A.+M.+Martelliauthor=G.+Bassoauthor=S.+Najmaldinauthor=A.+Khosraviauthor=F.+Rahimauthor=S.+Marmiroli&title=Dual+inhibition+of+PI3K%2FmTOR+signaling+in+chemoresistant+AML+primary+cells&doi=10.1016%2Fj.jbior.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells</span></div><div class="casAuthors">Bertacchini, Jessika; Frasson, Chiara; Chiarini, Francesca; D'Avella, Daniele; Accordi, Benedetta; Anselmi, Laura; Barozzi, Patrizia; Foghieri, Fabio; Luppi, Mario; Martelli, Alberto M.; Basso, Giuseppe; Najmaldin, Saki; Khosravi, Abbas; Rahim, Fakher; Marmiroli, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-9</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A main cause of treatment failure for AML patients is resistance to chemotherapy.  Survival of AML cells may depend on mechanisms that elude conventional drugs action and/or on the presence of leukemia initiating cells at diagnosis, and their persistence after therapy.  MDR1 gene is an ATP-dependent drug efflux pump known to be a risk factor for the emergence of resistance, when combined to unstable cytogenetic profile of AML patients.  In the present study, we analyzed the sensitivity to conventional chemotherapeutic drugs of 26 samples of primary blasts collected from AML patients at diagnosis.  Detection of cell viability and apoptosis allowed to identify two group of samples, one resistant and one sensitive to in vitro treatment.  The cells were then analyzed for the presence and the activity of P-glycoprotein.  A comparative anal. showed that resistant samples exhibited a high level of MDR1 mRNA as well as of P-glycoprotein content and activity.  Moreover, they also displayed high PI3K signaling.  Therefore, we checked whether the assocn. with signaling inhibitors might resensitize resistant samples to chemo-drugs.  The combination showed a very potent cytotoxic effect, possibly through down modulation of MDR1, which was maintained also when primary blasts were co-cultured with human stromal cells.  Remarkably, dual PI3K/mTOR inactivation was cytotoxic also to leukemia initiating cells.  All together, our findings indicate that signaling activation profiling assocd. to gene expression can be very useful to stratify patients and improve therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm8xJ3s8ZZU7Vg90H21EOLACvtfcHk0liN67oWUVL_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslKls7k%253D&md5=359542f2e020963c9b1cd3126ea6340d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBertacchini%26aufirst%3DJ.%26aulast%3DFrasson%26aufirst%3DC.%26aulast%3DChiarini%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Avella%26aufirst%3DD.%26aulast%3DAccordi%26aufirst%3DB.%26aulast%3DAnselmi%26aufirst%3DL.%26aulast%3DBarozzi%26aufirst%3DP.%26aulast%3DForghieri%26aufirst%3DF.%26aulast%3DLuppi%26aufirst%3DM.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DNajmaldin%26aufirst%3DS.%26aulast%3DKhosravi%26aufirst%3DA.%26aulast%3DRahim%26aufirst%3DF.%26aulast%3DMarmiroli%26aufirst%3DS.%26atitle%3DDual%2520inhibition%2520of%2520PI3K%252FmTOR%2520signaling%2520in%2520chemoresistant%2520AML%2520primary%2520cells%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2018%26volume%3D68%26spage%3D2%26epage%3D9%26doi%3D10.1016%2Fj.jbior.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6815</span>– <span class="NLM_lpage">6826</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-0832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-19-0832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31320594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslWitL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6815-6826&author=J.+Maauthor=S.+Zhaoauthor=X.+Qiaoauthor=T.+Knightauthor=H.+Edwardsauthor=L.+Polinauthor=J.+Kushnerauthor=S.+H.+Dzinicauthor=K.+Whiteauthor=G.+Wangauthor=L.+Zhaoauthor=H.+Linauthor=Y.+Wangauthor=J.+W.+Taubauthor=Y.+Ge&title=Inhibition+of+Bcl-2+synergistically+enhances+the+antileukemic+activity+of+midostaurin+and+gilteritinib+in+preclinical+models+of+FLT3-mutated+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-19-0832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia</span></div><div class="casAuthors">Ma, Jun; Zhao, Shoujing; Qiao, Xinan; Knight, Tristan; Edwards, Holly; Polin, Lisa; Kushner, Juiwanna; Dzinic, Sijana H.; White, Kathryn; Wang, Guan; Zhao, Lijing; Lin, Hai; Wang, Yue; Taub, Jeffrey W.; Ge, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6815-6826</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute myeloid leukemia (AML) and the underlying mol. mechanism.  Using both FLT3-ITD cell lines and primary patient samples, Annexin V-FITC/propidium iodide staining and flow cytometry anal. were used to quantify cell death induced by midostaurin or gilteritinib, alone or in combination with venetoclax.  The MV4-11-derived xenograft mouse model was used to assess in vivo efficacy of the combination of gilteritinib and venetoclax.  Lentiviral overexpression of Mcl-1 was used to confirm its role in cell death induced by midostaurin or gilteritinib with venetoclax.  Changes of Mcl-1 transcript levels were assessed by RT-PCR.  The combination of midostaurin or gilteritinib with venetoclax potently and synergistically induces apoptosis in FLT3-ITD AML cell lines and primary patient samples.  The FLT3 inhibitors induced downregulation of Mcl-1, enhancing venetoclax activity.  Phosphorylated-ERK expression is induced by venetoclax but abolished by the combination of venetoclax with midostaurin or gilteritinib.  Simultaneous downregulation of Mcl-1 by midostaurin or gilteritinib and inhibition of Bcl-2 by venetoclax results in "free" Bim, leading to synergistic induction of apoptosis.  Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3697_YrfXOLVg90H21EOLACvtfcHk0liN67oWUVL_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslWitL7K&md5=42c28d0013e3db22a2736939b1a75a5f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0832%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DQiao%26aufirst%3DX.%26aulast%3DKnight%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DGe%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520Bcl-2%2520synergistically%2520enhances%2520the%2520antileukemic%2520activity%2520of%2520midostaurin%2520and%2520gilteritinib%2520in%2520preclinical%2520models%2520of%2520FLT3-mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D6815%26epage%3D6826%26doi%3D10.1158%2F1078-0432.CCR-19-0832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Quizartinib (AC220): a promising option for acute myeloid leukemia</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S198950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2147%2FDDDT.S198950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31114157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1117-1125&author=F.+Zhouauthor=Z.+Geauthor=B.+Chen&title=Quizartinib+%28AC220%29%3A+a+promising+option+for+acute+myeloid+leukemia&doi=10.2147%2FDDDT.S198950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib (AC220): a promising option for acute myeloid leukemia</span></div><div class="casAuthors">Zhou, Fang; Ge, Zheng; Chen, Baoan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1117-1125</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells.  Multiple clin. trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation.  In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib.  We also summarize clin. experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation.  Quizartinib presents its advantages as a very promising agent in the treatment of AML, esp. in patients with FLT3-ITD mutations.  FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition.  Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clin. trials.  A larger sample of clin. trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estd. in clin. trials.  Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdQbluP81wNLVg90H21EOLACvtfcHk0liN67oWUVL_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K&md5=c172240b673571ce14933fa6de086b10</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S198950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S198950%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DQuizartinib%2520%2528AC220%2529%253A%2520a%2520promising%2520option%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1117%26epage%3D1125%26doi%3D10.2147%2FDDDT.S198950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1111/cas.14274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fcas.14274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31821677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2020&pages=312-322&author=H.+Kiyoiauthor=N.+Kawashimaauthor=Y.+Ishikawa&title=FLT3+mutations+in+acute+myeloid+leukemia%3A+Therapeutic+paradigm+beyond+inhibitor+development&doi=10.1111%2Fcas.14274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span></div><div class="casAuthors">Kiyoi, Hitoshi; Kawashima, Naomi; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-322</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation.  The most clin. important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic factor in acute myeloid leukemia (AML) patients.  There are two major types of FLT3 mutations: internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) and point mutations or deletion in the tyrosine kinase domain (FLT3-TKD).  Both mutant FLT3 mols. are activated through ligand-independent dimerization and trans-phosphorylation.  Mutant FLT3 induces the activation of multiple intracellular signaling pathways, mainly STAT5, MAPK and AKT signals, leading to cell proliferation and anti-apoptosis.  Because high-dose chemotherapy and allogeneic hematopoietic stem cell transplantation cannot sufficiently improve the prognosis, clin. development of FLT3 kinase inhibitors expected.  Although several FLT3 inhibitors have been developed, it takes more than 20 years from the first identification of FLT3 mutations until FLT3 inhibitors become clin. available for AML patients with FLT3 mutations.  To date, three FLT3 inhibitors have been clin. approved as monotherapy or combination therapy with conventional chemotherapeutic agents in Japan and/or Europe and United states.  However, several mechanisms of resistance to FLT3 inhibitors have already become apparent during their clin. trials.  The resistance mechanisms are complex and emerging resistant clones are heterogenous.  Further basic and clin. studies are required to establish the best therapeutic strategy for AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_Q3ByI5dqLVg90H21EOLACvtfcHk0ljs9fLaIFv56w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP&md5=79c7656f1836b2deda2b8c1203ad9719</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fcas.14274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.14274%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DKawashima%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%253A%2520Therapeutic%2520paradigm%2520beyond%2520inhibitor%2520development%26jtitle%3DCancer%2520Sci.%26date%3D2020%26volume%3D111%26spage%3D312%26epage%3D322%26doi%3D10.1111%2Fcas.14274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larrosa-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in acute myeloid leukemia: current status and future directions</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-16-0876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28576946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=991-1001&author=M.+Larrosa-Garciaauthor=M.+R.+Baer&title=FLT3+inhibitors+in+acute+myeloid+leukemia%3A+current+status+and+future+directions&doi=10.1158%2F1535-7163.MCT-16-0876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions</span></div><div class="casAuthors">Larrosa-Garcia, Maria; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">991-1001</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is expressed on acute myeloid leukemia (AML) cells in most patients.  Mutations of FLT3 resulting in constitutive signaling are common in AML, including internal tandem duplication (ITD) in the juxtamembrane domain in 25% of patients and point mutations in the tyrosine kinase domain in 5%.  Patients with AML with FLT3-ITD have a high relapse rate and short relapse-free and overall survival after chemotherapy and after transplant.  A no. of inhibitors of FLT3 signaling have been identified and are in clin. trials, both alone and with chemotherapy, with the goal of improving clin. outcomes in patients with AML with FLT3 mutations.  While inhibitor monotherapy produces clin. responses, they are usually incomplete and transient, and resistance develops rapidly.  Diverse combination therapies have been suggested to potentiate the efficacy of FLT3 inhibitors and to prevent development of resistance or overcome resistance.  Combinations with epigenetic therapies, proteasome inhibitors, downstream kinase inhibitors, phosphatase activators, and other drugs that alter signaling are being explored.  This review summarizes the current status of translational and clin. research on FLT3 inhibitors in AML, and discusses novel combination approaches.  Mol Cancer Ther; 16(6); 991-1001. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvp5t3cNnh3bVg90H21EOLACvtfcHk0ljs9fLaIFv56w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D&md5=7105f50a6f38c3ce41be4adb82a62413</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0876%26sid%3Dliteratum%253Aachs%26aulast%3DLarrosa-Garcia%26aufirst%3DM.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DFLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D991%26epage%3D1001%26doi%3D10.1158%2F1535-7163.MCT-16-0876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Type II kinase inhibitors: an opportunity in cancer for rational design</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.2174/1871520611313050008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+kinase+inhibitors%3A+an+opportunity+in+cancer+for+rational+design&doi=10.2174%2F1871520611313050008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0ljs9fLaIFv56w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520kinase%2520inhibitors%253A%2520an%2520opportunity%2520in%2520cancer%2520for%2520rational%2520design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747%26doi%3D10.2174%2F1871520611313050008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0ljSLagEvETw6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möbitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Type II inhibitors targeting CDK2</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2116</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2116-2125&author=L.+T.+Alexanderauthor=H.+M%C3%B6bitzauthor=P.+Drueckesauthor=P.+Savitskyauthor=O.+Fedorovauthor=J.+M.+Elkinsauthor=C.+M.+Deaneauthor=S.+W.+Cowan-Jacobauthor=S.+Knapp&title=Type+II+inhibitors+targeting+CDK2&doi=10.1021%2Facschembio.5b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Type II Inhibitors Targeting CDK2</span></div><div class="casAuthors">Alexander, Leila T.; Mobitz, Henrik; Drueckes, Peter; Savitsky, Pavel; Fedorov, Oleg; Elkins, Jonathan M.; Deane, Charlotte M.; Cowan-Jacob, Sandra W.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases can switch between active and inactive conformations of the ATP/Mg2+ binding motif DFG, which has been explored for the development of type I or type II inhibitors.  However, factors modulating DFG conformations remain poorly understood.  We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation.  We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochem. and biophys. characterization of the generated mutants.  As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors.  However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors.  Using protein crystallog. structural anal. of the CDK2 complex with an aminopyrimidine-Ph urea inhibitor (K03861) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 cocrystal structure.  We found that the identified type II inhibitors compete with binding of activating cyclins.  In addn., anal. of the binding kinetics of the identified inhibitors revealed slow off-rates.  The study highlights the importance of residues that may be distant to the ATP binding pocket in modulating the energetics of the DFG-out transition and hence inhibitor binding.  The presented data also provide the foundation for a new class of slow off-rate cyclin-competitive CDK2 inhibitors targeting the inactive DFG-out state of this important kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccF5AnJpk-7Vg90H21EOLACvtfcHk0ljSLagEvETw6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ&md5=dac10d551827decf3574e04f9f981d98</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00398%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BT.%26aulast%3DM%25C3%25B6bitz%26aufirst%3DH.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DDeane%26aufirst%3DC.%2BM.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DType%2520II%2520inhibitors%2520targeting%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2116%26epage%3D2125%26doi%3D10.1021%2Facschembio.5b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3–335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=875-892&author=X.+Liangauthor=B.+Wangauthor=C.+Chenauthor=A.+Wangauthor=C.+Huauthor=F.+Zouauthor=K.+Yuauthor=Q.+Liuauthor=F.+Liauthor=Z.+Huauthor=T.+Luauthor=J.+Wangauthor=L.+Wangauthor=E.+L.+Weisbergauthor=L.+Liauthor=R.+Xiaauthor=W.+Wangauthor=T.+Renauthor=J.+Geauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+N-%284-%286-acetamidopyrimidin-4-yloxy%29phenyl%29-2-%282-%28trifluoromethyl%29phenyl%29acetamide+%28CHMFL-FLT3%E2%80%93335%29+as+a+potent+FMS-like+tyrosine+kinase+3+internal+tandem+duplication+%28FLT3-ITD%29+mutant+selective+inhibitor+for+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.8b01594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia</span></div><div class="casAuthors">Liang, Xiaofei; Wang, Beilei; Chen, Cheng; Wang, Aoli; Hu, Chen; Zou, Fengming; Yu, Kailin; Liu, Qingwang; Li, Feng; Hu, Zhenquan; Lu, Tingting; Wang, Junjie; Wang, Li; Weisberg, Ellen L.; Li, Lili; Xia, Ruixiang; Wang, Wenchao; Ren, Tao; Ge, Jian; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">875-892</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most of the current FMS-like tyrosine kinase 3 (FLT3) inhibitors lack selectivity between FLT3 kinase and cKIT kinase as well as the FLT3 wt and internal tandem duplication (ITD) mutants.  We report a new compd. I, which displays GI50 values of 30-80 nM against different ITD mutants and achieves selectivity over both FLT3 wt (8-fold) and cKIT kinase in the transformed BaF3 cells (>300-fold). I potently inhibits the proliferation of the FLT3-ITD-pos. acute myeloid leukemia cancer lines through suppression of the phosphorylation of FLT3 kinase and downstream signaling pathways, induction of apoptosis, and arresting the cell cycle into the G0/G1 phase. I also displays potent antiproliferative effect against FLT3-ITD-pos. patient primary cells, whereas it does not apparently affect FLT3 wt primary cells.  In addn., it also exhibits a good therapeutic window to PBMC compared to PKC412.  In the in vivo studies, I demonstrates favorable PK profiles and suppresses the tumor growth in the MV4-11 cell inoculated mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdi_MAkOsXkLVg90H21EOLACvtfcHk0lg_IUo48x8A8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE&md5=b802859e517d8156353481f41128f7a1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01594%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520N-%25284-%25286-acetamidopyrimidin-4-yloxy%2529phenyl%2529-2-%25282-%2528trifluoromethyl%2529phenyl%2529acetamide%2520%2528CHMFL-FLT3%25E2%2580%2593335%2529%2520as%2520a%2520potent%2520FMS-like%2520tyrosine%2520kinase%25203%2520internal%2520tandem%2520duplication%2520%2528FLT3-ITD%2529%2520mutant%2520selective%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D875%26epage%3D892%26doi%3D10.1021%2Facs.jmedchem.8b01594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.phrs.2015.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26529477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=26-48&author=R.+Roskoski&title=Classification+of+small+molecule+protein+kinase+inhibitors+based+upon+the+structures+of+their+drug-enzyme+complexes&doi=10.1016%2Fj.phrs.2015.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-48</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because dysregulation and mutations of protein kinases play causal roles in human disease, this family of enzymes has become one of the most important drug targets over the past two decades.  The X-ray crystal structures of 21 of the 27 FDA-approved small mol. inhibitors bound to their target protein kinases are depicted in this paper.  The structure of the enzyme-bound antagonist complex is used in the classification of these inhibitors.  Type I inhibitors bind to the active protein kinase conformation (DFG-Asp in, αC-helix in).  Type I1/2 inhibitors bind to a DFG-Asp in inactive conformation while Type II inhibitors bind to a DFG-Asp out inactive conformation.  Type I, I1/2, and type II inhibitors occupy part of the adenine binding pocket and form hydrogen bonds with the hinge region connecting the small and large lobes of the enzyme.  Type III inhibitors bind next to the ATP-binding pocket and type IV inhibitors do not bind to the ATP or peptide substrate binding sites.  Type III and IV inhibitors are allosteric in nature.  Type V inhibitors bind to two different regions of the protein kinase domain and are therefore bivalent inhibitors.  The type I-V inhibitors are reversible.  In contrast, type VI inhibitors bind covalently to their target enzyme.  Type I, I1/2, and II inhibitors are divided into A and B subtypes.  The type A inhibitors bind in the front cleft, the back cleft, and near the gatekeeper residue, all of which occur within the region sepg. the small and large lobes of the protein kinase.  The type B inhibitors bind in the front cleft and gate area but do not extend into the back cleft.  An anal. of the limited available data indicates that type A inhibitors have a long residence time (minutes to hours) while the type B inhibitors have a short residence time (seconds to minutes).  The catalytic spine includes residues from the small and large lobes and interacts with the adenine ring of ATP.  Nearly all of the approved protein kinase inhibitors occupy the adenine-binding pocket; thus it is not surprising that these inhibitors interact with nearby catalytic spine (CS) residues.  Moreover, a significant no. of approved drugs also interact with regulatory spine (RS) residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0COwqC0CabVg90H21EOLACvtfcHk0lg_IUo48x8A8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN&md5=e6b45c8644e322f30f898e763780c64b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DClassification%2520of%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%2520based%2520upon%2520the%2520structures%2520of%2520their%2520drug-enzyme%2520complexes%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D103%26spage%3D26%26epage%3D48%26doi%3D10.1016%2Fj.phrs.2015.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirazian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1021/jm0204183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase&doi=10.1021%2Fjm0204183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lg_IUo48x8A8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119%26doi%3D10.1021%2Fjm0204183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Farrell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngai, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolich, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrington, J. M.</span></span> <span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3597</span>– <span class="NLM_lpage">3605</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-07-2307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2002-07-2307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=12531805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2002-07-2307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span></div><div class="casAuthors">O'Farrell, Anne-Marie; Abrams, Tinya J.; Yuen, Helene A.; Ngai, Theresa J.; Louie, Sharianne G.; Yee, Kevin W. H.; Wong, Lily M.; Hong, Weiru; Lee, Leslie B.; Town, Ajia; Smolich, Beverly D.; Manning, William C.; Murray, Lesley J.; Heinrich, Michael C.; Cherrington, Julie M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3597-3605</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells.  In blasts from acute myelogenous leukemia (AML) patients, 2 classes of FLT3 activating mutations have been identified: internal tandem duplication (ITD) mutations in the juxtamembrane domain (25%-30% of patients) and point mutations in the kinase domain activation loop (7%-8% of patients).  FLT3-ITD mutations are the most common mol. defect identified in AML and have been shown to be an independent prognostic factor for decreased survival.  FLT3-ITD is therefore an attractive mol. target for therapy.  SU11248 is a recently described selective inhibitor with selectivity for split kinase domain RTKs, including platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and KIT.  We show that SU11248 also has potent activity against wild-type FLT3 (FLT3-WT), FLT3-ITD, and FLT3 activation loop (FLT3-Asp835) mutants in phosphorylation assays.  SU11248 inhibits FLT3-driven phosphorylation and induces apoptosis in vitro.  In addn., SU11248 inhibits FLT3-induced VEGF prodn.  The in vivo efficacy of SU11248 was investigated in 2 FLT3-ITD models: a s.c. tumor xenograft model and a bone marrow engraftment model.  We show that SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the s.c. tumor xenograft model and prolongs survival in the bone marrow engraftment model.  Pharmacokinetic and pharmacodynamic anal. in s.c. tumors showed that a single administration of an efficacious drug dose potently inhibits FLT3-ITD phosphorylation for up to 16 h following a single dose.  These results suggest that further exploration of SU11248 activity in AML patients is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUcmQRlrUD7Vg90H21EOLACvtfcHk0lhiRlf-EZ7ZQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D&md5=f996fe320ccf9449951baf97e372c694</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-07-2307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-07-2307%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605%26doi%3D10.1182%2Fblood-2002-07-2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schittenhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göhring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1111/bjh.13353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fbjh.13353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25818407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2015&pages=694-700&author=W.+Fiedlerauthor=S.+Kayserauthor=M.+Kebenkoauthor=M.+Janningauthor=J.+Krauterauthor=M.+Schittenhelmauthor=K.+G%C3%B6tzeauthor=D.+Weberauthor=G.+G%C3%B6hringauthor=V.+Teleanuauthor=F.+Tholauthor=M.+Heuserauthor=K.+D%C3%B6hnerauthor=A.+Ganserauthor=H.+D%C3%B6hnerauthor=R.+F.+Schlenk&title=A+phase+I%2FII+study+of+sunitinib+and+intensive+chemotherapy+in+patients+over+60+years+of+age+with+acute+myeloid+leukaemia+and+activating+FLT3+mutations&doi=10.1111%2Fbjh.13353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations</span></div><div class="casAuthors">Fiedler, Walter; Kayser, Sabine; Kebenko, Maxim; Janning, Melanie; Krauter, Juergen; Schittenhelm, Marcus; Goetze, Katharina; Weber, Daniela; Goehring, Gudrun; Teleanu, Veronica; Thol, Felicitas; Heuser, Michael; Doehner, Konstanze; Ganser, Arnold; Doehner, Hartmut; Schlenk, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">694-700</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Acute myeloid leukemia (AML) with FLT3 mutation has a dismal prognosis in elderly patients.  Treatment with a combination of FLT3 inhibitors and std. chemotherapy has not been extensively studied.  Therefore, we instigated a phase I/II clin. trial of chemotherapy with cytosine arabinoside (Ara-C)/daunorubicin induction (7+3) followed by three cycles of intermediate-dose Ara-C consolidation in 22 AML patients with activating FLT3 mutations.  Sunitinib was added at predefined dose levels and as maintenance therapy for 2 years.  At dose level 1, sunitinib 25 mg daily continuously from day 1 onwards resulted in two cases with dose-limiting toxicity (DLT), prolonged hemotoxicity and hand-foot syndrome.  At dose level -1, sunitinib 25 mg was restricted to days 1-7 of each chemotherapy cycle.  One DLT was obsd. in six evaluable patients.  Six addnl. patients were treated in an extension phase.  Thirteen of 22 patients (59%; 8/14 with FLT3-internal tandem duplication and 5/8 with FLT3-tyrosine kinase domain) achieved a complete remission/complete remission with incomplete blood count recovery.  For the 17 patients included at the lower dose level, median overall, relapse-free and event-free survival were 1·6, 1·0 and 0·4 years, resp.  Four out of five analyzed patients with relapse during maintenance therapy lost their initial FLT3 mutation, suggesting outgrowth of FLT3 wild-type subclones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsGdfSxoqKHbVg90H21EOLACvtfcHk0lhiRlf-EZ7ZQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVajtrY%253D&md5=3baaa85250fb6c3e9f03109a17f7eb42</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13353%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DKebenko%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DSchittenhelm%26aufirst%3DM.%26aulast%3DG%25C3%25B6tze%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DD.%26aulast%3DG%25C3%25B6hring%26aufirst%3DG.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520sunitinib%2520and%2520intensive%2520chemotherapy%2520in%2520patients%2520over%252060%2520years%2520of%2520age%2520with%2520acute%2520myeloid%2520leukaemia%2520and%2520activating%2520FLT3%2520mutations%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D169%26spage%3D694%26epage%3D700%26doi%3D10.1111%2Fbjh.13353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNabola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shujath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eveleigh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voznesensky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7099</span>– <span class="NLM_lpage">7109</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F0008-5472.CAN-04-1443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=15466206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43%E2%80%939006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis&doi=10.1158%2F0008-5472.CAN-04-1443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span></div><div class="casAuthors">Wilhelm, Scott M.; Carter, Christopher; Tang, LiYa; Wilkie, Dean; McNabola, Angela; Rong, Hong; Chen, Charles; Zhang, Xiaomei; Vincent, Patrick; McHugh, Mark; Cao, Yichen; Shujath, Jaleel; Gawlak, Susan; Eveleigh, Deepa; Rowley, Bruce; Liu, Li; Adnane, Lila; Lynch, Mark; Auclair, Daniel; Taylor, Ian; Gedrich, Rich; Voznesensky, Andrei; Riedl, Bernd; Post, Leonard E.; Bollag, Gideon; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7099-7109</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis.  The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/MEK/ERK signaling pathway.  Addnl. characterization showed that BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro.  In addn., BAY 43-9006 demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, platelet-derived growth factor receptor β, Flt-3, and c-KIT.  In cellular mechanistic assays, BAY 43-9006 demonstrated inhibition of the mitogen-activated protein kinase pathway in colon, pancreatic, and breast tumor cell lines expressing mutant KRAS or wild-type or mutant BRAF, whereas non-small-cell lung cancer cell lines expressing mutant KRAS were insensitive to inhibition of the mitogen-activated protein kinase pathway by BAY 43-9006.  Potent inhibition of VEGFR-2, platelet-derived growth factor receptor β, and VEGFR-3 cellular receptor autophosphorylation was also obsd. for BAY 43-9006.  Once daily oral dosing of BAY 43-9006 demonstrated broad-spectrum antitumor activity in colon, breast, and non-small-cell lung cancer xenograft models.  Immunohistochem. demonstrated a close assocn. between inhibition of tumor growth and inhibition of the extracellular signal-regulated kinases (ERKs) 1/2 phosphorylation in two of three xenograft models examd., consistent with inhibition of the RAF/MEK/ERK pathway in some but not all models.  Addnl. analyses of microvessel d. and microvessel area in the same tumor sections using antimurine CD31 antibodies demonstrated significant inhibition of neovascularization in all three of the xenograft models.  These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy8IcVRGBZgbVg90H21EOLACvtfcHk0lhiRlf-EZ7ZQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFalsbk%253D&md5=4b92eb31d557009652349e4f9645b9f0</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043%25E2%2580%25939006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109%26doi%3D10.1158%2F0008-5472.CAN-04-1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shacham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span> <span> </span><span class="NLM_article-title">Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial</span>. <i>Haematologica.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1653</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.185082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3324%2Fhaematol.2017.185082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29773601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=1642-1653&author=W.+Zhangauthor=C.+Lyauthor=J.+Ishizawaauthor=H.+Muauthor=V.+Ruvoloauthor=S.+Shachamauthor=N.+Daverauthor=M.+Andreeff&title=Combinatorial+targeting+of+XPO1+and+FLT3+exerts+synergistic+anti-leukemia+effects+through+induction+of+differentiation+and+apoptosis+in+FLT3-mutated+acute+myeloid+leukemias%3A+from+concept+to+clinical+trial&doi=10.3324%2Fhaematol.2017.185082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial</span></div><div class="casAuthors">Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo; Mu, Hong; Ruvolo, Vivian; Shacham, Sharon; Daver, Naval; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1642-1653</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clin. efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K/AKT, and STAT5.  Activation of these addnl. kinases may also result in phosphorylation of tumor suppressor proteins promoting their nuclear export.  Thus, co-targeting nuclear export proteins (e.g., XPO1) and FLT3 concomitantly may be therapeutically effective.  Here we report on the combinatorial inhibition of XPO1 using selinexor and FLT3 using sorafenib.  Selinexor exerted marked cell killing of human and murine FLT3-mutant acute myeloid leukemia cells, including those harboring internal tandem duplication and/or tyrosine kinase domain point mutations.  Interestingly, selinexor treatment of murine FLT3-mutant acute myeloid leukemia cells activated FLT3 and its downstream MAPK or AKT signaling pathways.  When combined with sorafenib, selinexor triggered marked synergistic pro-apoptotic effects.  This was preceded by elevated nuclear levels of ERK, AKT, NFκB, and FOXO3a.  Five days of in vitro combination treatment using low doses (i.e., 5 to 10 nM) of each agent promoted early myeloid differentiation of MOLM13 and MOLM14 cells without noticeable cell killing.  The combinatorial therapy demonstrated profound in vivo anti-leukemia efficacy in a human FLT3- mutated xenograft model.  In an ongoing phase IB clin. trial the selinexor/ sorafenib combination induced complete/partial remissions in six of 14 patients with refractory acute myeloid leukemia, who had received a median of three prior therapies (ClinicalTrials.gov: NCT02530476).  These results provide pre-clin. and clin. evidence for an effective combinatorial treatment strategy targeting XPO1 and FLT3 in FLT3- mutated acute myeloid leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMRh5rQBQPWrVg90H21EOLACvtfcHk0ljPJXjTze9SyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjt7nN&md5=55763028facdecd4c23d9ba6adfdaf5c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.185082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.185082%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DC.%26aulast%3DIshizawa%26aufirst%3DJ.%26aulast%3DMu%26aufirst%3DH.%26aulast%3DRuvolo%26aufirst%3DV.%26aulast%3DShacham%26aufirst%3DS.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DCombinatorial%2520targeting%2520of%2520XPO1%2520and%2520FLT3%2520exerts%2520synergistic%2520anti-leukemia%2520effects%2520through%2520induction%2520of%2520differentiation%2520and%2520apoptosis%2520in%2520FLT3-mutated%2520acute%2520myeloid%2520leukemias%253A%2520from%2520concept%2520to%2520clinical%2520trial%26jtitle%3DHaematologica.%26date%3D2018%26volume%3D103%26spage%3D1642%26epage%3D1653%26doi%3D10.3324%2Fhaematol.2017.185082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mett, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(99)00005-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS0163-7258%2899%2900005-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10454207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=293-301&author=D.+Fabbroauthor=E.+Buchdungerauthor=J.+Woodauthor=J.+Mestanauthor=F.+Hofmannauthor=S.+Ferrariauthor=H.+Mettauthor=T.+O%E2%80%99Reillyauthor=T.+Meyer&title=Inhibitors+of+protein+kinases%3A+CGP+41251%2C+a+protein+kinase+inhibitor+with+potential+as+an+anticancer+agent&doi=10.1016%2FS0163-7258%2899%2900005-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent</span></div><div class="casAuthors">Fabbro, Doriano; Buchdunger, Elisabeth; Wood, Jeannette; Mestan, Jurgen; Hofmann, Francesco; Ferrari, Stefano; Mett, Helmut; O'Reilly, Terence; Meyer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">293-301</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with many refs.  CGP 41251 was originally identified as an inhibitor of protein kinase C (PKC), inhibiting mainly the conventional PKC subtypes, and subsequently shown to inhibit the vascular endothelial growth factor (VEGF) receptor kinase insert domain-contg. receptor, which is involved in angiogenesis.  CGP 41251 inhibits reversibly intracellular PKC activity, induction of c-fos and the corresponding activation of the mitogen-activated protein kinase induced by either tumor promoting phorbol esters, platelet-derived growth factor, or basic fibroblast growth factor, but not by the epidermal growth factor.  CGP 41251 inhibited the ligand-induced autophosphorylation of the receptors for platelet-derived growth factor, stem cell factor, and VEGF (kinase insert domain-contg. receptor) that correlated with the inhibition of the mitogen-activated protein kinase activation, but did not affect the ligand-induced autophosphorylation of the receptors for insulin, insulin-like growth factor-I, or epidermal growth factor.  CGP 41251 showed broad antiproliferative activity against various tumor and normal cell lines in vitro, and is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro.  CGP 41251 showed in vivo antitumor activity as single agent and inhibited angiogenesis in vivo.  Thus, CGP 41251 may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addn. to directly inhibiting tumor cell proliferation (via its effects on PKCs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc-p7mVgqqZrVg90H21EOLACvtfcHk0ljPJXjTze9SyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOhtLY%253D&md5=00ea18d0abc5871a8d9bc4b420b3ab3c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2899%2900005-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252899%252900005-4%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DInhibitors%2520of%2520protein%2520kinases%253A%2520CGP%252041251%252C%2520a%2520protein%2520kinase%2520inhibitor%2520with%2520potential%2520as%2520an%2520anticancer%2520agent%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D293%26epage%3D301%26doi%3D10.1016%2FS0163-7258%2899%2900005-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4479</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-07-101238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2007-07-101238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=17827387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Wr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=4476-4479&author=E.+V.+Barryauthor=J.+J.+Clarkauthor=J.+Coolsauthor=J.+Roeselauthor=D.+G.+Gilliland&title=Uniform+sensitivity+of+FLT3+activation+loop+mutants+to+the+tyrosine+kinase+inhibitor+midostaurin&doi=10.1182%2Fblood-2007-07-101238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span></div><div class="casAuthors">Barry, Elly V.; Clark, Jennifer J.; Cools, Jan; Roesel, Johannes; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4476-4479</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Small mol. inhibitors that target fms-like tyrosine kinase 3 (FLT3)-activating mutations have potential in the treatment of leukemias.  However, certain mutations can simultaneously activate the tyrosine kinase, and confer resistance to small mol. inhibitors.  We therefore tested the sensitivity of 8 FLT3 activation loop mutants to midostaurin.  Each mutant conferred IL-3 factor-independent proliferation to Ba/F3 cells, and each resulted in the constitutive activation of FLT3 and its targets, signal transducer and activator of transcription 5 (STAT5) and extracellular stimuli-responsive kinase (ERK).  For each mutant tested, midostaurin inhibited cell growth and phosphorylation of FLT3, STAT5, and ERK.  In contrast, midostaruin did not inhibit Ba/F3 cells stably transduced with FLT3-internal tandem duplications contg. a G697R mutation that confers resistance to midostaurin, demonstrating that midostaurin inhibition of FLT3 activation loop mutants was not due to off-target effects.  We conclude that midostaurin is a potent inhibitor of a spectrum of FLT3 activation loop mutations, and that acute myeloid leukemia patients with such mutations are potential candidates for clin. trials involving midostaurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdwABqNKHecLVg90H21EOLACvtfcHk0ljPJXjTze9SyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Wr&md5=a4093ba0c60d4c239226a25eba2a266c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-07-101238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-07-101238%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DE.%2BV.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DUniform%2520sensitivity%2520of%2520FLT3%2520activation%2520loop%2520mutants%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520midostaurin%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D4476%26epage%3D4479%26doi%3D10.1182%2Fblood-2007-07-101238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilkes, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A. K.</span></span> <span> </span><span class="NLM_article-title">The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">3494</span>– <span class="NLM_lpage">3503</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-04-015487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2006-04-015487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16868253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3494-3503&author=S.+Knapperauthor=K.+I.+Millsauthor=A.+F.+Gilkesauthor=S.+J.+Austinauthor=V.+Walshauthor=A.+K.+Burnett&title=The+effects+of+lestaurtinib+%28CEP701%29+and+PKC412+on+primary+AML+blasts%3A+the+induction+of+cytotoxicity+varies+with+dependence+on+FLT3+signaling+in+both+FLT3-mutated+and+wild-type+cases&doi=10.1182%2Fblood-2006-04-015487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases</span></div><div class="casAuthors">Knapper, Steven; Mills, Kenneth I.; Gilkes, Amanda F.; Austin, Steve J.; Walsh, Val; Burnett, Alan K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3494-3503</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase FLT3 is a promising mol. therapeutic target in acute myeloid leukemia (AML).  Activating mutations of FLT3 are present in approx. 1/3 of patients, while many nonmutants show evidence of FLT3 activation, which appears to play a significant role in leukemogenesis.  We studied the effects of lestaurtinib (CEP701) and PKC412, 2 small mol. inhibitors of FLT3, on 65 diagnostic AML blast samples.  Both agents induced concn.-dependent cytotoxicity in most cases, although responses to PKC412 required higher drug concns.  Cytotoxic responses were highly heterogeneous and were only weakly assocd. with FLT3 mutation status and FLT3 expression.  Importantly, lestaurtinib induced cytotoxicity in a synergistic fashion with cytarabine, particularly in FLT3 mutant samples.  Both lestaurtinib and PKC412 caused inhibition of FLT3 phosphorylation in all samples.  Translation of FLT3 inhibition into cytotoxicity was influenced by the degree of residual FLT3 phosphorylation remaining and correlated with deactivation of STAT5 and MAP kinase.  FLT3 mutant and wild-type cases both varied considerably in their dependence on FLT3 signaling for survival.  These findings support the continued clin. assessment of FLT3 inhibitors in combination with cytotoxic chemotherapy: Entry to future clin. trials should include FLT3 wild-type patients and should remain unrestricted by FLT3 expression level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ULL0PPxlqrVg90H21EOLACvtfcHk0lg5GGDQIRiD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzL&md5=cdcb226038e720a73725cee8371ebc4b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-04-015487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-04-015487%26sid%3Dliteratum%253Aachs%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DK.%2BI.%26aulast%3DGilkes%26aufirst%3DA.%2BF.%26aulast%3DAustin%26aufirst%3DS.%2BJ.%26aulast%3DWalsh%26aufirst%3DV.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26atitle%3DThe%2520effects%2520of%2520lestaurtinib%2520%2528CEP701%2529%2520and%2520PKC412%2520on%2520primary%2520AML%2520blasts%253A%2520the%2520induction%2520of%2520cytotoxicity%2520varies%2520with%2520dependence%2520on%2520FLT3%2520signaling%2520in%2520both%2520FLT3-mutated%2520and%2520wild-type%2520cases%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3494%26epage%3D3503%26doi%3D10.1182%2Fblood-2006-04-015487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allebach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">3885</span>– <span class="NLM_lpage">3891</span>, <span class="refDoi"> DOI: 10.1182/blood.V99.11.3885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood.V99.11.3885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=12010785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=3885-3891&author=M.+Levisauthor=J.+Allebachauthor=K.+F.+Tseauthor=R.+Zhengauthor=B.+R.+Baldwinauthor=B.+D.+Smithauthor=S.+Jones-Bolinauthor=B.+Ruggeriauthor=C.+Dionneauthor=D.+Small&title=A+FLT3-targeted+tyrosine+kinase+inhibitor+is+cytotoxic+to+leukemia+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood.V99.11.3885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span></div><div class="casAuthors">Levis, Mark; Allebach, Jeffrey; Tse, Kam-Fai; Zheng, Rui; Baldwin, Brenda R.; Smith, B. Douglas; Jones-Bolin, Susan; Ruggeri, Bruce; Dionne, Craig; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3885-3891</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutively activating internal tandem duplication (ITD) and point mutations of the receptor tyrosine kinase FLT3 are present in ≤41% of patients with acute myeloid leukemia (AML).  These FLT3/ITD mutations are likely to be important because their presence is assocd. with a poor prognosis.  Both types of mutations appear to activate the tyrosine kinase activity of FLT3.  The authors describe here the identification and characterization of the indolocarbazole deriv. CEP-701 as a FLT3 inhibitor.  This drug potently and selectively inhibits autophosphorylation of wild-type and constitutively activated mutant FLT3 in vitro in FLT3/ITD-transfected cells and in human FLT3-expressing myeloid leukemia-derived cell lines.  The authors demonstrate that CEP-701 induces a cytotoxic effect on cells in a dose-responsive fashion that parallels the inhibition of FLT3.  STAT5 and ERK1/2, downstream targets of FLT3 in the signaling pathway, are inhibited in response to FLT3 inhibition.  In primary leukemia blasts from AML patients harboring FLT3/ITD mutations, FLT3 is also inhibited, with an assocd. cytotoxic response.  Finally, using a mouse model of FLT3/ITD leukemia, the authors demonstrate that the drug inhibits FLT3 phosphorylation in vivo and prolongs survival.  These findings form the basis for a planned clin. trial of CEP-701 in patients with AML harboring FLT3-activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXL7nbYZzBSrVg90H21EOLACvtfcHk0lg5GGDQIRiD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D&md5=3808e2bf314d769c9ae1c11324df4aba</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.11.3885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.11.3885%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DB.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520FLT3-targeted%2520tyrosine%2520kinase%2520inhibitor%2520is%2520cytotoxic%2520to%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D3885%26epage%3D3891%26doi%3D10.1182%2Fblood.V99.11.3885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hills, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovanovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runglall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valganon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khwaja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ommen, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overgaard, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitzky-Basso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolousis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danby, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnegan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craddock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spearing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span> <span> </span><span class="NLM_article-title">Molecular MRD status and outcome after transplantation in NPM1-mutated AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1182/blood.2019002959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood.2019002959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31932839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVGrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2020&pages=680-688&author=R.+Dillonauthor=R.+Hillsauthor=S.+Freemanauthor=N.+Potterauthor=J.+Jovanovicauthor=A.+Iveyauthor=A.+S.+Kandaauthor=M.+Runglallauthor=N.+Footauthor=M.+Valganonauthor=A.+Khwajaauthor=J.+Cavenaghauthor=M.+Smithauthor=H.+B.+Ommenauthor=U.+M.+Overgaardauthor=M.+Dennisauthor=S.+Knapperauthor=H.+Kaurauthor=D.+Taussigauthor=P.+Mehtaauthor=K.+Rajauthor=I.+Novitzky-Bassoauthor=E.+Nikolousisauthor=R.+Danbyauthor=P.+Krishnamurthyauthor=K.+Hillauthor=D.+Finneganauthor=S.+Alimamauthor=E.+Hurstauthor=P.+Johnsonauthor=A.+Khanauthor=R.+Salimauthor=C.+Craddockauthor=R.+Spearingauthor=A.+Gilkesauthor=R.+Galeauthor=A.+Burnettauthor=N.+H.+Russellauthor=D.+Grimwade&title=Molecular+MRD+status+and+outcome+after+transplantation+in+NPM1-mutated+AML&doi=10.1182%2Fblood.2019002959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular MRD status and outcome after transplantation in NPM1-mutated AML</span></div><div class="casAuthors">Dillon, Richard; Hills, Robert; Freeman, Sylvie; Potter, Nicola; Jovanovic, Jelena; Ivey, Adam; Kanda, Anju Shankar; Runglall, Manohursingh; Foot, Nicola; Valganon, Mikel; Khwaja, Asim; Cavenagh, Jamie; Smith, Matthew; Ommen, Hans Beier; Overgaard, Ulrik Malthe; Dennis, Mike; Knapper, Steven; Kaur, Harpreet; Taussig, David; Mehta, Priyanka; Raj, Kavita; Novitzky-Basso, Igor; Nikolousis, Emmanouil; Danby, Robert; Krishnamurthy, Pramila; Hill, Kate; Finnegan, Damian; Alimam, Samah; Hurst, Erin; Johnson, Peter; Khan, Anjum; Salim, Rahuman; Craddock, Charles; Spearing, Ruth; Gilkes, Amanda; Gale, Rosemary; Burnett, Alan; Russell, Nigel H.; Grimwade, David</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">680-688</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Relapse remains the most common cause of treatment failure for patients with acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prognosis.  Multiple studies have identified the presence of measurable residual disease (MRD) assessed by flow cytometry before alloSCT as a strong predictor of relapse, but it is not clear how these findings apply to patients who test pos. in mol. MRD assays, which have far greater sensitivity.  We analyzed pretransplant blood and bone marrow samples by reverse-transcription polymerase chain reaction in 107 patients with NPM1-mutant AML enrolled in the UK National Cancer Research Institute AML17 study.  After a median follow-up of 4.9 years, patients with neg., low (<200 copies per 105 ABL in the peripheral blood and <1000 copies in the bone marrow aspirate), and high levels of MRD had an estd. 2-yr overall survival (2y-OS) of 83%, 63%, and 13%, resp. (P < .0001).  Focusing on patients with low-level MRD before alloSCT, those with FLT3 internal tandem duplications (ITDs) had significantly poorer outcome (hazard ratio [HR], 6.14; P = .01).  T-depletion was assocd. with significantly reduced survival both in the entire cohort (2y-OS, 56% vs 96%; HR, 3.24; P = .0005) and in MRD-pos. patients (2y-OS, 34% vs 100%; HR, 3.78; P = .003), but there was no significant effect of either conditioning regimen or donor source on outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEa5acML_SzrVg90H21EOLACvtfcHk0lg5GGDQIRiD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVGrt74%253D&md5=e5e8165dd6ae2ebcb2311893d691ecbc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1182%2Fblood.2019002959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2019002959%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DR.%26aulast%3DHills%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DPotter%26aufirst%3DN.%26aulast%3DJovanovic%26aufirst%3DJ.%26aulast%3DIvey%26aufirst%3DA.%26aulast%3DKanda%26aufirst%3DA.%2BS.%26aulast%3DRunglall%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DN.%26aulast%3DValganon%26aufirst%3DM.%26aulast%3DKhwaja%26aufirst%3DA.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DOmmen%26aufirst%3DH.%2BB.%26aulast%3DOvergaard%26aufirst%3DU.%2BM.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DH.%26aulast%3DTaussig%26aufirst%3DD.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DRaj%26aufirst%3DK.%26aulast%3DNovitzky-Basso%26aufirst%3DI.%26aulast%3DNikolousis%26aufirst%3DE.%26aulast%3DDanby%26aufirst%3DR.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DK.%26aulast%3DFinnegan%26aufirst%3DD.%26aulast%3DAlimam%26aufirst%3DS.%26aulast%3DHurst%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DSalim%26aufirst%3DR.%26aulast%3DCraddock%26aufirst%3DC.%26aulast%3DSpearing%26aufirst%3DR.%26aulast%3DGilkes%26aufirst%3DA.%26aulast%3DGale%26aufirst%3DR.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DGrimwade%26aufirst%3DD.%26atitle%3DMolecular%2520MRD%2520status%2520and%2520outcome%2520after%2520transplantation%2520in%2520NPM1-mutated%2520AML%26jtitle%3DBlood%26date%3D2020%26volume%3D135%26spage%3D680%26epage%3D688%26doi%3D10.1182%2Fblood.2019002959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apatira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curley, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarborough, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokker, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, N. A.</span></span> <span> </span><span class="NLM_article-title">CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(02)00070-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS1535-6108%2802%2900070-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=12124172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVKjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=421-432&author=L.+M.+Kellyauthor=J.+C.+Yuauthor=C.+L.+Boultonauthor=M.+Apatiraauthor=J.+Liauthor=C.+M.+Sullivanauthor=I.+Williamsauthor=S.+M.+Amaralauthor=D.+P.+Curleyauthor=N.+Duclosauthor=D.+Neubergauthor=R.+M.+Scarboroughauthor=A.+Pandeyauthor=S.+Hollenbachauthor=K.+Abeauthor=N.+A.+Lokkerauthor=D.+G.+Gillilandauthor=N.+A.+Giese&title=CT53518%2C+a+novel+selective+FLT3+antagonist+for+the+treatment+of+acute+myelogenous+leukemia+%28AML%29&doi=10.1016%2FS1535-6108%2802%2900070-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)</span></div><div class="casAuthors">Kelly, Louise M.; Yu, Jin-Chen; Boulton, Christina L.; Apatira, Mutiah; Li, Jason; Sullivan, Carol M.; Williams, Ifor; Amaral, Sonia M.; Curley, David P.; Duclos, Nicole; Neuberg, Donna; Scarborough, Robert M.; Pandey, Anjali; Hollenbach, Stanley; Abe, Keith; Lokker, Nathalie A.; Gilliland, D. Gary; Giese, Neill A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-432</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy.  For this purpose we have developed CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit (IC50 ∼200 nM), while other tyrosine or serine/threonine kinases were not significantly inhibited.  In Ba/F3 cells expressing different FLT3-ITD mutants, CT53518 inhibited IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10-100 nM.  In human FLT3-ITD-pos. AML cell lines, CT53518 induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways.  Therapeutic efficacy of CT53518 was demonstrated both in a nude mouse model and in a murine bone marrow transplant model of FLT3-ITD-induced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5ZTWex8ZXLrVg90H21EOLACvtfcHk0lgagtuH19ypBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVKjsLc%253D&md5=5ef6442b8ff343aea4687b89693a506c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900070-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900070-3%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DYu%26aufirst%3DJ.%2BC.%26aulast%3DBoulton%26aufirst%3DC.%2BL.%26aulast%3DApatira%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DC.%2BM.%26aulast%3DWilliams%26aufirst%3DI.%26aulast%3DAmaral%26aufirst%3DS.%2BM.%26aulast%3DCurley%26aufirst%3DD.%2BP.%26aulast%3DDuclos%26aufirst%3DN.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DLokker%26aufirst%3DN.%2BA.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCT53518%252C%2520a%2520novel%2520selective%2520FLT3%2520antagonist%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520%2528AML%2529%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D1%26spage%3D421%26epage%3D432%26doi%3D10.1016%2FS1535-6108%2802%2900070-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namuyinga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30150-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS1470-2045%2819%2930150-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31175001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=984-997&author=J.+E.+Cortesauthor=S.+Khaledauthor=G.+Martinelliauthor=A.+E.+Perlauthor=S.+Gangulyauthor=N.+Russellauthor=A.+Kr%C3%A4merauthor=H.+Dombretauthor=D.+Hoggeauthor=B.+A.+Jonasauthor=A.+Y.+Leungauthor=P.+Mehtaauthor=P.+Montesinosauthor=M.+Radsakauthor=S.+Sicaauthor=M.+Arunachalamauthor=M.+Holmesauthor=K.+Kobayashiauthor=R.+Namuyingaauthor=N.+Geauthor=A.+Yverauthor=Y.+Zhangauthor=M.+J.+Levis&title=Quizartinib+versus+salvage+chemotherapy+in+relapsed+or+refractory+FLT3-ITD+acute+myeloid+leukaemia+%28QuANTUM-R%29%3A+a+multicentre%2C+randomised%2C+controlled%2C+open-label%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2819%2930150-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span></div><div class="casAuthors">Cortes, Jorge E.; Khaled, Samer; Martinelli, Giovanni; Perl, Alexander E.; Ganguly, Siddhartha; Russell, Nigel; Kramer, Alwin; Dombret, Herve; Hogge, Donna; Jonas, Brian A.; Leung, Anskar Yu-Hung; Mehta, Priyanka; Montesinos, Pau; Radsak, Markus; Sica, Simona; Arunachalam, Meena; Holmes, Melissa; Kobayashi, Ken; Namuyinga, Ruth; Ge, Nanxiang; Yver, Antoine; Zhang, Yufen; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-997</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-pos. acute myeloid leukemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease.  We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival vs. salvage chemotherapy.  QuANTUM-R is a randomized, controlled, phase 3 trial done at 152 hospitals and cancer centers in 19 countries.  Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first composite complete remission ≤6 mo) FLT3-ITD acute myeloid leukemia after std. therapy with or without allogeneic hemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: s.c. low-dose cytarabine (s.c. injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycles); i.v. infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1-5 of up to two 28-day cycles); or i.v. granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day s.c. on days 1-5), fludarabine (i.v. infusion 30 mg/m2 per day on days 2-6), cytarabine (i.v. infusion 2000 mg/m2 per day on days 2-6), and idarubicin (i.v. infusion 10 mg/m2 per day on days 2-4 in up to two 28-day cycles).  Patients proceeding to hemopoietic stem-cell transplantation after quizartinib could resume quizartinib after hemopoietic stem-cell transplantation.  The primary endpoint was overall survival in the intention-to-treat population.  This trial is registered with ClinicalTrials.gov, no. NCT02039726, and follow-up is ongoing.  Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy.  Four patients in the quizartinib group and 28 in the chemotherapy group were not treated.  Median follow-up was 23.5 mo (IQR 15.4-32.3).  Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0.76 [95% CI 0.58-0.98; p = 0.02]).  Median overall survival was 6.2 mo (5.3-7.2) in the quizartinib group and 4.7 mo (4.0-5.5) in the chemotherapy group.  The most common non-haematol. grade 3-5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalemia (28 [12%] vs eight [9%]).  The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group.  Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred.  There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events).  Treatment with quizartinib had a survival benefit vs. salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis.  Quizartinib could be considered a new std. of care.  Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.Daiichi Sankyo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcMb6SW1_b7Vg90H21EOLACvtfcHk0lgagtuH19ypBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM&md5=63619aa2e4ea4fcc29b74d2aef43f224</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930150-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930150-0%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DKhaled%26aufirst%3DS.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DN.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DJonas%26aufirst%3DB.%2BA.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DSica%26aufirst%3DS.%26aulast%3DArunachalam%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DNamuyinga%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DN.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DQuizartinib%2520versus%2520salvage%2520chemotherapy%2520in%2520relapsed%2520or%2520refractory%2520FLT3-ITD%2520acute%2520myeloid%2520leukaemia%2520%2528QuANTUM-R%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520controlled%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D984%26epage%3D997%26doi%3D10.1016%2FS1470-2045%2819%2930150-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0lgGwoZ8cQ2egg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galanis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-10-529313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-10-529313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24227820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=94-100&author=A.+Galanisauthor=H.+Maauthor=T.+Rajkhowaauthor=A.+Ramachandranauthor=D.+Smallauthor=J.+Cortesauthor=M.+Levis&title=Crenolanib+is+a+potent+inhibitor+of+FLT3+with+activity+against+resistance-conferring+point+mutants&doi=10.1182%2Fblood-2013-10-529313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span></div><div class="casAuthors">Galanis, Allison; Ma, Hayley; Rajkhowa, Trivikram; Ramachandran, Abhijit; Small, Donald; Cortes, Jorge; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-100</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of the type III receptor tyrosine kinase FLT3 occur in approx. 30% of acute myeloid leukemia patients and lead to constitutive activation.  This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease.  As more potent FLT3 inhibitors are developed, a predictable development of resistance-conferring point mutations, commonly at residue D835, has been obsd.  Crenolanib is a highly selective and potent FLT3 tyrosine kinase inhibitor (TKI) with activity against the internal tandem duplication (FLT3/ITD) mutants and the FLT3/D835 point mutants.  We tested crenolanib against a panel of D835 mutant cell lines and primary patient blasts and obsd. superior cytotoxic effects when compared with other available FLT3 TKIs such as quizartinib and sorafenib.  Another potential advantage of crenolanib is its reduced inhibition of c-Kit compared with quizartinib.  In progenitor cell assays, crenolanib was less disruptive of erythroid colony growth, which may result in relatively less myelosuppression than quizartinib.  Finally, correlative data from an ongoing clin. trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo.  Crenolanib is thus an important next-generation FLT3 TKI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmTJQsMqjR3rVg90H21EOLACvtfcHk0lgGwoZ8cQ2egg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D&md5=c622e44844e5038fe3567735ea3fee7e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-10-529313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-10-529313%26sid%3Dliteratum%253Aachs%26aulast%3DGalanis%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DCrenolanib%2520is%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520resistance-conferring%2520point%2520mutants%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D94%26epage%3D100%26doi%3D10.1182%2Fblood-2013-10-529313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buaboonnam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3607</span>– <span class="NLM_lpage">3615</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-513044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-07-513044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24046014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3607-3615&author=E.+I.+Zimmermanauthor=D.+C.+Turnerauthor=J.+Buaboonnamauthor=S.+Huauthor=S.+Orwickauthor=M.+S.+Robertsauthor=L.+J.+Jankeauthor=A.+Ramachandranauthor=C.+F.+Stewartauthor=H.+Inabaauthor=S.+D.+Baker&title=Crenolanib+is+active+against+models+of+drug-resistant+FLT3-ITD-positive+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-07-513044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span></div><div class="casAuthors">Zimmerman, Eric I.; Turner, David C.; Buaboonnam, Jassada; Hu, Shuiying; Orwick, Shelley; Roberts, Michael S.; Janke, Laura J.; Ramachandran, Abhijit; Stewart, Clinton F.; Inaba, Hiroto; Baker, Sharyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3607-3615</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are assocd. with poor clin. outcomes.  Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are obsd. in FLT3-ITD-pos. patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691.  Using biochem. assays, we detd. that crenolanib, a novel TKI, demonstrates type I properties and is active against FLT3 contg. ITD and/or D835- or F691-activating mutations.  Potent activity was obsd. in FLT3-ITD-pos. AML cell lines.  Crenolanib delayed the outgrowth of MV4-11 cells in a xenograft mouse model, whereas in combination with the type II TKI sorafenib, a significant decrease in leukemic burden (P < .001) and prolonged survival (P < .01) was obsd. compared with either type I or II TKI alone.  Crenolanib was active against Ba/F3 cells harboring FLT3-ITD and secondary KD mutations and sorafenib-resistant MOLM-13 cells contg. FLT3-ITD/D835Y both in vitro and in vivo.  In addn., crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.  These preclin. data demonstrate that crenolanib is effective against FLT3-ITD contg. secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBQ8ZNZvhAw7Vg90H21EOLACvtfcHk0liZ-FVPaEoHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE&md5=5d4052c5b3d470a2a9d14104286271ce</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-513044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-513044%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DD.%2BC.%26aulast%3DBuaboonnam%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOrwick%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26aulast%3DInaba%26aufirst%3DH.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26atitle%3DCrenolanib%2520is%2520active%2520against%2520models%2520of%2520drug-resistant%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3607%26epage%3D3615%26doi%3D10.1182%2Fblood-2013-07-513044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAXL+inhibitor%2C+shows+antileukemic+activity+in+mouse+models+of+FLT3+mutated+acute+myeloid+leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0liZ-FVPaEoHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAXL%2520inhibitor%252C%2520shows%2520antileukemic%2520activity%2520in%2520mouse%2520models%2520of%2520FLT3%2520mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-745133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2016-10-745133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27908881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=257-260&author=L.+Y.+Leeauthor=D.+Hernandezauthor=T.+Rajkhowaauthor=S.+C.+Smithauthor=J.+R.+Ramanauthor=B.+Nguyenauthor=D.+Smallauthor=M.+Levis&title=Preclinical+studies+of+gilteritinib%2C+a+next-generation+FLT3+inhibitor&doi=10.1182%2Fblood-2016-10-745133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span></div><div class="casAuthors">Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes about the activity of gilteritinib and compared it with 4 other FLT3 TKIs in clin. development: midostaurin, sorafenib, quizartinib, and crenolanib.  In this article, inhibitory activity of gilteritinib against different forms of FLT3 in leukemia cells are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpTUQzYy5lrVg90H21EOLACvtfcHk0lieTjjO2cYXhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D&md5=75429ea03b906ea92d24033613f0315b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-745133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-745133%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DRaman%26aufirst%3DJ.%2BR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPreclinical%2520studies%2520of%2520gilteritinib%252C%2520a%2520next-generation%2520FLT3%2520inhibitor%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2016-10-745133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+novel+irreversible+FLT3+inhibitor%2C+FF-10101%2C+shows+excellent+efficacy+against+AML+cells+with+FLT3+mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lieTjjO2cYXhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520novel%2520irreversible%2520FLT3%2520inhibitor%252C%2520FF-10101%252C%2520shows%2520excellent%2520efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.911839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1517%2F13543784.2014.911839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24749672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=943-954&author=N.+Pemmarajuauthor=H.+Kantarjianauthor=M.+Andreeffauthor=J.+Cortesauthor=F.+Ravandi&title=Investigational+FMS-like+tyrosine+kinase+3+inhibitors+in+treatment+of+acute+myeloid+leukemia&doi=10.1517%2F13543784.2014.911839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span></div><div class="casAuthors">Pemmaraju, Naveen; Kantarjian, Hagop; Andreeff, Michael; Cortes, Jorge; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">943-954</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor.  Over the past decade, significant progress has been made in the understanding of the cytogenetic and mol. determinants of AML pathogenesis.  One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3).  Currently, this marker, which appears in approx. one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy.  FLT3 inhibitors have now undergone clin. evaluation in Phase I, II and III clin. trials, as both single agents and in combination with chemotherapeutics.  Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML.  Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.  Areas covered: This review aims to highlight the agents furthest along in their development.  It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.  Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML.  The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTT7YoH9KV7Vg90H21EOLACvtfcHk0lhZ6lUnbhzJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D&md5=b624124fc07e406fe1c802b2e6f6a94c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.911839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.911839%26sid%3Dliteratum%253Aachs%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DInvestigational%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520in%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D943%26epage%3D954%26doi%3D10.1517%2F13543784.2014.911839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5929</span>– <span class="NLM_lpage">5941</span>, <span class="refDoi"> DOI: 10.1021/jm1001869</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1001869" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1WhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5929-5941&author=C.+C.+Chiangauthor=Y.+H.+Linauthor=S.+F.+Linauthor=C.+L.+Laiauthor=C.+Liuauthor=W.+Y.+Weiauthor=S.+C.+Yangauthor=R.+W.+Wangauthor=L.+W.+Tengauthor=S.+H.+Chuangauthor=J.+M.+Changauthor=T.+T.+Yuanauthor=Y.+S.+Leeauthor=P.+Chenauthor=W.+K.+Chiauthor=J.+Y.+Yangauthor=H.+J.+Huangauthor=C.+B.+Liaoauthor=J.+J.+Huang&title=Discovery+of+pyrrole-indoline-2-ones+as+Aurora+kinase+inhibitors+with+a+different+inhibition+profile&doi=10.1021%2Fjm1001869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrrole-Indolin-2-ones as Aurora Kinase Inhibitors with a Different Inhibition Profile</span></div><div class="casAuthors">Chiang, Chao-Cheng; Lin, Yu-Hsiang; Lin, Shu Fu; Lai, Chun-Liang; Liu, Chiawei; Wei, Win-Yin; Yang, Sheng-chuan; Wang, Ru-Wen; Teng, Li-Wei; Chuang, Shih-Hsien; Chang, Jia-Ming; Yuan, Ta-Tung; Lee, Ying-Shuen; Chen, Paonien; Chi, Wei-Kuang; Yang, Ju-Ying; Huang, Hung-Jyun; Liao, Chu-Bin; Huang, Jiann-Jyh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5929-5941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrrole-indolin-2-ones were synthesized; and their inhibition profile for Aurora kinases was studied.  The potent compd. I (R1 = COOH)(II) with phenylsulfonamido at the C-5 position and a carboxyethyl group at the C-3' position selectively inhibited Aurora A over Aurora B with IC50 values of 12 and 156 nM, resp.  Replacement of the carboxyl group with an amino group led to compd. I (R1 = Me2NCH2)(III), which retained the activity for Aurora B and lost activity for Aurora A (IC50 = 2.19 μM).  Computation modeling was used to address the different inhibition profiles of II and III.  Compds. III and I (R1 = COOEt) inhibited the proliferation of HCT-116 and HT-29 cells and suppressed levels of the phosphorylated substrates of Aurora A and Aurora B in the Western blots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfVXFbZCr6bVg90H21EOLACvtfcHk0lhZ6lUnbhzJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1WhsLg%253D&md5=00ae36d58067c40a693253f7d7121b9f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm1001869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1001869%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DS.%2BF.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DW.%2BY.%26aulast%3DYang%26aufirst%3DS.%2BC.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DTeng%26aufirst%3DL.%2BW.%26aulast%3DChuang%26aufirst%3DS.%2BH.%26aulast%3DChang%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DT.%2BT.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DChi%26aufirst%3DW.%2BK.%26aulast%3DYang%26aufirst%3DJ.%2BY.%26aulast%3DHuang%26aufirst%3DH.%2BJ.%26aulast%3DLiao%26aufirst%3DC.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520pyrrole-indoline-2-ones%2520as%2520Aurora%2520kinase%2520inhibitors%2520with%2520a%2520different%2520inhibition%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5929%26epage%3D5941%26doi%3D10.1021%2Fjm1001869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaba, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhavale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagchi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Avignon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakerdge, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacskai, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotzbauer, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and characterization of 3-(benzylidene)indolin-2-one derivatives as ligands for α-synuclein fibrils</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6002</span>– <span class="NLM_lpage">6017</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00571</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00571" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOlsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6002-6017&author=W.+Chuauthor=D.+Zhouauthor=V.+Gabaauthor=J.+Liuauthor=S.+Liauthor=X.+Pengauthor=J.+Xuauthor=D.+Dhavaleauthor=D.+P.+Bagchiauthor=A.+d%E2%80%99Avignonauthor=N.+B.+Shakerdgeauthor=B.+J.+Bacskaiauthor=Z.+Tuauthor=P.+T.+Kotzbauerauthor=R.+H.+Mach&title=Design%2C+synthesis%2C+and+characterization+of+3-%28benzylidene%29indolin-2-one+derivatives+as+ligands+for+%CE%B1-synuclein+fibrils&doi=10.1021%2Facs.jmedchem.5b00571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils</span></div><div class="casAuthors">Chu, Wenhua; Zhou, Dong; Gaba, Vrinda; Liu, Jialu; Li, Shihong; Peng, Xin; Xu, Jinbin; Dhavale, Dhruva; Bagchi, Devika P.; d'Avignon, Andre; Shakerdge, Naomi B.; Bacskai, Brian J.; Tu, Zhude; Kotzbauer, Paul T.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6002-6017</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(benzylidine)indolin-2-one derivs. were synthesized and evaluated for their in vitro binding to alpha synuclein (α-syn), beta amyloid (Aβ), and tau fibrils.  Compds. with a single double bond in the 3-position had only a modest affinity for α-syn and no selectivity for α-syn vs. Aβ or tau fibrils.  Homologation to the corresponding diene analogs yielded a mixt. of Z,E and E,E isomers; substitution of the indoline nitrogen with an N-benzyl group resulted in increased binding to α-syn and reasonable selectivity for α-syn vs. Aβ and tau.  Introduction of a para-nitro group into the benzene ring of the diene enabled sepn. of the Z,E and E,E isomers and led to the identification of the Z,E configuration as the more active regioisomer I.  The data described here provide key structural information in the design of probes which bind preferentially to α-syn vs. Aβ or tau fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQNEJSQjpIC7Vg90H21EOLACvtfcHk0lhZ6lUnbhzJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOlsL3I&md5=10515999b1fff6aa4079fcd8340546ac</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00571%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DGaba%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDhavale%26aufirst%3DD.%26aulast%3DBagchi%26aufirst%3DD.%2BP.%26aulast%3Dd%25E2%2580%2599Avignon%26aufirst%3DA.%26aulast%3DShakerdge%26aufirst%3DN.%2BB.%26aulast%3DBacskai%26aufirst%3DB.%2BJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DKotzbauer%26aufirst%3DP.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520characterization%2520of%25203-%2528benzylidene%2529indolin-2-one%2520derivatives%2520as%2520ligands%2520for%2520%25CE%25B1-synuclein%2520fibrils%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6002%26epage%3D6017%26doi%3D10.1021%2Facs.jmedchem.5b00571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, S.</span></span> <span> </span><span class="NLM_article-title">Indolinones as promising scaffold as kinase inhibitors: a review</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.2174/138955712798995039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2174%2F138955712798995039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22372601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFSqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=98-119&author=C.+R.+Prakashauthor=S.+Raja&title=Indolinones+as+promising+scaffold+as+kinase+inhibitors%3A+a+review&doi=10.2174%2F138955712798995039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Indolinones as promising scaffold as kinase inhibitors: a review</span></div><div class="casAuthors">Prakash, C. R.; Raja, S.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-119</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases are probably the most important signaling enzymes, which represent about 20% of the druggable genome.  Currently, more than 150 kinases are known.  So, kinase inhibition therapy has become a very important area of drug research since most of our diseases are related to intra or intercellular signaling by kinases.  Indole alkaloids are extensively studied for their biol. activities in several pharmaceutical areas, including, for example, antitumor.  Among this chem. family, indolinone displays very promising antitumor properties by inhibiting various kinase families.  These small mols. have a low mol. wt. and most of them bind to protein kinases competing with ATP for the ATP-binding site.  This review focuses on the indolinone based drugs approved for the treatment of cancer, drugs under clin. trial and then chem. diversity of various synthetic analogs of indolinone and their metabolites as various kinase inhibitors.  This review also focused on structural activity relationship (SAR), mechanisms of action and biol. targets through which indolinone and its derivs. display their antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBE65_guK-XrVg90H21EOLACvtfcHk0ljOZ9jUjf3v5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFSqtbY%253D&md5=0cdd80efd45309dc2e5a9f2370d6385e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.2174%2F138955712798995039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955712798995039%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DC.%2BR.%26aulast%3DRaja%26aufirst%3DS.%26atitle%3DIndolinones%2520as%2520promising%2520scaffold%2520as%2520kinase%2520inhibitors%253A%2520a%2520review%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D98%26epage%3D119%26doi%3D10.2174%2F138955712798995039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-08-523035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-08-523035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24408321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlOnsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=1525-1534&author=H.+Maauthor=B.+Nguyenauthor=L.+Liauthor=S.+Greenblattauthor=A.+Williamsauthor=M.+Zhaoauthor=M.+Levisauthor=M.+Rudekauthor=A.+Duffieldauthor=D.+Small&title=TTT-3002+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+activity+against+FLT3-associated+leukemias+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2013-08-523035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo</span></div><div class="casAuthors">Ma, Hayley; Nguyen, Bao; Li, Li; Greenblatt, Sarah; Williams, Allen; Zhao, Ming; Levis, Mark; Rudek, Michelle; Duffield, Amy; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1525-1534</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">More than 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating mutation in FMS-like tyrosine kinase-3 (FLT3).  The most common type, internal tandem duplication (ITD), confers poor prognosis.  We report for the first time on TTT-3002, a tyrosine kinase inhibitor (TKI) that is one of the most potent FLT3 inhibitors discovered to date.  Studies using human FLT3/ITD mutant leukemia cell lines revealed the half maximal inhibitory concn. (IC50) for inhibiting FLT3 autophosphorylation is from 100 to 250 pM.  The proliferation IC50 for TTT-3002 in these same cells was from 490 to 920 pM.  TTT-3002 also showed potent activity when tested against the most frequently occurring FLT3-activating point mutation, FLT3/D835Y, against which many current TKIs are ineffective.  These findings were validated in vivo by using mouse models of FLT3-assocd. AML.  Survival and tumor burden of mice in several FLT3/ITD transplantation models is significantly improved by administration of TTT-3002 via oral dosing.  Finally, we demonstrated that TTT-3002 is cytotoxic to leukemic blasts isolated from FLT3/ITD-expressing AML patients, while displaying minimal toxicity to normal hematopoietic stem/progenitor cells from healthy blood and bone marrow donors.  Therefore, TTT-3002 has demonstrated preclin. potential as a promising new FLT3 TKI in the treatment of FLT3-mutant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry55X4DcrgWbVg90H21EOLACvtfcHk0ljOZ9jUjf3v5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlOnsLo%253D&md5=b04f0416b03ffccfc35bdb5134d7cd52</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-08-523035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-08-523035%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGreenblatt%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DRudek%26aufirst%3DM.%26aulast%3DDuffield%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DTTT-3002%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520activity%2520against%2520FLT3-associated%2520leukemias%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D1525%26epage%3D1534%26doi%3D10.1182%2Fblood-2013-08-523035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5206</span>– <span class="NLM_lpage">5217</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F0008-5472.CAN-14-1028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25060518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFChur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5206-5217&author=H.+S.+Maauthor=B.+Nguyenauthor=A.+S.+Duffieldauthor=L.+Liauthor=A.+Galanisauthor=A.+B.+Williamsauthor=P.+A.+Brownauthor=M.+J.+Levisauthor=D.+J.+Leahyauthor=D.+Small&title=FLT3+kinase+inhibitor+TTT-3002+overcomes+both+activating+and+drug+resistance+mutations+in+FLT3+in+acute+myeloid+leukemia&doi=10.1158%2F0008-5472.CAN-14-1028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia</span></div><div class="casAuthors">Ma, Hayley S.; Nguyen, Bao; Duffield, Amy S.; Li, Li; Galanis, Allison; Williams, Allen B.; Brown, Patrick A.; Levis, Mark J.; Leahy, Daniel J.; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5206-5217</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There have been a no. of clin. trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors (TBC1) in patients with acute myeloid leukemia (AML) harboring a constitutively activating mutation in FLT3.  However, there has been limited efficacy, most often because of inadequate achievement of FLT3 inhibition through a variety of mechanisms.  In a previous study, TTT-3002 was identified as a novel FLT3 inhibitor with the most potent activity to date against FLT3 internal tandem duplication (FLT3/1TD) mutations.  Here, the activity of TTT-3002 is demonstrated against a broad spectrum of FLT3-activating point mutations, including the most frequently occurring D835 mutations.  The compd. is also active against a no. of point mutations selected for in FLT3/1TD alleles that confer resistance to other TBC1s, including the F691L gatekeeper mutation.  TTT-3002 maintains activity against patients with relapsed AML samples that are resistant to sorafenib and AC220.  Studies utilizing human plasma samples from healthy donors and patients with AML indicate that TTT-3002 is only moderately protein bound compared with several other TBQs currently in clin. trials.  Tumor burden of mice in a FLT3 TBQ-resistant transplant model is significantly improved by oral dosing of TTT-3002.  Therefore, TTT-3002 has demonstrated preclin. potential as a promising new FLT3 TK1 that may overcome some of the limitations of other TK1s in the treatment of FLT3-mutant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrixEzcXb7up7Vg90H21EOLACvtfcHk0ljOZ9jUjf3v5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFChur7K&md5=cad8c94b1222156359a4b70b596b4150</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1028%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DH.%2BS.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DDuffield%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGalanis%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DA.%2BB.%26aulast%3DBrown%26aufirst%3DP.%2BA.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520kinase%2520inhibitor%2520TTT-3002%2520overcomes%2520both%2520activating%2520and%2520drug%2520resistance%2520mutations%2520in%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5206%26epage%3D5217%26doi%3D10.1158%2F0008-5472.CAN-14-1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ookura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zokumasu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span> <span> </span><span class="NLM_article-title">Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2014.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bcp.2014.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24735609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslahtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2014&pages=16-24&author=A.+Yoshidaauthor=M.+Ookuraauthor=K.+Zokumasuauthor=T.+Ueda&title=G%C3%B66976%2C+a+FLT3+kinase+inhibitor%2C+exerts+potent+cytotoxic+activity+against+acute+leukemia+via+inhibition+of+survivin+and+MCL-1&doi=10.1016%2Fj.bcp.2014.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Go6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1</span></div><div class="casAuthors">Yoshida, Akira; Ookura, Miyuki; Zokumasu, Kouichi; Ueda, Takanori</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mutations of the FMS-like tyrosine kinase 3 (FLT3) have been reported in about a third of patients with acute myeloid leukemia (AML).  The presence of FLT3 mutations confers a poor prognosis.  Thus, pharmacol. inhibitors of FLT3 are of therapeutic interest for AML.  Go6976 is an indolocarbazole with a similar structural backbone to staurosporine.  In the present study, the authors demonstrated that Go6976 displays a potent inhibitory activity against recombinant FLT3 using an in vitro kinase assay, with an IC50 value of 0.7 nM.  Go6976 markedly inhibited the proliferation of human leukemia cells having FLT3-ITD such as MV4-11 and MOLM13.  The authors also obsd. that Go6976 showed minimal toxicity for human normal CD34(+) cells.  Go6976 suppressed the phosphorylation of FLT3 and downstream signaling mols. such as STAT3/5, Erk1/2, and Akt in MV4-11 and MOLM13 cells.  Interestingly, induction of apoptosis by Go6976 was assocd. with rapid and pronounced down-regulation of the anti-apoptotic protein survivin and MCL-1.  Suppression of survivin protein expression by Go6976 was due to the inhibition of transcription via the suppression of STAT3/5.  Go6976 induced proteasome-mediated degrdn. of MCL-1.  Previously described FLT3 inhibitors such as PKC412 are bound by the human plasma protein, α1-acid glycoprotein, resulting in diminished inhibitory activity against FLT3.  In contrast, the authors found that Go6976 potently inhibited phosphorylation of FLT3 and exerted cytotoxicity in the presence of human serum.  In conclusion, Go6976 is a potent FLT3 inhibitor that displays a significant antiproliferative activity against leukemia cells with FLT3-ITD through the profound down-regulation of survivin and MCL-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUNQ6_U3s_SLVg90H21EOLACvtfcHk0lji2UDI0kZV6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslahtL0%253D&md5=3b3c80c72aa3ecf5a80214d05dc83028</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DA.%26aulast%3DOokura%26aufirst%3DM.%26aulast%3DZokumasu%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DT.%26atitle%3DG%25C3%25B66976%252C%2520a%2520FLT3%2520kinase%2520inhibitor%252C%2520exerts%2520potent%2520cytotoxic%2520activity%2520against%2520acute%2520leukemia%2520via%2520inhibition%2520of%2520survivin%2520and%2520MCL-1%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D90%26spage%3D16%26epage%3D24%26doi%3D10.1016%2Fj.bcp.2014.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puente-Moncada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antolín, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermosilla, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Escuredo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ríos-Lombardía, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Sanchez, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luño, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morís, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-17-0530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29339551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslKks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=614-624&author=N.+Puente-Moncadaauthor=P.+Costalesauthor=I.+Antol%C3%ADnauthor=L.+E.+N%C3%BA%C3%B1ezauthor=P.+Oroauthor=M.+A.+Hermosillaauthor=J.+P%C3%A9rez-Escuredoauthor=N.+R%C3%ADos-Lombard%C3%ADaauthor=A.+M.+Sanchez-Sanchezauthor=E.+Lu%C3%B1oauthor=C.+Rodr%C3%ADguezauthor=V.+Mart%C3%ADnauthor=F.+Mor%C3%ADs&title=Inhibition+of+FLT3+and+PIM+kinases+by+EC-70124+exerts+potent+activity+in+preclinical+models+of+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-17-0530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia</span></div><div class="casAuthors">Puente-Moncada, Noelia; Costales, Paula; Antolin, Isaac; Nunez, Luz-Elena; Oro, Patricia; Hermosilla, Maria Ana; Perez-Escuredo, Jhudit; Rios-Lombardia, Nicolas; Sanchez-Sanchez, Ana M.; Luno, Elisa; Rodriguez, Carmen; Martin, Vanesa; Moris, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">614-624</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) or tyrosine kinase domain mutations of FLT3 is the most frequent genetic alteration in acute myelogenous leukemia (AML) and are assocd. with poor disease outcome.  Despite considerable efforts to develop single-target FLT3 drugs, so far, the most promising clin. response has been achieved using the multikinase inhibitor midostaurin.  Here, we explore the activity of the indolocarbazole EC-70124, from the same chem. space as midostaurin, in preclin. models of AML, focusing on those bearing FLT3-ITD mutations.  EC-70124 potently inhibits wild-type and mutant FLT3, and also other important kinases such as PIM kinases.  EC-70124 inhibits proliferation of AML cell lines, inducing cell-cycle arrest and apoptosis.  EC-70124 is orally bioavailable and displays higher metabolic stability and lower human protein plasma binding compared with midostaurin.  Both in vitro and in vivo pharmacodynamic analyses demonstrate inhibition of FLT3-STAT5, Akt-mTOR-S6, and PIM-BAD pathways.  Oral administration of EC-70124 in FLT3-ITD xenograft models demonstrates high efficacy, reaching complete tumor regression.  Ex vivo, EC-70124 impaired cell viability in leukemic blasts, esp. from FLT3-ITD patients.  Our results demonstrate the ability of EC-70124 to reduce proliferation and induce cell death in AML cell lines, patient-derived leukemic blast and xenograft animal models, reaching best results in FLT3 mutants that carry other mol. pathways' alterations.  Thus, its unique inhibition profile warrants EC-70124 as a promising agent for AML treatment based on its ability to interfere the complex oncogenic events activated in AML at several levels.  Mol Cancer Ther; 17(3); 614-24. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQ9fNZW2JAbVg90H21EOLACvtfcHk0lji2UDI0kZV6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslKks78%253D&md5=a344bc7ff7f94e8897e140e9947fc1fb</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0530%26sid%3Dliteratum%253Aachs%26aulast%3DPuente-Moncada%26aufirst%3DN.%26aulast%3DCostales%26aufirst%3DP.%26aulast%3DAntol%25C3%25ADn%26aufirst%3DI.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DL.%2BE.%26aulast%3DOro%26aufirst%3DP.%26aulast%3DHermosilla%26aufirst%3DM.%2BA.%26aulast%3DP%25C3%25A9rez-Escuredo%26aufirst%3DJ.%26aulast%3DR%25C3%25ADos-Lombard%25C3%25ADa%26aufirst%3DN.%26aulast%3DSanchez-Sanchez%26aufirst%3DA.%2BM.%26aulast%3DLu%25C3%25B1o%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DC.%26aulast%3DMart%25C3%25ADn%26aufirst%3DV.%26aulast%3DMor%25C3%25ADs%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520FLT3%2520and%2520PIM%2520kinases%2520by%2520EC-70124%2520exerts%2520potent%2520activity%2520in%2520preclinical%2520models%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D614%26epage%3D624%26doi%3D10.1158%2F1535-7163.MCT-17-0530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Civenni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longoni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García Inclán, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morís, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span> <span> </span><span class="NLM_article-title">EC-70124, a novel glycosylated indolocarbazole multikinase inhibitor, reverts tumorigenic and stem cell properties in prostate cancer by inhibiting STAT3 and NF-κB</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-15-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26826115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt12kurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=806-818&author=G.+Civenniauthor=N.+Longoniauthor=P.+Costalesauthor=C.+Dallavalleauthor=C.+Garc%C3%ADa+Incl%C3%A1nauthor=D.+Albinoauthor=L.+E.+Nu%C3%B1ezauthor=F.+Mor%C3%ADsauthor=G.+M.+Carboneauthor=C.+V.+Catapano&title=EC-70124%2C+a+novel+glycosylated+indolocarbazole+multikinase+inhibitor%2C+reverts+tumorigenic+and+stem+cell+properties+in+prostate+cancer+by+inhibiting+STAT3+and+NF-%CE%BAB&doi=10.1158%2F1535-7163.MCT-15-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB</span></div><div class="casAuthors">Civenni, Gianluca; Longoni, Nicole; Costales, Paula; Dallavalle, Cecilia; Garcia Inclian, Cristina; Albino, Domenico; Nuianez, Luz Elena; Morianis, Francisco; Carbone, Giuseppina M.; Catapano, Carlo V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">806-818</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer stem cells (CSC) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance to current therapies.  The transcription factors NF-κB and STAT3 are frequently activated in advanced prostate cancer and sustain expansion of prostate CSCs.  EC-70124 is a novel chimeric indolocarbazole compd. generated by metabolic engineering of the biosynthetic pathways of glycosylated indolocarbazoles, such as staurosporine and rebeccamycin.  In vitro kinome analyses revealed that EC-70124 acted as a multikinase inhibitor with potent activity against IKKβ and JAK2.  In this study, we show that EC-70124 blocked concomitantly NF-κB and STAT3 in prostate cancer cells and particularly prostate CSCs, which exhibited overactivation of these transcription factors.  Phosphorylation of IkB and STAT3 (Tyr705), the immediate targets of IKKβ and JAK2, resp., was rapidly inhibited in vitro by EC-70124 at concns. that were well below plasma levels in mice.  Furthermore, the drug blocked activation of NF-κB and STAT3 reporters and suppressed transcription of their target genes.  Treatment with EC-70124 impaired proliferation and colony formation in vitro and delayed development of prostate tumor xenografts.  Notably, EC-70124 had profound effects on the prostate CSC subpopulation both in vitro and in vivo.  Thus, EC-70124 is a potent inhibitor of the NF-κB and STAT3 signaling pathways and blocked tumor growth and maintenance of prostate CSCs.  EC-70124 may provide the basis for developing new therapeutic strategies that combine agents directed to the CSC component and the bulk tumor cell population for treatment of advanced prostate cancer.  Mol Cancer Ther; 15(5); 806-18. cpr2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBpNvOhVgoyLVg90H21EOLACvtfcHk0lh14WkVg12xoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt12kurs%253D&md5=aa370ca82631a8ba1bb4015a27fbd17f</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0791%26sid%3Dliteratum%253Aachs%26aulast%3DCivenni%26aufirst%3DG.%26aulast%3DLongoni%26aufirst%3DN.%26aulast%3DCostales%26aufirst%3DP.%26aulast%3DDallavalle%26aufirst%3DC.%26aulast%3DGarc%25C3%25ADa%2BIncl%25C3%25A1n%26aufirst%3DC.%26aulast%3DAlbino%26aufirst%3DD.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DL.%2BE.%26aulast%3DMor%25C3%25ADs%26aufirst%3DF.%26aulast%3DCarbone%26aufirst%3DG.%2BM.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26atitle%3DEC-70124%252C%2520a%2520novel%2520glycosylated%2520indolocarbazole%2520multikinase%2520inhibitor%252C%2520reverts%2520tumorigenic%2520and%2520stem%2520cell%2520properties%2520in%2520prostate%2520cancer%2520by%2520inhibiting%2520STAT3%2520and%2520NF-%25CE%25BAB%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D806%26epage%3D818%26doi%3D10.1158%2F1535-7163.MCT-15-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2019.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31207462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1SrsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=468-483&author=T.+Yuanauthor=B.+Qiauthor=Z.+Jiangauthor=W.+Dongauthor=L.+Zhongauthor=L.+Baiauthor=R.+Tongauthor=J.+Yuauthor=J.+Shi&title=Dual+FLT3+inhibitors%3A+against+the+drug+resistance+of+acute+myeloid+leukemia+in+recent+decade&doi=10.1016%2Fj.ejmech.2019.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade</span></div><div class="casAuthors">Yuan, Ting; Qi, Baowen; Jiang, Zhongliang; Dong, Wenjuan; Zhong, Lei; Bai, Lan; Tong, Rongsheng; Yu, Jiying; Shi, Jianyou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">468-483</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth and differentiation of hematopoietic stem cells.  Although the pathogenesis has not been fully elucidated, many specific gene mutations have been found in AML.  Fms-like tyrosine kinase 3 (FLT3) is recognized as a drug target for the treatment of AML, and the activation mutations of FLT3 were found in about 30% of AML patients.  Targeted inhibition of FLT3 receptor tyrosine kinase has shown promising results in the treatment of FLT3 mutation AML.  Unfortunately, the therapeutic effects of FLT3 tyrosine kinase inhibitors used as AML monotherapy are usually accompanied by the high risk of resistance development within a few months after treatment.  FLT3 dual inhibitors were generated with the co-inhibition of FLT3 and another target, such as CDK4, JAK2, MEK, Mer, Pim, etc., to solve the problems mentioned above.  As a result, the therapeutic effect of the drug is significantly improved, while the toxic and side effects are reduced.  Besides, the life quality of AML patients with FLT3 mutation has been effectively improved.  In this paper, we reviewed the studies of dual FLT3 inhibitors that have been discovered in recent years for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom3VPbgD-eHbVg90H21EOLACvtfcHk0lh14WkVg12xoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1SrsbrO&md5=3d22e4e96fcaee23470677de454bf557</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DTong%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DDual%2520FLT3%2520inhibitors%253A%2520against%2520the%2520drug%2520resistance%2520of%2520acute%2520myeloid%2520leukemia%2520in%2520recent%2520decade%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D468%26epage%3D483%26doi%3D10.1016%2Fj.ejmech.2019.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondekar, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.07.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2014.07.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25089810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GqsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=268-288&author=A.+D.+Jagtapauthor=P.+T.+Changauthor=J.+R.+Liuauthor=H.+C.+Wangauthor=N.+B.+Kondekarauthor=L.+J.+Shenauthor=H.+W.+Tsengauthor=G.+S.+Chenauthor=J.+W.+Chern&title=Novel+acylureidoindolin-2-one+derivatives+as+dual+Aurora+B%2FFLT3+inhibitors+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1016%2Fj.ejmech.2014.07.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Jagtap, Ajit Dhananjay; Chang, Pei-Teh; Liu, Jia-Rong; Wang, Hsiao-Chun; Kondekar, Nagendra B.; Shen, Li-Jiuan; Tseng, Hsiang-Wen; Chen, Grace Shiahuy; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">268-288</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 6-acylureido derivs. contg. a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide I was identified as a dual Aurora B/FLT3 inhibitor (IC50 = 0.4 nM and 0.5 nM, resp.).  Compd. I also exhibited potent cytotoxicity with single-digit nanomolar IC50 values against the FLT3 mutant-assocd. human acute myeloid leukemia (AML) cell lines MV4-11 (FLT3-ITD) and MOLM-13 (FLT3-ITD).  Compd. I also specifically induced extrinsic apoptosis by inhibiting the phosphorylation of the Aurora B and FLT3 pathways in MOLM-13 cells.  Compd. I had a moderate pharmacokinetic profile.  The mesylate salt of I efficiently inhibited tumor growth and reduced the mortality of BALB/c nude mice (s.c. xenograft model) that had been implanted with AML MOLM-13 cells.  Compd. 54 is more potent than sunitinib not only against FLT3-WT AML cells but also active against sunitinib-resistant FLT3-ITD AML cells.  This study demonstrates the significance of dual Aurora B/FLT3 inhibitors for the development of potential agents to treat AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpsREAI85CULVg90H21EOLACvtfcHk0lh14WkVg12xoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GqsrfJ&md5=402a36cc073d35716a90b33f2011eb9a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.07.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.07.108%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DA.%2BD.%26aulast%3DChang%26aufirst%3DP.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DH.%2BC.%26aulast%3DKondekar%26aufirst%3DN.%2BB.%26aulast%3DShen%26aufirst%3DL.%2BJ.%26aulast%3DTseng%26aufirst%3DH.%2BW.%26aulast%3DChen%26aufirst%3DG.%2BS.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DNovel%2520acylureidoindolin-2-one%2520derivatives%2520as%2520dual%2520Aurora%2520B%252FFLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D85%26spage%3D268%26epage%3D288%26doi%3D10.1016%2Fj.ejmech.2014.07.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2016.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28038328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=72-86&author=F.+Maauthor=P.+Liuauthor=M.+Leiauthor=J.+Liuauthor=H.+Wangauthor=S.+Zhaoauthor=L.+Hu&title=Design%2C+synthesis+and+biological+evaluation+of+indolin-2-one-based+derivatives+as+potent%2C+selective+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase3+%28FLT3%29&doi=10.1016%2Fj.ejmech.2016.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)</span></div><div class="casAuthors">Ma, Fei; Liu, Peng; Lei, Min; Liu, Jian; Wang, Hongtao; Zhao, Shaohua; Hu, Lihong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-86</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approx. one third of acute myeloid leukemia (AML) patients, which has been proposed as a promising drug target for AML therapy.  A series of indolin-2-one derivs. bearing different groups at the solvent interface position based on sunitinib as FLT3 inhibitors were designed, synthesized and evaluated in FLT3-dependent human AML cell line MV4-11.  Structure-activity relationship (SAR)anal. showed that heterocyclic alkane at the solvent interface position could significantly increase the potency for the inhibition of proliferation of MV4-11 cell line.  Compd. I and II exhibited better efficacy (MV4-11, IC50: 14.7 nM for 10a and 24.8 nM for 10d) than pos. control sunitinib (MV4-11, IC50: 38.5 nM).  The kinase and cellular inhibition assay exhibited that II (FLT3, IC50: 5.3 nM) was a potent and selective FLT3 inhibitor.  Furthermore, the pharmacokinetic expts. showed that II had good properties of oral bioavailability, Cmax, Tmax, T1/2 and AUC in mice, resp.  The in vivo study indicated that 10d could significantly suppress tumor growth in MV4-11 xenografts nude mice model and occupied with a commendable therapeutic window compared to sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGombpAwcRUoKLVg90H21EOLACvtfcHk0lilBIPjv0W8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSksw%253D%253D&md5=02b3a5a36defa999945f359774c15fbc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520indolin-2-one-based%2520derivatives%2520as%2520potent%252C%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase3%2520%2528FLT3%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D72%26epage%3D86%26doi%3D10.1016%2Fj.ejmech.2016.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quast, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolanus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trebicka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D.</span></span> <span> </span><span class="NLM_article-title">The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2123</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2016.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27220666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2ksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=2119-2123&author=J.+Rudolphauthor=A.+Heineauthor=T.+Quastauthor=W.+Kolanusauthor=J.+Trebickaauthor=P.+Brossartauthor=D.+Wolf&title=The+JAK+inhibitor+ruxolitinib+impairs+dendritic+cell+migration+via+off-target+inhibition+of+ROCK&doi=10.1038%2Fleu.2016.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK</span></div><div class="casAuthors">Rudolph, J.; Heine, A.; Quast, T.; Kolanus, W.; Trebicka, J.; Brossart, P.; Wolf, D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2119-2123</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative neoplasms (MPNs) are clonal neoplastic disorders of hematopoiesis, leading to a hypercellular bone marrow and eventually to severe fibrosis, termed myelofibrosis (MF).1 Particularly advanced stage MF patients suffer from splenomegaly, anemia and constitutional symptoms due to elevated levels of proinflammatory cytokines.  A gain-of-function V617F mutation in the JAK2 kinase causes the constitutive activation of the JAK/STAT pathway and is supposed to be at least in part responsible for the disease phenotype of MPN.  As the mutation is present in 65% of primary MF patients, 95% of polycythemia vera (PV) patients and 55% of essential thrombocythemia (ET) patients, various JAK inhibitors are currently tested as targeted therapeutics in MPN.2.  Ruxolitinib is an oral JAK inhibitor recently approved for treatment of primary and secondary MF that shows impressive symptom control by suppression of inflammation irresp. of the JAK mutational status.  Moreover, ruxolitinib is also a promising drug for acute and chronic GvHD treatment.3, 4 We recently described various aspects of immune modulation by ruxolitinib5, 6 including impaired DC function.7.  DCs are important antigen-presenting cells maturing and migrating via afferent lymphatic vessels from peripheral organs into T-cell areas of draining lymph nodes (LNs) upon antigen contact.8.  This process is guided by chemokine gradients and requires cytoskeletal rearrangement promoting cell movement.  CCR7 is expressed on DCs upon antigen contact and senses chemokine gradients of CCL19 and CCL21.  CCL19 is essential for guiding DCs into draining LNs.9, 10.  Notably, recent work suggested that activation of JAKs is involved in lymphocyte migration.11.  The aim of this study was a detailed anal. of the impact of ruxolitinib on DC migration with a particular focus on short-term effects of the drug and the identification of potential target mols. mediating these effects.  We recently already described that in vivo DC migration under conditions of inflammation is impaired after long-term exposure with ruxolitinib.7 We now extended our previous findings by evaluating the effects of ruxolitinib on DC migration.  Using a set-up of an ex vivo crawl-in assay within explanted ear dermis, we could visualize DCs migrating towards and entering afferent lymphatic vessels.  Vehicle-treated bmDCs (green) appropriately migrate to and localize around lymphatics (stained for laminin in red), while ruxolitinib-exposed bmDCs cannot be detected around lymphatic vessels (Figure 1a).  We then analyzed the effect of ruxolitinib on chemokine-induced migration of LPS-matured human moDCs in vitro using three-dimensional (3D) collagen matrixes.  After collagen polymn., cells are embedded in a complex network of fibrils, mimicking the extracellular matrix.  Again, the JAK inhibitor ruxolitinib was added directly to the assay, limiting the max. exposure of the cells to 4 h.  Thus, the obsd. effects are unlikely due to dedifferentiation or dematuration of DCs, which are usually seen as early as 48 h after drug exposure.7.  Ruxolitinib dose-dependently impairs directional migration of moDCs towards a CCL19 gradient, as mirrored by reduced velocity and accumulated distance (Figures 1b and c).  Toxicity of the drug was excluded by annexin V/7-AAD staining (data not shown).  Importantly, ruxolitinib-exposed moDCs are still able to sense the chemokine gradient as they form lamellipodia at the leading edge of the cell, whereas retraction of the uropod is clearly inhibited, resulting in an elongated cell body of the cells (Supplementary Videos 1 and 2).  According to proper chemokine sensing, ruxolitinib does not alter the expression of the CCL19-sensing chemokine receptor CCR7 (data not shown).  Anal. of the cell cytoskeleton by fluorescent labeling of the actin and tubulin network also revealed no overt structural alterations after ruxolitinib exposure (Figure 1d).  To investigate if the obsd. defects in DC migration after ruxolitinib treatment are based on an imbalance of adhesion, migration of talin1-deficient moDCs in 3D collagen matrixes, static adhesion analyses on different two-dimensional (2D) substrates and flow cytometry-based characterization of integrin subsets was performed.  As talin is of crit. importance for integrin activation and the coupling of integrins to the actin cytoskeleton,12 talin1-deficient moDCs were evaluated for their migratory capacity within complex collagen networks.  In accordance with the previous reports, the absence of talin had no impact on the migratory ability, as DCs are able to switch between integrin-dependent and -independent migration modes (Figure 1e).  Knockdown efficiency of talin1 was proven by western blot anal. (Figure 1f).  Of note, the migratory defects seen in ruxolitinib-treated control cells could be induced irresp. of the presence or absence of talin (Figure 1e).  In line with these observations, we could not detect any changes of adhesion of mature moDCs to fibronectin or collagen (Figure 1g) as a potential reason for decreased migration due to increased 'stickiness' of the moDCs.  As expected, in contrast to the migration within 3D environments, adhesion of talin1-deficient moDCs to both substrates was markedly impaired.  Ruxolitinib treatment did not further reduce adhesion in the 2D setting.  Similarly, no alteration of integrin expression levels could be detected in ruxolitinib-exposed DC (Figure 1h).  Due to the highly conserved structure of the catalytic sites of protein kinases, ATP-competitive inhibitors like ruxolitinib often show side effects due to unspecific binding to different target kinases.  It is known that ruxolitinib impairs the function of other kinases in addn. to JAKs.13 Therefore, we first tested whether siRNAs targeting either JAK1, JAK2 or JAK1 and 2 affect moDC migration towards CCL19 in the 3D migration assay.  Interestingly, CCL19-induced chemotaxis is not significantly altered in the absence of JAK1 and/or JAK2 expression (Figure 2a), highlighting that the inhibitory effects of ruxolitinib are independent of JAK1 and/or JAK2, the main targets of the drug.  Knockdown efficiency was verified by western blot anal. of the resp. JAKs (Figure 2b).  This data is in contrast to recent publications reporting a functional involvement of JAKs in lymphocyte migration,11 as JAK1/JAK2-deficient lymphocytes do not properly migrate in vitro and their homing to LNs in vivo is also reduced.  However, in these reports intranodal localization and motility of lymphocytes were not affected by JAK deficiency.  The study performed by Stein et al. also applied relatively high concns. of AG490, a JAK inhibitor currently not used/tested in clin. praxis.  We confirmed our pharmacol. data by using momelotinib, another clin. tested JAK inhibitor, mimicking the redn. of the migratory capacity induced by ruxolitinib (data not shown) and the discrepancy may also at least in part be explained by the different cell types (lymphocytes vs. DCs) examd.  On the basis of literature findings describing 33 kinases inhibited more than 50% in the presence of 1 μM of ruxolitinib, we next aimed to identify the target of the drug mediating the migration defects.  Interestingly, the screen revealed two kinases, Rho-assocd. coiled-coil kinase 1 and 2 (ROCK1 and ROCK2), with a functional impairment of 71 and 65% after ruxolitinib treatment.13 The serine-threonine kinase ROCK controls non-muscle myosin II activity, thereby regulating reorganization and contraction of cellular actin-myosin filaments14 and is of crit. importance in DC migration as it mediates the deadhesion of cells from ICAM-1 and propels the rigid nucleus through narrow gaps of the extracellular matrix.12, 15.  To evaluate the data from the kinase screen in our cellular setup, we analyzed various target proteins known to be regulated by ROCK.  Therapeutic doses of ruxolitinib clearly inhibit ROCK activity as phosphorylation of myosin phosphatase targeting subunit 1 (pMYPT1), a downstream target of ROCK (Figure 2c), was clearly reduced.  As a consequence, the phosphorylation of moesin in LPS-matured moDCs was also affected (Figure 2d) and more of the phosphorylated inactive form of cofilin could be detected (Figure 2e).  To compare the effect of ROCK inhibition on migration behavior obsd. in ruxolitinib-treated moDCs, Y-27632 an ATP-competitive ROCK inhibitor was added to the migration assays.  Similar to ruxolitinib, Y-27632 potently inhibited moDC migration (Figure 2f) and induced a morphol. phenotype showing conserved chemokine sensing but impaired uropod retraction (Supplementary Video 3).  In contrast to ruxolitinib,7 sole inhibition of ROCK by Y-27632 did not induce any phenotypic changes of bona fide DC markers or the in vitro differentiation from monocytes (data not shown).  Hence, while inhibition of DC migration is independent of JAK, the effects on DC differentiation and maturation cannot be explained by the here-described off-target inhibition of ROCK.  Consequently, the immunosuppressive effects induced by ruxolitinib are most likely a consequence of a combined targeting of several kinases involved in the regulation of immune cell functions.  In summary, we here provide the mol. basis for a deeper understanding of ruxolitinib-mediated inhibition of DC migration, as we identified ROCK as ruxolitinib target.  Thus via interference with ROCK activation, ruxolitinib profoundly impairs DC migration.  Subsequently, the loss of trafficking DCs may lead to reduced activation of T cells in draining LNs and might therefore explain the abundance of these proinflammatory cells from the blood of MPN patients after ruxolitinib treatment.5.  Our data may be of importance to better understand the immune-modulatory effects of ruxolitinib in vivo and add further pieces to the puzzle how pleiotropic ruxolitinib-mediated immune-suppressive effects in mice and men may be.  The data also complement recent reports on the immune-suppressive role of this compd. class for the treatment of immune-mediated diseases, such as GvHD.3, 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ2L03q1y7yLVg90H21EOLACvtfcHk0lilBIPjv0W8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2ksb8%253D&md5=29121a00b0afd89b9d005912c8e1c204</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.155%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DQuast%26aufirst%3DT.%26aulast%3DKolanus%26aufirst%3DW.%26aulast%3DTrebicka%26aufirst%3DJ.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DWolf%26aufirst%3DD.%26atitle%3DThe%2520JAK%2520inhibitor%2520ruxolitinib%2520impairs%2520dendritic%2520cell%2520migration%2520via%2520off-target%2520inhibition%2520of%2520ROCK%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D2119%26epage%3D2123%26doi%3D10.1038%2Fleu.2016.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fancher, K. M.</span></span> <span> </span><span class="NLM_article-title">Off-target effects of BCR-ABL and JAK2 inhibitors</span>. <i>Am. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1097/COC.0000000000000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1097%2FCOC.0000000000000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24351780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=76-84&author=M.+R.+Greenauthor=M.+D.+Newtonauthor=K.+M.+Fancher&title=Off-target+effects+of+BCR-ABL+and+JAK2+inhibitors&doi=10.1097%2FCOC.0000000000000023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Off-Target Effects of BCR-ABL and JAK2 Inhibitors</span></div><div class="casAuthors">Green, Myke R.; Newton, Michael D.; Fancher, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-84</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The advent of targeted oncolytic agents has created a revolution in the treatment of malignancies.  Perhaps best exemplified in myeloproliferative neoplasms (MPN), the tyrosine kinase inhibitors, including inhibitors of BCR-ABL tyrosine kinase and JAK2, have dramatically changed outcomes in persons with MPN.  However, clin. relevant dosing of these ATP-mimetic agents in humans leads to inhibition of numerous tyrosine kinases beyond those touted by drug manufacturers and studied in landmark clin. trials.  These so-called off-target effects have been linked to both clin. efficacy and toxicity.  Rational drug development and serendipitous discovery of drug mols. allows the clinician to select targeted oncolytic agents to treat a specific clin. diagnosis and/or avoid exacerbation of concomitant disease states due to effects upon signaling pathways.  Understanding the off-target binding and effects upon signaling pathway of the agents approved for the treatment of MPN will empower the clinician to adroitly select pharmacotherapy, predict toxicities, and utilize these agents in clin. practice for indications beyond MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj0y3czkLgvrVg90H21EOLACvtfcHk0liHqFppJ8GbcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGru70%253D&md5=cad05d4b8798b00ea8a4c9b370075d87</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1097%2FCOC.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0000000000000023%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DM.%2BR.%26aulast%3DNewton%26aufirst%3DM.%2BD.%26aulast%3DFancher%26aufirst%3DK.%2BM.%26atitle%3DOff-target%2520effects%2520of%2520BCR-ABL%2520and%2520JAK2%2520inhibitors%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D39%26spage%3D76%26epage%3D84%26doi%3D10.1097%2FCOC.0000000000000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornace, A. J.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, H. J.</span></span> <span> </span><span class="NLM_article-title">Off-target response of a Wip1 chemical inhibitor in skin keratinocytes</span>. <i>J. Dermatol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.jdermsci.2013.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.jdermsci.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24126074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Wit7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=125-134&author=J.+S.+Leeauthor=J.+R.+Parkauthor=O.+S.+Kwonauthor=H.+Kimauthor=A.+J.+Fornaceauthor=H.+J.+Cha&title=Off-target+response+of+a+Wip1+chemical+inhibitor+in+skin+keratinocytes&doi=10.1016%2Fj.jdermsci.2013.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Off-target response of a Wip1 chemical inhibitor in skin keratinocytes</span></div><div class="casAuthors">Lee, Ji-Seon; Park, Jeong-Rak; Kwon, Ok-Seon; Kim, Hyongbum; Fornace, Albert J.; Cha, Hyuk-Jin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">JDSCEI</span>;
        ISSN:<span class="NLM_cas:issn">0923-1811</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The wild type p53 inducible phosphatase (Wip1) plays an important role in modulating not only stress responses by various environmental stresses, but when overexpressed it also impairs the intrinsic tumor surveillance networks that are frequently found in a no. of cancers including skin cancers.  As a result, using a pharmacol. inhibitor of Wip1 has been suggested to be a novel chemotherapeutic approach to recover the innate tumor surveillance in a variety of cancers.  We studied the effect of a pharmacol. inhibitor of Wip1 in skin keratinocytes, under a ultra-violet (UV) stress condition.  A human keratinocyte cell line or human epidermal keratinocytes were exposed to UV, with or without the sole com. available chem. inhibitor of Wip1, CCT007093; subsequently, we detd. the diverse stress responses, including apoptosis and the activation of stress signaling.  We demonstrate that the Wip1 inhibitor unexpectedly attenuated the UV-mediated apoptotic response in skin keratinocytes, as a consequence of attenuated JNK activation and reduced H2AX phosphorylation in both, skin keratinocytes and a Wip1-null cell model.  On the other hand, the loss of Wip1 expression, either by knockout or knockdown in mice or human keratinocytes resp., promoted apoptosis and potentiated H2AX phosphorylation following UV treatment.  Of note, CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression.  Thus, our studies suggest that the development of a more potent and specific Wip1 inhibitor is necessary to achieve the desired chemotherapeutic potential and to avoid off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqAM70hic0irVg90H21EOLACvtfcHk0liHqFppJ8GbcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Wit7%252FI&md5=9d385da3dc9d4ff237d9f70427de5ffa</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.jdermsci.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdermsci.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DJ.%2BR.%26aulast%3DKwon%26aufirst%3DO.%2BS.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DFornace%26aufirst%3DA.%2BJ.%26aulast%3DCha%26aufirst%3DH.%2BJ.%26atitle%3DOff-target%2520response%2520of%2520a%2520Wip1%2520chemical%2520inhibitor%2520in%2520skin%2520keratinocytes%26jtitle%3DJ.%2520Dermatol.%2520Sci.%26date%3D2014%26volume%3D73%26spage%3D125%26epage%3D134%26doi%3D10.1016%2Fj.jdermsci.2013.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takács-Novák, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Völgyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horváth, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szokol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breza, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szántai-Kis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illyés, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Őrfi, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2018.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29935772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2qsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2391-2398&author=Z.+Nemesauthor=K.+Tak%C3%A1cs-Nov%C3%A1kauthor=G.+V%C3%B6lgyiauthor=K.+Valkoauthor=S.+B%C3%A9niauthor=Z.+Horv%C3%A1thauthor=B.+Szokolauthor=N.+Brezaauthor=J.+Dobosauthor=C.+Sz%C3%A1ntai-Kisauthor=E.+Illy%C3%A9sauthor=S.+Borosauthor=R.+J.+Kokauthor=L.+%C5%90rfi&title=Synthesis+and+characterization+of+amino+acid+substituted+sunitinib+analogues+for+the+treatment+of+AML&doi=10.1016%2Fj.bmcl.2018.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML</span></div><div class="casAuthors">Nemes, Zoltan; Takacs-Novak, Krisztina; Volgyi, Gergely; Valko, Klara; Beni, Szabolcs; Horvath, Zoltan; Szokol, Balint; Breza, Nora; Dobos, Judit; Szantai-Kis, Csaba; Illyes, Eszter; Boros, Sandor; Kok, Robbert Jan; Orfi, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2391-2398</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common type of leukemia in adults.  Sunitinib, a multikinase inhibitor, was the first Fms-like tyrosine kinase 3 (FLT3) inhibitor clin. used against AML.  Off-target effects are a major concern for multikinase inhibitors.  As targeted delivery may reduce such undesired side effects, our goal was to develop novel amino acid substituted derivs. of sunitinib which are potent candidates to be used conjugated with antibodies and peptides.  In the current paper we present the synthesis, physicochem. and in vitro characterization of sixty two Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutant kinase inhibitors, bearing amino acid moieties, fit to be conjugated with peptide-based delivery systems via their carboxyl group.  We detd. the soly., pKa, CHI and LogP values of the compds. along with their inhibition potential against FLT3-ITD mutant kinase and on MV4-11 cell line.  The ester derivs. of the compds. inhibit the growth of the MV4-11 leukemia cell line at submicromolar concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrebu-EoBV6bVg90H21EOLACvtfcHk0liH0jRiGlxM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2qsbvL&md5=a4c6c132752aaf839729a8f31e57e2db</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DNemes%26aufirst%3DZ.%26aulast%3DTak%25C3%25A1cs-Nov%25C3%25A1k%26aufirst%3DK.%26aulast%3DV%25C3%25B6lgyi%26aufirst%3DG.%26aulast%3DValko%26aufirst%3DK.%26aulast%3DB%25C3%25A9ni%26aufirst%3DS.%26aulast%3DHorv%25C3%25A1th%26aufirst%3DZ.%26aulast%3DSzokol%26aufirst%3DB.%26aulast%3DBreza%26aufirst%3DN.%26aulast%3DDobos%26aufirst%3DJ.%26aulast%3DSz%25C3%25A1ntai-Kis%26aufirst%3DC.%26aulast%3DIlly%25C3%25A9s%26aufirst%3DE.%26aulast%3DBoros%26aufirst%3DS.%26aulast%3DKok%26aufirst%3DR.%2BJ.%26aulast%3D%25C5%2590rfi%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520amino%2520acid%2520substituted%2520sunitinib%2520analogues%2520for%2520the%2520treatment%2520of%2520AML%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2391%26epage%3D2398%26doi%3D10.1016%2Fj.bmcl.2018.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovelman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, K. J.</span></span> <span> </span><span class="NLM_article-title">A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>451</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1042/BJ20121418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1042%2FBJ20121418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23398362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvFOgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=451&publication_year=2013&pages=313-328&author=Y.+Gaoauthor=S.+P.+Daviesauthor=M.+Augustinauthor=A.+Woodwardauthor=U.+A.+Patelauthor=R.+Kovelmanauthor=K.+J.+Harvey&title=A+broad+activity+screen+in+support+of+a+chemogenomic+map+for+kinase+signalling+research+and+drug+discovery&doi=10.1042%2FBJ20121418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery</span></div><div class="casAuthors">Gao, Yinghong; Davies, Stephen P.; Augustin, Martin; Woodward, Anna; Patel, Umesh A.; Kovelman, Robert; Harvey, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">451</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-328</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Despite the development of a no. of efficacious kinase inhibitors, the strategies for rational design of these compds. have been limited by target promiscuity.  In an effort to better understand the nature of kinase inhibition across the kinome, esp. as it relates to off-target effects, we screened a well-defined collection of kinase inhibitors using biochem. assays for inhibitory activity against 234 active human kinases and kinase complexes, representing all branches of the kinome tree.  For our study we employed 158 small mols. initially identified in the literature as potent and specific inhibitors of kinases important as therapeutic targets and/or signal transduction regulators.  Hierarchical clustering of these benchmark kinase inhibitors on the basis of their kinome activity profiles illustrates how they relate to chem. structure similarities and provides new insights into inhibitor specificity and potential applications for probing new targets.  Using this broad dataset, we provide a framework for assessing polypharmacol.  We not only discover likely off-target inhibitor activities and recommend specific inhibitors for existing targets, but also identify potential new uses for known small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNLU0ONM4SALVg90H21EOLACvtfcHk0liH0jRiGlxM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvFOgs7g%253D&md5=9e0f17ec5cac10198fe28b27e70b4966</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1042%2FBJ20121418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121418%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DWoodward%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DU.%2BA.%26aulast%3DKovelman%26aufirst%3DR.%26aulast%3DHarvey%26aufirst%3DK.%2BJ.%26atitle%3DA%2520broad%2520activity%2520screen%2520in%2520support%2520of%2520a%2520chemogenomic%2520map%2520for%2520kinase%2520signalling%2520research%2520and%2520drug%2520discovery%26jtitle%3DBiochem.%2520J.%26date%3D2013%26volume%3D451%26spage%3D313%26epage%3D328%26doi%3D10.1042%2FBJ20121418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lochner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moolman, J. A.</span></span> <span> </span><span class="NLM_article-title">The many faces of H89: a review</span>. <i>Cardiovasc. Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3466.2006.00261.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fj.1527-3466.2006.00261.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=17214602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWisLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=261-274&author=A.+Lochnerauthor=J.+A.+Moolman&title=The+many+faces+of+H89%3A+a+review&doi=10.1111%2Fj.1527-3466.2006.00261.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">The many faces of H89: a review</span></div><div class="casAuthors">Lochner, A.; Moolman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">261-274</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  H89 is marketed as a selective and potent inhibitor of protein kinase A (PKA).  Since its discovery, it has been used extensively for evaluation of the role of PKA in the heart, osteoblasts, hepatocytes, smooth muscle cells, neuronal tissue, epithelial cells, etc.  Despite the frequent use of H89, its mode of specific inhibition of PKA is still not completely understood.  It has also been shown that H89 inhibits at least 8 other kinases, while having a relatively large no. of PKA-independent effects which may seriously compromise interpretation of data.  Thus, while recognizing its kinase inhibiting properties, it is advised that H89 should not be used as the single source of evidence of PKA involvement.  H-89 should be used in conjunction with other PKA inhibitors, such as Rp-cAMPS or PKA analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgjvr_RF9KrVg90H21EOLACvtfcHk0liH0jRiGlxM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWisLfJ&md5=d1a07a95a053662b725fcfe19fd1378a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.2006.00261.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.2006.00261.x%26sid%3Dliteratum%253Aachs%26aulast%3DLochner%26aufirst%3DA.%26aulast%3DMoolman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520many%2520faces%2520of%2520H89%253A%2520a%2520review%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D2006%26volume%3D24%26spage%3D261%26epage%3D274%26doi%3D10.1111%2Fj.1527-3466.2006.00261.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagestein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keijzer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijdeven, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenselink, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuin, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Westen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2019.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30661740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVehu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=692-699&author=S.+H.+Grimmauthor=B.+Gagesteinauthor=J.+F.+Keijzerauthor=N.+Liuauthor=R.+H.+Wijdevenauthor=E.+B.+Lenselinkauthor=A.+W.+Tuinauthor=A.+van+den+Nieuwendijkauthor=G.+van+Westenauthor=C.+van+Boeckelauthor=H.+S.+Overkleeftauthor=J.+Neefjesauthor=M.+van+der%0AStelt&title=Comprehensive+structure-activity-relationship+of+azaindoles+as+highly+potent+FLT3+inhibitors&doi=10.1016%2Fj.bmc.2019.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors</span></div><div class="casAuthors">Grimm, Sebastian H.; Gagestein, Berend; Keijzer, Jordi F.; Liu, Nora; Wijdeven, Ruud H.; Lenselink, Eelke B.; Tuin, Adriaan W.; van den Nieuwendijk, Adrianus M. C. H.; van Westen, Gerard J. P.; van Boeckel, Constant A. A.; Overkleeft, Herman S.; Neefjes, Jacques; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">692-699</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is characterized by fast progression and low survival rates, in which Fms-like tyrosine kinase 3 (FLT3) receptor mutations have been identified as a driver mutation in cancer progression in a subgroup of AML patients.  Clin. trials have shown emergence of drug resistant mutants, emphasizing the ongoing need for new chem. matter to enable the treatment of this disease.  Here, we present the discovery and topol. structure-activity relationship (SAR) study of analogs of isoquinolinesulfonamide H-89, a well-known PKA inhibitor, as FLT3 inhibitors.  Surprisingly, we found that the SAR was not consistent with the obsd. binding mode of H-89 in PKA.  Matched mol. pair anal. resulted in the identification of highly active sub-nanomolar azaindoles as novel FLT3-inhibitors.  Structure based modeling using the FLT3 crystal structure suggested an alternative, flipped binding orientation of the new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT5rwrdjbivbVg90H21EOLACvtfcHk0lhxc3cVQIbJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVehu7o%253D&md5=20e2230d003c1f058f5d675dcdfbb544</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DS.%2BH.%26aulast%3DGagestein%26aufirst%3DB.%26aulast%3DKeijzer%26aufirst%3DJ.%2BF.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DWijdeven%26aufirst%3DR.%2BH.%26aulast%3DLenselink%26aufirst%3DE.%2BB.%26aulast%3DTuin%26aufirst%3DA.%2BW.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%26aulast%3Dvan%2BWesten%26aufirst%3DG.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DNeefjes%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DComprehensive%2520structure-activity-relationship%2520of%2520azaindoles%2520as%2520highly%2520potent%2520FLT3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D692%26epage%3D699%26doi%3D10.1016%2Fj.bmc.2019.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scarpino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span> <span> </span><span class="NLM_article-title">Comparative evaluation of covalent docking tools</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1441</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00228</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00228" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSmsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=1441-1458&author=A.+Scarpinoauthor=G.+G.+Ferenczyauthor=G.+M.+Keser%C5%B1&title=Comparative+evaluation+of+covalent+docking+tools&doi=10.1021%2Facs.jcim.8b00228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Evaluation of Covalent Docking Tools</span></div><div class="casAuthors">Scarpino, Andrea; Ferenczy, Gyorgy G.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1441-1458</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Increased interest in covalent drug discovery led to the development of computer programs predicting binding mode and affinity of covalent inhibitors.  Here we compare the performance of six covalent docking tools, AutoDock4, CovDock, FITTED, GOLD, ICM-Pro, and MOE, for reproducing exptl. binding modes in an unprecedently large and diverse set of covalent complexes.  It was found that 40-60% of the top scoring ligand poses are within 2.0 Å RMSD from the exptl. binding mode.  This rate showed program dependent increase and achieved 50-90% when the best RMSD among the top ten scoring poses was considered.  This performance is comparable to that of noncovalent docking tools and therefore suggests that anchoring the ligand does not necessarily improve the accuracy of the prediction.  The effect of various ligand and protein features on the docking performance was investigated.  At the level of warhead chem., higher success rate was found for Michael addns., nucleophilic addns. and nucleophilic substitutions than for ring opening reactions and disulfide formation.  Increasing ligand size and flexibility generally affects pose predictions unfavorably, although AutoDock4, FITTED, and ICM-Pro were found to be less sensitive up to 35 heavy atoms.  Increasing the accessibility of the target cysteine tends to result in improved binding mode predictions.  Docking programs show protein dependent performance suggesting a target-dependent choice of the optimal docking tool.  It was found that noncovalent docking into Cys/Ala mutated proteins by ICM-Pro and Glide reproduced exptl. binding modes with only slightly lower performance and at a significantly lower computational expense than covalent docking did.  Overall, our results highlight the key factors influencing the docking performance of the investigated tools and they give guidelines for selecting the optimal combination of warheads, ligands, and tools for the system investigated.  Results also identify the most important aspects to be considered for developing improved protocols for docking and virtual screening of covalent ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozylYIfr8i8rVg90H21EOLACvtfcHk0lhxc3cVQIbJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSmsLzE&md5=d74695be1f047ac840527161c510692d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00228%26sid%3Dliteratum%253Aachs%26aulast%3DScarpino%26aufirst%3DA.%26aulast%3DFerenczy%26aufirst%3DG.%2BG.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DComparative%2520evaluation%2520of%2520covalent%2520docking%2520tools%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D1441%26epage%3D1458%26doi%3D10.1021%2Facs.jcim.8b00228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waßmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engemann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identifies irreversible FMS-like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2446</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01714</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01714" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2428-2446&author=D.+Bensingerauthor=D.+Stubbaauthor=A.+Cremerauthor=V.+Kohlauthor=T.+Wa%C3%9Fmerauthor=J.+Stuckertauthor=V.+Engemannauthor=K.+Stegmaierauthor=K.+Schmitzauthor=B.+Schmidt&title=Virtual+screening+identifies+irreversible+FMS-like+tyrosine+kinase+3+inhibitors+with+activity+toward+resistance-conferring+mutations&doi=10.1021%2Facs.jmedchem.8b01714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations</span></div><div class="casAuthors">Bensinger, Dennis; Stubba, Daniel; Cremer, Anjali; Kohl, Vanessa; Wassmer, Theresa; Stuckert, Johanna; Engemann, Victoria; Stegmaier, Kimberly; Schmitz, Katja; Schmidt, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2428-2446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of covalent irreversible binding inhibitors is an established concept for drug development.  Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed.  Herein, the authors report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia.  A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chem. reactive groups.  Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds.  Lead compd. I (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compds. in recent clin. trials and overcomes drug-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquy_8BkIpJILVg90H21EOLACvtfcHk0lhxc3cVQIbJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D&md5=336bed5b86809d78cfaf8b74d934ef68</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01714%26sid%3Dliteratum%253Aachs%26aulast%3DBensinger%26aufirst%3DD.%26aulast%3DStubba%26aufirst%3DD.%26aulast%3DCremer%26aufirst%3DA.%26aulast%3DKohl%26aufirst%3DV.%26aulast%3DWa%25C3%259Fmer%26aufirst%3DT.%26aulast%3DStuckert%26aufirst%3DJ.%26aulast%3DEngemann%26aufirst%3DV.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DSchmitz%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DVirtual%2520screening%2520identifies%2520irreversible%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520with%2520activity%2520toward%2520resistance-conferring%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2428%26epage%3D2446%26doi%3D10.1021%2Facs.jmedchem.8b01714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondekar, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Ureas: applications in drug design</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.2174/0929867323666161129124915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2174%2F0929867323666161129124915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27897114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVChurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=622-651&author=A.+D.+Jagtapauthor=N.+B.+Kondekarauthor=A.+A.+Sadaniauthor=J.+W.+Chern&title=Ureas%3A+applications+in+drug+design&doi=10.2174%2F0929867323666161129124915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Ureas: Applications in Drug Design</span></div><div class="casAuthors">Jagtap, Ajit Dhananjay; Kondekar, Nagendra Bharatrao; Sadani, Amit A.; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">622-651</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The unique hydrogen binding capabilities of ureas make them an important functional group to make drug-target interactions and thus incorporated in small mols. displaying broad range of bioactivities.  The related research and numerous excellent achievements of ureas applicability in drug design for the modulation of selectivity, stability, toxicity and pharmacokinetic profile of lead mols. have become active topic.  This review aims to provide insights in to the significance of urea in drug design by summarizing successful studies of various urea derivs. as modulators biol. targets (viz. kinases, NAMPT, sol. epoxide hydrolases, mTOR, proteases, gyrB/parE, and epigenetic enzymes such as HDAC, PRMT or DOT1L etc.).  The findings of this review confirm the importance of urea moiety in medicinal chem. and stimulate its use as a structural motif with rational decision making approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql4bGowxpMbbVg90H21EOLACvtfcHk0lg4JE6N4YfuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVChurg%253D&md5=a3b883c65d950d7e698b40bb71a7f938</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.2174%2F0929867323666161129124915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666161129124915%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DA.%2BD.%26aulast%3DKondekar%26aufirst%3DN.%2BB.%26aulast%3DSadani%26aufirst%3DA.%2BA.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DUreas%253A%2520applications%2520in%2520drug%2520design%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D622%26epage%3D651%26doi%3D10.2174%2F0929867323666161129124915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang
Hsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H. P.</span></span> <span> </span><span class="NLM_article-title">Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1002%2Fcmdc.201300571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24665000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1Omsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=953-961&author=Y.+Chang%0AHsuauthor=Y.+Y.+Keauthor=H.+Y.+Shiaoauthor=C.+C.+Leeauthor=W.+H.+Linauthor=C.+H.+Chenauthor=K.+J.+Yenauthor=J.+T.+Hsuauthor=C.+Changauthor=H.+P.+Hsieh&title=Facile+identification+of+dual+FLT3-Aurora+A+inhibitors%3A+a+computer-guided+drug+design+approach&doi=10.1002%2Fcmdc.201300571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer-Guided Drug Design Approach</span></div><div class="casAuthors">Chang Hsu, Yung; Ke, Yi-Yu; Shiao, Hui-Yi; Lee, Chieh-Chien; Lin, Wen-Hsing; Chen, Chun-Hwa; Yen, Kuei-Jung; Hsu, John T.-A.; Chang, Chungming; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">953-961</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Computer-guided drug design is a powerful tool for drug discovery.  Herein we disclose the use of this approach for the discovery of dual FMS-like receptor tyrosine kinase-3 (FLT3)-Aurora A inhibitors against cancer.  An Aurora hit compd. was selected as a starting point, from which 288 virtual mols. were screened.  Subsequently, some of these were synthesized and evaluated for their capacity to inhibit FLT3 and Aurora kinase A.  To further enhance FLT3 inhibition, structure-activity relationship studies of the lead compd. were conducted through a simplification strategy and bioisosteric replacement, followed by the use of computer-guided drug design to prioritize mols. bearing a variety of different terminal groups in terms of favorable binding energy.  Selected compds. were then synthesized, and their bioactivity was evaluated.  Of these, one novel inhibitor was found to exhibit excellent inhibition of FLT3 and Aurora kinase A and exert a dramatic antiproliferative effect on MOLM-13 and MV4-11 cells, with an IC50 value of 7 nM.  Accordingly, it is considered a highly promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ni1CGTzIErVg90H21EOLACvtfcHk0lg4JE6N4YfuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1Omsb0%253D&md5=122eecc6e0497fd90f7e0acc9a3dc94c</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300571%26sid%3Dliteratum%253Aachs%26aulast%3DChang%2BHsu%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DY.%2BY.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DFacile%2520identification%2520of%2520dual%2520FLT3-Aurora%2520A%2520inhibitors%253A%2520a%2520computer-guided%2520drug%2520design%2520approach%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D953%26epage%3D961%26doi%3D10.1002%2Fcmdc.201300571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Göring, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumann, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span> <span> </span><span class="NLM_article-title">Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1002%2Fcmdc.201402477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25677073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC2MrltVOjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=511-522&author=S.+G%C3%B6ringauthor=D.+Bensingerauthor=E.+C.+Naumannauthor=B.+Schmidt&title=Computer-guided+design%2C+synthesis%2C+and+biological+evaluation+of+quinoxalinebisarylureas+as+FLT3+inhibitors&doi=10.1002%2Fcmdc.201402477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors</span></div><div class="casAuthors">Goring Stefan; Bensinger Dennis; Naumann Eva C; Schmidt Boris</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">511-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in ∼30 % of patients with acute myeloid leukemia (AML) and are associated with poor prognosis.  Point mutations in the tyrosine kinase domain (TKD) are observed as primary mutations or are acquired as secondary mutations in FLT3 with internal tandem duplications (ITDs) after treatment with tyrosine kinase inhibitors (TKIs).  Although dozens of potent inhibitors against FLT3 ITD have been reported, activating TKD point mutations, especially at residues F691 and D835, remain the leading cause for therapy resistance, highlighting the consistent need for new potent inhibitors.  Herein we report the identification and characterization of novel quinoxaline-based FLT3 inhibitors.  We used the pharmacophore features of diverse known inhibitors as a starting point for a new optimization algorithm for type II TKIs, starting from an in silico library pharmacophore search and induced-fit docking in the known FLT3 structure.  This led to the design of a set of diverse quinoxalinebisarylureas, which were profiled in an FLT3 kinase activity assay.  The most promising compounds were further evaluated in a zebrafish embryo phenotype assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_wpMj6Vi8LZggzHGM8X5CfW6udTcc2eZEl0Hbk680wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrltVOjsA%253D%253D&md5=cb23aedbe8ad7d196e784f0f4d1ff4cd</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402477%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6ring%26aufirst%3DS.%26aulast%3DBensinger%26aufirst%3DD.%26aulast%3DNaumann%26aufirst%3DE.%2BC.%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DComputer-guided%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520quinoxalinebisarylureas%2520as%2520FLT3%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D511%26epage%3D522%26doi%3D10.1002%2Fcmdc.201402477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W. T.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26081023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=151-161&author=C.+T.+Chenauthor=J.+T.+Hsuauthor=W.+H.+Linauthor=C.+T.+Luauthor=S.+C.+Yenauthor=T.+Hsuauthor=Y.+L.+Huangauthor=J.+S.+Songauthor=C.+H.+Chenauthor=L.+H.+Chouauthor=K.+J.+Yenauthor=C.+P.+Chenauthor=P.+C.+Kuoauthor=C.+L.+Huangauthor=H.+E.+Liuauthor=Y.+S.+Chaoauthor=T.+K.+Yehauthor=W.+T.+Jiaang&title=Identification+of+a+potent+5-phenyl-thiazol-2-ylamine-based+inhibitor+of+FLT3+with+activity+against+drug+resistance-conferring+point+mutations&doi=10.1016%2Fj.ejmech.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span></div><div class="casAuthors">Chen, Chiung-Tong; Hsu, John T.-A.; Lin, Wen-Hsing; Lu, Cheng-Tai; Yen, Shih-Chieh; Hsu, Tsu; Huang, Yu-Ling; Song, Jen-Shin; Chen, Chun-Hwa; Chou, Ling-Hui; Yen, Kuei-Jung; Chen, Ching-Ping; Kuo, Po-Chu; Huang, Chen-Lung; Liu, H. Eugene; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML).  However, clin. data have been not encouraging due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated with these older agents.  The authors previously developed a series of 3-phenyl-1H-5-pyrazolylamine derivs. as highly potent and selective FLT3 inhibitors with good in vivo efficacy using an i.v. (IV) route.  However, the poor bioavailability of these pyrazole compds. limits the development of these promising antileukemic compds. for clin. use.  Herein, the authors describe a novel class of 5-phenyl-thiazol-2-ylamine compds. that are multitargeted FLT3 inhibitors.  From this class of compds., compd. I was very potent against AML cell lines and exhibited excellent oral efficacy in AML xenograft models.  In addn., further studies demonstrated that compd. I exhibited potent in vitro and in vivo activities against clin. relevant AC220 (3)-resistant kinase domain mutants of FLT3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KrlNgs-LL7Vg90H21EOLACvtfcHk0lhkBfZLu7POHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI&md5=d51f2152965d841a378c3c38dbcde6c7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DKuo%26aufirst%3DP.%2BC.%26aulast%3DHuang%26aufirst%3DC.%2BL.%26aulast%3DLiu%26aufirst%3DH.%2BE.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3DIdentification%2520of%2520a%2520potent%25205-phenyl-thiazol-2-ylamine-based%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520drug%2520resistance-conferring%2520point%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D100%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.ejmech.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N’-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4333</span>– <span class="NLM_lpage">4343</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2015.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26142317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2it73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4333-4343&author=Y.+Xuauthor=N.+Y.+Wangauthor=X.+J.+Songauthor=Q.+Leiauthor=T.+H.+Yeauthor=X.+Y.+Youauthor=W.+Q.+Zuoauthor=Y.+Xiaauthor=L.+D.+Zhangauthor=L.+T.+Yu&title=Discovery+of+novel+N-%285-%28tert-butyl%29isoxazol-3-yl%29-N%E2%80%99-phenylurea+analogs+as+potent+FLT3+inhibitors+and+evaluation+of+their+activity+against+acute+myeloid+leukemia+in+vitro+and+in+vivo&doi=10.1016%2Fj.bmc.2015.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo</span></div><div class="casAuthors">Xu, Ying; Wang, Ning-Yu; Song, Xue-Jiao; Lei, Qian; Ye, Ting-Hong; You, Xin-Yu; Zuo, Wei-Qiong; Xia, Yong; Zhang, Li-Dan; Yu, Luo-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4333-4343</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">FLT3 inhibitors have been explored as a viable therapy for acute myeloid leukemia (AML).  However, the clin. outcomes of these FLT3 inhibitors were underwhelming except AC220.  Therefore, the development of novel FLT3 inhibitors with high potency against both FLT3-WT and FLT3-ITD mutants are strongly demanded at the present time.  In this study, we designed and synthesized a series of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea derivs. as FLT3 inhibitors.  SAR studies focused on the fused rings led to the discovery of a series of compds. with high potency against FLT3-ITD-bearing MV4-11 cells and significantly inhibitory activity toward FLT3.  Among these compds., N-(5-(tert-butyl)isoxazol-3-yl)-N'-(4-(7-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl)urea (16i), displayed acceptable aq. soly., desirable pharmacokinetic profile and high cytotoxicity selectivity against MV4-11 cells.  This compd. can inhibit phosphorylation of FLT3 and induce apoptosis in a concn.-dependent manner.  Further in vivo antitumor studies showed that 16i led to complete tumor regression in the MV4-11 xenograft model at a dose of 60 mg/kg/d while without observable body wt. loss.  This study had provided us a new chemotype of FLT3 inhibitors as novel therapeutic candidates for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqCNY34V2V7Vg90H21EOLACvtfcHk0lhkBfZLu7POHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2it73F&md5=6cb879cc03de46bc7761063fb35195b7</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DN.%2BY.%26aulast%3DSong%26aufirst%3DX.%2BJ.%26aulast%3DLei%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DT.%2BH.%26aulast%3DYou%26aufirst%3DX.%2BY.%26aulast%3DZuo%26aufirst%3DW.%2BQ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%2BD.%26aulast%3DYu%26aufirst%3DL.%2BT.%26atitle%3DDiscovery%2520of%2520novel%2520N-%25285-%2528tert-butyl%2529isoxazol-3-yl%2529-N%25E2%2580%2599-phenylurea%2520analogs%2520as%2520potent%2520FLT3%2520inhibitors%2520and%2520evaluation%2520of%2520their%2520activity%2520against%2520acute%2520myeloid%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4333%26epage%3D4343%26doi%3D10.1016%2Fj.bmc.2015.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4534</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2015.08.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26342867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4534-4538&author=X.+D.+Linauthor=H.+W.+Yangauthor=S.+Maauthor=W.+W.+Liauthor=C.+H.+Zhangauthor=W.+J.+Wangauthor=R.+Xiangauthor=L.+L.+Liauthor=S.+Y.+Yang&title=Discovery+of+6-phenylimidazo%5B2%2C1-b%5Dthiazole+derivatives+as+a+new+type+of+FLT3+inhibitors&doi=10.1016%2Fj.bmcl.2015.08.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors</span></div><div class="casAuthors">Lin, Xing-Dong; Yang, Hui-Wen; Ma, Shuang; Li, Wei-Wei; Zhang, Chun-Hui; Wang, Wen-Jing; Xiang, Rong; Li, Lin-Li; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4534-4538</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this investigation, a series of 6-phenylimidazo[2,1-b]thiazole derivs. were synthesized.  Structure-activity relationship (SAR) anal. of these compds. based on cellular assays led to the discovery of a no. of compds. that showed potent activity against FLT3-dependent human acute myeloid leukemia (AML) cell line MV4-11, but very weak or no activity against FLT3-independent human cervical cancer cell line HeLa.  FLT3 kinase inhibition assays were then performed on the three most active compds.  Among these compds., 6-(4-(3-(5-(tert-butyl)isoxazol-3-yl)ureido)phenyl)-N-(3-(dimethylamino)propyl)imidazo[2,1-b]thiazole-3-carboxamide (I) exhibited the highest potency in both cellular (MV4-11, IC50: 0.002 μM) and enzymic (FLT3, IC50: 0.022 μM) assays.  Further in-depth in vitro anti-AML activity and mechanism of action studies were carried out on compd. I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdn7IogHRnRrVg90H21EOLACvtfcHk0liDGLddgTAXaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmsrbI&md5=ccb7f2021e9e20cde5cbc01ead16e273</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.068%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DYang%26aufirst%3DH.%2BW.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DW.%2BJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%25206-phenylimidazo%255B2%252C1-b%255Dthiazole%2520derivatives%2520as%2520a%2520new%2520type%2520of%2520FLT3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4534%26epage%3D4538%26doi%3D10.1016%2Fj.bmcl.2015.08.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.</span></span> <span> </span><span class="NLM_article-title">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2016.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27773927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=913-921&author=B.+Xuauthor=Y.+Zhaoauthor=X.+Wangauthor=P.+Gongauthor=W.+Ge&title=MZH29+is+a+novel+potent+inhibitor+that+overcomes+drug+resistance+FLT3+mutations+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2016.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span></div><div class="casAuthors">Xu, B.; Zhao, Y.; Wang, X.; Gong, P.; Ge, W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">913-921</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant mutations in Fms-like tyrosine kinase 3 (FLT3).  Among them, the internal tandem duplication (ITD) mutation predicts poor prognosis.  MZH29 is a novel FLT3 inhibitor synthesized in our lab. that showed that cellular and kinase assays sustained inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants.  More importantly, MZH29 retained its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220.  MZH29 is a type II FLT3 inhibitor that tolerated the F691L mutation in mol. docking studies.  Oral administration of 10 mg/kg MZH29 caused complete tumor regression and extended survival in a mouse model of AML with less toxicity.  Subsequent proteomics study revealed less proteome perturbation in the MZH29-treated group than in the AC220-treated group.  MZH29 demonstrates potential and potent novel FLT3 inhibitory effects for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypie-S2V6M7Vg90H21EOLACvtfcHk0liDGLddgTAXaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI&md5=76a4ff225ff13fc14e810826e75572fc</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.297%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DGe%26aufirst%3DW.%26atitle%3DMZH29%2520is%2520a%2520novel%2520potent%2520inhibitor%2520that%2520overcomes%2520drug%2520resistance%2520FLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D913%26epage%3D921%26doi%3D10.1038%2Fleu.2016.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4735</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30121211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFeqtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4735-4744&author=Z.+H.+Shiauthor=F.+T.+Liuauthor=H.+Z.+Tianauthor=Y.+M.+Zhangauthor=N.+G.+Liauthor=T.+Lu&title=Design%2C+synthesis+and+structure-activity+relationship+of+diaryl-ureas+with+novel+isoxazol%5B3%2C4-b%5Dpyridine-3-amino-structure+as+multi-target+inhibitors+against+receptor+tyrosine+kinase&doi=10.1016%2Fj.bmc.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase</span></div><div class="casAuthors">Shi, Zhi-Hao; Liu, Feng-Tao; Tian, Hao-Zhong; Zhang, Yan-Min; Li, Nian-Guang; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4735-4744</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inspired by that the multi-target inhibitors against receptor tyrosine kinases (RTKs) have significantly improved the effect of clin. treatment for cancer, and based on the chem. structure of Linifanib (ABT-869, Abbott), two series of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure were designed and synthesized as multi-target inhibitors against RTKs.  The preliminary biol. evaluation showed that several compds. exhibited comparable potency with Linifanib.  Compd. S21 was identified as the most potent inhibitor against Fms-like tyrosine kinase 3 (FLT-3), kinase insert domain contg. receptor (KDR) and platelet-derived growth factor receptor β (PDGFR-β) with its IC50 values were 4 nM, 3 nM and 8 nM resp., it also showed potent inhibitory activities against several cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAmdxzd3Mv5bVg90H21EOLACvtfcHk0liDGLddgTAXaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFeqtLnF&md5=f171dd14fc3b5d924be73439fd6cec24</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%2BH.%26aulast%3DLiu%26aufirst%3DF.%2BT.%26aulast%3DTian%26aufirst%3DH.%2BZ.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DN.%2BG.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520of%2520diaryl-ureas%2520with%2520novel%2520isoxazol%255B3%252C4-b%255Dpyridine-3-amino-structure%2520as%2520multi-target%2520inhibitors%2520against%2520receptor%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4735%26epage%3D4744%26doi%3D10.1016%2Fj.bmc.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0liDGLddgTAXaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2019.03.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30940564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=2127-2139&author=B.+Qiauthor=X.+Xuauthor=Y.+Yangauthor=Y.+Zhouauthor=T.+Chenauthor=G.+Gongauthor=X.+Yueauthor=X.+Xuauthor=L.+Huauthor=H.+He&title=Discovery+of+thiazolidin-4-one+urea+analogues+as+novel+multikinase+inhibitors+that+potently+inhibit+FLT3+and+VEGFR2&doi=10.1016%2Fj.bmc.2019.03.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2</span></div><div class="casAuthors">Qi, Baohui; Xu, Xingwei; Yang, Ying; Zhou, Yuting; Chen, Tao; Gong, Guowei; Yue, Xupeng; Xu, Xin; Hu, Liping; He, Huan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2127-2139</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel thiazolidine-4-one urea analogs were designed, synthesized and biol. evaluated.  The structure-activity relationship (SAR) at several positions of the scaffolds was investigated and its binding mode was analyzed by mol. modeling studies.  Compd. 17b proved to be the most potent one, and IC50 values against A549 and HT-29 cancer cell lines were 0.65 μM and 0.11 μM, resp.  The results of kinase profile demonstrated that compd. 17b is a multikinase inhibitor that potently inhibits FLT3 (IC50 = 8.6 nM) and VEGFR2 (IC50 = 18.7 nM).  The results of real-time live-cell imaging indicated that compd. 17b showed excellent cytotoxicity and anti-proliferative activity against HT-29 cancer cells in a time- and dose-dependent manner, which was significantly potent than that of Cabozantinib.  In addn., in vitro antitumor activity was assocd. with inducing cancer cell apoptosis and suppression of cancer cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYiQyPetitWrVg90H21EOLACvtfcHk0lhT9oFYMDuvdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOqsr4%253D&md5=63e95dbef3a82115f1c94a93ff6dc9ac</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.049%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DYue%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520thiazolidin-4-one%2520urea%2520analogues%2520as%2520novel%2520multikinase%2520inhibitors%2520that%2520potently%2520inhibit%2520FLT3%2520and%2520VEGFR2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D2127%26epage%3D2139%26doi%3D10.1016%2Fj.bmc.2019.03.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter-Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintim, H. O.</span></span> <span> </span><span class="NLM_article-title">Identification of new FLT3 inhibitors that potently inhibit AML cell lines via an azo click-it/staple-it approach</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=492-497&author=X.+Maauthor=J.+Zhouauthor=C.+Wangauthor=B.+Carter-Cooperauthor=F.+Yangauthor=E.+Larocqueauthor=J.+Fineauthor=G.+Tsujiauthor=G.+Chopraauthor=R.+G.+Lapidusauthor=H.+O.+Sintim&title=Identification+of+new+FLT3+inhibitors+that+potently+inhibit+AML+cell+lines+via+an+azo+click-it%2Fstaple-it+approach&doi=10.1021%2Facsmedchemlett.6b00468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach</span></div><div class="casAuthors">Ma, Xiaochu; Zhou, Jie; Wang, Changhao; Carter-Cooper, Brandon; Yang, Fan; Larocque, Elizabeth; Fine, Jonathan; Tsuji, Genichiro; Chopra, Gaurav; Lapidus, Rena G.; Sintim, Herman O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">492-497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is an aggressive malignancy with only a handful of therapeutic options.  About 30% of AML patients harbor mutated FLT3 kinase and thus this cancer-driver has become a hotly pursued AML target.  Herein we report a new class of FLT3 inhibitors, which potently inhibit the of acute myeloid leukemia (AML) cells at nanomolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-9N0byp2-K7Vg90H21EOLACvtfcHk0lhT9oFYMDuvdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyjs7g%253D&md5=1e325dddb25a1a93a48e7cfa05fed6ac</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00468%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DCarter-Cooper%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLarocque%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DJ.%26aulast%3DTsuji%26aufirst%3DG.%26aulast%3DChopra%26aufirst%3DG.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DSintim%26aufirst%3DH.%2BO.%26atitle%3DIdentification%2520of%2520new%2520FLT3%2520inhibitors%2520that%2520potently%2520inhibit%2520AML%2520cell%2520lines%2520via%2520an%2520azo%2520click-it%252Fstaple-it%2520approach%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D492%26epage%3D497%26doi%3D10.1021%2Facsmedchemlett.6b00468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamli, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of quinolinone derivatives as potent FLT3 inhibitors</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>445</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bbrc.2014.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24530392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVWqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2014&pages=561-565&author=H.+J.+Chungauthor=M.+R.+Kamliauthor=H.+J.+Leeauthor=J.+D.+Haauthor=S.+Y.+Choauthor=J.+Leeauthor=J.+Y.+Kongauthor=S.+Y.+Han&title=Discovery+of+quinolinone+derivatives+as+potent+FLT3+inhibitors&doi=10.1016%2Fj.bbrc.2014.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of quinolinone derivatives as potent FLT3 inhibitors</span></div><div class="casAuthors">Chung, Hye Jin; Kamli, Majid Rasool; Lee, Hyo Jeong; Ha, Jae Du; Cho, Sung Yun; Lee, Jongkook; Kong, Jae Yang; Han, Sun-Young</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">561-565</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently some fms-like tyrosine kinase 3 (FLT3) inhibitors have shown good efficacy in acute myeloid leukemia (AML) patients.  In an effort to develop anti-leukemic drugs, we investigated quinolinone derivs. as novel FLT3 inhibitors.  Two substituted quinolinones, KR65367 and KR65370 were subjected to FLT3 kinase activity assay and showed potent inhibition against FLT3 kinase activity in vitro, with IC50 of 2.7 and 0.57 nM, resp.  As a measure of selectivity, effects on the activity of other kinases were also tested.  Both compds. have negligible activity against Met, Ron, epidermal growth factor receptor, Aurora A, Janus kinase 2, and insulin receptor; with IC50 greater than 10 μM.  KR compds. showed strong growth inhibition in MV4;11 AML cells and increased the apoptotic cell death in flow cytometric analyses.  A decrease in STAT5 phosphorylation by KR compds. was obsd. in MV4;11 cells.  Furthermore, in vitro evaluation of compds. structurally related to KR65367 and KR65370 showed a good structure-activity relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-JuYaVQVxE7Vg90H21EOLACvtfcHk0lg4lI0Q64rPEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVWqtbk%253D&md5=d7453c5b158262c372eef20a0978bc9d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DH.%2BJ.%26aulast%3DKamli%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DJ.%2BY.%26aulast%3DHan%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520quinolinone%2520derivatives%2520as%2520potent%2520FLT3%2520inhibitors%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D445%26spage%3D561%26epage%3D565%26doi%3D10.1016%2Fj.bbrc.2014.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku-Temeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter-Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintim, H. O.</span></span> <span> </span><span class="NLM_article-title">Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.4155/fmc-2017-0067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.4155%2Ffmc-2017-0067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28490193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2qsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1213-1225&author=E.+Larocqueauthor=N.+Nagannaauthor=X.+Maauthor=C.+Opoku-Temengauthor=B.+Carter-Cooperauthor=G.+Chopraauthor=R.+G.+Lapidusauthor=H.+O.+Sintim&title=Aminoisoquinoline+benzamides%2C+FLT3+and+Src-family+kinase+inhibitors%2C+potently+inhibit+proliferation+of+acute+myeloid+leukemia+cell+lines&doi=10.4155%2Ffmc-2017-0067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoisoquinoline benzamides, flt3 and src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines</span></div><div class="casAuthors">Larocque, Elizabeth; Naganna, N.; Ma, Xiaochu; Opoku-Temeng, Clement; Carter-Cooper, Brandon; Chopra, Gaurav; Lapidus, Rena G.; Sintim, Herman O.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1213-1225</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Aim: Mutated or overexpressed FLT3 drives about 30% of reported acute myeloid leukemia (AML).  Currently, FLT3 inhibitors have shown durable clin. responses but a complete remission of AML with FLT3 inhibitors remains elusive due to mutation-driven resistance mechanisms.  The development of FLT3 inhibitors that also target other downstream oncogenic kinases may combat the resistance mechanism.  Results: 4-substituted aminoisoquinoline benzamides potently inhibit Src-family kinases and FLT3, including secondary mutations, such as FLT3D835.  Modifications of aminoisoquinoline benzamide to aminoquinoline or aminoquinazoline abrogated FLT3 and Src-family kinase binding.  Conclusion: The lead aminoisoquinolines potently inhibited FLT3-driven AML cell lines, MV4-11 and MOLM-14.  These aminoisoquinoline benzamides represent new kinase scaffolds with high potential to be translated into anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvu4O-4pq_3bVg90H21EOLACvtfcHk0lg4lI0Q64rPEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2qsLbJ&md5=9363dc08a85ef1adf7daa661c6f7ae46</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2017-0067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2017-0067%26sid%3Dliteratum%253Aachs%26aulast%3DLarocque%26aufirst%3DE.%26aulast%3DNaganna%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DOpoku-Temeng%26aufirst%3DC.%26aulast%3DCarter-Cooper%26aufirst%3DB.%26aulast%3DChopra%26aufirst%3DG.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DSintim%26aufirst%3DH.%2BO.%26atitle%3DAminoisoquinoline%2520benzamides%252C%2520FLT3%2520and%2520Src-family%2520kinase%2520inhibitors%252C%2520potently%2520inhibit%2520proliferation%2520of%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D1213%26epage%3D1225%26doi%3D10.4155%2Ffmc-2017-0067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naganna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku-Temeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter-Cooper, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torregrosa-Allen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintim, H. O.</span></span> <span> </span><span class="NLM_article-title">Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice</span>. <i>EBioMedicine.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2019.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ebiom.2019.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30686755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3cjlslKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=231-239&author=N.+Nagannaauthor=C.+Opoku-Temengauthor=E.+Y.+Choiauthor=E.+Larocqueauthor=E.+T.+Changauthor=B.+A.+Carter-Cooperauthor=M.+Wangauthor=S.+E.+Torregrosa-Allenauthor=B.+D.+Elzeyauthor=R.+G.+Lapidusauthor=H.+O.+Sintim&title=Amino+alkynylisoquinoline+and+alkynylnaphthyridine+compounds+potently+inhibit+acute+myeloid+leukemia+proliferation+in+mice&doi=10.1016%2Fj.ebiom.2019.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice</span></div><div class="casAuthors">Naganna N; Larocque Elizabeth; Wang Modi; Opoku-Temeng Clement; Choi Eun Yong; Chang Elizabeth T; Carter-Cooper Brandon A; Lapidus Rena G; Torregrosa-Allen Sandra E; Elzey Bennett D; Sintim Herman O</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-239</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics.  Currently, the 5-year survival of AML patients is about 30% and for elderly patients, the rate drops to <10%.  About 30% of AML patients harbor an activating mutation in the tyrosine kinase domain (TKD) of Fms-Like Tyrosine kinase 3 (FLT3) or a FLT3 internal tandem duplication (FLT3-ITD).  Inhibitors of FLT3, such as Rydapt that was recently approved by the FDA, have shown good initial response but patients often relapse due to secondary mutations in the FLT3 TKD, like D835Y and F691 L mutations.  METHODS:  Alkynyl aminoisoquinoline and naphthyridine compounds were synthesized via Sonogashira coupling.  The compounds were evaluated for their in vitro and in vivo effects on leukemia growth.  FINDINGS:  The compounds inhibited FLT3 kinase activity at low nanomolar concentrations.  The lead compound, HSN431, also inhibited Src kinase activity.  The compounds potently inhibited the viability of MV4-11 and MOLM-14 AML cells with IC50 values <1 nM.  Furthermore, the viability of drug-resistant AML cells harboring the D835Y and F691 L mutations were potently inhibited.  In vivo efficacy studies in mice demonstrated that the compounds could drastically reduce AML proliferation in mice.  INTERPRETATION:  Compounds that inhibit FLT3 and downstream targets like Src (for example HSN431) are good leads for development as anti-AML agents.  FUND: Purdue University, Purdue Institute for Drug Discovery (PIDD), Purdue University Center for Cancer Research, Elks Foundation and NIH P30 CA023168.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbXsDtlq8R1ZagfuraLLzSfW6udTcc2eYnid-2u38sm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjlslKnsw%253D%253D&md5=9ddc0c74c5b1f1998bc427084f13f0a3</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2019.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2019.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DNaganna%26aufirst%3DN.%26aulast%3DOpoku-Temeng%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DE.%2BY.%26aulast%3DLarocque%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DE.%2BT.%26aulast%3DCarter-Cooper%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DTorregrosa-Allen%26aufirst%3DS.%2BE.%26aulast%3DElzey%26aufirst%3DB.%2BD.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DSintim%26aufirst%3DH.%2BO.%26atitle%3DAmino%2520alkynylisoquinoline%2520and%2520alkynylnaphthyridine%2520compounds%2520potently%2520inhibit%2520acute%2520myeloid%2520leukemia%2520proliferation%2520in%2520mice%26jtitle%3DEBioMedicine.%26date%3D2019%26volume%3D40%26spage%3D231%26epage%3D239%26doi%3D10.1016%2Fj.ebiom.2019.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126630</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2019.126630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31466809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yhu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126630&author=Q.+Xuauthor=B.+Daiauthor=Z.+Liauthor=L.+Xuauthor=D.+Yangauthor=P.+Gongauthor=Y.+Houauthor=Y.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+4-%28%286%2C7-dimethoxyquinoline-4-yl%29oxy%29aniline+derivatives+as+FLT3+inhibitors+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1016%2Fj.bmcl.2019.126630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Xu, Qiaoling; Dai, Baozhu; Li, Zhiwei; Xu, Le; Yang, Di; Gong, Ping; Hou, Yunlei; Liu, Yajing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">126630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) was an important therapeutic target in acute myeloid leukemia (AML).  We synthesized two series of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivs. possessing the semicarbazide moiety and 2,2,2-trifluoro-N,N'-dimethylacetamide moiety as the linker.  The cell proliferation assay in vitro against HL-60 and MV4-11 cell lines demonstrated that most series I compds. contg. semicarbazide moiety had more potent than Cabozantinib.  Furthermore, the enzyme assay showed that compd. I and II were potent FLT3 inhibitors with IC50 values of 312 nM and 384 nM, resp.  Following that, mol. docking anal. was also performed to det. possible binding mode between FLT3 and the target compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKiKqqRR0A27Vg90H21EOLACvtfcHk0ljXRMofzwvnQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yhu7zE&md5=bb50806ab6a53173b899a2ae6fb60ae2</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126630%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25204-%2528%25286%252C7-dimethoxyquinoline-4-yl%2529oxy%2529aniline%2520derivatives%2520as%2520FLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126630%26doi%3D10.1016%2Fj.bmcl.2019.126630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2655</span>– <span class="NLM_lpage">2660</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2014.04.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24813730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2655-2660&author=C.+H.+Parkauthor=C.+Leeauthor=J.+S.+Yangauthor=B.+Y.+Joeauthor=K.+Chunauthor=H.+Kimauthor=H.+Y.+Kimauthor=J.+S.+Kangauthor=J.+I.+Leeauthor=M.+H.+Kimauthor=G.+Han&title=Discovery+of+thienopyrimidine-based+FLT3+inhibitors+from+the+structural+modification+of+known+IKK%CE%B2+inhibitors&doi=10.1016%2Fj.bmcl.2014.04.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors</span></div><div class="casAuthors">Park, Chun-Ho; Lee, Chulho; Yang, Jee Sun; Joe, Bo-Young; Chun, Kwangwoo; Kim, Hyuntae; Kim, Hye Yun; Kang, Jong Soon; Lee, Jangik I.; Kim, Myung-Hwa; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2655-2660</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inactivation of the NF-κB signaling pathway by inhibition of IKKβ is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer.  Thienopyrimidine-based analogs were designed through modification of the known IKKβ inhibitor, SPC-839, and then biol. evaluated.  The resulting analogs had good inhibitory activity against both nitric oxide and TNF-α, which are well-known inflammatory responses generated by activated NF-κB.  However, no inhibitory activity against IKKβ was obsd. with these compds.  The thienopyrimidine-based analogs were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified.  Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 μM.  Overall, these compds. represent a promising family of inhibitors for future development of a treatment for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSn5PgGCIn17Vg90H21EOLACvtfcHk0lgmlnQu0sc6FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSnt7Y%253D&md5=75b4124026a81eae8d8670ed06d3c463</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.058%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DJoe%26aufirst%3DB.%2BY.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520thienopyrimidine-based%2520FLT3%2520inhibitors%2520from%2520the%2520structural%2520modification%2520of%2520known%2520IKK%25CE%25B2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2655%26epage%3D2660%26doi%3D10.1016%2Fj.bmcl.2014.04.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2014.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25108079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KjsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=399-407&author=J.+S.+Yangauthor=C.+H.+Parkauthor=C.+Leeauthor=H.+Kimauthor=C.+Ohauthor=Y.+Choiauthor=J.+S.+Kangauthor=J.+Yunauthor=J.+H.+Jeongauthor=M.+H.+Kimauthor=G.+Han&title=Synthesis+and+biological+evaluation+of+novel+thieno%5B2%2C3-d%5Dpyrimidine-based+FLT3+inhibitors+as+anti-leukemic+agents&doi=10.1016%2Fj.ejmech.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents</span></div><div class="casAuthors">Yang, Jee Sun; Park, Chun-Ho; Lee, Chulho; Kim, Hwan; Oh, Changmok; Choi, Yejoo; Kang, Jong Soon; Yun, Jieun; Jeong, Jin-Hyun; Kim, Myung-Hwa; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">399-407</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3).  Therefore, FLT3 is regarded as a potential target for the treatment of AML.  A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors.  All synthesized compds. were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60).  Among these compds., compd. 1-[6-Methoxy-5-methyl-2-(thiophen-2-yl)thieno[2,3-d]pyrimidin-4-ylamino]-3-methyl-1H-pyrrole-2,5-dione, which possesses relatively short and simple substituents at the C6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent.  Compd. 1-[6-Methoxy-5-methyl-2-(thiophen-2-yl)thieno[2,3-d]pyrimidin-4-ylamino]-3-methyl-1H-pyrrole-2,5-dione exhibited potent inhibition of FLT3-pos. leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML.  The data supports the further study of this class of compds. as potential anti-leukemic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquZGzLnO11GbVg90H21EOLACvtfcHk0lgmlnQu0sc6FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KjsrnJ&md5=1f0389e4cda56e486ed0bec48ae143b9</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520thieno%255B2%252C3-d%255Dpyrimidine-based%2520FLT3%2520inhibitors%2520as%2520anti-leukemic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D85%26spage%3D399%26epage%3D407%26doi%3D10.1016%2Fj.ejmech.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2016.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27187860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2016&pages=74-85&author=H.+Kimauthor=C.+Leeauthor=J.+S.+Yangauthor=S.+Choiauthor=C.+H.+Parkauthor=J.+S.+Kangauthor=S.+J.+Ohauthor=J.+Yunauthor=M.+H.+Kimauthor=G.+Han&title=Structural+modifications+at+the+6-position+of+thieno%5B2%2C3-d%5Dpyrimidines+and+their+effects+on+potency+at+FLT3+for+treatment+of+acute+myeloid+leukemia&doi=10.1016%2Fj.ejmech.2016.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia</span></div><div class="casAuthors">Kim, Hyuntae; Lee, Chulho; Yang, Jee Sun; Choi, Seonghwi; Park, Chun-Ho; Kang, Jong Soon; Oh, Soo Jin; Yun, Jieun; Kim, Myung-Hwa; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-85</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of thieno[2,3-d]pyrimidines I (R1 = Me, CH2OH, 4-MeOC6H4, etc.; R2 = H, Me) modified at the 6-position were synthesized to identify effective FLT3 inhibitors.  Previously synthesized thieno[2,3-d]pyrimidine derivs. emerged as promising FLT3 inhibitors among the synthesized compds., but these compds. exhibited poor metabolic stability in human and rat liver microsomes.  Hence, further optimization was required for the discovery of FLT3 inhibitors, with a focus on improving metabolic stability.  The compd. I [R1 = 4-(MeNHCH2CH2O)C6H4; R2 = Me; (II)] exhibited good inhibitory activity against FLT3 and showed effective antiproliferative activity against four leukemia cell lines, including MV4-11 and also displayed enhanced metabolic stability.  The results of this study indicated that the compd. II could be a promising compd. for further optimization and development as a potent FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozXOKzSI0MqLVg90H21EOLACvtfcHk0lhhUR-1hhHZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wqtb8%253D&md5=7a373e4072b799e89366133745503967</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DOh%26aufirst%3DS.%2BJ.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DStructural%2520modifications%2520at%2520the%25206-position%2520of%2520thieno%255B2%252C3-d%255Dpyrimidines%2520and%2520their%2520effects%2520on%2520potency%2520at%2520FLT3%2520for%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D120%26spage%3D74%26epage%3D85%26doi%3D10.1016%2Fj.ejmech.2016.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C<sub>2</sub> and C<sub>6</sub> positions</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.12.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2016.12.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28043794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=496-500&author=C.+Ohauthor=H.+Kimauthor=J.+S.+Kangauthor=J.+Yunauthor=J.+Simauthor=H.+M.+Kimauthor=G.+Han&title=Synthetic+strategy+for+increasing+solubility+of+potential+FLT3+inhibitor+thieno%5B2%2C3-d%5Dpyrimidine+derivatives+through+structural+modifications+at+the+C2+and+C6+positions&doi=10.1016%2Fj.bmcl.2016.12.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C2 and C6 positions</span></div><div class="casAuthors">Oh, Changmok; Kim, Hyuntae; Kang, Jong Soon; Yun, Jieun; Sim, Jaejun; Kim, Hwan-Mook; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">496-500</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cell.  In AML, a mutation in FLT3 is commonly occurs and is assocd. with poor prognosis.  The authors have previously reported that thieno[2,3-d]pyrimidine deriv. compd. (I) exhibited better antiproliferative activity against MV4-11 cells which harbor mutant FLT3 than AC220, which is a well-known FLT3 inhibitor, and has good microsomal stability.  However, compd. (I) had poor soly.  The authors then carried out further structural modification at the C2 and the C6 positions of thieno[2,3-d]pyrimidine scaffold.  Compd. 13b (II), which possesses a thiazole moiety at the C2 position, exhibited better antiproliferative activity than compd. (I) and showed increased soly. and moderate microsomal stability.  These results indicate that compd. 13b could be a promising potential FLT inhibitor for AML chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlu-ZWgtlWurVg90H21EOLACvtfcHk0lhhUR-1hhHZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVylug%253D%253D&md5=33d2f34fd8d1a267dc4396f7e726fd5c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.034%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DSynthetic%2520strategy%2520for%2520increasing%2520solubility%2520of%2520potential%2520FLT3%2520inhibitor%2520thieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520through%2520structural%2520modifications%2520at%2520the%2520C2%2520and%2520C6%2520positions%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D496%26epage%3D500%26doi%3D10.1016%2Fj.bmcl.2016.12.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Cesco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittermaier, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitessier, N.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors design and discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2017.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28651155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=96-114&author=S.+De+Cescoauthor=J.+Kurianauthor=C.+Dufresneauthor=A.+K.+Mittermaierauthor=N.+Moitessier&title=Covalent+inhibitors+design+and+discovery&doi=10.1016%2Fj.ejmech.2017.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors design and discovery</span></div><div class="casAuthors">De Cesco, Stephane; Kurian, Jerry; Dufresne, Caroline; Mittermaier, Anthony K.; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-114</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the history of therapeutics, covalent drugs occupy a very distinct category.  While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biol. target.  In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.  All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods.  The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLNDmLtBdB7Vg90H21EOLACvtfcHk0ljAkZFLVnlTFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI&md5=551c9a9c4bd69d4ad4d9156c315d5a94</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DJ.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DMittermaier%26aufirst%3DA.%2BK.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DCovalent%2520inhibitors%2520design%2520and%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114%26doi%3D10.1016%2Fj.ejmech.2017.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. J.</span></span> <span> </span><span class="NLM_article-title">G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">2209</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-04-493916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-04-493916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24532805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVOju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=2209-2219&author=H.+K.+Leeauthor=H.+W.+Kimauthor=I.+Y.+Leeauthor=J.+Leeauthor=J.+Leeauthor=D.+S.+Jungauthor=S.+Y.+Leeauthor=S.+H.+Parkauthor=H.+Hwangauthor=J.+S.+Choiauthor=J.+H.+Kimauthor=S.+W.+Kimauthor=J.+K.+Kimauthor=J.+Coolsauthor=J.+S.+Kohauthor=H.+J.+Song&title=G-749%2C+a+novel+FLT3+kinase+inhibitor%2C+can+overcome+drug+resistance+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-04-493916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Lee, Hee Kyu; Kim, Hong Woo; Lee, In Yong; Lee, Jungmi; Lee, Jaekyoo; Jung, Dong Sik; Lee, Sang Yeop; Park, Sung Ho; Hwang, Haejun; Choi, Jang-Sik; Kim, Jung-Ho; Kim, Se Won; Kim, Jung Keun; Cools, Jan; Koh, Jong Sung; Song, Ho-Juhn</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Aberrant activations of Fms-like tyrosine receptor kinase (FLT) 3 are implicated in the pathogenesis of 20% to 30% of patients with acute myeloid leukemia (AML).  G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants including FLT3-ITD, FLT3-D835Y, FLT3-ITD/N676D, and FLT3-ITD/F691L in cellular assays.  G-749 retained its inhibitory potency in various drug-resistance milieus such as patient plasma, FLT3 ligand surge, and stromal protection.  Furthermore, it displayed potent antileukemic activity in bone marrow blasts from AML patients regardless of FLT3 mutation status, including those with little or only minor responses to AC220 or PKC412.  Oral administration of G-749 yielded complete tumor regression and increased life span in animal models.  Thus, G-749 appears to be a promising next-generation drug candidate for the treatment of relapsed and refractory AML patients with various FLT3-ITD/FLT3-TKD mutants and further shows the ability to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1dwuSRK6JrVg90H21EOLACvtfcHk0ljAkZFLVnlTFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVOju74%253D&md5=07b23569d047a3a16789d673fe904c6b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-04-493916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-04-493916%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DD.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DHwang%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DKoh%26aufirst%3DJ.%2BS.%26aulast%3DSong%26aufirst%3DH.%2BJ.%26atitle%3DG-749%252C%2520a%2520novel%2520FLT3%2520kinase%2520inhibitor%252C%2520can%2520overcome%2520drug%2520resistance%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D2209%26epage%3D2219%26doi%3D10.1182%2Fblood-2013-04-493916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.+M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lheuNVq-ZPqFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.%2BM.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lj_RrIiQuhzIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenback, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quéva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-13-0858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24526162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=880-889&author=K.+Keeganauthor=C.+Liauthor=Z.+Liauthor=J.+Maauthor=M.+Ragainsauthor=S.+Coberlyauthor=D.+Hollenbackauthor=J.+Eksterowiczauthor=L.+Liangauthor=M.+Weidnerauthor=J.+Huardauthor=X.+Wangauthor=G.+Albaauthor=J.+Orfauthor=M.+C.+Loauthor=S.+Zhaoauthor=R.+Ngoauthor=A.+Chenauthor=L.+Liuauthor=T.+Carlsonauthor=C.+Qu%C3%A9vaauthor=L.+R.+McGeeauthor=J.+Medinaauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=Preclinical+evaluation+of+AMG+925%2C+a+FLT3%2FCDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-13-0858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia</span></div><div class="casAuthors">Keegan, Kathleen; Li, Cong; Li, Zhihong; Ma, Ji; Ragains, Mark; Coberly, Suzanne; Hollenback, David; Eksterowicz, John; Liang, Lingming; Weidner, Margaret; Huard, Justin; Wang, Xianghong; Alba, Grace; Orf, Jessica; Lo, Mei-Chu; Zhao, Sharon; Ngo, Rachel; Chen, Ada; Liu, Lily; Carlson, Timothy; Queva, Christophe; McGee, Lawrence R.; Medina, Julio; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a serious unmet medical need.  Despite high remission rates with chemotherapy std.-of-care treatment, the disease eventually relapses in a major proportion of patients.  Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approx. 30% of patients with AML.  Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML.  Responses, however, are not sustained and acquired resistance has been a clin. challenge.  Treatment options to overcome resistance are currently the focus of research.  We report here the preclin. evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.  AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body wt. loss.  The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, resp.  In addn., AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib).  CDK4 is a cyclin D-dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals.  A crit. role of the CDK4-RB pathway in cancer development has been well established.  CDK4-specific inhibitors are being developed for treating RB-pos. cancer.  AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clin. responses.  Mol Cancer Ther; 13(4); 880-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4p2uOyF0ObVg90H21EOLACvtfcHk0lj_RrIiQuhzIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D&md5=7343fdb82e66c9115c8b018a260aadde</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0858%26sid%3Dliteratum%253Aachs%26aulast%3DKeegan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRagains%26aufirst%3DM.%26aulast%3DCoberly%26aufirst%3DS.%26aulast%3DHollenback%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DWeidner%26aufirst%3DM.%26aulast%3DHuard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlba%26aufirst%3DG.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DQu%25C3%25A9va%26aufirst%3DC.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520AMG%2520925%252C%2520a%2520FLT3%252FCDK4%2520dual%2520kinase%2520inhibitor%2520for%2520treating%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D880%26epage%3D889%26doi%3D10.1158%2F1535-7163.MCT-13-0858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase inhibitor with potentially high efficiency against acute myelocytic leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1499-1518&author=Y.+Wangauthor=Y.+Zhiauthor=Q.+Jinauthor=S.+Luauthor=G.+Linauthor=H.+Yuanauthor=T.+Yangauthor=Z.+Wangauthor=C.+Yaoauthor=J.+Lingauthor=H.+Guoauthor=T.+Liauthor=J.+Jinauthor=B.+Liauthor=L.+Zhangauthor=Y.+Chenauthor=T.+Lu&title=Discovery+of+4-%28%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29-N-%284-%28%284-methylpiperazin-1-yl%29methyl%29phenyl%29-1H-pyrazole-3-carboxamide+%28FN-1501%29%2C+an+FLT3-+and+CDK-Kinase+inhibitor+with+potentially+high+efficiency+against+acute+myelocytic+leukemia&doi=10.1021%2Facs.jmedchem.7b01261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></div><div class="casAuthors">Wang, Yue; Zhi, Yanle; Jin, Qiaomei; Lu, Shuai; Lin, Guowu; Yuan, Haoliang; Yang, Taotao; Wang, Zhanwei; Yao, Chao; Ling, Jun; Guo, Hao; Li, Tonghui; Jin, Jianlin; Li, Baoquan; Zhang, Li; Chen, Yadong; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1499-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1-H-pyrazole-3-carboxamide derivs. have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities.  A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is crit. for FLT3 and CDK inhibition.  Compd. 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis.  Acute-toxicity studies in mice show that compd. I (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg).  In MV4-11 xenografts in a nude-mouse model, compd. I can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg).  Taken together, these results demonstrate the potential of this unique compd. for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfX9S4QkGccbVg90H21EOLACvtfcHk0lh2wrxa-WC9Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D&md5=2757ad7559e655c5d96f0a8af8c74aa5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25204-%2528%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2520%2528FN-1501%2529%252C%2520an%2520FLT3-%2520and%2520CDK-Kinase%2520inhibitor%2520with%2520potentially%2520high%2520efficiency%2520against%2520acute%2520myelocytic%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1499%26epage%3D1518%26doi%3D10.1021%2Facs.jmedchem.7b01261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee-Sherick, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGranahan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armistead, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGary, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsucker, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span> <span> </span><span class="NLM_article-title">Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5368</span>, <span class="refDoi"> DOI: 10.1038/onc.2013.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fonc.2013.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23474756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslKmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=5359-5368&author=A.+B.+Lee-Sherickauthor=K.+M.+Eisenmanauthor=S.+Satherauthor=A.+McGranahanauthor=P.+M.+Armisteadauthor=C.+S.+McGaryauthor=S.+A.+Hunsuckerauthor=J.+Schlegelauthor=H.+Martinsonauthor=C.+Cannonauthor=A.+K.+Keatingauthor=H.+S.+Earpauthor=X.+Liangauthor=D.+DeRyckereauthor=D.+K.+Graham&title=Aberrant+Mer+receptor+tyrosine+kinase+expression+contributes+to+leukemogenesis+in+acute+myeloid+leukemia&doi=10.1038%2Fonc.2013.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia</span></div><div class="casAuthors">Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; McGranahan, A.; Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">5359-5368</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clin. response to conventional therapy.  Abnormal tyrosine kinase activation in AML has been assocd. with poor prognosis and provides strategic targets for novel therapy development.  We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult (10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse.  Mer was also found to be expressed in 12 of 14 AML cell lines (86%).  In contrast, normal bone marrow myeloid precursors expressed little to no Mer.  Following AML cell line stimulation with Gas6, a Mer ligand, we obsd. activation of prosurvival and proliferative signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6.  To assess the phenotypic role of Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines Nomo-1 and Kasumi-1.  Redn. of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in response to serum starvation.  Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation by 67-87%, relative to control cell lines (P<0.01).  NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines (median survival 17 days in parental and control cell lines, vs. 32-36 days in Mer knockdown cell lines, P<0.0001).  These data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective therapeutic strategy in pediatric and adult AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSaqXGJx3YcbVg90H21EOLACvtfcHk0ljahm69x03Ktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslKmtL0%253D&md5=9dcd6e614aa7ff40c38eeebe26950db9</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.40%26sid%3Dliteratum%253Aachs%26aulast%3DLee-Sherick%26aufirst%3DA.%2BB.%26aulast%3DEisenman%26aufirst%3DK.%2BM.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMcGranahan%26aufirst%3DA.%26aulast%3DArmistead%26aufirst%3DP.%2BM.%26aulast%3DMcGary%26aufirst%3DC.%2BS.%26aulast%3DHunsucker%26aufirst%3DS.%2BA.%26aulast%3DSchlegel%26aufirst%3DJ.%26aulast%3DMartinson%26aufirst%3DH.%26aulast%3DCannon%26aufirst%3DC.%26aulast%3DKeating%26aufirst%3DA.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DAberrant%2520Mer%2520receptor%2520tyrosine%2520kinase%2520expression%2520contributes%2520to%2520leukemogenesis%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D5359%26epage%3D5368%26doi%3D10.1038%2Fonc.2013.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaros, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7031</span>– <span class="NLM_lpage">7041</span>, <span class="refDoi"> DOI: 10.1021/jm500749d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500749d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7031-7041&author=W.+Zhangauthor=D.+DeRyckereauthor=D.+Hunterauthor=J.+Liuauthor=M.+A.+Stashkoauthor=K.+A.+Minsonauthor=C.+T.+Cummingsauthor=M.+Leeauthor=T.+G.+Glarosauthor=D.+L.+Newtonauthor=S.+Satherauthor=D.+Zhangauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC2025%2C+a+potent+and+orally+bioavailable+MER%2FFLT3+dual+inhibitor&doi=10.1021%2Fjm500749d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor</span></div><div class="casAuthors">Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra; Liu, Jing; Stashko, Michael A.; Minson, Katherine A.; Cummings, Christopher T.; Lee, Minjung; Glaros, Trevor G.; Newton, Dianne L.; Sather, Susan; Zhang, Dehui; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7031-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported a potent small mol. Mer tyrosine kinase inhibitor UNC1062.  However, its poor PK properties prevented further assessment in vivo.  We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examg. phospho-Mer in leukemic blasts from mouse bone marrow.  Kinome profiling vs. more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an addnl. important target in acute myelogenous leukemia (AML), with pharmacol. useful selectivity vs. other kinases examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIu8sRwBmPqrVg90H21EOLACvtfcHk0ljahm69x03Ktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN&md5=b3be89f194e6f5ea853d82aa67aea939</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm500749d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500749d%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMinson%26aufirst%3DK.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DGlaros%26aufirst%3DT.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC2025%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520MER%252FFLT3%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7031%26epage%3D7041%26doi%3D10.1021%2Fjm500749d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deryckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayakody, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">UNC1062, a new and potent Mer inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2013.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23693152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=83-93&author=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=D.+Deryckereauthor=C.+T.+Cummingsauthor=D.+Hunterauthor=C.+Yangauthor=C.+N.+Jayakodyauthor=N.+Chengauthor=C.+Simpsonauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC1062%2C+a+new+and+potent+Mer+inhibitor&doi=10.1016%2Fj.ejmech.2013.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">UNC1062, a new and potent Mer inhibitor</span></div><div class="casAuthors">Liu, Jing; Zhang, Weihe; Stashko, Michael A.; DeRyckere, Deborah; Cummings, Christopher T.; Hunter, Debra; Yang, Chao; Jayakody, Chatura N.; Cheng, Nancy; Simpson, Catherine; Norris-Drouin, Jacqueline; Sather, Susan; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma.  The authors have discovered a new family of small mol. Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer.  Importantly, these compds. do not demonstrate significant hERG activity in the PatchXpress assay.  Through structure-activity relationship studies, UNC1062 was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor.  When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar.  Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrAMT5879KW7Vg90H21EOLACvtfcHk0liZZiWiwJ8FJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE&md5=fde1dd50f35af93a0e671932fb7c579d</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DJayakody%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC1062%252C%2520a%2520new%2520and%2520potent%2520Mer%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D83%26epage%3D93%26doi%3D10.1016%2Fj.ejmech.2013.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2015.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26139428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1emu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=754-757&author=H.+Wuauthor=C.+Huauthor=A.+Wangauthor=E.+L.+Weisbergauthor=W.+Wangauthor=C.+Chenauthor=Z.+Zhaoauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=A.+Nonamiauthor=L.+Wangauthor=B.+Wangauthor=R.+M.+Stoneauthor=S.+Liuauthor=J.+D.+Griffinauthor=J.+Liuauthor=Q.+Liu&title=Ibrutinib+selectively+targets+FLT3-ITD+in+mutant+FLT3-positive+AML&doi=10.1038%2Fleu.2015.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML</span></div><div class="casAuthors">Wu, H.; Hu, C.; Wang, A.; Weisberg, E. L.; Wang, W.; Chen, C.; Zhao, Z.; Yu, K.; Liu, J.; Wu, J.; Nonami, A.; Wang, L.; Wang, B.; Stone, R. M.; Liu, S.; Griffin, J. D.; Liu, J.; Liu, Q.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">754-757</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that has been extensively used as a tool compd. to validate the role of BTK kinase in B cell related malignances.1, 2.  Ibrutinib has been shown in preclin. studies to inhibit the proliferation of diffuse large B-cell lymphoma cells, mantle cell lymphoma cells, chronic lymphocytic leukemia cells and multiple myeloma cells by blocking BTK kinase activity; ibrutinib was recently approved for the clin. application on mantle cell lymphoma and chronic lymphocytic leukemia cells.3, 4, 5, 6, 7.  Ibrutinib has also exhibited anti-inflammatory effects in preclin. models.8, 9.  Recently, it has been reported that ibrutinib is also effective against epidermal growth factor receptor mutant-pos. non-small cell lung cancers through inhibition of epidermal growth factor receptor kinase activities.10.  In addn., there is evidence showing that BTK is also an important target for Acute Myeloid Leukemia (AML).11.  Despite the evidence that BTK knockdown impaired AML cancer cell growth, which suggested that BTK was important for AML cell proliferation, BTK kinase inhibition through use of a small mol. inhibitor like ibrutinib led only to moderate inhibition of proliferation of U937 cells with no apparent activity against other AML cell lines such as HL-60, TF-1 and THP-1.11.  To further investigate the potency and Interestingly, we found that only FLT3-internal tandem duplication (ITD) mutant AML cell lines (MOLM13, MOLM14 and MV4-11) were sensitive to ibrutinib (Figure 1a and Supplementary Table 1).  This is similar to what has been obsd. with the highly potent and selective FLT3 inhibitor, AC220, but differs from that obsd. for the targeted BTK kinase inhibitor, CGI-1746.12, 13 The selective antiproliferative activity was further confirmed in the clonogenic assay (GI50: 170-478 nM) (Supplementary Figure 1).  This suggests that ibrutinib might target FLT3 kinase in addn. to BTK kinase.  We then investigated the effect of ibrutinib on FLT3-ITD mediated signaling in drug-sensitive cell lines.  (Figure 1b) Ibrutinib potently inhibited FLT3-ITD auto-phosphorylation (EC50: 318, 39 and 356 nM resp. for MOLM13, MOLM14 and MV4-11) (Supplementary Figure 2A).  Phosphorylation of STAT5, a well-established downstream target, also was significantly inhibited with an EC50 between 100 and 200 nM (Supplementary Figure 2B).  In addn., c-Myc expression was inhibited with an EC50 between 185 and 315 nM.  (Supplementary Figure 2C) However, in FLT3 wt-expressing cell lines such as NOMO-1, HL-60, OCI-AML-3 and U937 cells, FLT3 signaling was not affected by ibrutinib upon FLT3 ligand stimulation (Supplementary Figure 2D).  Interestingly, despite the expression of the FLT3 wt kinase in all four cell lines, the induction of FLT3 auto-phosphorylation upon FLT3 ligand treatment was not obsd. in NOMO-1 and HL-60 cells like what was obsd. in the OCI-AML-3 and U937 cells, which might be due to the different genetic background and require further detailed mechanistic study.  The FLT3 inhibitor AC220 demonstrated similar inhibitory activity to ibrutinib in FLT3-mediated signaling pathways in the FLT3-ITD pos. cell lines.  However, the BTK inhibitors, CGI-1746 and AVL-292, did not exhibit any effect on the signaling14 (Figure 2b and Supplementary Figure 2D).  As all of these cell lines express BTK kinase, we then studied the effect of ibrutinib on BTK signaling.  Upon anti-IgM (IgM) stimulation of B-cell receptor to active the BTK kinase signaling pathway, we found that only in the FLT3 wild-type (wt)-expressing cell lines (U937 and OCI-AML3), downstream mediators of BTK kinase were affected despite BTK phosphorylation having been inhibited in both FLT3 wt and FLT3-ITD cell lines.9 This suggests that FLT3-ITD mutant cell lines might not rely on BTK signaling for growth (Supplementary Figure 3A).  Interestingly, except NOMO-1 and U937 cells, the phosphorylation of BTKY223 of MOLM14, MOLM13, MV4-11, OCI-AML-3 and HL-60 cells did not respond to anti-IgM stimulation apparently, which might be due to the basal-level expression of the IgM in these AML cells (Supplementary Figure 3B).  AC220 did not affect BTK kinase activity and its direct downstream target PLCγ but instead inhibited phosphorylation of protein kinase B and extracellular-signal-regulated kinase.  The BTK inhibitors, CGI-1746 and AVL-292, were effective against BTK kinase and PLCγ kinase phosphorylation, but had no effect on the phosphorylation of protein kinase B and extracellular-signal-regulated kinase.  These results suggest that ibrutinib may mainly exert its inhibitory activity through FLT3 kinase but not BTK kinase in the FLT3-ITD pos. cells.  To further confirm this, we knocked down BTK kinase in MOLM14 (FLT3-ITD), MOLM13 (FLT3-ITD), human erythroleukemia cell (HEL) (FLT3 wt) and NB4 (FLT3 wt) cells and found that the growth of MOLM14 and MOLM13 was only minimally affected; however NB4 cells were significantly inhibited and HEL cells were moderately inhibited (Figures 2a and b).  The fact that BTK knockdown in HEL cells did not lead to suppressed growth may be due to the fact that mutant JAK2 is the oncogenic driver in this cell line.15 In addn., the finding that ibrutinib still significantly blocked the growth of BTK-knockdown MOLM14 and MOLM13 cells further validated that the growth inhibitory effect of ibrutinib is likely dependent mainly on FLT3-ITD inhibition.  However, BTK kinase inhibition may also exert a combinatorial effect (Figure 2c).  It has recently been reported that BTK kinase is activated by FLT3-ITD in FLT3-ITD pos. cell lines and dual inhibition of BTK and FLT3 kinase demonstrates combinatorial effects; these findings further confirm this observation.16 Previous kinase selectivity profiling revealed that FLT3 wt might be an addnl. target of ibrutinib.9 The biochem. ADP-Glo assay confirmed that ibrutinib has an IC50 of 205.8 nM/65.65 nM against FLT3 wt and FLT3-ITD, resp. (Supplementary Figure 4A).  In the FLT3-ITD-dependent isogenic BaF3 cell line, ibrutinib demonstrated a GI50 of 120 nM; this inhibitory effect could be completely rescued by interleukin-3 treatment (Supplementary Figure 4B).  Interestingly, it also potently inhibited the FLT3-D835H-BaF3 isogenic cell (GI50: 0.063 μM) and moderately inhibited FLT3-D835Y-BaF3 as well as TEL-FLT3-wt-BaF3 isogenic cells (GI50: 0.5 μ/0.46 μ), however was less active against ITD-D835Y, ITD-F691L and FLT3-K663Q mutations.  (Supplementary Figure 5A) In addn., ibrutinib did not affect the growth of other oncogene-expressing Ba/F3 cells, such as c-Kit, PDGFRα, BCR-ABL and NRAS (Supplementary Figure 5B).  Although there are cysteine residues in the ATP-binding pocket, binding mode examn. with mol. modeling demonstrates that unlike the mode of inhibition against BTK kinase, ibrutinib inhibits FLT3 kinase through reversible binding and this is further confirmed by the washing-out expt. (Supplementary Figure 4C and D).  Ibrutinib induced apoptotic cell death in a concn.- and time-dependent manner in FLT3-ITD cell lines but not FLT3 wt-expressing cell lines (Supplementary Figure 6).  Cell cycle anal. revealed that ibrutinib, but not the highly selective BTK kinase inhibitor, CGI-1746, could induce a concn.-dependent manner-arrest cells in G0/G1 phase (Supplementary Figure 7).  In addn., ibrutinib exhibited dose-dependent anti-proliferation activity against FLT3-ITD mutant-expressing primary patient cells but not FLT3 wt-expressing and multiple mutants such as FLT3-ITD/FLT3-D835Y and FLT3-D835Y/E mutants expressing samples, which further confirms that ibrutinib is FLT3-ITD selective (Figure 2d).  AML still remains a serious unmet medical need and the FLT3-ITD mutant has been found in ∼30% of AML patients.  Besides std. chemotherapy, there is no targeted therapy approved in the clinic to date despite several inhibitors that are presently under clin. investigation.17 Currently, ibrutinib is under extensive clin. investigation against a variety of different B-cell malignancies.  Given the fact that the safety profile of ibrutinib is tolerated in the patients, our results might help to expand the application of this drug to AML patients harboring the FLT3-ITD mutant.  Interestingly, despite the fact that the effective concn. of ibrutinib in the in vitro studies in the FLT3-ITD pos. cell lines falls within the range of the peak plasma concn. used in human clin. trials (around 150 ng/mL at 560 mg/day dosage), the concn. required for the induction of apoptosis and cell cycle arrest for ibrutinib is higher, which suggests that an alternative formulation might be needed such as nano technol., to allow the increase of the plasma concns. in the human patients while simultaneously retaining the safety profile for the potential clin. application.18.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9uujF_Uu1FbVg90H21EOLACvtfcHk0lirXN3EqSJJrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1emu7vO&md5=cc08960c1d1db9a9f83c9c67bac15f85</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.175%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520targets%2520FLT3-ITD%2520in%2520mutant%2520FLT3-positive%2520AML%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D754%26epage%3D757%26doi%3D10.1038%2Fleu.2015.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3–122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9625</span>– <span class="NLM_lpage">9638</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9625-9638&author=X.+Liauthor=A.+Wangauthor=K.+Yuauthor=Z.+Qiauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=H.+Wuauthor=J.+Wuauthor=Z.+Zhaoauthor=J.+Liuauthor=F.+Zouauthor=L.+Wangauthor=B.+Wangauthor=W.+Wangauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-amino-3-%284-phenoxyphenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-1-yl%29-2-%28dimethylamino%29ethanone+%28CHMFL-FLT3%E2%80%93122%29+as+a+potent+and+orally+available+FLT3+kinase+inhibitor+for+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia</span></div><div class="casAuthors">Li, Xixiang; Wang, Aoli; Yu, Kailin; Qi, Ziping; Chen, Cheng; Wang, Wenchao; Hu, Chen; Wu, Hong; Wu, Jiaxin; Zhao, Zheng; Liu, Juan; Zou, Fengming; Wang, Li; Wang, Beilei; Wang, Wei; Zhang, Shanchun; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9625-9638</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, the authors have discovered compd. 18 (CHMFL-FLT3-122, I), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold).  It significantly inhibited the proliferation of FLT3-ITD pos. AML cancer cell lines MV4-11 (GIC50 = 22 nM), MOLM13/14 (GIC50 = 21 nM/42 nM).  More importantly, compd. 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GIC50 = 11 nM vs. 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity.  In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase.  In the in vivo studies compd. 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity.  Compd. 18 might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotxBPmnbEZ17Vg90H21EOLACvtfcHk0lirXN3EqSJJrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ&md5=f0d6f5f767f35c4aed3b20c02de06e86</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529-2-%2528dimethylamino%2529ethanone%2520%2528CHMFL-FLT3%25E2%2580%2593122%2529%2520as%2520a%2520potent%2520and%2520orally%2520available%2520FLT3%2520kinase%2520inhibitor%2520for%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9625%26epage%3D9638%26doi%3D10.1021%2Facs.jmedchem.5b01611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a highly potent type II FLT3 kinase inhibitor capable of overcoming a variety of FLT3 kinase mutants in FLT3-ITD positive AML</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8407</span>– <span class="NLM_lpage">8424</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8407-8424&author=A.+Wangauthor=X.+Liauthor=C.+Chenauthor=H.+Wuauthor=Z.+Qiauthor=C.+Huauthor=K.+Yuauthor=J.+Wuauthor=J.+Liuauthor=X.+Liuauthor=Z.+Huauthor=W.+Wangauthor=W.+Wangauthor=W.+Wangauthor=L.+Wangauthor=B.+Wangauthor=Q.+Liuauthor=L.+Liauthor=J.+Geauthor=T.+Renauthor=S.+Zhangauthor=R.+Xiaauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+1-%284-%284-amino-3-%284-%282-morpholinoethoxy%29phenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29phenyl%29-3-%285-%28tert-butyl%29isoxazol-3-yl%29urea+%28CHMFL-FLT3-213%29+as+a+highly+potent+type+II+FLT3+kinase+inhibitor+capable+of+overcoming+a+variety+of+FLT3+kinase+mutants+in+FLT3-ITD+positive+AML&doi=10.1021%2Facs.jmedchem.7b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML</span></div><div class="casAuthors">Wang, Aoli; Li, Xixiang; Chen, Cheng; Wu, Hong; Qi, Ziping; Hu, Chen; Yu, Kailin; Wu, Jiaxin; Liu, Juan; Liu, Xiaochuan; Hu, Zhenquan; Wang, Wei; Wang, Wenliang; Wang, Wenchao; Wang, Li; Wang, Beilei; Liu, Qingwang; Li, Lili; Ge, Jian; Ren, Tao; Zhang, Shanchun; Xia, Ruixiang; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8407-8424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of our previous study that ibrutinib exhibited selective and moderate inhibitory activity against FLT3-ITD pos. AML cells, through a structure-guided drug design approach, we have discovered a new type II FLT3 kinase inhibitor, compd. I (CHMFL-FLT3-213), which exhibited highly potent inhibitory effects against FLT3-ITD mutant and assocd. oncogenic mutations (including FLT3-D835Y/H/V, FLT3-ITD-D835Y/I/N/A/G/Del, and FLT3-ITD-F691L).  In the cellular context I strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting cell cycle into G0/G1 phase.  In the in vivo studies I demonstrated an acceptable bioavailability (F = 19%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (15 mg kg-1 day-1, TGI = 97%) without exhibiting obvious toxicity.  Compd. I might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1tbOp_Bxu-LVg90H21EOLACvtfcHk0liDZgxyGUY8RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN&md5=e4f3a47069f8ea615a3e1543b24a19b9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00840%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%25201-%25284-%25284-amino-3-%25284-%25282-morpholinoethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529phenyl%2529-3-%25285-%2528tert-butyl%2529isoxazol-3-yl%2529urea%2520%2528CHMFL-FLT3-213%2529%2520as%2520a%2520highly%2520potent%2520type%2520II%2520FLT3%2520kinase%2520inhibitor%2520capable%2520of%2520overcoming%2520a%2520variety%2520of%2520FLT3%2520kinase%2520mutants%2520in%2520FLT3-ITD%2520positive%2520AML%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8407%26epage%3D8424%26doi%3D10.1021%2Facs.jmedchem.7b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrrolo[2,3-d]pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4158</span>– <span class="NLM_lpage">4173</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4158-4173&author=X.+Yuanauthor=Y.+Chenauthor=W.+Zhangauthor=J.+Heauthor=L.+Leiauthor=M.+Tangauthor=J.+Liuauthor=M.+Liauthor=C.+Douauthor=T.+Yangauthor=L.+Yangauthor=S.+Yangauthor=Y.+Weiauthor=A.+Pengauthor=T.+Niuauthor=M.+Xiangauthor=H.+Yeauthor=L.+Chen&title=Identification+of+pyrrolo%5B2%2C3-d%5Dpyrimidine-based+derivatives+as+potent+and+orally+effective+Fms-like+tyrosine+receptor+kinase+3+%28FLT3%29+inhibitors+for+treating+acute+myelogenous+leukemia&doi=10.1021%2Facs.jmedchem.9b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia</span></div><div class="casAuthors">Yuan, Xue; Chen, Yong; Zhang, Wanhua; He, Jun; Lei, Lei; Tang, Minghai; Liu, Jiang; Li, Muzhou; Dou, Caixia; Yang, Tao; Yang, Linyu; Yang, Shengyong; Wei, Yuquan; Peng, Aihua; Niu, Ting; Xiang, Mingli; Ye, Haoyu; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4158-4173</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrrolo[2,3-d]pyrimidine derivs. were prepd. and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells.  Among them, compd. I possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13 cells.  It also showed excellent inhibitory activities in FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to quizartinib.  Furthermore, I exhibited over 40-fold selectivity toward FLT3 relative to c-Kit kinase, which might reduce myelosuppression toxicity.  Cellular assays demonstrated that I inhibited phosphorylated FLT3 and downstream signaling factors and also induced cell cycle arrest in the G0/G1 stage and apoptosis in MV4-11 and Molm-13 cells.  Oral administration of I at 10 mg/kg could achieve rapid tumor extinction in the MV4-11 xenograft model and significantly inhibit the tumor growth in the MOLM-13 xenograft model with a tumor growth inhibitory rate of 96% without obvious toxicity.  Addnl., I demonstrated high bioavailability (F = 59.5%) and suitable eliminated half-life time (T1/2 = 2.06 h), suggesting that I may be a potent candidate for treating acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc5FKDBj_PA7Vg90H21EOLACvtfcHk0lhRtpsbqWQzbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D&md5=37666941adb79cb2a5d8a4115ddd2519</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDou%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DA.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520pyrrolo%255B2%252C3-d%255Dpyrimidine-based%2520derivatives%2520as%2520potent%2520and%2520orally%2520effective%2520Fms-like%2520tyrosine%2520receptor%2520kinase%25203%2520%2528FLT3%2529%2520inhibitors%2520for%2520treating%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4158%26epage%3D4173%26doi%3D10.1021%2Facs.jmedchem.9b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and rational design of pteridin-7(8H)-one-based inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6187</span>– <span class="NLM_lpage">6200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVCltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6187-6200&author=D.+Sunauthor=Y.+Yangauthor=J.+Lyuauthor=W.+Zhouauthor=W.+Songauthor=Z.+Zhaoauthor=Z.+Chenauthor=Y.+Xuauthor=H.+Li&title=Discovery+and+rational+design+of+pteridin-7%288H%29-one-based+inhibitors+targeting+FMS-like+tyrosine+kinase+3+%28FLT3%29+and+its+mutants&doi=10.1021%2Facs.jmedchem.6b00374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants</span></div><div class="casAuthors">Sun, Deheng; Yang, Yu; Lyu, Jiankun; Zhou, Wei; Song, Wenlin; Zhao, Zhenjiang; Chen, Zhuo; Xu, Yufang; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6187-6200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML).  In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 inhibitors derived from structural optimizations on irreversible EGFR inhibitors.  The representative inhibitor (31) demonstrates single-digit nanomolar inhibition against FLT3 and subnanomolar KD for drug-resistance FLT3 mutants.  In profiling of the in vitro tumor cell lines, it shows good selectivity against AML cells harboring FLT3-ITD mutations over other leukemia and solid tumor cell lines.  The mechanism of action study illustrates that pteridin-7(8H)-one derivs. suppress the phosphorylation of FLT3 and its downstream pathways, thereby inducing G0/G1 cell cycle arrest and apoptosis in AML cells.  In in vivo studies, 31 significantly suppresses the tumor growth in MV4-11 xenograft model.  Overall, we provide a structurally distinct chem. scaffold with which to develop FLT3 mutants-selective inhibitors for AML treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOmpGYdXfHlbVg90H21EOLACvtfcHk0lhRtpsbqWQzbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVCltrc%253D&md5=b672eb968645a0ca88f0af371c67629d</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00374%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520rational%2520design%2520of%2520pteridin-7%25288H%2529-one-based%2520inhibitors%2520targeting%2520FMS-like%2520tyrosine%2520kinase%25203%2520%2528FLT3%2529%2520and%2520its%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6187%26epage%3D6200%26doi%3D10.1021%2Facs.jmedchem.6b00374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarusiewicz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of a diaminopyrimidine FLT3 inhibitor active against acute myeloid leukemia</span>. <i>ACS Omega.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1985</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/acsomega.7b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.7b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVegu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=1985-2009&author=J.+A.+Jarusiewiczauthor=J.+Y.+Jeonauthor=M.+C.+Connellyauthor=Y.+Chenauthor=L.+Yangauthor=S.+D.+Bakerauthor=R.+K.+Guy&title=Discovery+of+a+diaminopyrimidine+FLT3+inhibitor+active+against+acute+myeloid+leukemia&doi=10.1021%2Facsomega.7b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia</span></div><div class="casAuthors">Jarusiewicz, Jamie A.; Jeon, Jae Yoon; Connelly, Michele C.; Chen, Yizhe; Yang, Lei; Baker, Sharyn D.; Guy, R. Kiplin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1985-2009</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Profiling of the kinase-binding capabilities of an aminopyrimidine analog detected in a cellular screen of the St.  Jude small-mol. collection led to the identification of a novel series of FMS-like tyrosine kinase 3 (FLT3) inhibitors.  Structure-activity relationship studies led to the development of compds. exhibiting good potency against MV4-11 and MOLM13 acute myelogenous leukemia cells driven by FLT3, regardless of their FLT3 mutation status.  In vitro pharmacol. profiling demonstrated that compd. 5e shows characteristics suitable for further preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG8D0TrL7uCbVg90H21EOLACvtfcHk0ljMyhcE1w4G6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVegu7w%253D&md5=653dacc5371930c67aa79246e1a35846</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facsomega.7b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.7b00144%26sid%3Dliteratum%253Aachs%26aulast%3DJarusiewicz%26aufirst%3DJ.%2BA.%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DConnelly%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3DDiscovery%2520of%2520a%2520diaminopyrimidine%2520FLT3%2520inhibitor%2520active%2520against%2520acute%2520myeloid%2520leukemia%26jtitle%3DACS%2520Omega.%26date%3D2017%26volume%3D2%26spage%3D1985%26epage%3D2009%26doi%3D10.1021%2Facsomega.7b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelaziz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28863357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaht73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=762-772&author=S.+Diabauthor=A.+M.+Abdelazizauthor=P.+Liauthor=T.+Teoauthor=S.+Basnetauthor=B.+Nollauthor=M.+H.+Rahamanauthor=J.+Luauthor=J.+Houauthor=M.+Yuauthor=B.+T.+Leauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+Wang&title=Dual+inhibition+of+Mnk2+and+FLT3+for+potential+treatment+of+acute+myeloid+leukaemia&doi=10.1016%2Fj.ejmech.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia</span></div><div class="casAuthors">Diab, Sarah; Abdelaziz, Ahmad M.; Li, Peng; Teo, Theodosia; Basnet, Sunita K. C.; Noll, Ben; Rahaman, Muhammed H.; Lu, Jingfeng; Hou, Jinqiang; Yu, Mingfeng; Le, Bich T.; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">762-772</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The discovery of novel anti-AML therapeutic agents is urgently needed, but the complex heterogeneity of the disease has so far hampered the development of a curative treatment.  FLT3 inhibitors have shown therapeutic potential in clin. trials; but a monotherapy regimen has been assocd. with resistance mediated by the activation of parallel signaling circuitry, including MAPK and mTOR.  Therefore, inhibiting a nexus of the two signaling pathways along with inhibition of FLT3 might be advantageous.  Herein, the authors propose that a dual inhibition of FLT3 and Mnk would provide a better clin. option for AML patients compared to targeting FLT3 alone.  Thus, a series of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amines and 4-(indol-3-yl)-N-phenylpyrimidin-2-amines were prepd.  Potent Mnk2 inhibitors, FLT3 inhibitors, and dual inhibitors of Mnk2 and FLT3 were identified and their antiproliferative activities assessed against MV4-11 AML cell lines.  Dual inhibition of FLT3 and Mnk2 caused the increased apoptotic cell death of MV4-11 cells compared to inhibition of FLT3 or Mnk2 alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeSmNto09qL7Vg90H21EOLACvtfcHk0ljMyhcE1w4G6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaht73F&md5=439b0e509af9800c168beb69c9d2b1a0</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DAbdelaziz%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DBasnet%26aufirst%3DS.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDual%2520inhibition%2520of%2520Mnk2%2520and%2520FLT3%2520for%2520potential%2520treatment%2520of%2520acute%2520myeloid%2520leukaemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D762%26epage%3D772%26doi%3D10.1016%2Fj.ejmech.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radošová Muchová, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klejová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malínková, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepšík, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divoký, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of N<sup>2</sup>-(4-amino-cyclohexyl)-9-cyclopentyl- N<sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3855-3869&author=T.+Guck%C3%BDauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+Rado%C5%A1ov%C3%A1+Muchov%C3%A1author=R.+Jordaauthor=Z.+Klejov%C3%A1author=V.+Mal%C3%ADnkov%C3%A1author=K.+Berkaauthor=V.+Bazgierauthor=H.+Ajaniauthor=M.+Lep%C5%A1%C3%ADkauthor=V.+Divok%C3%BDauthor=V.+Kry%C5%A1tof&title=Discovery+of+N2-%284-amino-cyclohexyl%29-9-cyclopentyl-+N6-%284-morpholin-4-ylmethyl-phenyl%29-9H-purine-2%2C6-diamine+as+a+potent+FLT3+kinase+inhibitor+for+acute+myeloid+leukemia+with+FLT3+mutations&doi=10.1021%2Facs.jmedchem.7b01529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></div><div class="casAuthors">Gucky, Tomas; Reznickova, Eva; Radosova Muchova, Tereza; Jorda, Radek; Klejova, Zuzana; Malinkova, Veronika; Berka, Karel; Bazgier, Vaclav; Ajani, Haresh; Lepsik, Martin; Divoky, Vladimir; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3.  We present novel 2,6,9-trisubstituted purine derivs. with potent FLT3 inhibitory activity.  The lead compd. 7d displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive.  The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis.  Addnl., a single dose of 7d in mice with s.c. MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ88Wx0YxwWLVg90H21EOLACvtfcHk0lgZ1S_P9rkGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D&md5=cbc982a08f1905840e273e23c825a134</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DRado%25C5%25A1ov%25C3%25A1%2BMuchov%25C3%25A1%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKlejov%25C3%25A1%26aufirst%3DZ.%26aulast%3DMal%25C3%25ADnkov%25C3%25A1%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DLep%25C5%25A1%25C3%25ADk%26aufirst%3DM.%26aulast%3DDivok%25C3%25BD%26aufirst%3DV.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520N2-%25284-amino-cyclohexyl%2529-9-cyclopentyl-%2520N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2520as%2520a%2520potent%2520FLT3%2520kinase%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3855%26epage%3D3869%26doi%3D10.1021%2Facs.jmedchem.7b01529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111590</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2019.111590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31408808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111590&author=Y.+Liauthor=T.+Yeauthor=L.+Xuauthor=Y.+Dongauthor=Y.+Luoauthor=C.+Wangauthor=Y.+Hanauthor=K.+Chenauthor=M.+Qinauthor=Y.+Liuauthor=Y.+Zhao&title=Discovery+of+4-piperazinyl-2-aminopyrimidine+derivatives+as+dual+inhibitors+of+JAK2+and+FLT3&doi=10.1016%2Fj.ejmech.2019.111590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span></div><div class="casAuthors">Li, Yingxiu; Ye, Tianyu; Xu, Le; Dong, Yuhong; Luo, Yong; Wang, Chu; Han, Yufei; Chen, Ke; Qin, Mingze; Liu, Yajing; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111590</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design.  In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivs.  All compds. were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compds. with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60).  The structure-activity relationship studies were conducted through variations in two regions, the "A" Ph ring and "B" Ph ring.  Compd. 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines.  In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs61BoDk0-lbVg90H21EOLACvtfcHk0lgZ1S_P9rkGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO&md5=787f97231f5494a8f85f581521486b25</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111590%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25204-piperazinyl-2-aminopyrimidine%2520derivatives%2520as%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520FLT3%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111590%26doi%3D10.1016%2Fj.ejmech.2019.111590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally effective dual Janus Kinase 2/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10305</span>– <span class="NLM_lpage">10320</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10305-10320&author=T.+Yangauthor=M.+Huauthor=W.+Qiauthor=Z.+Yangauthor=M.+Tangauthor=J.+Heauthor=Y.+Chenauthor=P.+Baiauthor=X.+Yuanauthor=C.+Zhangauthor=K.+Liuauthor=Y.+Luauthor=M.+Xiangauthor=L.+Chen&title=Discovery+of+potent+and+orally+effective+dual+Janus+Kinase+2%2FFLT3+inhibitors+for+the+treatment+of+acute+myelogenous+leukemia+and+myeloproliferative+neoplasms&doi=10.1021%2Facs.jmedchem.9b01348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></div><div class="casAuthors">Yang, Tao; Hu, Mengshi; Qi, Wenyan; Yang, Zhuang; Tang, Minghai; He, Jun; Chen, Yong; Bai, Peng; Yuan, Xue; Zhang, Chufeng; Liu, Kongjun; Lu, Yulin; Xiang, Mingli; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10305-10320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivs. that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases is described.  These screening cascades revealed that I was a preferred compd. with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, resp.  Moreover, I was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, resp., and possessed an excellent selectivity profile over the other 100 representative kinases.  In a series of cytokine-stimulated cell-based assays, I exhibited a higher JAK2 selectivity over other JAK isoforms.  The oral administration of 60 mg/kg of I could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, resp.  Addnl., I showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that I might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHnNcuajGNcLVg90H21EOLACvtfcHk0lj17y02l7D38Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE&md5=86c811cf77a95a7250996456cd29e6dc</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520effective%2520dual%2520Janus%2520Kinase%25202%252FFLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10305%26epage%3D10320%26doi%3D10.1021%2Facs.jmedchem.9b01348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1066</span>– <span class="NLM_lpage">1076</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2017.11.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29232583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1066-1076&author=H.+Daiauthor=S.+Geauthor=J.+Guoauthor=S.+Chenauthor=M.+Huangauthor=J.+Yangauthor=S.+Sunauthor=Y.+Lingauthor=Y.+Shi&title=Development+of+novel+bis-pyrazole+derivatives+as+antitumor+agents+with+potent+apoptosis+induction+effects+and+DNA+damage&doi=10.1016%2Fj.ejmech.2017.11.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage</span></div><div class="casAuthors">Dai, Hong; Ge, Shushan; Guo, Jing; Chen, Shi; Huang, Meiling; Yang, Jiaying; Sun, Siyu; Ling, Yong; Shi, Yujun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1066-1076</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of bis-pyrazole derivs. I (R1 = Et, 4-fluorophenyl, 4-chlorophenyl; R2 = 2-F, 3-Me, 4-OCF3, etc.) was designed and synthesized, and their antitumor effects in vitro and in vivo were investigated.  Several compds. displayed good antiproliferative activity with IC50 values in low-micromolar range against three human cancer cell lines in vitro, superior to 5-FU.  The most potent compd. I (R1 = 4-chlorophenyl; R2 = 4-OCH3) selectively inhibited human hepatocellular carcinoma cells but not non-tumor liver cell proliferation in vitro, and significantly triggered SMMC-7721 cell apoptosis by cleavage of both PARP and caspase-3 in a concn.-dependent manner.  Further study revealed that the potent activity in the cell growth inhibition and apoptosis induction effects of compd. I (R1 = 4-chlorophenyl; R2 = 4-OCH3) were related to DNA damage and activation of the p53 signaling pathway.  Moreover, compd. I (R1 = 4-chlorophenyl; R2 = 4-OCH3) showed low acute toxicity to mice and significant growth inhibition of the hepatoma tumor in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2FnwsxrlS67Vg90H21EOLACvtfcHk0lj17y02l7D38Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3K&md5=ecbc99d1c9ad62e443791b4f0a1b28c0</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.098%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520novel%2520bis-pyrazole%2520derivatives%2520as%2520antitumor%2520agents%2520with%2520potent%2520apoptosis%2520induction%2520effects%2520and%2520DNA%2520damage%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1066%26epage%3D1076%26doi%3D10.1016%2Fj.ejmech.2017.11.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span> <span> </span><span class="NLM_article-title">Pyrazole scaffold: a remarkable tool in the development of anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2013.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24161702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOqurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=248-258&author=H.+Kumarauthor=D.+Sainiauthor=S.+Jainauthor=N.+Jain&title=Pyrazole+scaffold%3A+a+remarkable+tool+in+the+development+of+anticancer+agents&doi=10.1016%2Fj.ejmech.2013.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole scaffold: A remarkable tool in the development of anticancer agents</span></div><div class="casAuthors">Kumar, Harish; Saini, Deepika; Jain, Sandeep; Jain, Neelam</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">248-258</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Pyrazole has been the topic of interest for thousands of researchers across the world because of its wide spectrum pharmacol. activities.  Various structural modifications of the pyrazole nucleus have been made to explore its characteristics and biol. potential.  The present work aims to review the use of mol. modeling in the designing of novel pyrazole analogs that may target various receptors such as protein kinase inhibitor, tyrosine kinase, Aurora-A kinase, tumor growth factor (TGF), cyclin dependent kinase (CDK) and fibroblast growth factor (FGF), which are significant for the management of cancer.  An insight has been given in this article for the importance of pyrazoles in the treatment of cancer and the perspectives that they hold for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf4c2cE6IwfrVg90H21EOLACvtfcHk0linW1U_mzB5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOqurjE&md5=a1c1f41aa2949d40a8f6adc57ee4fc4e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DH.%26aulast%3DSaini%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DN.%26atitle%3DPyrazole%2520scaffold%253A%2520a%2520remarkable%2520tool%2520in%2520the%2520development%2520of%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D70%26spage%3D248%26epage%3D258%26doi%3D10.1016%2Fj.ejmech.2013.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Qudah, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbuTayeh, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, S. A.</span></span> <span> </span><span class="NLM_article-title">Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.02.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.canlet.2016.02.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26916980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=199-208&author=A.+M.+Salehauthor=M.+O.+Tahaauthor=M.+A.+Azizauthor=M.+A.+Al-Qudahauthor=R.+F.+AbuTayehauthor=S.+A.+Rizvi&title=Novel+anticancer+compound+%5Btrifluoromethyl-substituted+pyrazole+N-nucleoside%5D+inhibits+FLT3+activity+to+induce+differentiation+in+acute+myeloid+leukemia+cells&doi=10.1016%2Fj.canlet.2016.02.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells</span></div><div class="casAuthors">Saleh, Ayman M.; Taha, Mutasem O.; Aziz, Mohammad A.; Al-Qudah, Mahmoud A.; AbuTayeh, Reem F.; Rizvi, Syed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-208</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anticancer properties of chem. synthesized compds. have continuously been optimized for better efficacy and selectivity.  Derivs. of heterocyclic compds. are well known to have selective antiproliferative effect against many types of cancer.  In this study, we investigated the ability of an indigenously synthesized anticancer mol., G-11 [1-(2",3",4",6"-Tetra-O-acetyl-β-D-glucopyranosyl)-4-(3'-trifluoromethylphenylhydrazono)-3-trifluoromethyl-1,4-dihydropyrazol-5-one], to cause selective cytotoxicity and induce differentiation in the acute myeloid leukemia HL-60 cells.  G-11 was able to exert cytotoxic effect on hematol. (Jurkat, U937, K562, HL-60, CCRF-SB) and solid tumor (MCF-7, HepG2, HeLa, Caco-2) cell lines, with IC50 values significantly lower than noncancerous cells (HEK-293, BJ and Vero) and normal peripheral blood mononuclear cells.  G-11 induced differentiation of HL-60 cells to granulocytes and monocytes/macrophages by inhibiting the activation of FLT3 (CD135 tyrosine kinase).  ITD-FLT3 mutation found in many acute myeloid leukemia patients could also be targeted by G-11 as exhibited by its inhibitory effect on MOLM-13 and MV4-11 cell lines.  Mol. docking studies suggest the involvement of Leu616, Asp698, Cys694 and Cys828 residues in binding of G-11 to FLT3.  The ability of G-11 to cause selective cytotoxicity and induce differentiation in cancer cells could be clin. relevant for therapeutic gains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG___Toist2rVg90H21EOLACvtfcHk0linW1U_mzB5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCntr0%253D&md5=ca9f0c932e024759b69245c983a1ea81</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.02.028%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DA.%2BM.%26aulast%3DTaha%26aufirst%3DM.%2BO.%26aulast%3DAziz%26aufirst%3DM.%2BA.%26aulast%3DAl-Qudah%26aufirst%3DM.%2BA.%26aulast%3DAbuTayeh%26aufirst%3DR.%2BF.%26aulast%3DRizvi%26aufirst%3DS.%2BA.%26atitle%3DNovel%2520anticancer%2520compound%2520%255Btrifluoromethyl-substituted%2520pyrazole%2520N-nucleoside%255D%2520inhibits%2520FLT3%2520activity%2520to%2520induce%2520differentiation%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D375%26spage%3D199%26epage%3D208%26doi%3D10.1016%2Fj.canlet.2016.02.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagano, T.</span></span> <span> </span><span class="NLM_article-title">Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2370</span>– <span class="NLM_lpage">2374</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2016.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26995531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2370-2374&author=H.+Nakanoauthor=T.+Hasegawaauthor=R.+Imamuraauthor=N.+Saitoauthor=H.+Kojimaauthor=T.+Okabeauthor=T.+Nagano&title=Development+of+a+potent+and+selective+FLT3+kinase+inhibitor+by+systematic+expansion+of+a+non-selective+fragment-screening+hit&doi=10.1016%2Fj.bmcl.2016.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit</span></div><div class="casAuthors">Nakano, Hirofumi; Hasegawa, Tsukasa; Imamura, Riyo; Saito, Nae; Kojima, Hirotatsu; Okabe, Takayoshi; Nagano, Tetsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2370-2374</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A nonselective inhibitor (1) of FMS-like tyrosine kinase-3 (FLT3) was identified by fragment screening and systematically modified to afford a potent and selective inhibitor I.  The authors confirmed that I inhibited the growth of FLT-3-activated human acute myeloid leukemia cell line MV4-11.  The design strategy enabled rapid development of a novel type of FLT3 inhibitor from the hit fragment in the absence of target-structural information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSnyMZHnQnP7Vg90H21EOLACvtfcHk0lhHIqRDNDQB-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGhs70%253D&md5=76f8dcdcaa318db08018378135dafb13</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DNakano%26aufirst%3DH.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DImamura%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DN.%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DT.%26aulast%3DNagano%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520a%2520potent%2520and%2520selective%2520FLT3%2520kinase%2520inhibitor%2520by%2520systematic%2520expansion%2520of%2520a%2520non-selective%2520fragment-screening%2520hit%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2370%26epage%3D2374%26doi%3D10.1016%2Fj.bmcl.2016.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2018.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29894944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=303-315&author=Y.+Zhiauthor=B.+Liauthor=C.+Yaoauthor=H.+Liauthor=P.+Chenauthor=J.+Baoauthor=T.+Qinauthor=Y.+Wangauthor=T.+Luauthor=S.+Lu&title=Discovery+of+the+selective+and+efficacious+inhibitors+of+FLT3+mutations&doi=10.1016%2Fj.ejmech.2018.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span></div><div class="casAuthors">Zhi, Yanle; Li, Baoquan; Yao, Chao; Li, Hongmei; Chen, Puzhou; Bao, Jiyin; Qin, Tianren; Wang, Yue; Lu, Tao; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">303-315</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy.  Starting from the lead compd. LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivs. were synthesized to improve the FLT3 inhibitory potency and selectivity.  Among them, compd. 50 (4-((2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide) was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib.  Compd. 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants.  Inversely, compd. 50 displayed no cytotoxicity to FLT3-independent cells, and the biochem. analyses showed that its effects were related to the inhibition of FLT3 signal pathways.  Addnl., compd. 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry.  Moreover, compd. 50 showed enhanced metabolic stability.  Altogether, it was concluded that compd. 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUFIlbd1kxabVg90H21EOLACvtfcHk0lhHIqRDNDQB-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ&md5=8b82ebdbf00f4693a7e7b94b32c9f1b7</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FLT3%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D303%26epage%3D315%26doi%3D10.1016%2Fj.ejmech.2018.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2018.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30508668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWksbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=195-206&author=H.+Hengauthor=Y.+Zhiauthor=H.+Yuanauthor=Z.+Wangauthor=H.+Liauthor=S.+Wangauthor=J.+Tianauthor=H.+Liuauthor=Y.+Chenauthor=T.+Luauthor=T.+Ranauthor=S.+Lu&title=Discovery+of+a+highly+selective+FLT3+inhibitor+with+specific+proliferation+inhibition+against+AML+cells+harboring+FLT3-ITD+mutation&doi=10.1016%2Fj.ejmech.2018.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation</span></div><div class="casAuthors">Heng, Hao; Zhi, Yanle; Yuan, Haoliang; Wang, Zhijie; Li, Hongmei; Wang, Shuxian; Tian, Jieyi; Liu, Haichun; Chen, Yadong; Lu, Tao; Ran, Ting; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">FLT3 is often over-expressed in AML, and FLT3 mutants, esp. FLT-ITD, are closely related to the poor prognosis in AML patients.  Thus, FLT3 has become an attractive target for AML therapy.  A series of FLT3 inhibitors have been evaluated in various clin. trials, one of which was approved for AML.  However, current FLT3 inhibitors still faced the challenges of kinase selectivity and drug resistance due to concurrent FLT3-ITD-TKD mutations.  In this work, a new FLT3 inhibitor (compd. 1) with simple structure was discovered through virtually screening an inhouse mol. database which contains numerous compds. with kinase-inhibition activity.  Compd. 1(I) was identified with potent inhibitory activity against several FLT3 mutants and high FLT3 selectivity over other kinases.  Moreover, its anti-growth effects on tumor cells in vitro were dependent on the expression of FLT3-ITD, and it showed little cytotoxicity to MV4-11 and human normal cells.  Mechanism studies illustrated that compd. 1 blocked FLT3 pathway, caused cell cycle arrest and induced apoptosis in MV4-11 cells.  Finally, the binding mode of compd. 1 was studied by mol. dynamics simulations, which provides insights into key residues involved in intermol. binding and further structural optimization strategy.  Compd. 1 can thus serve as a good starting point for the research on FLT3 inhibitors towards the kinase selectivity and potential to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolUgNd6f7RQ7Vg90H21EOLACvtfcHk0lgnMpXR7Q5Kdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWksbvL&md5=065281d4737ba15abd098930ae7de6e0</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DHeng%26aufirst%3DH.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520selective%2520FLT3%2520inhibitor%2520with%2520specific%2520proliferation%2520inhibition%2520against%2520AML%2520cells%2520harboring%2520FLT3-ITD%2520mutation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2018.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2019.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31103903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=248-267&author=H.+Hengauthor=Z.+Wangauthor=H.+Liauthor=Y.+Huangauthor=Q.+Lanauthor=X.+Guoauthor=L.+Zhangauthor=Y.+Zhiauthor=J.+Caiauthor=T.+Qinauthor=L.+Xiangauthor=S.+Wangauthor=Y.+Chenauthor=T.+Luauthor=S.+Lu&title=Combining+structure-+and+property-based+optimization+to+identify+selective+FLT3-ITD+inhibitors+with+good+antitumor+efficacy+in+AML+cell+inoculated+mouse+xenograft+model&doi=10.1016%2Fj.ejmech.2019.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model</span></div><div class="casAuthors">Heng, Hao; Wang, Zhijie; Li, Hongmei; Huang, Yatian; Lan, Qingyuan; Guo, Xiaoxing; Zhang, Liang; Zhi, Yanle; Cai, Jiongheng; Qin, Tianren; Xiang, Li; Wang, Shuxian; Chen, Yadong; Lu, Tao; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">248-267</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients.  Recently, FLT3 inhibitors have been approved for AML therapy.  Herein, a series of new compds. with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD.  Compd. 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line.  Furthermore, the apoptosis and down regulation of P-STAT5 were also obsd. in tumor cells extd. from the MV4-11 cell xenografts model upon compd. 46 treatment.  Compd. 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo.  Compd. 46 showed no toxicity to the viscera of mice and caused no decrease in body wt. of mice.  In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compd. 46 was worthy of further development as potential drug candidate to treat AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIoN2WJhKLwrVg90H21EOLACvtfcHk0lgnMpXR7Q5Kdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsLc%253D&md5=cfd4e6fc9b38b1a4272199267102a31d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DHeng%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DCombining%2520structure-%2520and%2520property-based%2520optimization%2520to%2520identify%2520selective%2520FLT3-ITD%2520inhibitors%2520with%2520good%2520antitumor%2520efficacy%2520in%2520AML%2520cell%2520inoculated%2520mouse%2520xenograft%2520model%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D176%26spage%3D248%26epage%3D267%26doi%3D10.1016%2Fj.ejmech.2019.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, C. L. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6625</span>– <span class="NLM_lpage">6637</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2014.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25456387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGgu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=6625-6637&author=J.+Xuauthor=E.+H.+Q.+Ongauthor=J.+Hillauthor=A.+Chenauthor=C.+L.+L.+Chai&title=Design%2C+synthesis+and+biological+evaluation+of+FLT3+covalent+inhibitors+with+a+resorcylic+acid+core&doi=10.1016%2Fj.bmc.2014.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core</span></div><div class="casAuthors">Xu, Jin; Ong, Esther H. Q.; Hill, Jeffrey; Chen, Anqi; Chai, Christina L. L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6625-6637</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of simplified ring-opened resorcylic acid lactones were conveniently synthesized to target FLT3 and its mutants either irreversibly or reversibly.  The design of covalent FLT3 inhibitors is based on cis-enone lactones (e.g., L-783,277) that have a β-resorcylic acid as the core structure.  The designed compds. contain three types of Michael acceptors (acrylamide, vinylsulfonamide and maleimide) as potential covalent traps of a cysteine residue at the binding site of kinases.  A variety of functional substitutions were also introduced to maximize the binding interactions.  Biol. evaluations revealed that compd. I, despite the presence of a highly reactive maleimide Michael acceptor, is a potent covalent FLT3 inhibitor which shows some specificity in cellular assays.  On the other hand, compds. II [R1 = 3-morpholinopropyl, R2 = iso-Pr, R3 = acryl] and II [R1 = Me, R2 = iso-Pr, R3 = vinylsulfonyl] contg. acrylamide or vinylsulfonamide groups are reversible towards FLT3 binding, and are potent and selective inhibitors of mutant FLT3-ITD vs. wt-FLT3.  They also inhibit cell proliferation in FLT3-ITD expressing cell line MV-4-11 as compared to wt-FLT3 expressing cell line THP-1 and non-FLT3 cell lines (K562, HL60 and Hek-293T).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5eFfzrhOk6rVg90H21EOLACvtfcHk0lijE6DxreNnfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGgu7fL&md5=9a2bbc42d3af387ed5a0051a25dd4e75</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DE.%2BH.%2BQ.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChai%26aufirst%3DC.%2BL.%2BL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520FLT3%2520covalent%2520inhibitors%2520with%2520a%2520resorcylic%2520acid%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D6625%26epage%3D6637%26doi%3D10.1016%2Fj.bmc.2014.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e69</span> <span class="refDoi"> DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22829971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.+C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+oral+HDAC+inhibitor+pracinostat+%28SB939%29+is+efficacious+and+synergistic+with+the+JAK2+inhibitor+pacritinib+%28SB1518%29+in+preclinical+models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520oral%2520HDAC%2520inhibitor%2520pracinostat%2520%2528SB939%2529%2520is%2520efficacious%2520and%2520synergistic%2520with%2520the%2520JAK2%2520inhibitor%2520pacritinib%2520%2528SB1518%2529%2520in%2520preclinical%2520models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N. F.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2015.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25800646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=104-115&author=C.+Q.+Ningauthor=C.+Luauthor=L.+Huauthor=Y.+J.+Biauthor=L.+Yaoauthor=Y.+J.+Heauthor=L.+F.+Liuauthor=X.+Y.+Liuauthor=N.+F.+Yu&title=Macrocyclic+compounds+as+anti-cancer+agents%3A+design+and+synthesis+of+multi-acting+inhibitors+against+HDAC%2C+FLT3+and+JAK2&doi=10.1016%2Fj.ejmech.2015.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span></div><div class="casAuthors">Ning, Cheng-Qing; Lu, Cheng; Hu, Liang; Bi, Yan-Jing; Yao, Lei; He, Yu-Jun; Liu, Li-Fei; Liu, Xiao-Yu; Yu, Nie-Fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of macrocyclic compds. I [X = O, CH2O; Y = CH2, CO; n = 1, 2; m = 1-5] were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2.  Some of these compds. exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions.  In vitro antiproliferative assay indicated that these compds. were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2V617F mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvwiDjzqtazLVg90H21EOLACvtfcHk0ljOVvkqWby_qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D&md5=fc2b93fcbce2998ecd2d6de46a01811d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DY.%2BJ.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DYu%26aufirst%3DN.%2BF.%26atitle%3DMacrocyclic%2520compounds%2520as%2520anti-cancer%2520agents%253A%2520design%2520and%2520synthesis%2520of%2520multi-acting%2520inhibitors%2520against%2520HDAC%252C%2520FLT3%2520and%2520JAK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2015.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holladay, M. W.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3441</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2015.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26208887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3436-3441&author=G.+Liuauthor=S.+Abrahamauthor=X.+Liuauthor=S.+Xuauthor=A.+M.+Rooksauthor=R.+Nepomucenoauthor=A.+Daoauthor=D.+Brighamauthor=D.+Gitnickauthor=D.+E.+Inskoauthor=M.+F.+Gardnerauthor=P.+P.+Zarrinkarauthor=R.+Christopherauthor=B.+Belliauthor=R.+C.+Armstrongauthor=M.+W.+Holladay&title=Discovery+and+optimization+of+a+highly+efficacious+class+of+5-aryl-2-aminopyridines+as+FMS-like+tyrosine+kinase+3+%28FLT3%29+inhibitors&doi=10.1016%2Fj.bmcl.2015.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors</span></div><div class="casAuthors">Liu, Gang; Abraham, Sunny; Liu, Xing; Xu, Shimin; Rooks, Allison M.; Nepomuceno, Ron; Dao, Alan; Brigham, Daniel; Gitnick, Dana; Insko, Darren E.; Gardner, Michael F.; Zarrinkar, Patrick P.; Christopher, Ron; Belli, Barbara; Armstrong, Robert C.; Holladay, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3436-3441</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on a putative binding mode of quizartinib, a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor in Phase III clin. development, the authors have designed de novo a simpler aminopyridine-based hinge binding motif.  Further optimization focusing on maximizing in vivo efficacy and minimizing CYP3A4 time-dependent inhibition resulted in a highly efficacious compd. I in tumor xenograft model for further preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOVKXkqpRELbVg90H21EOLACvtfcHk0lhucmqclRMnwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7I&md5=e0af0933baacfafe789ab3f49aa26f55</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DRooks%26aufirst%3DA.%2BM.%26aulast%3DNepomuceno%26aufirst%3DR.%26aulast%3DDao%26aufirst%3DA.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DChristopher%26aufirst%3DR.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520highly%2520efficacious%2520class%2520of%25205-aryl-2-aminopyridines%2520as%2520FMS-like%2520tyrosine%2520kinase%25203%2520%2528FLT3%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3436%26epage%3D3441%26doi%3D10.1016%2Fj.bmcl.2015.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103248</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bioorg.2019.103248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31548092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCnu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103248&author=J.+Baoauthor=H.+Liuauthor=Y.+Zhiauthor=W.+Yangauthor=J.+Zhangauthor=T.+Luauthor=Y.+Wangauthor=S.+Lu&title=Discovery+of+benzo%5Bd%5Doxazole+derivatives+as+the+potent+type-I+FLT3-ITD+inhibitors&doi=10.1016%2Fj.bioorg.2019.103248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors</span></div><div class="casAuthors">Bao, Jiyin; Liu, Haichun; Zhi, Yanle; Yang, Wenqianzi; Zhang, Jiawei; Lu, Tao; Wang, Yue; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103248</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of compds. I [R1 = H, Me, F, MeO; R2 = diethylamino, piperidinyl, piperazin-1-yl, etc.; R3 = Ph, pyridin-3-yl, pyridin-4-yl, etc.] were designed and synthesized based on benzo[d]oxazole-2-amine scaffold to discover new potent Fms-like tyrosine kinase 3 inhibitors.  During the medicinal chem. works, flexible mol. docking was used to provide design rationale and study the binding modes of the target compds.  Through the mixed SAR exploration based on the enzymic and cellular activities, compd. I [R1 = MeO; R2 = piperazin-1-yl; R3 = 3-carbamoylphenyl] was identified with potent FLT3-ITD inhibitory (IC50: 0.41 nM) and anti-proliferative (IC50: 0.037μM against MV4-11 cells) activities.  And the binding mode of I [R1 = MeO; R2 = piperazin-1-yl; R3 = 3-carbamoylphenyl] with ''DFG-in'' FLT3 was simulated by a 20-ns mol. dynamics run, providing some insights into further medicinal chem. efforts toward novel FLT3 inhibitors in AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojrKPWJTNcubVg90H21EOLACvtfcHk0li0xEfru3Ikaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCnu7nK&md5=a29ee98c55772848cb822c604a5048ba</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103248%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520benzo%255Bd%255Doxazole%2520derivatives%2520as%2520the%2520potent%2520type-I%2520FLT3-ITD%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103248%26doi%3D10.1016%2Fj.bioorg.2019.103248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salk, J. J.</span></span> <span> </span><span class="NLM_article-title">The influence of subclonal resistance mutations on targeted cancer therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fnrclinonc.2015.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26483300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslaksLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=335-347&author=M.+W.+Schmittauthor=L.+A.+Loebauthor=J.+J.+Salk&title=The+influence+of+subclonal+resistance+mutations+on+targeted+cancer+therapy&doi=10.1038%2Fnrclinonc.2015.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of subclonal resistance mutations on targeted cancer therapy</span></div><div class="casAuthors">Schmitt, Michael W.; Loeb, Lawrence A.; Salk, Jesse J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-347</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Clin. oncol. is being revolutionized by the increasing use of molecularly targeted therapies.  This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge.  Evidence continues to emerge that cancers are characterized by extensive intratumor genetic heterogeneity, and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a minority of cells.  Indeed, multiple examples of pre-existing subclonal resistance mutations to various molecularly targeted agents have been described, which we review herein.  Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective.  We consider how monitoring of drug resistance could be incorporated into clin. practice to optimize the use of targeted therapies in individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxT2q0nGx_PbVg90H21EOLACvtfcHk0li0xEfru3Ikaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslaksLrF&md5=b20adb7d5dc96fedd40c8905840c3aa1</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.175%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DM.%2BW.%26aulast%3DLoeb%26aufirst%3DL.%2BA.%26aulast%3DSalk%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520influence%2520of%2520subclonal%2520resistance%2520mutations%2520on%2520targeted%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D13%26spage%3D335%26epage%3D347%26doi%3D10.1038%2Fnrclinonc.2015.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F2159-8290.CD-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskisauthor=R.+Shellooeauthor=G.+Tsangauthor=H.+Cariasauthor=B.+Powellauthor=E.+A.+Burtonauthor=B.+Matusowauthor=J.+Zhangauthor=W.+Spevakauthor=P.+N.+Ibrahimauthor=M.+H.+Leauthor=H.+H.+Hsuauthor=G.+Habetsauthor=B.+L.+Westauthor=G.+Bollagauthor=N.+P.+Shah&title=Characterizing+and+overriding+the+structural+mechanism+of+the+quizartinib-resistant+FLT3+%E2%80%9Cgatekeeper%E2%80%9D+F691L+mutation+with+PLX3397&doi=10.1158%2F2159-8290.CD-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0ljsJrp6_aDXCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DLe%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCharacterizing%2520and%2520overriding%2520the%2520structural%2520mechanism%2520of%2520the%2520quizartinib-resistant%2520FLT3%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520F691L%2520mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.CD-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodcock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrman, R. E.</span></span> <span> </span><span class="NLM_article-title">Development of novel combination therapies</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1101548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1056%2FNEJMp1101548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=21323535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtlSlsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=985-987&author=J.+Woodcockauthor=J.+P.+Griffinauthor=R.+E.+Behrman&title=Development+of+novel+combination+therapies&doi=10.1056%2FNEJMp1101548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: development of novel combination therapies</span></div><div class="casAuthors">Woodcock, Janet; Griffin, Joseph P.; Behrman, Rachel E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">985-987</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8vvzDTmHJzbVg90H21EOLACvtfcHk0ljsJrp6_aDXCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtlSlsLc%253D&md5=980327e1a25278595653a6546e76ccea</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1101548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1101548%26sid%3Dliteratum%253Aachs%26aulast%3DWoodcock%26aufirst%3DJ.%26aulast%3DGriffin%26aufirst%3DJ.%2BP.%26aulast%3DBehrman%26aufirst%3DR.%2BE.%26atitle%3DDevelopment%2520of%2520novel%2520combination%2520therapies%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D985%26epage%3D987%26doi%3D10.1056%2FNEJMp1101548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of drug combinations: interaction and network perspectives</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1038/nrd2683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fnrd2683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=19180105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=111-128&author=J.+Jiaauthor=F.+Zhuauthor=X.+Maauthor=Z.+W.+Caoauthor=Y.+X.+Liauthor=Y.+Z.+Chen&title=Mechanisms+of+drug+combinations%3A+interaction+and+network+perspectives&doi=10.1038%2Fnrd2683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug combinations: interaction and network perspectives</span></div><div class="casAuthors">Jia, Jia; Zhu, Feng; Ma, Xiaohua; Cao, Zhiwei W.; Li, Yixue X.; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-128</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Understanding the mol. mechanisms underlying synergistic, potentiative and antagonistic effects of drug combinations could facilitate the discovery of novel efficacious combinations and multi-targeted agents.  In this article, we describe an extensive investigation of the published literature on drug combinations for which the combination effect has been evaluated by rigorous anal. methods and for which relevant mol. interaction profiles of the drugs involved are available.  Anal. of the 117 drug combinations identified reveals general and specific modes of action, and highlights the potential value of mol. interaction profiles in the discovery of novel multicomponent therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwawbpKWy27Vg90H21EOLACvtfcHk0liXytU-gQ2BkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7w%253D&md5=87ab00309751229f6f91b83448c82daf</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnrd2683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2683%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DZ.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BX.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DMechanisms%2520of%2520drug%2520combinations%253A%2520interaction%2520and%2520network%2520perspectives%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D111%26epage%3D128%26doi%3D10.1038%2Fnrd2683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+a+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0liXytU-gQ2BkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia</span>. <i>Biomark Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/s40364-019-0170-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1186%2Fs40364-019-0170-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31528345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3MrpsFSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=19&author=J.+Zhaoauthor=Y.+Songauthor=D.+Liu&title=Gilteritinib%3A+a+novel+FLT3+inhibitor+for+acute+myeloid+leukemia&doi=10.1186%2Fs40364-019-0170-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia</span></div><div class="casAuthors">Zhao Juanjuan; Song Yongping; Liu Delong; Liu Delong</div><div class="citationInfo"><span class="NLM_cas:title">Biomarker research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn">2050-7771</span>.
    </div><div class="casAbstract">FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics.  The FLT3-ITD and FLT3-TKD (tyrosine kinase domain) mutations are biomarkers for high risk AML and are associated with drug resistance and high risk of relapse.  Multiple FLT3 inhibitors are in clinical development, including lestaurtinib, tandutinib, quizartinib, midostaurin, gilteritinib, and crenolanib.  Midostaurin and gilteritinib have been approved by FDA for Flt3 mutated AML.  Gilteritinib (ASP2215, Xospata) is a small molecule dual inhibitor of FLT3/AXL.  The ADMIRAL study showed that longer overall survival and higher response rate are associated with gilteritinib in comparison with salvage chemotherapy for relapse /refractory (R/R) AML.  These data from the ADMIRAL study may lead to the therapy paradigm shift and establish gilteritinib as the new standard therapy for R/R FLT3-mutated AML.  Currently, multiple clinical trials are ongoing to evaluate the combination of gilteritinib with other agents and regimens.  This study summarized clinical trials of gilteritinib for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx25RB8hEeSGgRQsDqrjW_fW6udTcc2eakfTgZogVXW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrpsFSjtw%253D%253D&md5=f0e2376879c61e28d9eec81dd4efbff6</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1186%2Fs40364-019-0170-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40364-019-0170-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DGilteritinib%253A%2520a%2520novel%2520FLT3%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DBiomark%2520Res.%26date%3D2019%26volume%3D7%26spage%3D19%26doi%3D10.1186%2Fs40364-019-0170-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostic, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in selective and irreversible covalent ligand development and validation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1486</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.chembiol.2019.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31631011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1486-1500&author=T.+Zhangauthor=J.+M.+Hatcherauthor=M.+Tengauthor=N.+S.+Grayauthor=M.+Kostic&title=Recent+advances+in+selective+and+irreversible+covalent+ligand+development+and+validation&doi=10.1016%2Fj.chembiol.2019.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation</span></div><div class="casAuthors">Zhang, Tinghu; Hatcher, John M.; Teng, Mingxing; Gray, Nathanael S.; Kostic, Milka</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1486-1500</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Some of the most widely used drugs, such as aspirin and penicillin, are covalent drugs.  Covalent binding can improve potency, selectivity, and duration of the effects, but the intrinsic reactivity represents a potential liability and may result in idiosyncratic toxicity.  For decades, the cons were believed to outweigh the pros, and covalent targeting was deprioritized in drug discovery.  Recently, several covalent inhibitors have been approved for cancer treatment, thus rebooting the field.  In this review, we briefly reflect on the history of selective covalent targeting, and provide a comprehensive overview of emerging developments from a chem. biol. stand-point.  Our discussion will reflect on efforts to validate irreversible covalent ligands, expand the scope of targets, and discover new ligands and warheads.  We conclude with a brief commentary of remaining limitations and emerging opportunities in selective covalent targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc9UIuWjfX97Vg90H21EOLACvtfcHk0lhh-uP3D7L-5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO&md5=ce957a868ca27f545243d28e60dc5868</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKostic%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520selective%2520and%2520irreversible%2520covalent%2520ligand%2520development%2520and%2520validation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D1486%26epage%3D1500%26doi%3D10.1016%2Fj.chembiol.2019.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Claro, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfuma, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hakim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3586</span>– <span class="NLM_lpage">3590</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-14-2225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26275952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKltr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3586-3590&author=R.+A.+de+Claroauthor=K.+M.+McGinnauthor=N.+Verdunauthor=S.+L.+Leeauthor=H.+J.+Chiuauthor=H.+Saberauthor=M.+E.+Browerauthor=C.+J.+Changauthor=E.+Pfumaauthor=B.+Habtemariamauthor=J.+Bullockauthor=Y.+Wangauthor=L.+Nieauthor=X.+H.+Chenauthor=D.+R.+Luauthor=A.+Al-Hakimauthor=R.+C.+Kaneauthor=E.+Kaminskasauthor=R.+Justiceauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval%3A+ibrutinib+for+patients+with+previously+treated+mantle+cell+lymphoma+and+previously+treated+chronic+lymphocytic+leukemia&doi=10.1158%2F1078-0432.CCR-14-2225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia</span></div><div class="casAuthors">de Claro, R. Angelo; McGinn, Karen M.; Verdun, Nicole; Lee, Shwu-Luan; Chiu, Haw-Jyh; Saber, Haleh; Brower, Margaret E.; Chang, C. J. George; Pfuma, Elimika; Habtemariam, Bahru; Bullock, Julie; Wang, Yun; Nie, Lei; Chen, Xiao-Hong; Lu, Donghao; Al-Hakim, Ali; Kane, Robert C.; Kaminskas, Edvardas; Justice, Robert; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3586-3590</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Nov. 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.  On Feb. 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.  Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval.  Both approvals were based on overall response rate (ORR) and duration of response (DOR) in single-arm clin. trials in patients with prior treatment.  In MCL (N = 111), the complete and partial response rates were 17.1% and 48.6%, resp., for an ORR of 65.8% [95% confidence interval (CI), 56.2%-74.5%].  The median DOR was 17.5 mo (95% CI, 15.8-not reached).  In CLL (N = 48), the ORR was 58.3% (95% CI, 43.2%-72.4%), and the DOR ranged from 5.6 to 24.2 mo.  The most common adverse reactions (≥30% in either trial) were thrombocytopenia, diarrhea, neutropenia, bruising, upper respiratory tract infection, anemia, fatigue, musculoskeletal pain, peripheral edema, and nausea.  Clin Cancer Res; 21(16); 3586-90. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn3L2XMvoW6LVg90H21EOLACvtfcHk0lihWuBhaCDSpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKltr%252FE&md5=75a4f6ffb6a20a0cd08413c79d020f88</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2225%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DMcGinn%26aufirst%3DK.%2BM.%26aulast%3DVerdun%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DS.%2BL.%26aulast%3DChiu%26aufirst%3DH.%2BJ.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DBrower%26aufirst%3DM.%2BE.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DPfuma%26aufirst%3DE.%26aulast%3DHabtemariam%26aufirst%3DB.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DLu%26aufirst%3DD.%2BR.%26aulast%3DAl-Hakim%26aufirst%3DA.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%253A%2520ibrutinib%2520for%2520patients%2520with%2520previously%2520treated%2520mantle%2520cell%2520lymphoma%2520and%2520previously%2520treated%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3586%26epage%3D3590%26doi%3D10.1158%2F1078-0432.CCR-14-2225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Neetu Dayal, Eva Řezníčková, Delmis E. Hernandez, Miroslav Peřina, Sandra Torregrosa-Allen, Bennett D. Elzey, Jana Škerlová, Haresh Ajani, Stefan Djukic, Veronika Vojáčková, Martin Lepšík, Pavlína Řezáčová, Vladimír Kryštof, Radek Jorda, <span class="NLM_string-name hlFld-ContribAuthor">Herman O. Sintim</span>. </span><span class="cited-content_cbyCitation_article-title">3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00330%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D3H-Pyrazolo%25255B4%25252C3-f%25255Dquinoline-Based%252BKinase%252BInhibitors%252BInhibit%252Bthe%252BProliferation%252Bof%252BAcute%252BMyeloid%252BLeukemia%252BCells%252BIn%252BVivo%26aulast%3DDayal%26aufirst%3DNeetu%26date%3D2021%26date%3D2021%26date%3D22022021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0036.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ribbon (a) and surface (b) diagrams for the crystal structure of FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>). The N-terminal kinase domain (purple), the C-terminal kinase domain (blue), the activation loop (green), and the JM domain (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rest, activation, and mutation of FLT3 in HSCs. FLT3, which is an essential receptor for the life process of HSCs, consists of extracellular N-terminal and ECD, transmembrane TMD, as well as intracellular JMD, two TKDs, and C-terminal domains. Without the ligand, JMD inhibits the formation of receptor dimerization, leaving FLT3 in a resting state. Under physiological conditions, the survival, proliferation, and differentiation of HSCs depend on the activation of FLT3, which is achieved by binding to its ligand FL. At this time, JMD rests, TKDs are activated, and FLT3 dimer ia formed, causing autophosphorylation of the tyrosine residue in the intracellular portion of the receptor. As a result, HSCs can grow, reproduce, and differentiate healthily via activated downstream signalings including JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR. However, when a mutation occurs, the dimer can be irreversibly formed even in the absence of FL, resulting in indefinitely activated downstream signalings, which is associated with the onset of AML.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of indolocarbazole derivatives (a). Co-crystallized staurosporine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITQ">2ITQ</a>) was aligned with FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structure and design strategy for target compound <b>Chen-54</b> (a), <b>Hu-10d</b> (b), and <b>Őrfi-20a</b> (c).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structure and design strategy for target compound <b>van der Stelt-38</b> (a). Predicted “flipped” binding mode of <b>H-89</b> analogue (b) and <b>van der Stelt-38</b> (c) in FLT3 crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). (b,c) Reproduced with permission from ref <a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a>. Copyright 2019 Elsevier</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structure, design strategy and covalent docking pose for target compound <b>Bsc5371</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structure and design strategy for target compound <b>Hsieh-39</b> (a) and <b>Schmidt-12a</b> (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structure and design strategy for target compound <b>Jiaang-7h</b> (a), <b>Yu-16i</b> (b), and <b>Yang-19</b> (c).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structure of compound <b>MZH29</b> (a), molecular docking of <b>MZH29</b> with FLT3 in an inactive conformation (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (b), and hydrogen bonds formed with K614, E661, C694, and D829 residues (c).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure and design strategy for compound <b>Li-S21</b> (a). Molecular docking for target compound <b>Li-S21</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a>. Copyright 2018 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structure and design strategy for target compound <b>He-17b</b> (a). Molecular docking for compound <b>He-17b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structure of compounds <b>KR65367</b> and <b>KR65370</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structure and design strategy for compound <b>HSW630-1</b>, <b>HSW1651</b>, <b>HSN286</b>, and <b>HSN431</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structure and design strategy for compound <b>Liu-12c</b> and <b>Liu-12g</b> (a). The molecular docking of compound <b>Liu-12c</b> to FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (b). , Reproduced with permission from ref <a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure and design strategy for compound <b>Han-13i</b>, <b>Han-17a</b>, <b>Han-16d</b>, and <b>Han-13b</b> (a). The chemical structure for compound <b>G-749</b> (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure and design strategy for compound <b>AMG 925</b> (a). DFG-in kinase with <b>AMG 925</b> model with type I binding homology mode (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structure and design strategy for compound FN-1501 (a). FN-1501 docked into CDK2 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>) (b).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> FN-1501 docked into a homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (c).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure and design strategy for compound <b>UNC1666</b> and <b>UNC2025</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structure and design strategy for compound <b>CHMFL-FLT3-122</b> and <b>CHMFL-FLT3-213</b> (a). <b>CHMFL-FLT3-213</b> docked into the homology model of DFG-out conformation of FLT3-F691L mutant (site mutation from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structure and design strategy for compound <b>CHMFL-FLT3-335</b> (a). The binding mode of <b>CHMFL-FLT3-335</b> with FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Solid surface view of the hydrophobic pocket formed by residues Met664 and Met665 in FLT3 (c).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Solid surface view of the hydrophobic pocket formed by residues Val643 and Leu644 in c-KIT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) (d).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structure and design strategy for compound <b>Chen-9u</b> (a). Docking model with the FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structure and design strategy for compound <b>Li-31</b> (a). Compound <b>Li-31</b> docked into the active site of the FLT3 homology model (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structure and design strategy for compound <b>Guy-5e</b> (a) and <b>Wang-16a</b> (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structure and design strategy for compound <b>Krystof-7d</b> (a). <b>Krystof-7d</b> docked into a homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure and design strategy for compound <b>Zhao-14j</b> (a). <b>Zhao-14j</b> docked into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b). Reproduced with permission from ref <a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structure and design strategy for compound <b>Chen-18e</b> (a). Molecular docking of <b>Chen-18e</b> to the JAK2 protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>) (b).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Molecular docking of <b>Chen-18e</b> to the FLT3 protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>) (c).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structure for compound <b>G-11</b> (a). <b>G-11</b> docked into an inactive homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) (b). The chemical structure and design strategy for compound <b>Nagano-26</b> (c). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a>. Copyright 2016 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structure and design strategy for compound <b>Lu-50</b> (a). <b>Lu-50</b> docked into a homology model of FLT3 (c-Kit, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) (b). (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a>. Copyright 2018 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Chemical structure and design strategy for compound <b>LT-180-0712</b> and <b>Lu-46</b> (a). <b>Lu-46</b> docked into a homology model of FLT3 (based on multiple templates, PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P2H">2P2H</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UX0">4UX0</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHX">3RHX</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FGK">1FGK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN">4WUN</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JS2">3JS2</a>.) (b) (b) Reproduced with permission from ref <a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a>. Copyright 2019 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Chemical structure for compound <b>Chai-2</b>, <b>Chai-6</b>, and <b>Chai-15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Chemical structure and design strategy for compound <b>Yu-32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Chemical structure and design strategy for compound <b>Liu-6s</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Chemical structure and design strategy for compound <b>Lu-T24</b> (a). Interacting mode of <b>Lu-T24</b> with DFG-out conformation of FLT3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>) (b). (b) Reproduced with the permission from ref <a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a>. Copyright 2020 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/medium/jm0c00696_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Chemical structure for <b>Pexidartinib</b> (a). The binding mode of <b>Pexidartinib</b> is minimally affected by F691L (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H">4R7H</a>) (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00696/20201105/images/large/jm0c00696_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00696&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 150 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisdorf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1406184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1056%2FNEJMra1406184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26376137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1136-1152&author=H.+D%C3%B6hnerauthor=D.+J.+Weisdorfauthor=C.+D.+Bloomfield&title=Acute+myeloid+leukemia&doi=10.1056%2FNEJMra1406184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia</span></div><div class="casAuthors">Dohner Hartmut; Weisdorf Daniel J; Bloomfield Clara D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1136-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7_lmkXqa4eckU0YCbOU3EfW6udTcc2eYbjxaD52CtoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D&md5=a22a9f8b7b0e31e1084d2e76281bb35a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1406184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1406184%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DWeisdorf%26aufirst%3DD.%2BJ.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1136%26epage%3D1152%26doi%3D10.1056%2FNEJMra1406184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Short, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytting, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukaemia</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31041-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS0140-6736%2818%2931041-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30078459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=593-606&author=N.+J.+Shortauthor=M.+E.+Ryttingauthor=J.+E.+Cortes&title=Acute+myeloid+leukaemia&doi=10.1016%2FS0140-6736%2818%2931041-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukaemia</span></div><div class="casAuthors">Short Nicholas J; Rytting Michael E; Cortes Jorge E</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10147</span>),
    <span class="NLM_cas:pages">593-606</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia.  However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval.  In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies.  Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease.  Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-2ehJOMY27yA3UY9EwTNrfW6udTcc2eYbjxaD52CtoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D&md5=212ad7a55f4f9e1e1d90f2e265987f3c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931041-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931041-9%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DN.%2BJ.%26aulast%3DRytting%26aufirst%3DM.%2BE.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DAcute%2520myeloid%2520leukaemia%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D593%26epage%3D606%26doi%3D10.1016%2FS0140-6736%2818%2931041-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prada-Arismendy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arroyave, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röthlisberger, S.</span></span> <span> </span><span class="NLM_article-title">Molecular biomarkers in acute myeloid leukemia</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.blre.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27639498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVylu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=63-76&author=J.+Prada-Arismendyauthor=J.+C.+Arroyaveauthor=S.+R%C3%B6thlisberger&title=Molecular+biomarkers+in+acute+myeloid+leukemia&doi=10.1016%2Fj.blre.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biomarkers in acute myeloid leukemia</span></div><div class="casAuthors">Prada-Arismendy, Jeanette; Arroyave, Johanna C.; Rothlisberger, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-76</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common acute leukemia in adults.  The pathophysiol. of this disease is just beginning to be understood at the cellular and mol. level, and currently cytogenetic markers are the most important for risk stratification and treatment of AML patients.  However, with the advent of new technologies, the detection of other mol. markers such as point mutations and characterization of epigenetic and proteomic profiles, have begun to play an important role in how the disease is approached.  Recent evidence shows that the identification of new AML biomarkers contributes to a better understanding of the mol. basis of the disease, is significantly useful in screening, diagnosis, prognosis and monitoring of AML, as well as the possibility of predicting each individual's response to treatment.  This review summarizes the most relevant mol. (genetic, epigenetic, and protein) biomarkers assocd. with acute myeloid leukemia and discusses their clin. importance in terms of risk prediction, diagnosis and prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFTaiBaPaanLVg90H21EOLACvtfcHk0ljwJs1tUw3vrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVylu7jL&md5=34a5288290d85a69b4ac348d15c43009</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DPrada-Arismendy%26aufirst%3DJ.%26aulast%3DArroyave%26aufirst%3DJ.%2BC.%26aulast%3DR%25C3%25B6thlisberger%26aufirst%3DS.%26atitle%3DMolecular%2520biomarkers%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Rev.%26date%3D2017%26volume%3D31%26spage%3D63%26epage%3D76%26doi%3D10.1016%2Fj.blre.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maness, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shami, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogba, N.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology</span>. <i>J. Natl. Compr. Cancer Network</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.6004/jnccn.2017.0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.6004%2Fjnccn.2017.0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28687581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=926-957&author=M.+R.+O%E2%80%99Donnellauthor=M.+S.+Tallmanauthor=C.+N.+Abboudauthor=J.+K.+Altmanauthor=F.+R.+Appelbaumauthor=D.+A.+Arberauthor=V.+Bhattauthor=D.+Bixbyauthor=W.+Blumauthor=S.+E.+Coutreauthor=M.+De+Limaauthor=A.+T.+Fathiauthor=M.+Fiorellaauthor=J.+M.+Foranauthor=S.+D.+Goreauthor=A.+C.+Hallauthor=P.+Kropfauthor=J.+Lancetauthor=L.+J.+Manessauthor=G.+Marcucciauthor=M.+G.+Martinauthor=J.+O.+Mooreauthor=R.+Olinauthor=D.+Pekerauthor=D.+A.+Pollyeaauthor=K.+Pratzauthor=F.+Ravandiauthor=P.+J.+Shamiauthor=R.+M.+Stoneauthor=S.+A.+Stricklandauthor=E.+S.+Wangauthor=M.+Wieduwiltauthor=K.+Gregoryauthor=N.+Ogba&title=Acute+myeloid+leukemia%2C+version+3.2017%2C+NCCN+clinical+practice+guidelines+in+oncology&doi=10.6004%2Fjnccn.2017.0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology</span></div><div class="casAuthors">O'Donnell Margaret R; Tallman Martin S; Abboud Camille N; Altman Jessica K; Appelbaum Frederick R; Arber Daniel A; Bhatt Vijaya; Bixby Dale; Blum William; Coutre Steven E; De Lima Marcos; Fathi Amir T; Fiorella Melanie; Foran James M; Gore Steven D; Hall Aric C; Kropf Patricia; Lancet Jeffrey; Maness Lori J; Marcucci Guido; Martin Michael G; Moore Joseph O; Olin Rebecca; Peker Deniz; Pollyea Daniel A; Pratz Keith; Ravandi Farhad; Shami Paul J; Stone Richard M; Strickland Stephen A; Wang Eunice S; Wieduwilt Matthew; Gregory Kristina; Ogba Ndiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network : JNCCN</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-957</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.  This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2aszz8ssiQXl8icjszYl0fW6udTcc2ebw1z3KSyW_z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D&md5=6d087e673a8e9556532bdede9151f2e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.6004%2Fjnccn.2017.0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6004%252Fjnccn.2017.0116%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BR.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DAbboud%26aufirst%3DC.%2BN.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DBhatt%26aufirst%3DV.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DDe%2BLima%26aufirst%3DM.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DFiorella%26aufirst%3DM.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DHall%26aufirst%3DA.%2BC.%26aulast%3DKropf%26aufirst%3DP.%26aulast%3DLancet%26aufirst%3DJ.%26aulast%3DManess%26aufirst%3DL.%2BJ.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%2BG.%26aulast%3DMoore%26aufirst%3DJ.%2BO.%26aulast%3DOlin%26aufirst%3DR.%26aulast%3DPeker%26aufirst%3DD.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DPratz%26aufirst%3DK.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DShami%26aufirst%3DP.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DWieduwilt%26aufirst%3DM.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DOgba%26aufirst%3DN.%26atitle%3DAcute%2520myeloid%2520leukemia%252C%2520version%25203.2017%252C%2520NCCN%2520clinical%2520practice%2520guidelines%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2017%26volume%3D15%26spage%3D926%26epage%3D957%26doi%3D10.6004%2Fjnccn.2017.0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2020</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3322%2Fcaac.21590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31912902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3Mbns1emug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2020&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2020&doi=10.3322%2Fcaac.21590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2020</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence.  Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data (through 2017) were collected by the National Center for Health Statistics.  In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States.  The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted.  This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer.  In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017.  Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined.  Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013.  It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men.  In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOzlnUMKF5EwlCcfExbvbfW6udTcc2ebw1z3KSyW_z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mbns1emug%253D%253D&md5=a54b884bbc3c3f592921026db34b29db</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21590%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202020%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2020%26volume%3D70%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papaemmanuil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Loo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martincorena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greaves, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. J.</span></span> <span> </span><span class="NLM_article-title">Genomic classification and prognosis in acute myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">2209</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1516192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1056%2FNEJMoa1516192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27276561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1aisbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=2209-2221&author=E.+Papaemmanuilauthor=M.+Gerstungauthor=L.+Bullingerauthor=V.+I.+Gaidzikauthor=P.+Paschkaauthor=N.+D.+Robertsauthor=N.+E.+Potterauthor=M.+Heuserauthor=F.+Tholauthor=N.+Bolliauthor=G.+Gundemauthor=P.+Van+Looauthor=I.+Martincorenaauthor=P.+Ganlyauthor=L.+Mudieauthor=S.+McLarenauthor=S.+O%E2%80%99Mearaauthor=K.+Raineauthor=D.+R.+Jonesauthor=J.+W.+Teagueauthor=A.+P.+Butlerauthor=M.+F.+Greavesauthor=A.+Ganserauthor=K.+D%C3%B6hnerauthor=R.+F.+Schlenkauthor=H.+D%C3%B6hnerauthor=P.+J.+Campbell&title=Genomic+classification+and+prognosis+in+acute+myeloid+leukemia&doi=10.1056%2FNEJMoa1516192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic classification and prognosis in acute myeloid leukemia</span></div><div class="casAuthors">Papaemmanuil, Elli; Gerstung, Moritz; Bullinger, Lars; Gaidzik, Verena I.; Paschka, Peter; Roberts, Nicola D.; Potter, Nicola E.; Heuser, Michael; Thol, Felicitas; Bolli, Niccolo; Gundem, Gunes; Van Loo, Peter; Martincorena, Inigo; Ganly, Peter; Mudie, Laura; McLaren, Stuart; O'Meara, Sarah; Raine, Keiran; Jones, David R.; Teague, Jon W.; Butler, Adam P.; Greaves, Mel F.; Ganser, Arnold; Dohner, Konstanze; Schlenk, Richard F.; Dohner, Hartmut; Campbell, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2209-2221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML).  Our next challenge is to understand how this genetic diversity defines the pathophysiol. of AML and informs clin. practice. methods We enrolled a total of 1540 patients in three prospective trials of intensive therapy.  Combining driver mutations in 111 cancer genes with cytogenetic and clin. data, we defined AML genomic subgroups and their relevance to clin. outcomes.  Results: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients.  Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clin. outcomes.  In addn. to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2R172 mutations (in 1%).  Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome.  In addn. to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival.  The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations.  Such gene-gene interactions were esp. pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis.  These predictions require validation in prospective clin. trials. conclusions The driver landscape in AML reveals distinct mol. subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVvMgDMgsgpLVg90H21EOLACvtfcHk0lg43TtR8r4l8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1aisbbK&md5=848f1c0d24f22b2178d93eac75609301</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1516192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1516192%26sid%3Dliteratum%253Aachs%26aulast%3DPapaemmanuil%26aufirst%3DE.%26aulast%3DGerstung%26aufirst%3DM.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DN.%2BD.%26aulast%3DPotter%26aufirst%3DN.%2BE.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DBolli%26aufirst%3DN.%26aulast%3DGundem%26aufirst%3DG.%26aulast%3DVan%2BLoo%26aufirst%3DP.%26aulast%3DMartincorena%26aufirst%3DI.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DMudie%26aufirst%3DL.%26aulast%3DMcLaren%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DS.%26aulast%3DRaine%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DTeague%26aufirst%3DJ.%2BW.%26aulast%3DButler%26aufirst%3DA.%2BP.%26aulast%3DGreaves%26aufirst%3DM.%2BF.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26atitle%3DGenomic%2520classification%2520and%2520prognosis%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D2209%26epage%3D2221%26doi%3D10.1056%2FNEJMoa1516192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0357-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fs41375-018-0357-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30651634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=299-312&author=N.+Daverauthor=R.+F.+Schlenkauthor=N.+H.+Russellauthor=M.+J.+Levis&title=Targeting+FLT3+mutations+in+AML%3A+review+of+current+knowledge+and+evidence&doi=10.1038%2Fs41375-018-0357-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span></div><div class="casAuthors">Daver, Naval; Schlenk, Richard F.; Russell, Nigel H.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets.  Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approx. 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approx. 25% of all AML cases).  FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML.  The prognostic value of a FLT3 mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approx. 7-10% of all cases), is uncertain.  Accumulating evidence demonstrates that FLT3 mutational status evolves throughout the disease continuum.  This so-called clonal evolution, together with the identification of FLT3-ITD as a neg. prognostic marker, serves to highlight the importance of FLT3-ITD testing at diagnosis and again at relapse.  Earlier identification of FLT3 mutations will help provide a better understanding of the patient's disease and enable targeted treatment that may help patients achieve longer and more durable remissions.  First-generation FLT3 inhibitors developed for clin. use are broad-spectrum, multikinase inhibitors; however, next-generation FLT3 inhibitors are more specific, more potent, and have fewer toxicities assocd. with off-target effects.  Primary and secondary acquired resistance to FLT3 inhibitors remains a challenge and provides a rationale for combining FLT3 inhibitors with other therapies, both conventional and investigational.  This review focuses on the pathol. and prognostic role of FLT3 mutations in AML, clin. classification of the disease, recent progress with next-generation FLT3 inhibitors, and mechanisms of resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjK_p2nZ_9j7Vg90H21EOLACvtfcHk0lg43TtR8r4l8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI&md5=25ea007d2f7b670aaddeb02866f15c69</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0357-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0357-9%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520FLT3%2520mutations%2520in%2520AML%253A%2520review%2520of%2520current%2520knowledge%2520and%2520evidence%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D299%26epage%3D312%26doi%3D10.1038%2Fs41375-018-0357-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span> <span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazakiauthor=H.+Akiyamaauthor=K.+Saitoauthor=M.+Nishimuraauthor=T.+Motojiauthor=K.+Shinagawaauthor=A.+Takeshitaauthor=H.+Saitoauthor=R.+Uedaauthor=R.+Ohnoauthor=T.+Naoe&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0ljdXd7wnWNtLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DMotoji%26aufirst%3DT.%26aulast%3DShinagawa%26aufirst%3DK.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DOhno%26aufirst%3DR.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsapogas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolink, A.</span></span> <span> </span><span class="NLM_article-title">The cytokine Flt3-ligand in normal and malignant hematopoiesis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1115</span>, <span class="refDoi"> DOI: 10.3390/ijms18061115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3390%2Fijms18061115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOjt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1115&author=P.+Tsapogasauthor=C.+J.+Mooneyauthor=G.+Brownauthor=A.+Rolink&title=The+cytokine+Flt3-ligand+in+normal+and+malignant+hematopoiesis&doi=10.3390%2Fijms18061115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine Flt3-ligand in normal and malignant hematopoiesis</span></div><div class="casAuthors">Tsapogas, Panagiotis; Mooney, Ciaran James; Brown, Geoffrey; Rolink, Antonius</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1115/1-1115/23</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The cytokine Fms-like tyrosine kinase 3 ligand (FL) is an important regulator of hematopoiesis.  Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages.  Activating mutations of Flt3 are frequently found in acute myeloid leukemia (AML) patients and assocd. with a poor clin. prognosis.  In the present review we provide an overview of our current knowledge on the role of FL in the generation of blood cell lineages.  We examine recent studies on Flt3 expression by hematopoietic stem cells and its potential instructive action at early stages of hematopoiesis.  In addn., we review current findings on the role of mutated FLT3 in leukemia and the development of FLT3 inhibitors for therapeutic use to treat AML.  The importance of mouse models in elucidating the role of Flt3-ligand in normal and malignant hematopoiesis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZAD7KNkGLsLVg90H21EOLACvtfcHk0ljdXd7wnWNtLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOjt7zN&md5=30f9d6538ba9b7ec92d75353a384f270</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fijms18061115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18061115%26sid%3Dliteratum%253Aachs%26aulast%3DTsapogas%26aufirst%3DP.%26aulast%3DMooney%26aufirst%3DC.%2BJ.%26aulast%3DBrown%26aufirst%3DG.%26aulast%3DRolink%26aufirst%3DA.%26atitle%3DThe%2520cytokine%2520Flt3-ligand%2520in%2520normal%2520and%2520malignant%2520hematopoiesis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1115%26doi%3D10.3390%2Fijms18061115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstraete, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandriessche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Januar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elegheert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shkumatov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desfosses, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Craenenbroeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svergun, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutsche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savvides, S. N.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-01-329532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2011-01-329532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=21389326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=60-68&author=K.+Verstraeteauthor=G.+Vandriesscheauthor=M.+Januarauthor=J.+Elegheertauthor=A.+V.+Shkumatovauthor=A.+Desfossesauthor=K.+Van+Craenenbroeckauthor=D.+I.+Svergunauthor=I.+Gutscheauthor=B.+Vergauwenauthor=S.+N.+Savvides&title=Structural+insights+into+the+extracellular+assembly+of+the+hematopoietic+Flt3+signaling+complex&doi=10.1182%2Fblood-2011-01-329532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex</span></div><div class="casAuthors">Verstraete, Kenneth; Vandriessche, Gonzalez; Januar, Mariska; Elegheert, Jonathan; Shkumatov, Alexander V.; Desfosses, Ambroise; Van Craenenbroeck, Kathleen; Svergun, Dmitri I.; Gutsche, Irina; Vergauwen, Bjorn; Savvides, Savvas N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-68</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The class III receptor tyrosine kinase (RTKIII) Fms-like tyrosine kinase receptor 3 (Flt3) and its cytokine ligand (FL) play central roles in hematopoiesis and the immune system, by establishing signaling cascades crucial for the development and homeostasis of hematopoietic progenitors and antigen-presenting dendritic cells.  However, Flt3 is also one of the most frequently mutated receptors in hematol. malignancies and is currently a major prognostic factor and clin. target for acute myeloid leukemia.  Here, we report the structural basis for the Flt3 ligand-receptor complex and unveil an unanticipated extracellular assembly unlike any other RTKIII/V complex characterized to date.  FL induces dimerization of Flt3 via a remarkably compact binding epitope localized at the tip of extracellular domain 3 of Flt3, and it invokes a ternary complex devoid of homeotypic receptor interactions.  Comparisons of Flt3 with homologous receptors and available mutagenesis data for FL have allowed us to rationalize the unique features of the Flt3 extracellular assembly.  Furthermore, thermodn. dissection of complex formation points to a pronounced enthalpically driven binding event coupled to an entropic penalty.  Together, our data suggest that the high-affinity Flt3:FL complex is driven in part by a single preformed binding epitope on FL reminiscent of a "lock-and-key" binding mode, thereby setting the stage for antagonist design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF8FAW5sscnbVg90H21EOLACvtfcHk0lijVyFVYBrqkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSnt70%253D&md5=ae5624cf7885929c65436fe7524cc42d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-01-329532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-01-329532%26sid%3Dliteratum%253Aachs%26aulast%3DVerstraete%26aufirst%3DK.%26aulast%3DVandriessche%26aufirst%3DG.%26aulast%3DJanuar%26aufirst%3DM.%26aulast%3DElegheert%26aufirst%3DJ.%26aulast%3DShkumatov%26aufirst%3DA.%2BV.%26aulast%3DDesfosses%26aufirst%3DA.%26aulast%3DVan%2BCraenenbroeck%26aufirst%3DK.%26aulast%3DSvergun%26aufirst%3DD.%2BI.%26aulast%3DGutsche%26aufirst%3DI.%26aulast%3DVergauwen%26aufirst%3DB.%26aulast%3DSavvides%26aufirst%3DS.%2BN.%26atitle%3DStructural%2520insights%2520into%2520the%2520extracellular%2520assembly%2520of%2520the%2520hematopoietic%2520Flt3%2520signaling%2520complex%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D60%26epage%3D68%26doi%3D10.1182%2Fblood-2011-01-329532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faerman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span> <span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(03)00505-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain&doi=10.1016%2FS1097-2765%2803%2900505-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lijVyFVYBrqkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178%26doi%3D10.1016%2FS1097-2765%2803%2900505-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">STAT signaling in the pathogenesis and treatment of myeloid malignancies</span>. <i>JAKSTAT.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.4161/jkst.20006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.4161%2Fjkst.20006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24058751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt1yjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=55-64&author=M.+Bar-Natanauthor=E.+A.+Nelsonauthor=M.+Xiangauthor=D.+A.+Frank&title=STAT+signaling+in+the+pathogenesis+and+treatment+of+myeloid+malignancies&doi=10.4161%2Fjkst.20006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">STAT signaling in the pathogenesis and treatment of myeloid malignancies</span></div><div class="casAuthors">Bar-Natan Michal; Nelson Erik A; Xiang Michael; Frank David A</div><div class="citationInfo"><span class="NLM_cas:title">JAK-STAT</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">55-64</span>
        ISSN:<span class="NLM_cas:issn">2162-3988</span>.
    </div><div class="casAbstract">STAT transcription factors play a critical role in mediating the effects of cytokines on myeloid cells.  As STAT target genes control key processes such as survival, proliferation and self-renewal, it is not surprising that constitutive activation of STATs, particularly STAT3 and STAT5, are common events in many myeloid tumors.  STATs are activated both by mutant tyrosine kinases as well as other pathogenic events, and continued activation of STATs is common in the setting of resistance to kinase inhibitors.  Thus, the targeting of STATs, alone or in combination with other drugs, will likely have increasing importance for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4U-tZwxXjRaNc3HjJRoFAfW6udTcc2eYHSDJ2BuFlw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt1yjug%253D%253D&md5=e6bda357c68734bfd953780733bf918f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4161%2Fjkst.20006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.20006%26sid%3Dliteratum%253Aachs%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DSTAT%2520signaling%2520in%2520the%2520pathogenesis%2520and%2520treatment%2520of%2520myeloid%2520malignancies%26jtitle%3DJAKSTAT.%26date%3D2012%26volume%3D1%26spage%3D55%26epage%3D64%26doi%3D10.4161%2Fjkst.20006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamborini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virdis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsenigo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stacchiotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotti, S.</span></span> <span> </span><span class="NLM_article-title">Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1093/neuonc/noq003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1093%2Fneuonc%2Fnoq003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=20164240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFSlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=776-789&author=E.+Tamboriniauthor=E.+Virdisauthor=T.+Negriauthor=M.+Orsenigoauthor=S.+Brichauthor=E.+Concaauthor=A.+Gronchiauthor=S.+Stacchiottiauthor=G.+Manentiauthor=P.+G.+Casaliauthor=M.+A.+Pierottiauthor=S.+Pilotti&title=Analysis+of+receptor+tyrosine+kinases+%28RTKs%29+and+downstream+pathways+in+chordomas&doi=10.1093%2Fneuonc%2Fnoq003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas</span></div><div class="casAuthors">Tamborini, Elena; Virdis, Emanuela; Negri, Tiziana; Orsenigo, Marta; Brich, Silvia; Conca, Elena; Gronchi, Alessandro; Stacchiotti, Silvia; Manenti, Giacomo; Casali, Paolo G.; Pierotti, Marco A.; Pilotti, Silvana</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">776-789</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a no. of patients.  The aim of this study was to identify the possible presence of other activated RTKs and their downstream signaling effectors.  Cryopreserved material from 22 naive sporadic chordomas was investigated for the presence of activated RTKs and their cognate ligands and downstream signaling effectors by means of human phospho-RTK antibody arrays, Western blotting, and mol. anal.; immunohistochem. and fluorescence in situ hybridization were used to analyze the corresponding formalin-fixed and paraffin-embedded samples.  We detected activated PDGFRB, FLT3, and colony stimulating factor 1 receptor (CSF1R) of the PDGFR family and highly phosphorylated EGFR, HER2/neu, and (to a lesser extent) HER4 of the EGFR family.  The detection of PDGFRB/PDGFB confirmed our previous data.  The presence of activated EGFR was paralleled by the finding of high levels of epidermal growth factor (EGF) and transforming growth factor α (TGFα) and PDGFB co-expression and PDGFRB co-immunopptn.  Of the downstream effectors, the PI3K/AKT and RAS/MAPK pathways were both activated, thus leading to the phosphorylation of mammalian target of rapamycin (mTOR) and 4E-BP1 among the regulators involved in translational control.  Taken together, our results (i) provide a rationale for tailored treatments targeting upstream activated receptors, including the PDGFR and EGFR families; (ii) support the idea that a combination of upstream antagonists and mTOR inhibitors enhances the control of tumor growth; and (iii) indicate that the 4E-BP1/eIF4E pathway is a major regulator of protein synthesis in chordoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOgC0XrB2e1rVg90H21EOLACvtfcHk0lgagwwlJjsigA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFSlt7s%253D&md5=ad5f408f200ab2aa9b2a58b7288815e9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnoq003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnoq003%26sid%3Dliteratum%253Aachs%26aulast%3DTamborini%26aufirst%3DE.%26aulast%3DVirdis%26aufirst%3DE.%26aulast%3DNegri%26aufirst%3DT.%26aulast%3DOrsenigo%26aufirst%3DM.%26aulast%3DBrich%26aufirst%3DS.%26aulast%3DConca%26aufirst%3DE.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DStacchiotti%26aufirst%3DS.%26aulast%3DManenti%26aufirst%3DG.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DPilotti%26aufirst%3DS.%26atitle%3DAnalysis%2520of%2520receptor%2520tyrosine%2520kinases%2520%2528RTKs%2529%2520and%2520downstream%2520pathways%2520in%2520chordomas%26jtitle%3DNeuro%2520Oncol.%26date%3D2010%26volume%3D12%26spage%3D776%26epage%3D789%26doi%3D10.1093%2Fneuonc%2Fnoq003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönnstrand, L.</span></span> <span> </span><span class="NLM_article-title">FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1433</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1152/physrev.00029.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1152%2Fphysrev.00029.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31066629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGlurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2019&pages=1433-1466&author=J.+U.+Kaziauthor=L.+R%C3%B6nnstrand&title=FMS-like+tyrosine+kinase+3%2FFLT3%3A+from+basic+science+to+clinical+implications&doi=10.1152%2Fphysrev.00029.2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications</span></div><div class="casAuthors">Kazi, Julhash U.; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1433-1466</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">1522-1210</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is expressed almost exclusively in the hematopoietic compartment.  Its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity.  Activation of FLT3 leads to its autophosphorylation and initiation of several signal transduction cascades.  Signaling is initiated by the recruitment of signal transduction mols. to activated FLT3 through binding to specific phosphorylated tyrosine residues in the intracellular region of FLT3.  Activation of FLT3 mediates cell survival, cell proliferation, and differentiation of hematopoietic progenitor cells.  It acts in synergy with several other cytokines to promote its biol. effects.  Deregulated FLT3 activity has been implicated in several diseases, most prominently in acute myeloid leukemia where around one-third of patients carry an activating mutant of FLT3 which drives the disease and is correlated with poor prognosis.  Overactivity of FLT3 has also been implicated in autoimmune diseases, such as rheumatoid arthritis.  The observation that gain-of-function mutations of FLT3 can promote leukemogenesis has stimulated the development of inhibitors that target this receptor.  Many of these are in clin. trials, and some have been approved for clin. use.  However, problems with acquired resistance to these inhibitors are common and, furthermore, only a fraction of patients respond to these selective treatments.  This review provides a summary of our current knowledge regarding structural and functional aspects of FLT3 signaling, both under normal and pathol. conditions, and discusses challenges for the future regarding the use of targeted inhibition of these pathways for the treatment of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfuVERCf3VnLVg90H21EOLACvtfcHk0lgagwwlJjsigA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGlurrE&md5=ed99d5ecf4de02acb8196801e4e66e6a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00029.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00029.2018%26sid%3Dliteratum%253Aachs%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26atitle%3DFMS-like%2520tyrosine%2520kinase%25203%252FFLT3%253A%2520from%2520basic%2520science%2520to%2520clinical%2520implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2019%26volume%3D99%26spage%3D1433%26epage%3D1466%26doi%3D10.1152%2Fphysrev.00029.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, S.</span></span> <span> </span><span class="NLM_article-title">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+flt3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2ebi56dtCk8Ca7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520flt3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrintseva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vempati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnittger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwart, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfner, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span> <span> </span><span class="NLM_article-title">Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3700</span>– <span class="NLM_lpage">3707</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-06-2596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2005-06-2596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16410449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3700-3707&author=C.+Reindlauthor=K.+Bagrintsevaauthor=S.+Vempatiauthor=S.+Schnittgerauthor=J.+W.+Ellwartauthor=K.+Wenigauthor=K.+P.+Hopfnerauthor=W.+Hiddemannauthor=K.+Spiekermann&title=Point+mutations+in+the+juxtamembrane+domain+of+FLT3+define+a+new+class+of+activating+mutations+in+AML&doi=10.1182%2Fblood-2005-06-2596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML</span></div><div class="casAuthors">Reindl, Carola; Bagrintseva, Ksenia; Vempati, Sridhar; Schnittger, Susanne; Ellwart, Joachim W.; Wenig, Katja; Hopfner, Karl-Peter; Hiddemann, Wolfgang; Spiekermann, Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3700-3707</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In acute myeloid leukemia (AML), two clusters of activating mutations are known in the FMS-like tyrosine kinase-3 (FLT3) gene: FLT3-internal tandem duplications (FLT3-ITDs) in the juxtamembrane (JM) domain in 20% to 25% of patients, and FLT3 point mutations in the tyrosine-kinase domain (FLT3-TKD) in 7% to 10% of patients, resp.  Here, we have characterized a new class of activating point mutations (PMs) that cluster in a 16-amino acid stretch of the juxtamembrane domain of FLT3 (FLT3-JM-PMs).  Expression of 4 FLT3-JM-PMs in interleukin-3 (IL-3)-dependent Ba/F3 cells led to factor-independent growth, hyperresponsiveness to FLT3 ligand, and resistance to apoptotic cell death.  FLT3-JM-PM receptors were autophosphorylated and showed a higher constitutive dimerization rate compared with the FLT3-wild-type (WT) receptor.  As a mol. mechanism, we could show activation of STAT5 and up-regulation of Bcl-x(L) by all FLT3-JM-PMs.  The FLT3 inhibitor PKC412 abrogated the factor-independent growth of FLT3-JM-PM-expressing cells.  Compared with FLT3-ITD and FLT3-TKD mutants, the FLT3-JM-PMs showed a weaker transforming potential related to lower autophosphorylation of the receptor and its downstream target STAT5.  Mapping of the FLT3-JM-PMs on the crystal structure of FLT3 showed that these mutations reduce the stability of the autoinhibitory JM domain, and provides a structural basis for the transforming capacity of this new class of gain-of-function mutations of FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXOXwmMIS-7Vg90H21EOLACvtfcHk0li-VyBHI7xFNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7w%253D&md5=1ce45965aa65d75fb434eec4c09eb3bf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-06-2596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-06-2596%26sid%3Dliteratum%253Aachs%26aulast%3DReindl%26aufirst%3DC.%26aulast%3DBagrintseva%26aufirst%3DK.%26aulast%3DVempati%26aufirst%3DS.%26aulast%3DSchnittger%26aufirst%3DS.%26aulast%3DEllwart%26aufirst%3DJ.%2BW.%26aulast%3DWenig%26aufirst%3DK.%26aulast%3DHopfner%26aufirst%3DK.%2BP.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DSpiekermann%26aufirst%3DK.%26atitle%3DPoint%2520mutations%2520in%2520the%2520juxtamembrane%2520domain%2520of%2520FLT3%2520define%2520a%2520new%2520class%2520of%2520activating%2520mutations%2520in%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3700%26epage%3D3707%26doi%3D10.1182%2Fblood-2005-06-2596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-12-2087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23209034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=327-335&author=H.+J.+Leeauthor=N.+Daverauthor=H.+M.+Kantarjianauthor=S.+Verstovsekauthor=F.+Ravandi&title=The+role+of+JAK+pathway+dysregulation+in+the+pathogenesis+and+treatment+of+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-12-2087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Lee, Hun Ju; Daver, Naval; Kantarjian, Hagop M.; Verstovsek, Srdan; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-335</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase 2 (JAK2) V617F mutation has improved our understanding of the pathophysiol. of myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.  Before discovery of the JAK2 V617F mutation, there were no specific targeted therapies for patients with myeloproliferative neoplasms.  More recently, several small-mol. inhibitors have been developed that have shown therapeutic potential in the clin. setting.  There is evidence that the JAK2 pathway is dysregulated in some acute myeloid leukemias and may also represent a novel therapeutic target in this disease.  In this review, we describe the preclin., clin., and pathophysiol. evidence for using JAK inhibitors in the treatment of acute myeloid leukemias.  Clin Cancer Res; 19(2); 327-35. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVJg_eZ3d87Vg90H21EOLACvtfcHk0li-VyBHI7xFNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CgtL8%253D&md5=be1e8c2c096a02b0c331263f2e2b6911</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2087%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DThe%2520role%2520of%2520JAK%2520pathway%2520dysregulation%2520in%2520the%2520pathogenesis%2520and%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D327%26epage%3D335%26doi%3D10.1158%2F1078-0432.CCR-12-2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2601</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0ljL4nsv2kMfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eghtedar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faderl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">4614</span>– <span class="NLM_lpage">4618</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-12-400051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2011-12-400051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22422826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVKhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=4614-4618&author=A.+Eghtedarauthor=S.+Verstovsekauthor=Z.+Estrovauthor=J.+Burgerauthor=J.+Cortesauthor=C.+Bivinsauthor=S.+Faderlauthor=A.+Ferrajoliauthor=G.+Borthakurauthor=S.+Georgeauthor=P.+A.+Scherleauthor=R.+C.+Newtonauthor=H.+M.+Kantarjianauthor=F.+Ravandi&title=Phase+2+study+of+the+JAK+kinase+inhibitor+ruxolitinib+in+patients+with+refractory+leukemias%2C+including+postmyeloproliferative+neoplasm+acute+myeloid+leukemia&doi=10.1182%2Fblood-2011-12-400051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia</span></div><div class="casAuthors">Eghtedar, Alireza; Verstovsek, Srdan; Estrov, Zeev; Burger, Jan; Cortes, Jorge; Bivins, Carol; Faderl, Stefan; Ferrajoli, Alessandra; Borthakur, Gautam; George, Solly; Scherle, Peggy A.; Newton, Robert C.; Kantarjian, Hagop M.; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4614-4618</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias.  Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 wk (1 cycle).  Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression.  Dose escalation to 50 mg twice daily was permitted in patients demonstrating a benefit.  Thirty-eight patients, with a median age of 69 years (range, 45-88), were treated.  The median no. of prior therapies was 2 (range, 1-6).  Twelve patients had JAK2V617F mutation.  Patients received a median of 2 cycles of therapy (range, 1-22).  Three of 18 patients with postmyeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) showed a significant response; 2 achieved complete remission (CR) and one achieved a CR with insufficient recovery of blood counts (CRi).  The responding patients with palpable spleens also had significant redns. in spleen size.  Overall, ruxolitinib was very well tolerated with only 4 patients having grade 3 or higher toxicity.  Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtWHaQZwqMqLVg90H21EOLACvtfcHk0ljL4nsv2kMfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVKhur4%253D&md5=e87c29333ee00b38ff6b33ae9f7fe8e3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-12-400051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-12-400051%26sid%3Dliteratum%253Aachs%26aulast%3DEghtedar%26aufirst%3DA.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DBurger%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DBivins%26aufirst%3DC.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DPhase%25202%2520study%2520of%2520the%2520JAK%2520kinase%2520inhibitor%2520ruxolitinib%2520in%2520patients%2520with%2520refractory%2520leukemias%252C%2520including%2520postmyeloproliferative%2520neoplasm%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D4614%26epage%3D4618%26doi%3D10.1182%2Fblood-2011-12-400051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1933</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-12-0284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23406773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1933-1940&author=A.+Quint%C3%A1s-Cardamaauthor=S.+Verstovsek&title=Molecular+pathways%3A+Jak%2FSTAT+pathway%3A+mutations%2C+inhibitors%2C+and+resistance&doi=10.1158%2F1078-0432.CCR-12-0284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1933-1940</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease states, including inflammatory conditions, hematol. malignancies, and solid tumors.  For instance, a large proportion of patients with myeloproliferative neoplasms (MPN) carry the acquired gain-of-function JAK2 V617F somatic mutation.  This knowledge has dramatically improved our understanding of the pathogenesis of MPNs and has facilitated the development of therapeutics capable of suppressing the constitutive activation of the JAK/STAT pathway, now recognized as a common underlying biol. abnormality in MPNs.  Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematol. malignancies.  A series of agents with different specificities against different members of the JAK family of proteins is currently undergoing evaluation in clin. trials for patients with MPNs, lymphoma, and solid tumors such as breast or pancreatic cancer.  Despite the significant clin. activity exhibited by these agents in myelofibrosis, some patients fail to respond or progress during JAK kinase inhibitor therapy.  Recent reports have shed light into the mechanisms of resistance to JAK inhibitor therapy.  Several approaches hold promise to overcome such resistance.  Clin Cancer Res; 19(8); 1933-40. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyMnvN-07bLVg90H21EOLACvtfcHk0ljL4nsv2kMfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjs78%253D&md5=27cc6d84279e644740e82aa8a073eba6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0284%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DMolecular%2520pathways%253A%2520Jak%252FSTAT%2520pathway%253A%2520mutations%252C%2520inhibitors%252C%2520and%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D1933%26epage%3D1940%26doi%3D10.1158%2F1078-0432.CCR-12-0284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmukhaiah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu Rao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madkaikar, M.</span></span> <span> </span><span class="NLM_article-title">Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1111/ejh.12592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fejh.12592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26010294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVSmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=309-317&author=S.+Gargauthor=C.+Shanmukhaiahauthor=S.+Maratheauthor=P.+Mishraauthor=V.+Babu+Raoauthor=K.+Ghoshauthor=M.+Madkaikar&title=Differential+antigen+expression+and+aberrant+signaling+via+PI3%2FAKT%2C+MAP%2FERK%2C+JAK%2FSTAT%2C+and+Wnt%2F%CE%B2+catenin+pathways+in+Lin-%2FCD38-%2FCD34%2B+cells+in+acute+myeloid+leukemia&doi=10.1111%2Fejh.12592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia</span></div><div class="casAuthors">Garg, Swati; Shanmukhaiah, Chandrakala; Marathe, Supreet; Mishra, Prashant; Babu Rao, Vunditi; Ghosh, Kanjaksha; Madkaikar, Manisha</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-317</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Acute myeloid leukemia is often called as stem cell disease that presents with treatment failure and poor disease outcome.  Leukemic stem cells in acute myeloid leukemia (AML) are enriched in Lineage-/CD38-/CD34+ compartment of CD34-pos. AML.  Many markers important for stem cell biol. have been reported for their assocn. with leukemic stem cell population, but what remains clin. most important is a rapid identification of prognostic information.  In this study, we evaluated four signal transduction pathways and thirteen markers on Lin-/CD38-/CD34+ population in AML.  Expressions were compared in different AML subtypes, survival, and treatment outcome groups.  We obsd. that markers important in homing, cell quiescence, and signal propagation such as CD44, CD96, CD90, WT-1, CD123 and CD25 were most significantly differentially expressed on Lin-/CD38-/CD34+ population in AML from their normal counterparts (P < 0.05, Mann-Whitney).  Constitutive activation of phospho ERK, AKT, and STAT5 in these cells was assocd. with poor outcome.  Also, an increased frequency of putative leukemic stem cell population shows neg. impact on treatment outcome and overall survival, suggesting that initial evaluation of AML samples for pLSC frequency and constitutively activated signaling pathway can provide prognostic and therapeutic information at the time of diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw7QmEWUz6p7Vg90H21EOLACvtfcHk0ljL4nsv2kMfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVSmtr8%253D&md5=c39930bbd4f671beb89e7a52a04dad09</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fejh.12592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.12592%26sid%3Dliteratum%253Aachs%26aulast%3DGarg%26aufirst%3DS.%26aulast%3DShanmukhaiah%26aufirst%3DC.%26aulast%3DMarathe%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DBabu%2BRao%26aufirst%3DV.%26aulast%3DGhosh%26aufirst%3DK.%26aulast%3DMadkaikar%26aufirst%3DM.%26atitle%3DDifferential%2520antigen%2520expression%2520and%2520aberrant%2520signaling%2520via%2520PI3%252FAKT%252C%2520MAP%252FERK%252C%2520JAK%252FSTAT%252C%2520and%2520Wnt%252F%25CE%25B2%2520catenin%2520pathways%2520in%2520Lin-%252FCD38-%252FCD34%252B%2520cells%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2016%26volume%3D96%26spage%3D309%26epage%3D317%26doi%3D10.1111%2Fejh.12592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biethahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, F.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of STAT transcription factors in acute myelogenous leukemia</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1034/j.1600-0609.2001.t01-1-00385.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1034%2Fj.1600-0609.2001.t01-1-00385.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=11722592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos12ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2001&pages=63-71&author=K.+Spiekermannauthor=S.+Biethahnauthor=S.+Wildeauthor=W.+Hiddemannauthor=F.+Alves&title=Constitutive+activation+of+STAT+transcription+factors+in+acute+myelogenous+leukemia&doi=10.1034%2Fj.1600-0609.2001.t01-1-00385.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of STAT transcription factors in acute myelogenous leukemia</span></div><div class="casAuthors">Spiekermann, K.; Biethahn, S.; Wilde, S.; Hiddemann, W.; Alves, F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-71</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Hematopoietic growth factors (HGF) are essential for proliferation and differentiation of hematopoietic precursors and activate a distinct set of JAK-STAT (Janus kinases-signal transducers and activators of transcription) proteins.  Previous results from the authors' group have shown a strong expression of JAK-STAT proteins in primary acute myelogenous leukemia (AML) blasts and AML cell lines.  Here, the authors asked whether a constitutive activation of the JAK-STAT pathway might be involved in the pathogenesis of AML.  The authors could demonstrate a constitutive activation of STAT1, 3 and 5 by immunopptn. of the tyrosine phosphorylated proteins in different human AML cell lines.  Three patterns of STAT activation were found: (I) activation of only STAT1, (II) activation of STAT1 in combination with STAT3, and (III) activation of STAT1, 3 and 5.  Furthermore, STAT1 and 3 formed stable heterodimers only in cell lines with constitutive STAT3 activation.  In all cell lines analyzed, tyrosine phosphorylation of the four known Janus kinases could not be detected, although JAK1 was stably assocd. with STAT3.  To further analyze whether a constitutive activation of tyrosine kinases might contribute to the autonomous growth of AML blasts, inhibitor studies were performed.  The tyrphostin AG490, an inhibitor of the JAK-STAT pathway, but not A1, an inactive tyrphostin induced a time- and dose-dependent growth arrest without overt morphol. signs of differentiation in AML cell lines.  These results show that STAT transcription factors are constitutively activated in human AML cell lines and might contribute to the autonomous proliferation of AML blasts.  Inhibition of this pathway might be of interest for the establishment of more specific antileukemic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq23_sXX8Ss7rVg90H21EOLACvtfcHk0li60a-2TA5KAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos12ksrc%253D&md5=89865bf7cb7cf7cbc61acf75d6b1e646</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0609.2001.t01-1-00385.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0609.2001.t01-1-00385.x%26sid%3Dliteratum%253Aachs%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBiethahn%26aufirst%3DS.%26aulast%3DWilde%26aufirst%3DS.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DAlves%26aufirst%3DF.%26atitle%3DConstitutive%2520activation%2520of%2520STAT%2520transcription%2520factors%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2001%26volume%3D67%26spage%3D63%26epage%3D71%26doi%3D10.1034%2Fj.1600-0609.2001.t01-1-00385.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karjalainen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemovska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javarappa, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bychkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayoral Safont, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porkka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioniemi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckman, C. A.</span></span> <span> </span><span class="NLM_article-title">JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-02-699363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2016-02-699363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28619982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSku7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=789-802&author=R.+Karjalainenauthor=T.+Pemovskaauthor=M.+Popaauthor=M.+Liuauthor=K.+K.+Javarappaauthor=M.+M.+Majumderauthor=B.+Yadavauthor=D.+Tamboreroauthor=J.+Tangauthor=D.+Bychkovauthor=M.+Kontroauthor=A.+Parsonsauthor=M.+Suvelaauthor=M.+Mayoral+Safontauthor=K.+Porkkaauthor=T.+Aittokallioauthor=O.+Kallioniemiauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=K.+Wennerbergauthor=J.+Knowlesauthor=C.+A.+Heckman&title=JAK1%2F2+and+BCL2+inhibitors+synergize+to+counteract+bone+marrow+stromal+cell-induced+protection+of+AML&doi=10.1182%2Fblood-2016-02-699363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML</span></div><div class="casAuthors">Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir M.; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Safont, Mireia Mayoral; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjoern T.; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">789-802</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The bone marrow (BM) provides a protective microenvironment to support the survival of leukemic cells and influence their response to therapeutic agents.  In acute myeloid leukemia (AML), the high rate of relapse may in part be a result of the inability of current treatment to effectively overcome the protective influence of the BM niche.  To better understand the effect of the BM microenvironment on drug responses in AML, we conducted a comprehensive evaluation of 304 inhibitors, including approved and investigational agents, comparing ex vivo responses of primary AML cells in BM stroma-derived and std. culture conditions.  In the stroma-based conditions, the AML patient cells exhibited significantly reduced sensitivity to 12% of the tested compds., including topoisomerase II, B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), and many tyrosine kinase inhibitors (TKIs).  The loss of TKI sensitivity was most pronounced in patient samples harboring FLT3 or PDGFRB alterations.  In contrast, the stroma-derived conditions enhanced sensitivity to Janus kinase (JAK) inhibitors.  Increased cell viability and resistance to specific drug classes in the BM stroma-derived conditions was a result of activation of alternative signaling pathways mediated by factors secreted by BM stromal cells and involved a switch from BCL2 to BCLXL-dependent cell survival.  Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model.  These findings highlight the potential of JAK inhibitors to counteract stroma-induced resistance to BCL2 inhibitors in AML. (Blood. 2017;130(6):789-802).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWKjMWNILYfrVg90H21EOLACvtfcHk0li60a-2TA5KAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSku7bJ&md5=a43567040357a235c85cf4878f5579c7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-02-699363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-02-699363%26sid%3Dliteratum%253Aachs%26aulast%3DKarjalainen%26aufirst%3DR.%26aulast%3DPemovska%26aufirst%3DT.%26aulast%3DPopa%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DJavarappa%26aufirst%3DK.%2BK.%26aulast%3DMajumder%26aufirst%3DM.%2BM.%26aulast%3DYadav%26aufirst%3DB.%26aulast%3DTamborero%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DBychkov%26aufirst%3DD.%26aulast%3DKontro%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DA.%26aulast%3DSuvela%26aufirst%3DM.%26aulast%3DMayoral%2BSafont%26aufirst%3DM.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DAittokallio%26aufirst%3DT.%26aulast%3DKallioniemi%26aufirst%3DO.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DKnowles%26aufirst%3DJ.%26aulast%3DHeckman%26aufirst%3DC.%2BA.%26atitle%3DJAK1%252F2%2520and%2520BCL2%2520inhibitors%2520synergize%2520to%2520counteract%2520bone%2520marrow%2520stromal%2520cell-induced%2520protection%2520of%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D789%26epage%3D802%26doi%3D10.1182%2Fblood-2016-02-699363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobumoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2015.219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26260387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2296-2306&author=C.+Nishiokaauthor=T.+Ikezoeauthor=A.+Takeuchiauthor=A.+Nobumotoauthor=M.+Tsudaauthor=A.+Yokoyama&title=The+novel+function+of+CD82+and+its+impact+on+BCL2L12+via+AKT%2FSTAT5+signal+pathway+in+acute+myelogenous+leukemia+cells&doi=10.1038%2Fleu.2015.219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells</span></div><div class="casAuthors">Nishioka, C.; Ikezoe, T.; Takeuchi, A.; Nobumoto, A.; Tsuda, M.; Yokoyama, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2296-2306</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The aim of this study was to explore the biol. functions of a tetraspanin family protein CD82 expressed aberrantly in chemotherapy-resistant CD34+/CD38- acute myelogenous leukemia (AML) cells.  Microarray anal. of patient-isolated CD34+/CD38- AML cells revealed that the levels of anti-apoptotic protein BCL2L12 were downregulated after CD82 depletion by specific short hairpin RNA (shRNA).  Western blot anal. indicated that BCL2L12 was aberrantly expressed in patient-isolated AML cells and AML cell lines.  Furthermore, CD82 blockade by a specific antibody downregulated BCL2L12 in parallel with dephosphorylation of signal transducer and activator of transcription 5 (STAT5) and AKT, whereas pharmacol. inhibition of STAT5 and AKT activation decreased BCL2L12 expression in leukemia cells.  In addn., shRNA-mediated downregulation of BCL2L12 increased the levels of cleaved caspase-3 and suppressed proliferation of leukemia cells, impairing their engraftment in immunodeficient mice.  Taken together, our results indicate that CD82 regulated BCL2L12 expression via STAT5A and AKT signaling and stimulated proliferation and engrafting of leukemia cells, suggesting that CD82 and BCL2L12 may be promising therapeutic targets in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2TqXgTM7Ig7Vg90H21EOLACvtfcHk0lisJ33dDIckqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2gtbnL&md5=a329ddb1d1cce22509dbba37f7ec87a7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.219%26sid%3Dliteratum%253Aachs%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DA.%26aulast%3DNobumoto%26aufirst%3DA.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DThe%2520novel%2520function%2520of%2520CD82%2520and%2520its%2520impact%2520on%2520BCL2L12%2520via%2520AKT%252FSTAT5%2520signal%2520pathway%2520in%2520acute%2520myelogenous%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D2296%26epage%3D2306%26doi%3D10.1038%2Fleu.2015.219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Naggar, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.645805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1517%2F14728222.2011.645805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22239440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Wktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=103-119&author=L.+Santarpiaauthor=S.+M.+Lippmanauthor=A.+K.+El-Naggar&title=Targeting+the+MAPK-RAS-RAF+signaling+pathway+in+cancer+therapy&doi=10.1517%2F14728222.2011.645805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy</span></div><div class="casAuthors">Santarpia, Libero; Lippman, Scott M.; El-Naggar, Adel K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-119</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The MAPK pathway comprises several key signaling components and phosphorylation events that play a role in tumorigenesis.  These activated kinases transmit extracellular signals that regulate cell growth, differentiation, proliferation, apoptosis and migration functions.  Alteration of the RAS-RAF-MEK-ERK-MAPK (RAS-MAPK) pathway has been reported in human cancer as a result of abnormal activation of receptor tyrosine kinases or gain-of-function mutations mainly in the RAS or RAF genes.  These pathways are considered potential therapeutic targets for cancer treatment.  Recently, several small-mol. inhibitors targeting this pathway have been developed and are currently being tested in clin. trials.Areas covered: The biol. role of the RAS-MAPK pathway, the consequence of its disregulation and the development of small-mol. inhibitors.  The rationale for targeting the RAS-MAPK pathway and the application and the results of various inhibitory mols. as anticancer agents in clin. trials.Expert opinion: Inhibitors of MEK and particularly of RAF kinases have shown effectiveness in clin. trials with manageable side effects.  RAS and BRAF genes need to be analyzed for mutations as markers of response to treatments and to avoid paradoxical effects.  Further characterization of the RAS-MAPK mol. mechanisms regulation in malignant cells or underlying the acquired resistance to RAF inhibitors will facilitate development of novel combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFz0Tl-yNlE7Vg90H21EOLACvtfcHk0lisJ33dDIckqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Wktw%253D%253D&md5=67be09e29593e670071e8a94d8630012</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.645805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.645805%26sid%3Dliteratum%253Aachs%26aulast%3DSantarpia%26aufirst%3DL.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DEl-Naggar%26aufirst%3DA.%2BK.%26atitle%3DTargeting%2520the%2520MAPK-RAS-RAF%2520signaling%2520pathway%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26spage%3D103%26epage%3D119%26doi%3D10.1517%2F14728222.2011.645805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grafone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storti, S.</span></span> <span> </span><span class="NLM_article-title">An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment</span>. <i>Oncol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">8</span> <span class="refDoi"> DOI: 10.4081/oncol.2012.e8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.4081%2Foncol.2012.e8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&author=T.+Grafoneauthor=M.+Palmisanoauthor=C.+Nicciauthor=S.+Storti&title=An+overview+on+the+role+of+FLT3-tyrosine+kinase+receptor+in+acute+myeloid+leukemia%3A+biology+and+treatment&doi=10.4081%2Foncol.2012.e8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4081%2Foncol.2012.e8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4081%252Foncol.2012.e8%26sid%3Dliteratum%253Aachs%26aulast%3DGrafone%26aufirst%3DT.%26aulast%3DPalmisano%26aufirst%3DM.%26aulast%3DNicci%26aufirst%3DC.%26aulast%3DStorti%26aufirst%3DS.%26atitle%3DAn%2520overview%2520on%2520the%2520role%2520of%2520FLT3-tyrosine%2520kinase%2520receptor%2520in%2520acute%2520myeloid%2520leukemia%253A%2520biology%2520and%2520treatment%26jtitle%3DOncol.%2520Rev.%26date%3D2012%26volume%3D6%26doi%3D10.4081%2Foncol.2012.e8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sillar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germon, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeIuliis, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dun, M. D.</span></span> <span> </span><span class="NLM_article-title">The role of reactive oxygen species in acute myeloid leukaemia</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6003</span>, <span class="refDoi"> DOI: 10.3390/ijms20236003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3390%2Fijms20236003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFahsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=6003&author=J.+R.+Sillarauthor=Z.+P.+Germonauthor=G.+N.+DeIuliisauthor=M.+D.+Dun&title=The+role+of+reactive+oxygen+species+in+acute+myeloid+leukaemia&doi=10.3390%2Fijms20236003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The role of reactive oxygen species in acute myeloid leukaemia</span></div><div class="casAuthors">Sillar, Jonathan R.; Germon, Zacary P.; De Iuliis, Geoffry N.; Dun, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6003</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is an aggressive haematol. malignancy with a poor overall survival.  Reactive oxygen species (ROS) have been shown to be elevated in a wide range of cancers including AML.  While previously thought to be mere byproducts of cellular metab., it is now clear that ROS modulate the function of signalling proteins through oxidn. of crit. cysteine residues.  In this way, ROS have been shown to regulate normal haematopoiesis as well as promote leukaemogenesis in AML.  In addn., ROS promote genomic instability by damaging DNA, which promotes chemotherapy resistance.  The source of ROS in AML appears to be derived from members of the "NOX family" of NADPH oxidases.  Most studies link NOX-derived ROS to activating mutations in the Fms-like tyrosine kinase 3 (FLT3) and Ras-related C3 botulinum toxin substrate (Ras).  Targeting ROS through either ROS induction or ROS inhibition provides a novel therapeutic target in AML.  In this review, we summarise the role of ROS in normal haematopoiesis and in AML.We also explore the current treatments that modulate ROS levels in AML and discuss emerging drug targets based on pre-clin. work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpltnRR-iWAZrVg90H21EOLACvtfcHk0lisJ33dDIckqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFahsrvP&md5=792daf3dfa2709f4406de8f422a11916</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fijms20236003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20236003%26sid%3Dliteratum%253Aachs%26aulast%3DSillar%26aufirst%3DJ.%2BR.%26aulast%3DGermon%26aufirst%3DZ.%2BP.%26aulast%3DDeIuliis%26aufirst%3DG.%2BN.%26aulast%3DDun%26aufirst%3DM.%2BD.%26atitle%3DThe%2520role%2520of%2520reactive%2520oxygen%2520species%2520in%2520acute%2520myeloid%2520leukaemia%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D6003%26doi%3D10.3390%2Fijms20236003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4186</span>– <span class="NLM_lpage">4192</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-13-3270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24895460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4186-4192&author=D.+B.+Johnsonauthor=K.+S.+Smalleyauthor=J.+A.+Sosman&title=Molecular+pathways%3A+targeting+NRAS+in+melanoma+and+acute+myelogenous+leukemia&doi=10.1158%2F1078-0432.CCR-13-3270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia</span></div><div class="casAuthors">Johnson, Douglas B.; Smalley, Keiran S. M.; Sosman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4186-4192</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Successful targeting of specific oncogenic "driver" mutations with small-mol. inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years.  The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be an elusive target.  Activating mutations in RAS induce mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase-AKT pathway signaling and drive malignant progression in up to 30% of cancers.  Oncogenic NRAS mutations occur in several cancer types, notably melanoma, acute myelogenous leukemia (AML), and less commonly, colon adenocarcinoma, thyroid carcinoma, and other hematol. malignancies.  Although NRAS-mutant tumors have been recalcitrant to targeted therapeutic strategies historically, newer agents targeting MAP/ERK kinase 1 (MEK1)/2 have recently shown signs of clin. efficacy as monotherapy.  Combination strategies of MEK inhibitors with other targeted agents have strong preclin. support and are being evaluated in clin. trials.  This review discusses the recent preclin. and clin. studies about the role of NRAS in cancer, with a focus on melanoma and AML.  Clin Cancer Res; 20(16); 4186-92. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHb9TN00_uU7Vg90H21EOLACvtfcHk0lju2CAy3x7d8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK&md5=4656a7aa671cfa3989c09d93f4d60226</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3270%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520NRAS%2520in%2520melanoma%2520and%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D4186%26epage%3D4192%26doi%3D10.1158%2F1078-0432.CCR-13-3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatangelo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roshal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marteyn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnoud, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaemmanuil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakurta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-04-779447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2017-04-779447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28588019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSku77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=732-741&author=M.+D.+Amatangeloauthor=L.+Quekauthor=A.+Shihauthor=E.+M.+Steinauthor=M.+Roshalauthor=M.+D.+Davidauthor=B.+Marteynauthor=N.+R.+Farnoudauthor=S.+de+Bottonauthor=O.+A.+Bernardauthor=B.+Wuauthor=K.+E.+Yenauthor=M.+S.+Tallmanauthor=E.+Papaemmanuilauthor=V.+Penard-Lacroniqueauthor=A.+Thakurtaauthor=P.+Vyasauthor=R.+L.+Levine&title=Enasidenib+induces+acute+myeloid+leukemia+cell+differentiation+to+promote+clinical+response&doi=10.1182%2Fblood-2017-04-779447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response</span></div><div class="casAuthors">Amatangelo, Michael D.; Quek, Lynn; Shih, Alan; Stein, Eytan M.; Roshal, Mikhail; David, Muriel D.; Marteyn, Benoit; Farnoud, Noushin Rahnamay; de Botton, Stephane; Bernard, Olivier A.; Wu, Bin; Yen, Katharine E.; Tallman, Martin S.; Papaemmanuil, Elli; Penard-Lacronique, Virginie; Thakurta, Anjan; Vyas, Paresh; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">732-741</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML).  In preclin. models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block.  Single-agent enasidenib (AG-221/CC- 90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a phase 1 trial.  However, its mechanism of action and biomarkers assocd. with response remain unclear.  Here, we measured 2-HG, mIDH2 allele burden, and co-occurring somatic mutations in sequential patient samples from the clin. trial and correlated these with clin. response.  Furthermore, we used flow cytometry to assess inhibition of mIDH2 on hematopoietic differentiation.  We obsd. potent 2-HG suppression in both R140 and R172 mIDH2 AML subtypes, with different kinetics, which preceded clin. response.  Suppression of 2-HG alone did not predict response, because most nonresponding patients also exhibited 2-HG suppression.  Complete remission (CR) with persistence of mIDH2 and normalization of hematopoietic stem and progenitor compartments with emergence of functional mIDH2 neutrophils were obsd.  In a subset of CR patients, mIDH2 allele burden was reduced and remained undetectable with response.  Co-occurring mutations in NRAS and other MAPK pathway effectors were enriched in nonresponding patients, consistent with RAS signaling contributing to primary therapeutic resistance.  Together, these data support differentiation as the main mechanism of enasidenib efficacy in relapsed/refractory AML patients and provide insight into resistance mechanisms to inform future mechanism-based combination treatment studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCbUXE9c5Uc7Vg90H21EOLACvtfcHk0lju2CAy3x7d8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSku77F&md5=9ed74a28d17125b405156f8fa1600438</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-04-779447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-04-779447%26sid%3Dliteratum%253Aachs%26aulast%3DAmatangelo%26aufirst%3DM.%2BD.%26aulast%3DQuek%26aufirst%3DL.%26aulast%3DShih%26aufirst%3DA.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DRoshal%26aufirst%3DM.%26aulast%3DDavid%26aufirst%3DM.%2BD.%26aulast%3DMarteyn%26aufirst%3DB.%26aulast%3DFarnoud%26aufirst%3DN.%2BR.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DBernard%26aufirst%3DO.%2BA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DPapaemmanuil%26aufirst%3DE.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DThakurta%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DEnasidenib%2520induces%2520acute%2520myeloid%2520leukemia%2520cell%2520differentiation%2520to%2520promote%2520clinical%2520response%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D732%26epage%3D741%26doi%3D10.1182%2Fblood-2017-04-779447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canaani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissette, J. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastburn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durruthy-Durruthy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asthana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFilippis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peretz, C. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGary, L. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deihimi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span> <span> </span><span class="NLM_article-title">Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-1453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F2159-8290.CD-18-1453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31088841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1050-1063&author=C.+M.+McMahonauthor=T.+Ferngauthor=J.+Canaaniauthor=E.+S.+Wangauthor=J.+J.+D.+Morrissetteauthor=D.+J.+Eastburnauthor=M.+Pellegrinoauthor=R.+Durruthy-Durruthyauthor=C.+D.+Wattauthor=S.+Asthanaauthor=E.+A.+Lasaterauthor=R.+DeFilippisauthor=C.+A.+C.+Peretzauthor=L.+H.+F.+McGaryauthor=S.+Deihimiauthor=A.+C.+Loganauthor=S.+M.+Lugerauthor=N.+P.+Shahauthor=M.+Carrollauthor=C.+C.+Smithauthor=A.+E.+Perl&title=Clonal+selection+with+RAS+pathway+activation+mediates+secondary+clinical+resistance+to+selective+FLT3+inhibition+in+acute+myeloid+leukemia&doi=10.1158%2F2159-8290.CD-18-1453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia</span></div><div class="casAuthors">McMahon, Christine M.; Ferng, Timothy; Canaani, Jonathan; Wang, Eunice S.; Morrissette, Jennifer J. D.; Eastburn, Dennis J.; Pellegrino, Maurizio; Durruthy-Durruthy, Robert; Watt, Christopher D.; Asthana, Saurabh; Lasater, Elisabeth A.; DeFilippis, RosaAnna; Peretz, Cheryl A. C.; McGary, Lisa H. F.; Deihimi, Safoora; Logan, Aaron C.; Luger, Selina M.; Shah, Neil P.; Carroll, Martin; Smith, Catherine C.; Perl, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1050-1063</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clin. efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).  In this context, however, gilteritinib is not curative, and response duration is limited by the development of secondary resistance.  To evaluate resistance mechanisms, we analyzed baseline and progression samples from patients treated on clin. trials of gilteritinib.  Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in NRAS or KRAS.  Less frequently, secondary FLT3-F691L gatekeeper mutations or BCR-ABL1 fusions were identified at progression.  Single-cell targeted DNA sequencing revealed diverse patterns of clonal selection and evolution in response to FLT3 inhibition, including the emergence of RAS mutations in FLT3-mutated subclones, the expansion of alternative wild-type FLT3 subclones, or both patterns simultaneously.  These data illustrate dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5DKxLElhPrVg90H21EOLACvtfcHk0lju2CAy3x7d8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs77F&md5=229d18816b0cc7b69e14f0dc64a43af9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1453%26sid%3Dliteratum%253Aachs%26aulast%3DMcMahon%26aufirst%3DC.%2BM.%26aulast%3DFerng%26aufirst%3DT.%26aulast%3DCanaani%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DMorrissette%26aufirst%3DJ.%2BJ.%2BD.%26aulast%3DEastburn%26aufirst%3DD.%2BJ.%26aulast%3DPellegrino%26aufirst%3DM.%26aulast%3DDurruthy-Durruthy%26aufirst%3DR.%26aulast%3DWatt%26aufirst%3DC.%2BD.%26aulast%3DAsthana%26aufirst%3DS.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DDeFilippis%26aufirst%3DR.%26aulast%3DPeretz%26aufirst%3DC.%2BA.%2BC.%26aulast%3DMcGary%26aufirst%3DL.%2BH.%2BF.%26aulast%3DDeihimi%26aufirst%3DS.%26aulast%3DLogan%26aufirst%3DA.%2BC.%26aulast%3DLuger%26aufirst%3DS.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26atitle%3DClonal%2520selection%2520with%2520RAS%2520pathway%2520activation%2520mediates%2520secondary%2520clinical%2520resistance%2520to%2520selective%2520FLT3%2520inhibition%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D1050%26epage%3D1063%26doi%3D10.1158%2F2159-8290.CD-18-1453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of MEK inhibition in Nras-mutant AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3947</span>– <span class="NLM_lpage">3955</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-574582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2014-05-574582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25361812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFegsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3947-3955&author=M.+R.+Burgessauthor=E.+Hwangauthor=A.+J.+Firestoneauthor=T.+Huangauthor=J.+Xuauthor=J.+Zuberauthor=N.+Bohinauthor=T.+Wenauthor=S.+C.+Koganauthor=K.+M.+Haigisauthor=D.+Sampathauthor=S.+Loweauthor=K.+Shannonauthor=Q.+Li&title=Preclinical+efficacy+of+MEK+inhibition+in+Nras-mutant+AML&doi=10.1182%2Fblood-2014-05-574582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of MEK inhibition in Nras-mutant AML</span></div><div class="casAuthors">Burgess, Michael R.; Hwang, Eugene; Firestone, Ari J.; Huang, Tannie; Xu, Jin; Zuber, Johannes; Bohin, Natacha; Wen, Tiffany; Kogan, Scott C.; Haigis, Kevin M.; Sampath, Deepak; Lowe, Scott; Shannon, Kevin; Li, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3947-3955</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Oncogenic NRAS mutations are highly prevalent in acute myeloid leukemia (AML).  Genetic anal. supports the hypothesis that NRAS mutations cooperate with antecedent mol. lesions in leukemogenesis, but have limited independent prognostic significance.  Using short hairpin RNA-mediated knockdown in human cell lines and primary mouse leukemias, we show that AML cells with NRAS/Nras mutations are dependent on continued oncogene expression in vitro and in vivo.  Using the Mx1-Cre transgene to inactivate a conditional mutant Nras allele, we analyzed hematopoiesis and hematopoietic stem and progenitor cells (HSPCs) under normal and stressed conditions and found that HSPCs lacking Nras expression are functionally equiv. to normal HSPCs in the adult mouse.  Treating recipient mice transplanted with primary NrasG12D AMLs with 2 potent allosteric mitogen-activated protein kinase kinase (MEK) inhibitors (PD0325901 or trametinib/GlaxoSmithKline 1120212) significantly prolonged survival and reduced proliferation but did not induce apoptosis, promote differentiation, or drive clonal evolution.  The phosphatidylinositol 3-kinase inhibitor GDC-0941 was ineffective as a single agent and did not augment the activity of PD0325901.  All mice ultimately succumbed to progressive leukemia.  Together, these data validate oncogenic N-Ras signaling as a therapeutic target in AML and support testing combination regimens that include MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0a5noXfVE7Vg90H21EOLACvtfcHk0ljUm8S6HmFYrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFegsw%253D%253D&md5=cc33710e7207b1f4d934b0588051a70c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-574582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-574582%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DM.%2BR.%26aulast%3DHwang%26aufirst%3DE.%26aulast%3DFirestone%26aufirst%3DA.%2BJ.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DBohin%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DT.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DHaigis%26aufirst%3DK.%2BM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLowe%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DPreclinical%2520efficacy%2520of%2520MEK%2520inhibition%2520in%2520Nras-mutant%2520AML%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3947%26epage%3D3955%26doi%3D10.1182%2Fblood-2014-05-574582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5483</span>– <span class="NLM_lpage">5495</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-14-0902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25186968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5483-5495&author=E.+Weisbergauthor=A.+Nonamiauthor=Z.+Chenauthor=E.+Nelsonauthor=Y.+Chenauthor=F.+Liuauthor=H.+Choauthor=J.+Zhangauthor=M.+Sattlerauthor=C.+Mitsiadesauthor=K.+K.+Wongauthor=Q.+Liuauthor=N.+S.+Grayauthor=J.+D.+Griffin&title=Upregulation+of+IGF1R+by+mutant+RAS+in+leukemia+and+potentiation+of+RAS+signaling+inhibitors+by+small-molecule+inhibition+of+IGF1R&doi=10.1158%2F1078-0432.CCR-14-0902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R</span></div><div class="casAuthors">Weisberg, Ellen; Nonami, Atsushi; Chen, Zhao; Nelson, Erik; Chen, Yongfei; Liu, Feiyang; Cho, HaeYeon; Zhang, Jianming; Sattler, Martin; Mitsiades, Constantine; Wong, Kwok-Kin; Liu, Qingsong; Gray, Nathanael S.; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5483-5495</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activating mutations in the RAS oncogene occur frequently in human leukemias.  Direct targeting of RAS has proven to be challenging, although targeting of downstream RAS mediators, such as MEK, is currently being tested clin.  Given the complexity of RAS signaling, it is likely that combinations of targeted agents will be more effective than single agents.  Exptl. Design: A chem. screen using RAS-dependent leukemia cells was developed to identify compds. with unanticipated activity in the presence of an MEK inhibitor and led to identification of inhibitors of IGF1R.  Results were validated using cell-based proliferation, apoptosis, cell-cycle, and gene knockdown assays; immunopptn. and immunoblotting; and a noninvasive in vivo bioluminescence model of acute myeloid leukemia (AML).  Results: Mechanistically, IGF1R protein expression/activity was substantially increased in mutant RAS-expressing cells, and suppression of RAS led to decreases in IGF1R.  Synergy between MEK and IGF1R inhibitors correlated with induction of apoptosis, inhibition of cell-cycle progression, and decreased phospho-S6 and phospho-4E-BP1.  In vivo, NSG mice tail veins injected with OCI-AML3-luc+ cells showed significantly lower tumor burden following 1 wk of daily oral administration of 50 mg/kg NVP-AEW541 (IGF1R inhibitor) combined with 25 mg/kg AZD6244 (MEK inhibitor), as compared with mice treated with either agent alone.  Drug combination effects obsd. in cell-based assays were generalized to addnl. mutant RAS-pos. neoplasms.  Conclusions: The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clin. investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.  Clin Cancer Res; 20(21); 5483-95. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob8U93Vz-F3rVg90H21EOLACvtfcHk0ljUm8S6HmFYrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7vP&md5=9ce5a77cd145f6b351b1a319b4e88525</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0902%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DUpregulation%2520of%2520IGF1R%2520by%2520mutant%2520RAS%2520in%2520leukemia%2520and%2520potentiation%2520of%2520RAS%2520signaling%2520inhibitors%2520by%2520small-molecule%2520inhibition%2520of%2520IGF1R%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5483%26epage%3D5495%26doi%3D10.1158%2F1078-0432.CCR-14-0902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lien, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dibble, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span> <span> </span><span class="NLM_article-title">PI3K signaling in cancer: beyond AKT</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2017.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ceb.2017.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28343126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVCksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=62-71&author=E.+C.+Lienauthor=C.+C.+Dibbleauthor=A.+Toker&title=PI3K+signaling+in+cancer%3A+beyond+AKT&doi=10.1016%2Fj.ceb.2017.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K signaling in cancer: beyond AKT</span></div><div class="casAuthors">Lien, Evan C.; Dibble, Christian C.; Toker, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently altered pathways in human cancer and has a crit. role in driving tumor initiation and progression.  Although PI3K and its lipid product phosphatidylinositol-3,4,5-trisphosphate (PIP3) have been shown to activate multiple downstream signaling proteins, the vast majority of studies have focused on the protein kinase AKT as the dominant effector of PI3K signaling.  However, recent studies have demonstrated many contexts under which other PIP3-dependent signaling proteins critically contribute to cancer progression, illustrating the importance of understanding AKT-independent signaling downstream of PI3K.  Here, we highlight three PI3K-dependent, but AKT-independent, signaling branches that have recently been shown to have important roles in promoting phenotypes assocd. with malignancy.  First, the PDK1-mTORC2-SGK axis can substitute for AKT in survival, migration, and growth signaling and has emerged as a major mechanism of resistance to PI3K and AKT inhibitors.  Second, Rac signaling mediates the reorganization of the actin cytoskeleton to regulate cancer cell migration, invasion, and metab.  Finally, the TEC family kinase BTK has a crit. role in B cell function and malignancy and represents a recent example of an effective therapeutic target in cancer.  These mechanisms highlight how understanding PI3K-dependent, but AKT-independent, signaling mechanisms that drive cancer progression will be crucial for the development of novel and more effective approaches for targeting the PI3K pathway for therapeutic benefit in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFeOU2VGjLLVg90H21EOLACvtfcHk0ljUm8S6HmFYrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVCksbk%253D&md5=c9d37af3723a15bc37f079fa5a2d7d11</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2017.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2017.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DLien%26aufirst%3DE.%2BC.%26aulast%3DDibble%26aufirst%3DC.%2BC.%26aulast%3DToker%26aufirst%3DA.%26atitle%3DPI3K%2520signaling%2520in%2520cancer%253A%2520beyond%2520AKT%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2017%26volume%3D45%26spage%3D62%26epage%3D71%26doi%3D10.1016%2Fj.ceb.2017.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piddock, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rushworth, S. A.</span></span> <span> </span><span class="NLM_article-title">The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3390/cancers9040029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3390%2Fcancers9040029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=29&author=R.+E.+Piddockauthor=K.+M.+Bowlesauthor=S.+A.+Rushworth&title=The+role+of+PI3K+isoforms+in+regulating+bone+marrow+microenvironment+signaling+focusing+on+acute+myeloid+leukemia+and+multiple+myeloma&doi=10.3390%2Fcancers9040029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma</span></div><div class="casAuthors">Piddock, Rachel E.; Bowles, Kristian M.; Rushworth, Stuart A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">29/1-29/15</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Despite the development of novel treatments in the past 15 years, many blood cancers still remain ultimately fatal and difficult to treat, particularly acute myeloid leukemia (AML) and multiple myeloma (MM).  While significant progress has been made characterizing small-scale genetic mutations and larger-scale chromosomal translocations that contribute to the development of various blood cancers, less is understood about the complex microenvironment of the bone marrow (BM), which is known to be a key player in the pathogenesis of chronic lymphocytic leukemia (CLL), AML and MM.  This niche acts as a sanctuary for the cancerous cells, protecting them from chemotherapeutics and encouraging clonal cell survival.  It does this by upregulating a plethora of signalling cascades within the malignant cell, with the phosphatidylinositol-3-kinase (PI3K) pathway taking a crit. role.  This review will focus on how the PI3K pathway influences disease progression and the individualised role of the PI3K subunits.  We will also summarise the current clin. trials for PI3K inhibitors and how these trials impact the treatment of blood cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDmyAJz9HSLVg90H21EOLACvtfcHk0lgL7NzCnsqiFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKiurrJ&md5=d89e1ba98d8d00c26eca00e4fd55da1c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Fcancers9040029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers9040029%26sid%3Dliteratum%253Aachs%26aulast%3DPiddock%26aufirst%3DR.%2BE.%26aulast%3DBowles%26aufirst%3DK.%2BM.%26aulast%3DRushworth%26aufirst%3DS.%2BA.%26atitle%3DThe%2520role%2520of%2520PI3K%2520isoforms%2520in%2520regulating%2520bone%2520marrow%2520microenvironment%2520signaling%2520focusing%2520on%2520acute%2520myeloid%2520leukemia%2520and%2520multiple%2520myeloma%26jtitle%3DCancers%26date%3D2017%26volume%3D9%26spage%3D29%26doi%3D10.3390%2Fcancers9040029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillet-Lefebvre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span> <span> </span><span class="NLM_article-title">Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia</span>. <i>Haematologica.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.3324/haematol.2009.013797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3324%2Fhaematol.2009.013797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=19951971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yrsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=819-828&author=S.+Parkauthor=N.+Chapuisauthor=J.+Tamburiniauthor=V.+Bardetauthor=P.+Cornillet-Lefebvreauthor=L.+Willemsauthor=A.+Greenauthor=P.+Mayeuxauthor=C.+Lacombeauthor=D.+Bouscary&title=Role+of+the+PI3K%2FAKT+and+mTOR+signaling+pathways+in+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2009.013797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia</span></div><div class="casAuthors">Park, Sophie; Chapuis, Nicolas; Tamburini, Jerome; Bardet, Valerie; Cornillet-Lefebvre, Pascale; Willems, Lise; Green, Alexa; Mayeux, Patrick; Lacombe, Catherine; Bouscary, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">819-828</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">A review.  The PI3K/AKT and mTOR signaling pathways are activated in acute myeloid leukemia, including in the more immature leukemic populations.  Constitutive PI3K activation is detectable in 50% of acute myeloid leukemia samples whereas mTORC1 is activated in all cases of this disease.  In leukemic cells, the PI3K activity relates to the expression of the p110δ isoform of class IA PI3K.  Constitutive PI3K activation is the result of autocrine IGF-1/IGF-1R signaling in 70% of acute myeloid leukemia samples but specific inhibition of this pathway does not induce apoptosis.  Specific inhibition of PI3K/AKT or mTORC1 alone in vitro has antileukemic effects which are essentially exerted via the suppression of proliferation.  However, as mTORC1 activation is independent of PI3K/AKT in acute myeloid leukemia, dual PI3K and mTOR inhibitors may induce apoptosis in blast cells.  Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.  Recent data also indicate that mTORC1 does not control protein translation in acute myeloid leukemia.  These results open the way for the design of direct inhibitors of protein synthesis as novel acute myeloid leukemia therapies and also for the development of second generation mTOR inhibitors (the TORKinhibs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK4wSopw8w1LVg90H21EOLACvtfcHk0lgL7NzCnsqiFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yrsbzI&md5=51c773df2df0849e64c92e1c62187cb1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2009.013797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2009.013797%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DChapuis%26aufirst%3DN.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DBardet%26aufirst%3DV.%26aulast%3DCornillet-Lefebvre%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DL.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DBouscary%26aufirst%3DD.%26atitle%3DRole%2520of%2520the%2520PI3K%252FAKT%2520and%2520mTOR%2520signaling%2520pathways%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica.%26date%3D2010%26volume%3D95%26spage%3D819%26epage%3D828%26doi%3D10.3324%2Fhaematol.2009.013797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puliafito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primo, L.</span></span> <span> </span><span class="NLM_article-title">PDK1: at the crossroad of cancer signaling pathways</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2017.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.semcancer.2017.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28473254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlWkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=27-35&author=P.+A.+Gagliardiauthor=A.+Puliafitoauthor=L.+Primo&title=PDK1%3A+at+the+crossroad+of+cancer+signaling+pathways&doi=10.1016%2Fj.semcancer.2017.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">PDK1: At the crossroad of cancer signaling pathways</span></div><div class="casAuthors">Gagliardi, Paolo Armando; Puliafito, Alberto; Primo, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rational target therapy of cancer would benefit from the identification of new targets that can be easily inhibited by small mols.  An increasing amt. of evidence hints at 3-phosphoinositide dependent protein kinase-1 (PDK1 or PDPK1) as an intriguing and underexplored target for cancer therapy.  Several reports show that PDK1 expression is dysregulated in multiple cancer types.  Furthermore PDK1 is implicated in signaling pathways frequently altered in cancer, such as PI3K/Akt, Ras/MAPK and Myc.  PDK1 targeting has been proven to be effective in exptl. models harboring alterations of these pathways.  In this paper we review PDK1 main biochem. mechanisms, its alterations in cancer and interactions with relevant cancer pathways.  A potential role of PDK1 in tumor microenvironment is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSy7NtdFtBrVg90H21EOLACvtfcHk0lgL7NzCnsqiFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlWkur8%253D&md5=4d84028328442049486f410708038eb4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2017.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2017.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DGagliardi%26aufirst%3DP.%2BA.%26aulast%3DPuliafito%26aufirst%3DA.%26aulast%3DPrimo%26aufirst%3DL.%26atitle%3DPDK1%253A%2520at%2520the%2520crossroad%2520of%2520cancer%2520signaling%2520pathways%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2018%26volume%3D48%26spage%3D27%26epage%3D35%26doi%3D10.1016%2Fj.semcancer.2017.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, M. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmawardhane, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Rac and Cdc42 GTPases in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3101</span>– <span class="NLM_lpage">3111</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F0008-5472.CAN-18-0619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29858187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFeqs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3101-3111&author=M.+D.+M.+Maldonadoauthor=S.+Dharmawardhane&title=Targeting+Rac+and+Cdc42+GTPases+in+cancer&doi=10.1158%2F0008-5472.CAN-18-0619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Rac and Cdc42 GTPases in Cancer</span></div><div class="casAuthors">Maldonado, Maria del Mar; Dharmawardhane, Suranganie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3101-3111</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rac and Cdc42 are small GTPases that have been linked to multiple human cancers and are implicated in epithelial to mesenchymal transition, cell-cycle progression, migration/invasion, tumor growth, angiogenesis, and oncogenic transformation.  With the exception of the P29S driver mutation in melanoma, Rac and Cdc42 are not generally mutated in cancer, but are overexpressed (gene amplification and mRNA upregulation) or hyperactivated.  Rac and Cdc42 are hyperactivated via signaling through oncogenic cell surface receptors, such as growth factor receptors, which converge on the guanine nucleotide exchange factors that regulate their GDP/GTP exchange.  Hence, targeting Rac and Cdc42 represents a promising strategy for precise cancer therapy, as well as for inhibition of bypass signaling that promotes resistance to cell surface receptor-targeted therapies.  Therefore, an understanding of the regulatory mechanisms of these pivotal signaling intermediates is key for the development of effective inhibitors.  In this review, we focus on the role of Rac and Cdc42 in cancer and summarize the regulatory mechanisms, inhibitory efficacy, and the anticancer potential of Rac- and Cdc42-targeting agents.  Cancer Res; 78(12); 3101-11. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSDjwGurIUPrVg90H21EOLACvtfcHk0liV-lyPbSMMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFeqs7bN&md5=d4fbd989476469bed0a8e9a1960a9d15</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0619%26sid%3Dliteratum%253Aachs%26aulast%3DMaldonado%26aufirst%3DM.%2BD.%2BM.%26aulast%3DDharmawardhane%26aufirst%3DS.%26atitle%3DTargeting%2520Rac%2520and%2520Cdc42%2520GTPases%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3101%26epage%3D3111%26doi%3D10.1158%2F0008-5472.CAN-18-0619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujobert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylbersztejn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palama, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnais, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevier-Gobeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraisse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeissat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Récher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, N.</span></span> <span> </span><span class="NLM_article-title">High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2326</span>– <span class="NLM_lpage">2335</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2017.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28280275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=2326-2335&author=L.+Poulainauthor=P.+Sujobertauthor=F.+Zylbersztejnauthor=S.+Barreauauthor=L.+Stuaniauthor=M.+Lambertauthor=T.+L.+Palamaauthor=V.+Chesnaisauthor=R.+Birsenauthor=F.+Vergezauthor=T.+Fargeauthor=C.+Chenevier-Gobeauxauthor=M.+Fraisseauthor=F.+Bouillaudauthor=C.+Debeissatauthor=O.+Heraultauthor=C.+R%C3%A9cherauthor=C.+Lacombeauthor=M.+Fontenayauthor=P.+Mayeuxauthor=T.+T.+Macielauthor=J.+C.+Portaisauthor=J.+E.+Sarryauthor=J.+Tamburiniauthor=D.+Bouscaryauthor=N.+Chapuis&title=High+mTORC1+activity+drives+glycolysis+addiction+and+sensitivity+to+G6PD+inhibition+in+acute+myeloid+leukemia+cells&doi=10.1038%2Fleu.2017.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells</span></div><div class="casAuthors">Poulain, L.; Sujobert, P.; Zylbersztejn, F.; Barreau, S.; Stuani, L.; Lambert, M.; Palama, T. L.; Chesnais, V.; Birsen, R.; Vergez, F.; Farge, T.; Chenevier-Gobeaux, C.; Fraisse, M.; Bouillaud, F.; Debeissat, C.; Herault, O.; Recher, C.; Lacombe, C.; Fontenay, M.; Mayeux, P.; Maciel, T. T.; Portais, J.-C.; Sarry, J.-E.; Tamburini, J.; Bouscary, D.; Chapuis, N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2326-2335</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities.  Here we decipher the interplay between mTORC1 activity and glucose metab. in acute myeloid leukemia (AML).  We show that mTORC1 signaling that is constantly overactivated in AML cells promotes glycolysis and leads to glucose addiction.  The level of mTORC1 activity dets. the sensitivity of AML cells to glycolysis inhibition as switch-off mTORC1 activity leads to glucose-independent cell survival that is sustained by an increase in mitochondrial oxidative phosphorylation.  Metabolic anal. identified the pentose phosphate pathway (PPP) as an important pro-survival pathway for glucose metab. in AML cells with high mTORC1 activity and provided a clear rational for targeting glucose-6-phosphate dehydrogenase (G6PD) in AML.  Indeed, our anal. of the cancer genome atlas AML database pinpointed G6PD as a new biomarker in AML, as its overexpression correlated with an adverse prognosis in this cohort.  Targeting the PPP using the G6PD inhibitor 6-aminonicotinamide induces in vitro and in vivo cytotoxicity against AML cells and synergistically sensitizes leukemic cells to chemotherapy.  Our results demonstrate that high mTORC1 activity creates a specific vulnerability to G6PD inhibition that may work as a new AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAc8A3CaBnhrVg90H21EOLACvtfcHk0liV-lyPbSMMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWlu7c%253D&md5=53fb2baa221e40b32b1170c59ebc6354</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.81%26sid%3Dliteratum%253Aachs%26aulast%3DPoulain%26aufirst%3DL.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DZylbersztejn%26aufirst%3DF.%26aulast%3DBarreau%26aufirst%3DS.%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DLambert%26aufirst%3DM.%26aulast%3DPalama%26aufirst%3DT.%2BL.%26aulast%3DChesnais%26aufirst%3DV.%26aulast%3DBirsen%26aufirst%3DR.%26aulast%3DVergez%26aufirst%3DF.%26aulast%3DFarge%26aufirst%3DT.%26aulast%3DChenevier-Gobeaux%26aufirst%3DC.%26aulast%3DFraisse%26aufirst%3DM.%26aulast%3DBouillaud%26aufirst%3DF.%26aulast%3DDebeissat%26aufirst%3DC.%26aulast%3DHerault%26aufirst%3DO.%26aulast%3DR%25C3%25A9cher%26aufirst%3DC.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DFontenay%26aufirst%3DM.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DMaciel%26aufirst%3DT.%2BT.%26aulast%3DPortais%26aufirst%3DJ.%2BC.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DBouscary%26aufirst%3DD.%26aulast%3DChapuis%26aufirst%3DN.%26atitle%3DHigh%2520mTORC1%2520activity%2520drives%2520glycolysis%2520addiction%2520and%2520sensitivity%2520to%2520G6PD%2520inhibition%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D2326%26epage%3D2335%26doi%3D10.1038%2Fleu.2017.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyåkern, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tazzari, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, L.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fsj.leu.2404245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16642045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVylsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=911-928&author=A.+M.+Martelliauthor=M.+Ny%C3%A5kernauthor=G.+Tabelliniauthor=R.+Bortulauthor=P.+L.+Tazzariauthor=C.+Evangelistiauthor=L.+Cocco&title=Phosphoinositide+3-kinase%2FAkt+signaling+pathway+and+its+therapeutical+implications+for+human+acute+myeloid+leukemia&doi=10.1038%2Fsj.leu.2404245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia</span></div><div class="casAuthors">Martelli, A. M.; Nyakern, M.; Tabellini, G.; Bortul, R.; Tazzari, P. L.; Evangelisti, C.; Cocco, L.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">911-928</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is crucial to many aspects of cell growth, survival and apoptosis, and its constitutive activation has been implicated in the both the pathogenesis and the progression of a wide variety of neoplasias.  Hence, this pathway is an attractive target for the development of novel anticancer strategies.  Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells.  Upregulation of the PI3K/Akt network in AML may be due to several reasons, including FLT3, Ras or c-Kit mutations.  Small mols. designed to selectively target key components of this signal transduction cascade induce apoptosis and/or markedly increase conventional drug sensitivity of AML blasts in vitro.  Thus, inhibitory mols. are currently being developed for clin. use either as single agents or in combination with conventional therapies.  However, the PI3K/Akt pathway is important for many physiol. cellular functions and, in particular, for insulin signaling, so that its blockade in vivo might cause severe systemic side effects.  In this review, we summarize the existing knowledge about PI3K/Akt signaling in AML cells and we examine the rationale for targeting this fundamental signal transduction network by means of selective pharmacol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQE0BlR7fW2LVg90H21EOLACvtfcHk0liV-lyPbSMMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVylsr4%253D&md5=6a52e13e1818e1f81b43c8444fdfb877</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404245%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DNy%25C3%25A5kern%26aufirst%3DM.%26aulast%3DTabellini%26aufirst%3DG.%26aulast%3DBortul%26aufirst%3DR.%26aulast%3DTazzari%26aufirst%3DP.%2BL.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DCocco%26aufirst%3DL.%26atitle%3DPhosphoinositide%25203-kinase%252FAkt%2520signaling%2520pathway%2520and%2520its%2520therapeutical%2520implications%2520for%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D911%26epage%3D928%26doi%3D10.1038%2Fsj.leu.2404245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertacchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mediani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capitani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahjahani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saki, N.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K/AKT/mTOR network for treatment of leukemia</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2337</span>– <span class="NLM_lpage">2347</span>, <span class="refDoi"> DOI: 10.1007/s00018-015-1867-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1007%2Fs00018-015-1867-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25712020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlGjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=2337-2347&author=J.+Bertacchiniauthor=N.+Heidariauthor=L.+Medianiauthor=S.+Capitaniauthor=M.+Shahjahaniauthor=A.+Ahmadzadehauthor=N.+Saki&title=Targeting+PI3K%2FAKT%2FmTOR+network+for+treatment+of+leukemia&doi=10.1007%2Fs00018-015-1867-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K/AKT/mTOR network for treatment of leukemia</span></div><div class="casAuthors">Bertacchini, Jessika; Heidari, Nazanin; Mediani, Laura; Capitani, Silvano; Shahjahani, Mohammad; Ahmadzadeh, Ahmad; Saki, Najmaldin</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2337-2347</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Objective: Increased activity of PI3K/AKT/mTOR pathway has been obsd. in a huge no. of malignancies.  This pathway can function as a prosurvival factor in leukemia stem cells and early committed leukemic precursors and its inhibition is regarded as a therapeutic approach.  Accordingly, the aim of this review is to evaluate the PI3K/Akt/mTOR inhibitors used in leukemia models.  Discussion: Inhibition of the PI3K/AKT/mTOR pathway has been reported to have beneficial therapeutic effects in leukemias, both in vitro in leukemia cell lines and in vivo in animal models.  Overall, the use of dual PI3K/mTOR inhibitor, dual Akt/RTK inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor and dual PI3K/PDK1 inhibitor in CML, AML, APL, CLL, B-ALL and T-ALL has a better therapeutic effect than conventional treatments.  Conclusions: Targeting the PI3K/Akt/mTOR pathway may have pro-apoptotic and antiproliferative effects on hematol. malignancies.  Furthermore, modulation of miRNA can be used as a novel therapeutic approach to regulate the PI3K/Akt/mTOR pathway.  However, both aspects require further clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1oIfnyXtpfLVg90H21EOLACvtfcHk0lhsSyIAofF29A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlGjtr4%253D&md5=a0fa035a0fd7a43eed71861f10f19cb5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-1867-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-1867-5%26sid%3Dliteratum%253Aachs%26aulast%3DBertacchini%26aufirst%3DJ.%26aulast%3DHeidari%26aufirst%3DN.%26aulast%3DMediani%26aufirst%3DL.%26aulast%3DCapitani%26aufirst%3DS.%26aulast%3DShahjahani%26aufirst%3DM.%26aulast%3DAhmadzadeh%26aufirst%3DA.%26aulast%3DSaki%26aufirst%3DN.%26atitle%3DTargeting%2520PI3K%252FAKT%252FmTOR%2520network%2520for%2520treatment%2520of%2520leukemia%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26spage%3D2337%26epage%3D2347%26doi%3D10.1007%2Fs00018-015-1867-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herschbein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liesveld, J. L.</span></span> <span> </span><span class="NLM_article-title">Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2017.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.blre.2017.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29276026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVaktL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=235-248&author=L.+Herschbeinauthor=J.+L.+Liesveld&title=Dueling+for+dual+inhibition%3A+Means+to+enhance+effectiveness+of+PI3K%2FAkt%2FmTOR+inhibitors+in+AML&doi=10.1016%2Fj.blre.2017.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML</span></div><div class="casAuthors">Herschbein, Lauren; Liesveld, Jane L.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-248</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway is amplified in 60-80% of patients with acute myelogenous leukemia (AML).  Since this complex pathway is crucial to cell functions such as growth, proliferation, and survival, inhibition of this pathway would be postulated to inhibit leukemia initiation and propagation.  Inhibition of the mTORC1 pathway has met with limited success in AML due to multiple resistance mechanisms including direct insensitivity of the mTORC1 complex, feedback activation of the PI3k/Akt signaling network, insulin growth factor-1 (IGF-1) activation of PI3K, and others.  This review explores the role of mTOR inhibition in AML, mechanisms of resistance, and means to improve outcomes through use of dual mTORC1/2 inhibitors or dual TORC/PI3K inhibitors.  How these inhibitors interface with currently available therapies in AML will require addnl. preclin. expts. and conduct of well-designed clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQWul_8qSZULVg90H21EOLACvtfcHk0lhsSyIAofF29A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVaktL%252FK&md5=8a078e7eac1f44d0751edc4b496c095b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2017.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2017.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DHerschbein%26aufirst%3DL.%26aulast%3DLiesveld%26aufirst%3DJ.%2BL.%26atitle%3DDueling%2520for%2520dual%2520inhibition%253A%2520Means%2520to%2520enhance%2520effectiveness%2520of%2520PI3K%252FAkt%252FmTOR%2520inhibitors%2520in%2520AML%26jtitle%3DBlood%2520Rev.%26date%3D2018%26volume%3D32%26spage%3D235%26epage%3D248%26doi%3D10.1016%2Fj.blre.2017.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umezawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the STAT5/Pim kinase axis enhances cytotoxic effects of proteasome inhibitors on FLT3-ITD-positive AML cells by cooperatively inhibiting the mTORC1/4EBP1/S6K/Mcl-1 pathway</span>. <i>Transl Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.tranon.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30472492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3crksVSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=336-349&author=A.+Nogamiauthor=K.+Okadaauthor=S.+Ishidaauthor=H.+Akiyamaauthor=Y.+Umezawaauthor=O.+Miura&title=Inhibition+of+the+STAT5%2FPim+kinase+axis+enhances+cytotoxic+effects+of+proteasome+inhibitors+on+FLT3-ITD-positive+AML+cells+by+cooperatively+inhibiting+the+mTORC1%2F4EBP1%2FS6K%2FMcl-1+pathway&doi=10.1016%2Fj.tranon.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway</span></div><div class="casAuthors">Nogami Ayako; Okada Keigo; Ishida Shinya; Akiyama Hiroki; Umezawa Yoshihiro; Miura Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">336-349</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">FLT3-ITD and FLT3-TKD are the most frequent tyrosine kinase mutations in acute myeloid leukemia (AML), with the former conferring a poor prognosis.  We have recently revealed that FLT3-ITD confers resistance to the PI3K/AKT pathway inhibitors by protecting the mTORC1/4EBP1/Mcl-1 pathway through Pim kinases induced by STAT5 activation in AML.  The proteasome inhibitor bortezomib has recently been reported as a promising agent for treatment of AML.  Here, we show that the proteasome inhibitor bortezomib as well as carfilzomib induces apoptosis through the intrinsic pathway more conspicuously in cells transformed by FLT3-TKD than FLT3-ITD.  Mechanistically, bortezomib upregulated the stress-regulated protein REDD1 and induced downregulation of the mTORC1 pathway more distinctively in cells transformed by FLT3-TKD than FLT-ITD, while overexpression of Pim-1 partly prevented this downregulation and apoptosis in FLT3-TKD-transformed cells.  Genetic enhancement of the REDD1 induction or pharmacological inhibition of STAT5, Pim kinases, mTORC1, or S6K by specific inhibitors, such as pimozide, AZD1208, PIM447, rapamycin, and PF-4708671, accelerated the downregulation of mTORC1/Mcl-1 pathway to enhance bortezomib-induced apoptosis in FLT3-ITD-expressing cells, including primary AML cells, while overexpression of Mcl-1 prevented induction of apoptosis.  Thus, FLT3-ITD confers a resistance to the proteasome inhibitors on AML cells by protecting the mTORC1/Mcl-1 pathway through the STAT5/Pim axis, and inhibition of these signaling events remarkably enhances the therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCptdMoKFKJ1WTCLT8lX9SfW6udTcc2eZrYPDI0SMnWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crksVSluw%253D%253D&md5=131a28b46d5e8c27672fb534524d831a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DNogami%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DIshida%26aufirst%3DS.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DUmezawa%26aufirst%3DY.%26aulast%3DMiura%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520the%2520STAT5%252FPim%2520kinase%2520axis%2520enhances%2520cytotoxic%2520effects%2520of%2520proteasome%2520inhibitors%2520on%2520FLT3-ITD-positive%2520AML%2520cells%2520by%2520cooperatively%2520inhibiting%2520the%2520mTORC1%252F4EBP1%252FS6K%252FMcl-1%2520pathway%26jtitle%3DTransl%2520Oncol.%26date%3D2019%26volume%3D12%26spage%3D336%26epage%3D349%26doi%3D10.1016%2Fj.tranon.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindblad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallon-Christersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levander, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietras, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span> <span> </span><span class="NLM_article-title">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">5119</span>– <span class="NLM_lpage">5131</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fonc.2016.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26999641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=5119-5131&author=O.+Lindbladauthor=E.+Corderoauthor=A.+Puissantauthor=L.+Macaulayauthor=A.+Ramosauthor=N.+N.+Kabirauthor=J.+Sunauthor=J.+Vallon-Christerssonauthor=K.+Haraldssonauthor=M.+T.+Hemannauthor=%C3%85.+Borgauthor=F.+Levanderauthor=K.+Stegmaierauthor=K.+Pietrasauthor=L.+R%C3%B6nnstrandauthor=J.+U.+Kazi&title=Aberrant+activation+of+the+PI3K%2FmTOR+pathway+promotes+resistance+to+sorafenib+in+AML&doi=10.1038%2Fonc.2016.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span></div><div class="casAuthors">Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N. N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M. T.; Borg, Aa; Levander, F.; Stegmaier, K.; Pietras, K.; Roennstrand, L.; Kazi, J. U.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5119-5131</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient.  To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib.  Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors.  Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells.  Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent.  Gene expression anal. of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array anal.  Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines.  Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model.  Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfp1049FgsbVg90H21EOLACvtfcHk0lhNr3kmRsWCYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D&md5=94a7570e240d12c506af0850819c77d9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.41%26sid%3Dliteratum%253Aachs%26aulast%3DLindblad%26aufirst%3DO.%26aulast%3DCordero%26aufirst%3DE.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DMacaulay%26aufirst%3DL.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3DKabir%26aufirst%3DN.%2BN.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DVallon-Christersson%26aufirst%3DJ.%26aulast%3DHaraldsson%26aufirst%3DK.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DBorg%26aufirst%3D%25C3%2585.%26aulast%3DLevander%26aufirst%3DF.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26atitle%3DAberrant%2520activation%2520of%2520the%2520PI3K%252FmTOR%2520pathway%2520promotes%2520resistance%2520to%2520sorafenib%2520in%2520AML%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D5119%26epage%3D5131%26doi%3D10.1038%2Fonc.2016.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertacchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Avella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Accordi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barozzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forghieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luppi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najmaldin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosravi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmiroli, S.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.jbior.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29576448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslKls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=2-9&author=J.+Bertacchiniauthor=C.+Frassonauthor=F.+Chiariniauthor=D.+D%E2%80%99Avellaauthor=B.+Accordiauthor=L.+Anselmiauthor=P.+Barozziauthor=F.+Forghieriauthor=M.+Luppiauthor=A.+M.+Martelliauthor=G.+Bassoauthor=S.+Najmaldinauthor=A.+Khosraviauthor=F.+Rahimauthor=S.+Marmiroli&title=Dual+inhibition+of+PI3K%2FmTOR+signaling+in+chemoresistant+AML+primary+cells&doi=10.1016%2Fj.jbior.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells</span></div><div class="casAuthors">Bertacchini, Jessika; Frasson, Chiara; Chiarini, Francesca; D'Avella, Daniele; Accordi, Benedetta; Anselmi, Laura; Barozzi, Patrizia; Foghieri, Fabio; Luppi, Mario; Martelli, Alberto M.; Basso, Giuseppe; Najmaldin, Saki; Khosravi, Abbas; Rahim, Fakher; Marmiroli, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-9</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A main cause of treatment failure for AML patients is resistance to chemotherapy.  Survival of AML cells may depend on mechanisms that elude conventional drugs action and/or on the presence of leukemia initiating cells at diagnosis, and their persistence after therapy.  MDR1 gene is an ATP-dependent drug efflux pump known to be a risk factor for the emergence of resistance, when combined to unstable cytogenetic profile of AML patients.  In the present study, we analyzed the sensitivity to conventional chemotherapeutic drugs of 26 samples of primary blasts collected from AML patients at diagnosis.  Detection of cell viability and apoptosis allowed to identify two group of samples, one resistant and one sensitive to in vitro treatment.  The cells were then analyzed for the presence and the activity of P-glycoprotein.  A comparative anal. showed that resistant samples exhibited a high level of MDR1 mRNA as well as of P-glycoprotein content and activity.  Moreover, they also displayed high PI3K signaling.  Therefore, we checked whether the assocn. with signaling inhibitors might resensitize resistant samples to chemo-drugs.  The combination showed a very potent cytotoxic effect, possibly through down modulation of MDR1, which was maintained also when primary blasts were co-cultured with human stromal cells.  Remarkably, dual PI3K/mTOR inactivation was cytotoxic also to leukemia initiating cells.  All together, our findings indicate that signaling activation profiling assocd. to gene expression can be very useful to stratify patients and improve therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm8xJ3s8ZZU7Vg90H21EOLACvtfcHk0lhNr3kmRsWCYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslKls7k%253D&md5=359542f2e020963c9b1cd3126ea6340d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBertacchini%26aufirst%3DJ.%26aulast%3DFrasson%26aufirst%3DC.%26aulast%3DChiarini%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Avella%26aufirst%3DD.%26aulast%3DAccordi%26aufirst%3DB.%26aulast%3DAnselmi%26aufirst%3DL.%26aulast%3DBarozzi%26aufirst%3DP.%26aulast%3DForghieri%26aufirst%3DF.%26aulast%3DLuppi%26aufirst%3DM.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DNajmaldin%26aufirst%3DS.%26aulast%3DKhosravi%26aufirst%3DA.%26aulast%3DRahim%26aufirst%3DF.%26aulast%3DMarmiroli%26aufirst%3DS.%26atitle%3DDual%2520inhibition%2520of%2520PI3K%252FmTOR%2520signaling%2520in%2520chemoresistant%2520AML%2520primary%2520cells%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2018%26volume%3D68%26spage%3D2%26epage%3D9%26doi%3D10.1016%2Fj.jbior.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6815</span>– <span class="NLM_lpage">6826</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-0832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-19-0832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31320594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslWitL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6815-6826&author=J.+Maauthor=S.+Zhaoauthor=X.+Qiaoauthor=T.+Knightauthor=H.+Edwardsauthor=L.+Polinauthor=J.+Kushnerauthor=S.+H.+Dzinicauthor=K.+Whiteauthor=G.+Wangauthor=L.+Zhaoauthor=H.+Linauthor=Y.+Wangauthor=J.+W.+Taubauthor=Y.+Ge&title=Inhibition+of+Bcl-2+synergistically+enhances+the+antileukemic+activity+of+midostaurin+and+gilteritinib+in+preclinical+models+of+FLT3-mutated+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-19-0832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia</span></div><div class="casAuthors">Ma, Jun; Zhao, Shoujing; Qiao, Xinan; Knight, Tristan; Edwards, Holly; Polin, Lisa; Kushner, Juiwanna; Dzinic, Sijana H.; White, Kathryn; Wang, Guan; Zhao, Lijing; Lin, Hai; Wang, Yue; Taub, Jeffrey W.; Ge, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6815-6826</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute myeloid leukemia (AML) and the underlying mol. mechanism.  Using both FLT3-ITD cell lines and primary patient samples, Annexin V-FITC/propidium iodide staining and flow cytometry anal. were used to quantify cell death induced by midostaurin or gilteritinib, alone or in combination with venetoclax.  The MV4-11-derived xenograft mouse model was used to assess in vivo efficacy of the combination of gilteritinib and venetoclax.  Lentiviral overexpression of Mcl-1 was used to confirm its role in cell death induced by midostaurin or gilteritinib with venetoclax.  Changes of Mcl-1 transcript levels were assessed by RT-PCR.  The combination of midostaurin or gilteritinib with venetoclax potently and synergistically induces apoptosis in FLT3-ITD AML cell lines and primary patient samples.  The FLT3 inhibitors induced downregulation of Mcl-1, enhancing venetoclax activity.  Phosphorylated-ERK expression is induced by venetoclax but abolished by the combination of venetoclax with midostaurin or gilteritinib.  Simultaneous downregulation of Mcl-1 by midostaurin or gilteritinib and inhibition of Bcl-2 by venetoclax results in "free" Bim, leading to synergistic induction of apoptosis.  Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3697_YrfXOLVg90H21EOLACvtfcHk0lhlBL3NFBrlIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslWitL7K&md5=42c28d0013e3db22a2736939b1a75a5f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0832%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DQiao%26aufirst%3DX.%26aulast%3DKnight%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTaub%26aufirst%3DJ.%2BW.%26aulast%3DGe%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520Bcl-2%2520synergistically%2520enhances%2520the%2520antileukemic%2520activity%2520of%2520midostaurin%2520and%2520gilteritinib%2520in%2520preclinical%2520models%2520of%2520FLT3-mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D6815%26epage%3D6826%26doi%3D10.1158%2F1078-0432.CCR-19-0832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Quizartinib (AC220): a promising option for acute myeloid leukemia</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S198950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2147%2FDDDT.S198950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31114157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1117-1125&author=F.+Zhouauthor=Z.+Geauthor=B.+Chen&title=Quizartinib+%28AC220%29%3A+a+promising+option+for+acute+myeloid+leukemia&doi=10.2147%2FDDDT.S198950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib (AC220): a promising option for acute myeloid leukemia</span></div><div class="casAuthors">Zhou, Fang; Ge, Zheng; Chen, Baoan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1117-1125</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells.  Multiple clin. trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation.  In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib.  We also summarize clin. experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation.  Quizartinib presents its advantages as a very promising agent in the treatment of AML, esp. in patients with FLT3-ITD mutations.  FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition.  Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clin. trials.  A larger sample of clin. trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estd. in clin. trials.  Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdQbluP81wNLVg90H21EOLACvtfcHk0lhlBL3NFBrlIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K&md5=c172240b673571ce14933fa6de086b10</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S198950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S198950%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DQuizartinib%2520%2528AC220%2529%253A%2520a%2520promising%2520option%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1117%26epage%3D1125%26doi%3D10.2147%2FDDDT.S198950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1111/cas.14274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fcas.14274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31821677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2020&pages=312-322&author=H.+Kiyoiauthor=N.+Kawashimaauthor=Y.+Ishikawa&title=FLT3+mutations+in+acute+myeloid+leukemia%3A+Therapeutic+paradigm+beyond+inhibitor+development&doi=10.1111%2Fcas.14274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span></div><div class="casAuthors">Kiyoi, Hitoshi; Kawashima, Naomi; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-322</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation.  The most clin. important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic factor in acute myeloid leukemia (AML) patients.  There are two major types of FLT3 mutations: internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) and point mutations or deletion in the tyrosine kinase domain (FLT3-TKD).  Both mutant FLT3 mols. are activated through ligand-independent dimerization and trans-phosphorylation.  Mutant FLT3 induces the activation of multiple intracellular signaling pathways, mainly STAT5, MAPK and AKT signals, leading to cell proliferation and anti-apoptosis.  Because high-dose chemotherapy and allogeneic hematopoietic stem cell transplantation cannot sufficiently improve the prognosis, clin. development of FLT3 kinase inhibitors expected.  Although several FLT3 inhibitors have been developed, it takes more than 20 years from the first identification of FLT3 mutations until FLT3 inhibitors become clin. available for AML patients with FLT3 mutations.  To date, three FLT3 inhibitors have been clin. approved as monotherapy or combination therapy with conventional chemotherapeutic agents in Japan and/or Europe and United states.  However, several mechanisms of resistance to FLT3 inhibitors have already become apparent during their clin. trials.  The resistance mechanisms are complex and emerging resistant clones are heterogenous.  Further basic and clin. studies are required to establish the best therapeutic strategy for AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_Q3ByI5dqLVg90H21EOLACvtfcHk0lhlBL3NFBrlIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP&md5=79c7656f1836b2deda2b8c1203ad9719</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fcas.14274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.14274%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DKawashima%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%253A%2520Therapeutic%2520paradigm%2520beyond%2520inhibitor%2520development%26jtitle%3DCancer%2520Sci.%26date%3D2020%26volume%3D111%26spage%3D312%26epage%3D322%26doi%3D10.1111%2Fcas.14274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larrosa-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in acute myeloid leukemia: current status and future directions</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-16-0876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28576946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=991-1001&author=M.+Larrosa-Garciaauthor=M.+R.+Baer&title=FLT3+inhibitors+in+acute+myeloid+leukemia%3A+current+status+and+future+directions&doi=10.1158%2F1535-7163.MCT-16-0876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions</span></div><div class="casAuthors">Larrosa-Garcia, Maria; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">991-1001</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is expressed on acute myeloid leukemia (AML) cells in most patients.  Mutations of FLT3 resulting in constitutive signaling are common in AML, including internal tandem duplication (ITD) in the juxtamembrane domain in 25% of patients and point mutations in the tyrosine kinase domain in 5%.  Patients with AML with FLT3-ITD have a high relapse rate and short relapse-free and overall survival after chemotherapy and after transplant.  A no. of inhibitors of FLT3 signaling have been identified and are in clin. trials, both alone and with chemotherapy, with the goal of improving clin. outcomes in patients with AML with FLT3 mutations.  While inhibitor monotherapy produces clin. responses, they are usually incomplete and transient, and resistance develops rapidly.  Diverse combination therapies have been suggested to potentiate the efficacy of FLT3 inhibitors and to prevent development of resistance or overcome resistance.  Combinations with epigenetic therapies, proteasome inhibitors, downstream kinase inhibitors, phosphatase activators, and other drugs that alter signaling are being explored.  This review summarizes the current status of translational and clin. research on FLT3 inhibitors in AML, and discusses novel combination approaches.  Mol Cancer Ther; 16(6); 991-1001. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvp5t3cNnh3bVg90H21EOLACvtfcHk0lgDXgX6j00xAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D&md5=7105f50a6f38c3ce41be4adb82a62413</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0876%26sid%3Dliteratum%253Aachs%26aulast%3DLarrosa-Garcia%26aufirst%3DM.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DFLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D991%26epage%3D1001%26doi%3D10.1158%2F1535-7163.MCT-16-0876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Type II kinase inhibitors: an opportunity in cancer for rational design</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.2174/1871520611313050008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+kinase+inhibitors%3A+an+opportunity+in+cancer+for+rational+design&doi=10.2174%2F1871520611313050008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0lgDXgX6j00xAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520kinase%2520inhibitors%253A%2520an%2520opportunity%2520in%2520cancer%2520for%2520rational%2520design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747%26doi%3D10.2174%2F1871520611313050008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lgDXgX6j00xAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möbitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Type II inhibitors targeting CDK2</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2116</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2116-2125&author=L.+T.+Alexanderauthor=H.+M%C3%B6bitzauthor=P.+Drueckesauthor=P.+Savitskyauthor=O.+Fedorovauthor=J.+M.+Elkinsauthor=C.+M.+Deaneauthor=S.+W.+Cowan-Jacobauthor=S.+Knapp&title=Type+II+inhibitors+targeting+CDK2&doi=10.1021%2Facschembio.5b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Type II Inhibitors Targeting CDK2</span></div><div class="casAuthors">Alexander, Leila T.; Mobitz, Henrik; Drueckes, Peter; Savitsky, Pavel; Fedorov, Oleg; Elkins, Jonathan M.; Deane, Charlotte M.; Cowan-Jacob, Sandra W.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases can switch between active and inactive conformations of the ATP/Mg2+ binding motif DFG, which has been explored for the development of type I or type II inhibitors.  However, factors modulating DFG conformations remain poorly understood.  We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation.  We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochem. and biophys. characterization of the generated mutants.  As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors.  However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors.  Using protein crystallog. structural anal. of the CDK2 complex with an aminopyrimidine-Ph urea inhibitor (K03861) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 cocrystal structure.  We found that the identified type II inhibitors compete with binding of activating cyclins.  In addn., anal. of the binding kinetics of the identified inhibitors revealed slow off-rates.  The study highlights the importance of residues that may be distant to the ATP binding pocket in modulating the energetics of the DFG-out transition and hence inhibitor binding.  The presented data also provide the foundation for a new class of slow off-rate cyclin-competitive CDK2 inhibitors targeting the inactive DFG-out state of this important kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccF5AnJpk-7Vg90H21EOLACvtfcHk0liQOu_jlD8C1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ&md5=dac10d551827decf3574e04f9f981d98</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00398%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BT.%26aulast%3DM%25C3%25B6bitz%26aufirst%3DH.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DDeane%26aufirst%3DC.%2BM.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DType%2520II%2520inhibitors%2520targeting%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2116%26epage%3D2125%26doi%3D10.1021%2Facschembio.5b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3–335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=875-892&author=X.+Liangauthor=B.+Wangauthor=C.+Chenauthor=A.+Wangauthor=C.+Huauthor=F.+Zouauthor=K.+Yuauthor=Q.+Liuauthor=F.+Liauthor=Z.+Huauthor=T.+Luauthor=J.+Wangauthor=L.+Wangauthor=E.+L.+Weisbergauthor=L.+Liauthor=R.+Xiaauthor=W.+Wangauthor=T.+Renauthor=J.+Geauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+N-%284-%286-acetamidopyrimidin-4-yloxy%29phenyl%29-2-%282-%28trifluoromethyl%29phenyl%29acetamide+%28CHMFL-FLT3%E2%80%93335%29+as+a+potent+FMS-like+tyrosine+kinase+3+internal+tandem+duplication+%28FLT3-ITD%29+mutant+selective+inhibitor+for+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.8b01594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia</span></div><div class="casAuthors">Liang, Xiaofei; Wang, Beilei; Chen, Cheng; Wang, Aoli; Hu, Chen; Zou, Fengming; Yu, Kailin; Liu, Qingwang; Li, Feng; Hu, Zhenquan; Lu, Tingting; Wang, Junjie; Wang, Li; Weisberg, Ellen L.; Li, Lili; Xia, Ruixiang; Wang, Wenchao; Ren, Tao; Ge, Jian; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">875-892</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most of the current FMS-like tyrosine kinase 3 (FLT3) inhibitors lack selectivity between FLT3 kinase and cKIT kinase as well as the FLT3 wt and internal tandem duplication (ITD) mutants.  We report a new compd. I, which displays GI50 values of 30-80 nM against different ITD mutants and achieves selectivity over both FLT3 wt (8-fold) and cKIT kinase in the transformed BaF3 cells (>300-fold). I potently inhibits the proliferation of the FLT3-ITD-pos. acute myeloid leukemia cancer lines through suppression of the phosphorylation of FLT3 kinase and downstream signaling pathways, induction of apoptosis, and arresting the cell cycle into the G0/G1 phase. I also displays potent antiproliferative effect against FLT3-ITD-pos. patient primary cells, whereas it does not apparently affect FLT3 wt primary cells.  In addn., it also exhibits a good therapeutic window to PBMC compared to PKC412.  In the in vivo studies, I demonstrates favorable PK profiles and suppresses the tumor growth in the MV4-11 cell inoculated mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdi_MAkOsXkLVg90H21EOLACvtfcHk0liQOu_jlD8C1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKitbnE&md5=b802859e517d8156353481f41128f7a1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01594%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520N-%25284-%25286-acetamidopyrimidin-4-yloxy%2529phenyl%2529-2-%25282-%2528trifluoromethyl%2529phenyl%2529acetamide%2520%2528CHMFL-FLT3%25E2%2580%2593335%2529%2520as%2520a%2520potent%2520FMS-like%2520tyrosine%2520kinase%25203%2520internal%2520tandem%2520duplication%2520%2528FLT3-ITD%2529%2520mutant%2520selective%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D875%26epage%3D892%26doi%3D10.1021%2Facs.jmedchem.8b01594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.phrs.2015.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26529477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=26-48&author=R.+Roskoski&title=Classification+of+small+molecule+protein+kinase+inhibitors+based+upon+the+structures+of+their+drug-enzyme+complexes&doi=10.1016%2Fj.phrs.2015.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-48</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because dysregulation and mutations of protein kinases play causal roles in human disease, this family of enzymes has become one of the most important drug targets over the past two decades.  The X-ray crystal structures of 21 of the 27 FDA-approved small mol. inhibitors bound to their target protein kinases are depicted in this paper.  The structure of the enzyme-bound antagonist complex is used in the classification of these inhibitors.  Type I inhibitors bind to the active protein kinase conformation (DFG-Asp in, αC-helix in).  Type I1/2 inhibitors bind to a DFG-Asp in inactive conformation while Type II inhibitors bind to a DFG-Asp out inactive conformation.  Type I, I1/2, and type II inhibitors occupy part of the adenine binding pocket and form hydrogen bonds with the hinge region connecting the small and large lobes of the enzyme.  Type III inhibitors bind next to the ATP-binding pocket and type IV inhibitors do not bind to the ATP or peptide substrate binding sites.  Type III and IV inhibitors are allosteric in nature.  Type V inhibitors bind to two different regions of the protein kinase domain and are therefore bivalent inhibitors.  The type I-V inhibitors are reversible.  In contrast, type VI inhibitors bind covalently to their target enzyme.  Type I, I1/2, and II inhibitors are divided into A and B subtypes.  The type A inhibitors bind in the front cleft, the back cleft, and near the gatekeeper residue, all of which occur within the region sepg. the small and large lobes of the protein kinase.  The type B inhibitors bind in the front cleft and gate area but do not extend into the back cleft.  An anal. of the limited available data indicates that type A inhibitors have a long residence time (minutes to hours) while the type B inhibitors have a short residence time (seconds to minutes).  The catalytic spine includes residues from the small and large lobes and interacts with the adenine ring of ATP.  Nearly all of the approved protein kinase inhibitors occupy the adenine-binding pocket; thus it is not surprising that these inhibitors interact with nearby catalytic spine (CS) residues.  Moreover, a significant no. of approved drugs also interact with regulatory spine (RS) residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0COwqC0CabVg90H21EOLACvtfcHk0liQOu_jlD8C1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN&md5=e6b45c8644e322f30f898e763780c64b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DClassification%2520of%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%2520based%2520upon%2520the%2520structures%2520of%2520their%2520drug-enzyme%2520complexes%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D103%26spage%3D26%26epage%3D48%26doi%3D10.1016%2Fj.phrs.2015.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirazian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1021/jm0204183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase&doi=10.1021%2Fjm0204183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0li79_srCHdP4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119%26doi%3D10.1021%2Fjm0204183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Farrell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngai, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolich, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrington, J. M.</span></span> <span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3597</span>– <span class="NLM_lpage">3605</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-07-2307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2002-07-2307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=12531805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2002-07-2307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span></div><div class="casAuthors">O'Farrell, Anne-Marie; Abrams, Tinya J.; Yuen, Helene A.; Ngai, Theresa J.; Louie, Sharianne G.; Yee, Kevin W. H.; Wong, Lily M.; Hong, Weiru; Lee, Leslie B.; Town, Ajia; Smolich, Beverly D.; Manning, William C.; Murray, Lesley J.; Heinrich, Michael C.; Cherrington, Julie M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3597-3605</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells.  In blasts from acute myelogenous leukemia (AML) patients, 2 classes of FLT3 activating mutations have been identified: internal tandem duplication (ITD) mutations in the juxtamembrane domain (25%-30% of patients) and point mutations in the kinase domain activation loop (7%-8% of patients).  FLT3-ITD mutations are the most common mol. defect identified in AML and have been shown to be an independent prognostic factor for decreased survival.  FLT3-ITD is therefore an attractive mol. target for therapy.  SU11248 is a recently described selective inhibitor with selectivity for split kinase domain RTKs, including platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and KIT.  We show that SU11248 also has potent activity against wild-type FLT3 (FLT3-WT), FLT3-ITD, and FLT3 activation loop (FLT3-Asp835) mutants in phosphorylation assays.  SU11248 inhibits FLT3-driven phosphorylation and induces apoptosis in vitro.  In addn., SU11248 inhibits FLT3-induced VEGF prodn.  The in vivo efficacy of SU11248 was investigated in 2 FLT3-ITD models: a s.c. tumor xenograft model and a bone marrow engraftment model.  We show that SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the s.c. tumor xenograft model and prolongs survival in the bone marrow engraftment model.  Pharmacokinetic and pharmacodynamic anal. in s.c. tumors showed that a single administration of an efficacious drug dose potently inhibits FLT3-ITD phosphorylation for up to 16 h following a single dose.  These results suggest that further exploration of SU11248 activity in AML patients is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUcmQRlrUD7Vg90H21EOLACvtfcHk0li79_srCHdP4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D&md5=f996fe320ccf9449951baf97e372c694</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-07-2307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-07-2307%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605%26doi%3D10.1182%2Fblood-2002-07-2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schittenhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göhring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1111/bjh.13353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fbjh.13353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25818407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2015&pages=694-700&author=W.+Fiedlerauthor=S.+Kayserauthor=M.+Kebenkoauthor=M.+Janningauthor=J.+Krauterauthor=M.+Schittenhelmauthor=K.+G%C3%B6tzeauthor=D.+Weberauthor=G.+G%C3%B6hringauthor=V.+Teleanuauthor=F.+Tholauthor=M.+Heuserauthor=K.+D%C3%B6hnerauthor=A.+Ganserauthor=H.+D%C3%B6hnerauthor=R.+F.+Schlenk&title=A+phase+I%2FII+study+of+sunitinib+and+intensive+chemotherapy+in+patients+over+60+years+of+age+with+acute+myeloid+leukaemia+and+activating+FLT3+mutations&doi=10.1111%2Fbjh.13353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations</span></div><div class="casAuthors">Fiedler, Walter; Kayser, Sabine; Kebenko, Maxim; Janning, Melanie; Krauter, Juergen; Schittenhelm, Marcus; Goetze, Katharina; Weber, Daniela; Goehring, Gudrun; Teleanu, Veronica; Thol, Felicitas; Heuser, Michael; Doehner, Konstanze; Ganser, Arnold; Doehner, Hartmut; Schlenk, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">694-700</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Acute myeloid leukemia (AML) with FLT3 mutation has a dismal prognosis in elderly patients.  Treatment with a combination of FLT3 inhibitors and std. chemotherapy has not been extensively studied.  Therefore, we instigated a phase I/II clin. trial of chemotherapy with cytosine arabinoside (Ara-C)/daunorubicin induction (7+3) followed by three cycles of intermediate-dose Ara-C consolidation in 22 AML patients with activating FLT3 mutations.  Sunitinib was added at predefined dose levels and as maintenance therapy for 2 years.  At dose level 1, sunitinib 25 mg daily continuously from day 1 onwards resulted in two cases with dose-limiting toxicity (DLT), prolonged hemotoxicity and hand-foot syndrome.  At dose level -1, sunitinib 25 mg was restricted to days 1-7 of each chemotherapy cycle.  One DLT was obsd. in six evaluable patients.  Six addnl. patients were treated in an extension phase.  Thirteen of 22 patients (59%; 8/14 with FLT3-internal tandem duplication and 5/8 with FLT3-tyrosine kinase domain) achieved a complete remission/complete remission with incomplete blood count recovery.  For the 17 patients included at the lower dose level, median overall, relapse-free and event-free survival were 1·6, 1·0 and 0·4 years, resp.  Four out of five analyzed patients with relapse during maintenance therapy lost their initial FLT3 mutation, suggesting outgrowth of FLT3 wild-type subclones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsGdfSxoqKHbVg90H21EOLACvtfcHk0lgGotLtNmNOmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVajtrY%253D&md5=3baaa85250fb6c3e9f03109a17f7eb42</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13353%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DKebenko%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DSchittenhelm%26aufirst%3DM.%26aulast%3DG%25C3%25B6tze%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DD.%26aulast%3DG%25C3%25B6hring%26aufirst%3DG.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520sunitinib%2520and%2520intensive%2520chemotherapy%2520in%2520patients%2520over%252060%2520years%2520of%2520age%2520with%2520acute%2520myeloid%2520leukaemia%2520and%2520activating%2520FLT3%2520mutations%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D169%26spage%3D694%26epage%3D700%26doi%3D10.1111%2Fbjh.13353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNabola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shujath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eveleigh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voznesensky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7099</span>– <span class="NLM_lpage">7109</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F0008-5472.CAN-04-1443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=15466206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43%E2%80%939006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis&doi=10.1158%2F0008-5472.CAN-04-1443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span></div><div class="casAuthors">Wilhelm, Scott M.; Carter, Christopher; Tang, LiYa; Wilkie, Dean; McNabola, Angela; Rong, Hong; Chen, Charles; Zhang, Xiaomei; Vincent, Patrick; McHugh, Mark; Cao, Yichen; Shujath, Jaleel; Gawlak, Susan; Eveleigh, Deepa; Rowley, Bruce; Liu, Li; Adnane, Lila; Lynch, Mark; Auclair, Daniel; Taylor, Ian; Gedrich, Rich; Voznesensky, Andrei; Riedl, Bernd; Post, Leonard E.; Bollag, Gideon; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7099-7109</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis.  The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/MEK/ERK signaling pathway.  Addnl. characterization showed that BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro.  In addn., BAY 43-9006 demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, platelet-derived growth factor receptor β, Flt-3, and c-KIT.  In cellular mechanistic assays, BAY 43-9006 demonstrated inhibition of the mitogen-activated protein kinase pathway in colon, pancreatic, and breast tumor cell lines expressing mutant KRAS or wild-type or mutant BRAF, whereas non-small-cell lung cancer cell lines expressing mutant KRAS were insensitive to inhibition of the mitogen-activated protein kinase pathway by BAY 43-9006.  Potent inhibition of VEGFR-2, platelet-derived growth factor receptor β, and VEGFR-3 cellular receptor autophosphorylation was also obsd. for BAY 43-9006.  Once daily oral dosing of BAY 43-9006 demonstrated broad-spectrum antitumor activity in colon, breast, and non-small-cell lung cancer xenograft models.  Immunohistochem. demonstrated a close assocn. between inhibition of tumor growth and inhibition of the extracellular signal-regulated kinases (ERKs) 1/2 phosphorylation in two of three xenograft models examd., consistent with inhibition of the RAF/MEK/ERK pathway in some but not all models.  Addnl. analyses of microvessel d. and microvessel area in the same tumor sections using antimurine CD31 antibodies demonstrated significant inhibition of neovascularization in all three of the xenograft models.  These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy8IcVRGBZgbVg90H21EOLACvtfcHk0lgGotLtNmNOmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFalsbk%253D&md5=4b92eb31d557009652349e4f9645b9f0</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043%25E2%2580%25939006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109%26doi%3D10.1158%2F0008-5472.CAN-04-1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shacham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span> <span> </span><span class="NLM_article-title">Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial</span>. <i>Haematologica.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1653</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.185082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.3324%2Fhaematol.2017.185082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29773601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGjt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=1642-1653&author=W.+Zhangauthor=C.+Lyauthor=J.+Ishizawaauthor=H.+Muauthor=V.+Ruvoloauthor=S.+Shachamauthor=N.+Daverauthor=M.+Andreeff&title=Combinatorial+targeting+of+XPO1+and+FLT3+exerts+synergistic+anti-leukemia+effects+through+induction+of+differentiation+and+apoptosis+in+FLT3-mutated+acute+myeloid+leukemias%3A+from+concept+to+clinical+trial&doi=10.3324%2Fhaematol.2017.185082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial</span></div><div class="casAuthors">Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo; Mu, Hong; Ruvolo, Vivian; Shacham, Sharon; Daver, Naval; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1642-1653</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clin. efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K/AKT, and STAT5.  Activation of these addnl. kinases may also result in phosphorylation of tumor suppressor proteins promoting their nuclear export.  Thus, co-targeting nuclear export proteins (e.g., XPO1) and FLT3 concomitantly may be therapeutically effective.  Here we report on the combinatorial inhibition of XPO1 using selinexor and FLT3 using sorafenib.  Selinexor exerted marked cell killing of human and murine FLT3-mutant acute myeloid leukemia cells, including those harboring internal tandem duplication and/or tyrosine kinase domain point mutations.  Interestingly, selinexor treatment of murine FLT3-mutant acute myeloid leukemia cells activated FLT3 and its downstream MAPK or AKT signaling pathways.  When combined with sorafenib, selinexor triggered marked synergistic pro-apoptotic effects.  This was preceded by elevated nuclear levels of ERK, AKT, NFκB, and FOXO3a.  Five days of in vitro combination treatment using low doses (i.e., 5 to 10 nM) of each agent promoted early myeloid differentiation of MOLM13 and MOLM14 cells without noticeable cell killing.  The combinatorial therapy demonstrated profound in vivo anti-leukemia efficacy in a human FLT3- mutated xenograft model.  In an ongoing phase IB clin. trial the selinexor/ sorafenib combination induced complete/partial remissions in six of 14 patients with refractory acute myeloid leukemia, who had received a median of three prior therapies (ClinicalTrials.gov: NCT02530476).  These results provide pre-clin. and clin. evidence for an effective combinatorial treatment strategy targeting XPO1 and FLT3 in FLT3- mutated acute myeloid leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMRh5rQBQPWrVg90H21EOLACvtfcHk0lgGotLtNmNOmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGjt7nN&md5=55763028facdecd4c23d9ba6adfdaf5c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.185082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.185082%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DC.%26aulast%3DIshizawa%26aufirst%3DJ.%26aulast%3DMu%26aufirst%3DH.%26aulast%3DRuvolo%26aufirst%3DV.%26aulast%3DShacham%26aufirst%3DS.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DCombinatorial%2520targeting%2520of%2520XPO1%2520and%2520FLT3%2520exerts%2520synergistic%2520anti-leukemia%2520effects%2520through%2520induction%2520of%2520differentiation%2520and%2520apoptosis%2520in%2520FLT3-mutated%2520acute%2520myeloid%2520leukemias%253A%2520from%2520concept%2520to%2520clinical%2520trial%26jtitle%3DHaematologica.%26date%3D2018%26volume%3D103%26spage%3D1642%26epage%3D1653%26doi%3D10.3324%2Fhaematol.2017.185082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mett, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(99)00005-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS0163-7258%2899%2900005-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10454207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=293-301&author=D.+Fabbroauthor=E.+Buchdungerauthor=J.+Woodauthor=J.+Mestanauthor=F.+Hofmannauthor=S.+Ferrariauthor=H.+Mettauthor=T.+O%E2%80%99Reillyauthor=T.+Meyer&title=Inhibitors+of+protein+kinases%3A+CGP+41251%2C+a+protein+kinase+inhibitor+with+potential+as+an+anticancer+agent&doi=10.1016%2FS0163-7258%2899%2900005-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent</span></div><div class="casAuthors">Fabbro, Doriano; Buchdunger, Elisabeth; Wood, Jeannette; Mestan, Jurgen; Hofmann, Francesco; Ferrari, Stefano; Mett, Helmut; O'Reilly, Terence; Meyer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">293-301</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with many refs.  CGP 41251 was originally identified as an inhibitor of protein kinase C (PKC), inhibiting mainly the conventional PKC subtypes, and subsequently shown to inhibit the vascular endothelial growth factor (VEGF) receptor kinase insert domain-contg. receptor, which is involved in angiogenesis.  CGP 41251 inhibits reversibly intracellular PKC activity, induction of c-fos and the corresponding activation of the mitogen-activated protein kinase induced by either tumor promoting phorbol esters, platelet-derived growth factor, or basic fibroblast growth factor, but not by the epidermal growth factor.  CGP 41251 inhibited the ligand-induced autophosphorylation of the receptors for platelet-derived growth factor, stem cell factor, and VEGF (kinase insert domain-contg. receptor) that correlated with the inhibition of the mitogen-activated protein kinase activation, but did not affect the ligand-induced autophosphorylation of the receptors for insulin, insulin-like growth factor-I, or epidermal growth factor.  CGP 41251 showed broad antiproliferative activity against various tumor and normal cell lines in vitro, and is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro.  CGP 41251 showed in vivo antitumor activity as single agent and inhibited angiogenesis in vivo.  Thus, CGP 41251 may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addn. to directly inhibiting tumor cell proliferation (via its effects on PKCs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc-p7mVgqqZrVg90H21EOLACvtfcHk0lgqNrzo2ssCSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOhtLY%253D&md5=00ea18d0abc5871a8d9bc4b420b3ab3c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2899%2900005-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252899%252900005-4%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DInhibitors%2520of%2520protein%2520kinases%253A%2520CGP%252041251%252C%2520a%2520protein%2520kinase%2520inhibitor%2520with%2520potential%2520as%2520an%2520anticancer%2520agent%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D293%26epage%3D301%26doi%3D10.1016%2FS0163-7258%2899%2900005-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4479</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-07-101238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2007-07-101238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=17827387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Wr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=4476-4479&author=E.+V.+Barryauthor=J.+J.+Clarkauthor=J.+Coolsauthor=J.+Roeselauthor=D.+G.+Gilliland&title=Uniform+sensitivity+of+FLT3+activation+loop+mutants+to+the+tyrosine+kinase+inhibitor+midostaurin&doi=10.1182%2Fblood-2007-07-101238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span></div><div class="casAuthors">Barry, Elly V.; Clark, Jennifer J.; Cools, Jan; Roesel, Johannes; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4476-4479</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Small mol. inhibitors that target fms-like tyrosine kinase 3 (FLT3)-activating mutations have potential in the treatment of leukemias.  However, certain mutations can simultaneously activate the tyrosine kinase, and confer resistance to small mol. inhibitors.  We therefore tested the sensitivity of 8 FLT3 activation loop mutants to midostaurin.  Each mutant conferred IL-3 factor-independent proliferation to Ba/F3 cells, and each resulted in the constitutive activation of FLT3 and its targets, signal transducer and activator of transcription 5 (STAT5) and extracellular stimuli-responsive kinase (ERK).  For each mutant tested, midostaurin inhibited cell growth and phosphorylation of FLT3, STAT5, and ERK.  In contrast, midostaruin did not inhibit Ba/F3 cells stably transduced with FLT3-internal tandem duplications contg. a G697R mutation that confers resistance to midostaurin, demonstrating that midostaurin inhibition of FLT3 activation loop mutants was not due to off-target effects.  We conclude that midostaurin is a potent inhibitor of a spectrum of FLT3 activation loop mutations, and that acute myeloid leukemia patients with such mutations are potential candidates for clin. trials involving midostaurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdwABqNKHecLVg90H21EOLACvtfcHk0lgqNrzo2ssCSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Wr&md5=a4093ba0c60d4c239226a25eba2a266c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-07-101238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-07-101238%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DE.%2BV.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DUniform%2520sensitivity%2520of%2520FLT3%2520activation%2520loop%2520mutants%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520midostaurin%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D4476%26epage%3D4479%26doi%3D10.1182%2Fblood-2007-07-101238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilkes, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A. K.</span></span> <span> </span><span class="NLM_article-title">The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">3494</span>– <span class="NLM_lpage">3503</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-04-015487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2006-04-015487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=16868253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3494-3503&author=S.+Knapperauthor=K.+I.+Millsauthor=A.+F.+Gilkesauthor=S.+J.+Austinauthor=V.+Walshauthor=A.+K.+Burnett&title=The+effects+of+lestaurtinib+%28CEP701%29+and+PKC412+on+primary+AML+blasts%3A+the+induction+of+cytotoxicity+varies+with+dependence+on+FLT3+signaling+in+both+FLT3-mutated+and+wild-type+cases&doi=10.1182%2Fblood-2006-04-015487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases</span></div><div class="casAuthors">Knapper, Steven; Mills, Kenneth I.; Gilkes, Amanda F.; Austin, Steve J.; Walsh, Val; Burnett, Alan K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3494-3503</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase FLT3 is a promising mol. therapeutic target in acute myeloid leukemia (AML).  Activating mutations of FLT3 are present in approx. 1/3 of patients, while many nonmutants show evidence of FLT3 activation, which appears to play a significant role in leukemogenesis.  We studied the effects of lestaurtinib (CEP701) and PKC412, 2 small mol. inhibitors of FLT3, on 65 diagnostic AML blast samples.  Both agents induced concn.-dependent cytotoxicity in most cases, although responses to PKC412 required higher drug concns.  Cytotoxic responses were highly heterogeneous and were only weakly assocd. with FLT3 mutation status and FLT3 expression.  Importantly, lestaurtinib induced cytotoxicity in a synergistic fashion with cytarabine, particularly in FLT3 mutant samples.  Both lestaurtinib and PKC412 caused inhibition of FLT3 phosphorylation in all samples.  Translation of FLT3 inhibition into cytotoxicity was influenced by the degree of residual FLT3 phosphorylation remaining and correlated with deactivation of STAT5 and MAP kinase.  FLT3 mutant and wild-type cases both varied considerably in their dependence on FLT3 signaling for survival.  These findings support the continued clin. assessment of FLT3 inhibitors in combination with cytotoxic chemotherapy: Entry to future clin. trials should include FLT3 wild-type patients and should remain unrestricted by FLT3 expression level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ULL0PPxlqrVg90H21EOLACvtfcHk0lgqNrzo2ssCSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzL&md5=cdcb226038e720a73725cee8371ebc4b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-04-015487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-04-015487%26sid%3Dliteratum%253Aachs%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DK.%2BI.%26aulast%3DGilkes%26aufirst%3DA.%2BF.%26aulast%3DAustin%26aufirst%3DS.%2BJ.%26aulast%3DWalsh%26aufirst%3DV.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26atitle%3DThe%2520effects%2520of%2520lestaurtinib%2520%2528CEP701%2529%2520and%2520PKC412%2520on%2520primary%2520AML%2520blasts%253A%2520the%2520induction%2520of%2520cytotoxicity%2520varies%2520with%2520dependence%2520on%2520FLT3%2520signaling%2520in%2520both%2520FLT3-mutated%2520and%2520wild-type%2520cases%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3494%26epage%3D3503%26doi%3D10.1182%2Fblood-2006-04-015487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allebach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">3885</span>– <span class="NLM_lpage">3891</span>, <span class="refDoi"> DOI: 10.1182/blood.V99.11.3885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood.V99.11.3885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=12010785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=3885-3891&author=M.+Levisauthor=J.+Allebachauthor=K.+F.+Tseauthor=R.+Zhengauthor=B.+R.+Baldwinauthor=B.+D.+Smithauthor=S.+Jones-Bolinauthor=B.+Ruggeriauthor=C.+Dionneauthor=D.+Small&title=A+FLT3-targeted+tyrosine+kinase+inhibitor+is+cytotoxic+to+leukemia+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood.V99.11.3885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span></div><div class="casAuthors">Levis, Mark; Allebach, Jeffrey; Tse, Kam-Fai; Zheng, Rui; Baldwin, Brenda R.; Smith, B. Douglas; Jones-Bolin, Susan; Ruggeri, Bruce; Dionne, Craig; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3885-3891</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutively activating internal tandem duplication (ITD) and point mutations of the receptor tyrosine kinase FLT3 are present in ≤41% of patients with acute myeloid leukemia (AML).  These FLT3/ITD mutations are likely to be important because their presence is assocd. with a poor prognosis.  Both types of mutations appear to activate the tyrosine kinase activity of FLT3.  The authors describe here the identification and characterization of the indolocarbazole deriv. CEP-701 as a FLT3 inhibitor.  This drug potently and selectively inhibits autophosphorylation of wild-type and constitutively activated mutant FLT3 in vitro in FLT3/ITD-transfected cells and in human FLT3-expressing myeloid leukemia-derived cell lines.  The authors demonstrate that CEP-701 induces a cytotoxic effect on cells in a dose-responsive fashion that parallels the inhibition of FLT3.  STAT5 and ERK1/2, downstream targets of FLT3 in the signaling pathway, are inhibited in response to FLT3 inhibition.  In primary leukemia blasts from AML patients harboring FLT3/ITD mutations, FLT3 is also inhibited, with an assocd. cytotoxic response.  Finally, using a mouse model of FLT3/ITD leukemia, the authors demonstrate that the drug inhibits FLT3 phosphorylation in vivo and prolongs survival.  These findings form the basis for a planned clin. trial of CEP-701 in patients with AML harboring FLT3-activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXL7nbYZzBSrVg90H21EOLACvtfcHk0lgtNSQSX9-eQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D&md5=3808e2bf314d769c9ae1c11324df4aba</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.11.3885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.11.3885%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DB.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520FLT3-targeted%2520tyrosine%2520kinase%2520inhibitor%2520is%2520cytotoxic%2520to%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D3885%26epage%3D3891%26doi%3D10.1182%2Fblood.V99.11.3885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hills, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovanovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runglall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valganon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khwaja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ommen, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overgaard, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitzky-Basso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolousis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danby, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnegan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craddock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spearing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span> <span> </span><span class="NLM_article-title">Molecular MRD status and outcome after transplantation in NPM1-mutated AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1182/blood.2019002959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood.2019002959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31932839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVGrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2020&pages=680-688&author=R.+Dillonauthor=R.+Hillsauthor=S.+Freemanauthor=N.+Potterauthor=J.+Jovanovicauthor=A.+Iveyauthor=A.+S.+Kandaauthor=M.+Runglallauthor=N.+Footauthor=M.+Valganonauthor=A.+Khwajaauthor=J.+Cavenaghauthor=M.+Smithauthor=H.+B.+Ommenauthor=U.+M.+Overgaardauthor=M.+Dennisauthor=S.+Knapperauthor=H.+Kaurauthor=D.+Taussigauthor=P.+Mehtaauthor=K.+Rajauthor=I.+Novitzky-Bassoauthor=E.+Nikolousisauthor=R.+Danbyauthor=P.+Krishnamurthyauthor=K.+Hillauthor=D.+Finneganauthor=S.+Alimamauthor=E.+Hurstauthor=P.+Johnsonauthor=A.+Khanauthor=R.+Salimauthor=C.+Craddockauthor=R.+Spearingauthor=A.+Gilkesauthor=R.+Galeauthor=A.+Burnettauthor=N.+H.+Russellauthor=D.+Grimwade&title=Molecular+MRD+status+and+outcome+after+transplantation+in+NPM1-mutated+AML&doi=10.1182%2Fblood.2019002959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular MRD status and outcome after transplantation in NPM1-mutated AML</span></div><div class="casAuthors">Dillon, Richard; Hills, Robert; Freeman, Sylvie; Potter, Nicola; Jovanovic, Jelena; Ivey, Adam; Kanda, Anju Shankar; Runglall, Manohursingh; Foot, Nicola; Valganon, Mikel; Khwaja, Asim; Cavenagh, Jamie; Smith, Matthew; Ommen, Hans Beier; Overgaard, Ulrik Malthe; Dennis, Mike; Knapper, Steven; Kaur, Harpreet; Taussig, David; Mehta, Priyanka; Raj, Kavita; Novitzky-Basso, Igor; Nikolousis, Emmanouil; Danby, Robert; Krishnamurthy, Pramila; Hill, Kate; Finnegan, Damian; Alimam, Samah; Hurst, Erin; Johnson, Peter; Khan, Anjum; Salim, Rahuman; Craddock, Charles; Spearing, Ruth; Gilkes, Amanda; Gale, Rosemary; Burnett, Alan; Russell, Nigel H.; Grimwade, David</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">680-688</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Relapse remains the most common cause of treatment failure for patients with acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prognosis.  Multiple studies have identified the presence of measurable residual disease (MRD) assessed by flow cytometry before alloSCT as a strong predictor of relapse, but it is not clear how these findings apply to patients who test pos. in mol. MRD assays, which have far greater sensitivity.  We analyzed pretransplant blood and bone marrow samples by reverse-transcription polymerase chain reaction in 107 patients with NPM1-mutant AML enrolled in the UK National Cancer Research Institute AML17 study.  After a median follow-up of 4.9 years, patients with neg., low (<200 copies per 105 ABL in the peripheral blood and <1000 copies in the bone marrow aspirate), and high levels of MRD had an estd. 2-yr overall survival (2y-OS) of 83%, 63%, and 13%, resp. (P < .0001).  Focusing on patients with low-level MRD before alloSCT, those with FLT3 internal tandem duplications (ITDs) had significantly poorer outcome (hazard ratio [HR], 6.14; P = .01).  T-depletion was assocd. with significantly reduced survival both in the entire cohort (2y-OS, 56% vs 96%; HR, 3.24; P = .0005) and in MRD-pos. patients (2y-OS, 34% vs 100%; HR, 3.78; P = .003), but there was no significant effect of either conditioning regimen or donor source on outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEa5acML_SzrVg90H21EOLACvtfcHk0lgtNSQSX9-eQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVGrt74%253D&md5=e5e8165dd6ae2ebcb2311893d691ecbc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1182%2Fblood.2019002959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2019002959%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DR.%26aulast%3DHills%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DPotter%26aufirst%3DN.%26aulast%3DJovanovic%26aufirst%3DJ.%26aulast%3DIvey%26aufirst%3DA.%26aulast%3DKanda%26aufirst%3DA.%2BS.%26aulast%3DRunglall%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DN.%26aulast%3DValganon%26aufirst%3DM.%26aulast%3DKhwaja%26aufirst%3DA.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DOmmen%26aufirst%3DH.%2BB.%26aulast%3DOvergaard%26aufirst%3DU.%2BM.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DH.%26aulast%3DTaussig%26aufirst%3DD.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DRaj%26aufirst%3DK.%26aulast%3DNovitzky-Basso%26aufirst%3DI.%26aulast%3DNikolousis%26aufirst%3DE.%26aulast%3DDanby%26aufirst%3DR.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DK.%26aulast%3DFinnegan%26aufirst%3DD.%26aulast%3DAlimam%26aufirst%3DS.%26aulast%3DHurst%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DSalim%26aufirst%3DR.%26aulast%3DCraddock%26aufirst%3DC.%26aulast%3DSpearing%26aufirst%3DR.%26aulast%3DGilkes%26aufirst%3DA.%26aulast%3DGale%26aufirst%3DR.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DGrimwade%26aufirst%3DD.%26atitle%3DMolecular%2520MRD%2520status%2520and%2520outcome%2520after%2520transplantation%2520in%2520NPM1-mutated%2520AML%26jtitle%3DBlood%26date%3D2020%26volume%3D135%26spage%3D680%26epage%3D688%26doi%3D10.1182%2Fblood.2019002959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apatira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curley, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarborough, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokker, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, N. A.</span></span> <span> </span><span class="NLM_article-title">CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(02)00070-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS1535-6108%2802%2900070-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=12124172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVKjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=421-432&author=L.+M.+Kellyauthor=J.+C.+Yuauthor=C.+L.+Boultonauthor=M.+Apatiraauthor=J.+Liauthor=C.+M.+Sullivanauthor=I.+Williamsauthor=S.+M.+Amaralauthor=D.+P.+Curleyauthor=N.+Duclosauthor=D.+Neubergauthor=R.+M.+Scarboroughauthor=A.+Pandeyauthor=S.+Hollenbachauthor=K.+Abeauthor=N.+A.+Lokkerauthor=D.+G.+Gillilandauthor=N.+A.+Giese&title=CT53518%2C+a+novel+selective+FLT3+antagonist+for+the+treatment+of+acute+myelogenous+leukemia+%28AML%29&doi=10.1016%2FS1535-6108%2802%2900070-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)</span></div><div class="casAuthors">Kelly, Louise M.; Yu, Jin-Chen; Boulton, Christina L.; Apatira, Mutiah; Li, Jason; Sullivan, Carol M.; Williams, Ifor; Amaral, Sonia M.; Curley, David P.; Duclos, Nicole; Neuberg, Donna; Scarborough, Robert M.; Pandey, Anjali; Hollenbach, Stanley; Abe, Keith; Lokker, Nathalie A.; Gilliland, D. Gary; Giese, Neill A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-432</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy.  For this purpose we have developed CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit (IC50 ∼200 nM), while other tyrosine or serine/threonine kinases were not significantly inhibited.  In Ba/F3 cells expressing different FLT3-ITD mutants, CT53518 inhibited IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10-100 nM.  In human FLT3-ITD-pos. AML cell lines, CT53518 induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways.  Therapeutic efficacy of CT53518 was demonstrated both in a nude mouse model and in a murine bone marrow transplant model of FLT3-ITD-induced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5ZTWex8ZXLrVg90H21EOLACvtfcHk0lhhhMkC7Y5LNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVKjsLc%253D&md5=5ef6442b8ff343aea4687b89693a506c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900070-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900070-3%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DYu%26aufirst%3DJ.%2BC.%26aulast%3DBoulton%26aufirst%3DC.%2BL.%26aulast%3DApatira%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DC.%2BM.%26aulast%3DWilliams%26aufirst%3DI.%26aulast%3DAmaral%26aufirst%3DS.%2BM.%26aulast%3DCurley%26aufirst%3DD.%2BP.%26aulast%3DDuclos%26aufirst%3DN.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DLokker%26aufirst%3DN.%2BA.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCT53518%252C%2520a%2520novel%2520selective%2520FLT3%2520antagonist%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520%2528AML%2529%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D1%26spage%3D421%26epage%3D432%26doi%3D10.1016%2FS1535-6108%2802%2900070-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namuyinga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30150-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2FS1470-2045%2819%2930150-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31175001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=984-997&author=J.+E.+Cortesauthor=S.+Khaledauthor=G.+Martinelliauthor=A.+E.+Perlauthor=S.+Gangulyauthor=N.+Russellauthor=A.+Kr%C3%A4merauthor=H.+Dombretauthor=D.+Hoggeauthor=B.+A.+Jonasauthor=A.+Y.+Leungauthor=P.+Mehtaauthor=P.+Montesinosauthor=M.+Radsakauthor=S.+Sicaauthor=M.+Arunachalamauthor=M.+Holmesauthor=K.+Kobayashiauthor=R.+Namuyingaauthor=N.+Geauthor=A.+Yverauthor=Y.+Zhangauthor=M.+J.+Levis&title=Quizartinib+versus+salvage+chemotherapy+in+relapsed+or+refractory+FLT3-ITD+acute+myeloid+leukaemia+%28QuANTUM-R%29%3A+a+multicentre%2C+randomised%2C+controlled%2C+open-label%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2819%2930150-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span></div><div class="casAuthors">Cortes, Jorge E.; Khaled, Samer; Martinelli, Giovanni; Perl, Alexander E.; Ganguly, Siddhartha; Russell, Nigel; Kramer, Alwin; Dombret, Herve; Hogge, Donna; Jonas, Brian A.; Leung, Anskar Yu-Hung; Mehta, Priyanka; Montesinos, Pau; Radsak, Markus; Sica, Simona; Arunachalam, Meena; Holmes, Melissa; Kobayashi, Ken; Namuyinga, Ruth; Ge, Nanxiang; Yver, Antoine; Zhang, Yufen; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-997</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-pos. acute myeloid leukemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease.  We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival vs. salvage chemotherapy.  QuANTUM-R is a randomized, controlled, phase 3 trial done at 152 hospitals and cancer centers in 19 countries.  Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first composite complete remission ≤6 mo) FLT3-ITD acute myeloid leukemia after std. therapy with or without allogeneic hemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: s.c. low-dose cytarabine (s.c. injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycles); i.v. infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1-5 of up to two 28-day cycles); or i.v. granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day s.c. on days 1-5), fludarabine (i.v. infusion 30 mg/m2 per day on days 2-6), cytarabine (i.v. infusion 2000 mg/m2 per day on days 2-6), and idarubicin (i.v. infusion 10 mg/m2 per day on days 2-4 in up to two 28-day cycles).  Patients proceeding to hemopoietic stem-cell transplantation after quizartinib could resume quizartinib after hemopoietic stem-cell transplantation.  The primary endpoint was overall survival in the intention-to-treat population.  This trial is registered with ClinicalTrials.gov, no. NCT02039726, and follow-up is ongoing.  Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy.  Four patients in the quizartinib group and 28 in the chemotherapy group were not treated.  Median follow-up was 23.5 mo (IQR 15.4-32.3).  Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0.76 [95% CI 0.58-0.98; p = 0.02]).  Median overall survival was 6.2 mo (5.3-7.2) in the quizartinib group and 4.7 mo (4.0-5.5) in the chemotherapy group.  The most common non-haematol. grade 3-5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalemia (28 [12%] vs eight [9%]).  The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group.  Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred.  There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events).  Treatment with quizartinib had a survival benefit vs. salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis.  Quizartinib could be considered a new std. of care.  Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.Daiichi Sankyo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcMb6SW1_b7Vg90H21EOLACvtfcHk0lhhhMkC7Y5LNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM&md5=63619aa2e4ea4fcc29b74d2aef43f224</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930150-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930150-0%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DKhaled%26aufirst%3DS.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DN.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DJonas%26aufirst%3DB.%2BA.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DSica%26aufirst%3DS.%26aulast%3DArunachalam%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DNamuyinga%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DN.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DQuizartinib%2520versus%2520salvage%2520chemotherapy%2520in%2520relapsed%2520or%2520refractory%2520FLT3-ITD%2520acute%2520myeloid%2520leukaemia%2520%2528QuANTUM-R%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520controlled%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D984%26epage%3D997%26doi%3D10.1016%2FS1470-2045%2819%2930150-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0lifmfVjRMNTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galanis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-10-529313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-10-529313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24227820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=94-100&author=A.+Galanisauthor=H.+Maauthor=T.+Rajkhowaauthor=A.+Ramachandranauthor=D.+Smallauthor=J.+Cortesauthor=M.+Levis&title=Crenolanib+is+a+potent+inhibitor+of+FLT3+with+activity+against+resistance-conferring+point+mutants&doi=10.1182%2Fblood-2013-10-529313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span></div><div class="casAuthors">Galanis, Allison; Ma, Hayley; Rajkhowa, Trivikram; Ramachandran, Abhijit; Small, Donald; Cortes, Jorge; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-100</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of the type III receptor tyrosine kinase FLT3 occur in approx. 30% of acute myeloid leukemia patients and lead to constitutive activation.  This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease.  As more potent FLT3 inhibitors are developed, a predictable development of resistance-conferring point mutations, commonly at residue D835, has been obsd.  Crenolanib is a highly selective and potent FLT3 tyrosine kinase inhibitor (TKI) with activity against the internal tandem duplication (FLT3/ITD) mutants and the FLT3/D835 point mutants.  We tested crenolanib against a panel of D835 mutant cell lines and primary patient blasts and obsd. superior cytotoxic effects when compared with other available FLT3 TKIs such as quizartinib and sorafenib.  Another potential advantage of crenolanib is its reduced inhibition of c-Kit compared with quizartinib.  In progenitor cell assays, crenolanib was less disruptive of erythroid colony growth, which may result in relatively less myelosuppression than quizartinib.  Finally, correlative data from an ongoing clin. trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo.  Crenolanib is thus an important next-generation FLT3 TKI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmTJQsMqjR3rVg90H21EOLACvtfcHk0lifmfVjRMNTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D&md5=c622e44844e5038fe3567735ea3fee7e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-10-529313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-10-529313%26sid%3Dliteratum%253Aachs%26aulast%3DGalanis%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DCrenolanib%2520is%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520resistance-conferring%2520point%2520mutants%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D94%26epage%3D100%26doi%3D10.1182%2Fblood-2013-10-529313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buaboonnam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3607</span>– <span class="NLM_lpage">3615</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-513044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-07-513044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24046014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3607-3615&author=E.+I.+Zimmermanauthor=D.+C.+Turnerauthor=J.+Buaboonnamauthor=S.+Huauthor=S.+Orwickauthor=M.+S.+Robertsauthor=L.+J.+Jankeauthor=A.+Ramachandranauthor=C.+F.+Stewartauthor=H.+Inabaauthor=S.+D.+Baker&title=Crenolanib+is+active+against+models+of+drug-resistant+FLT3-ITD-positive+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-07-513044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span></div><div class="casAuthors">Zimmerman, Eric I.; Turner, David C.; Buaboonnam, Jassada; Hu, Shuiying; Orwick, Shelley; Roberts, Michael S.; Janke, Laura J.; Ramachandran, Abhijit; Stewart, Clinton F.; Inaba, Hiroto; Baker, Sharyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3607-3615</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are assocd. with poor clin. outcomes.  Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are obsd. in FLT3-ITD-pos. patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691.  Using biochem. assays, we detd. that crenolanib, a novel TKI, demonstrates type I properties and is active against FLT3 contg. ITD and/or D835- or F691-activating mutations.  Potent activity was obsd. in FLT3-ITD-pos. AML cell lines.  Crenolanib delayed the outgrowth of MV4-11 cells in a xenograft mouse model, whereas in combination with the type II TKI sorafenib, a significant decrease in leukemic burden (P < .001) and prolonged survival (P < .01) was obsd. compared with either type I or II TKI alone.  Crenolanib was active against Ba/F3 cells harboring FLT3-ITD and secondary KD mutations and sorafenib-resistant MOLM-13 cells contg. FLT3-ITD/D835Y both in vitro and in vivo.  In addn., crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.  These preclin. data demonstrate that crenolanib is effective against FLT3-ITD contg. secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBQ8ZNZvhAw7Vg90H21EOLACvtfcHk0lifmfVjRMNTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE&md5=5d4052c5b3d470a2a9d14104286271ce</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-513044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-513044%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DD.%2BC.%26aulast%3DBuaboonnam%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOrwick%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26aulast%3DInaba%26aufirst%3DH.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26atitle%3DCrenolanib%2520is%2520active%2520against%2520models%2520of%2520drug-resistant%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3607%26epage%3D3615%26doi%3D10.1182%2Fblood-2013-07-513044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAXL+inhibitor%2C+shows+antileukemic+activity+in+mouse+models+of+FLT3+mutated+acute+myeloid+leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0ljPOMM8uA1wjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAXL%2520inhibitor%252C%2520shows%2520antileukemic%2520activity%2520in%2520mouse%2520models%2520of%2520FLT3%2520mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-745133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2016-10-745133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27908881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=257-260&author=L.+Y.+Leeauthor=D.+Hernandezauthor=T.+Rajkhowaauthor=S.+C.+Smithauthor=J.+R.+Ramanauthor=B.+Nguyenauthor=D.+Smallauthor=M.+Levis&title=Preclinical+studies+of+gilteritinib%2C+a+next-generation+FLT3+inhibitor&doi=10.1182%2Fblood-2016-10-745133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span></div><div class="casAuthors">Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes about the activity of gilteritinib and compared it with 4 other FLT3 TKIs in clin. development: midostaurin, sorafenib, quizartinib, and crenolanib.  In this article, inhibitory activity of gilteritinib against different forms of FLT3 in leukemia cells are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpTUQzYy5lrVg90H21EOLACvtfcHk0ljPOMM8uA1wjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D&md5=75429ea03b906ea92d24033613f0315b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-745133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-745133%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DRaman%26aufirst%3DJ.%2BR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPreclinical%2520studies%2520of%2520gilteritinib%252C%2520a%2520next-generation%2520FLT3%2520inhibitor%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2016-10-745133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+novel+irreversible+FLT3+inhibitor%2C+FF-10101%2C+shows+excellent+efficacy+against+AML+cells+with+FLT3+mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lhPLVy-iEe4Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520novel%2520irreversible%2520FLT3%2520inhibitor%252C%2520FF-10101%252C%2520shows%2520excellent%2520efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.911839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1517%2F13543784.2014.911839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24749672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=943-954&author=N.+Pemmarajuauthor=H.+Kantarjianauthor=M.+Andreeffauthor=J.+Cortesauthor=F.+Ravandi&title=Investigational+FMS-like+tyrosine+kinase+3+inhibitors+in+treatment+of+acute+myeloid+leukemia&doi=10.1517%2F13543784.2014.911839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span></div><div class="casAuthors">Pemmaraju, Naveen; Kantarjian, Hagop; Andreeff, Michael; Cortes, Jorge; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">943-954</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor.  Over the past decade, significant progress has been made in the understanding of the cytogenetic and mol. determinants of AML pathogenesis.  One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3).  Currently, this marker, which appears in approx. one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy.  FLT3 inhibitors have now undergone clin. evaluation in Phase I, II and III clin. trials, as both single agents and in combination with chemotherapeutics.  Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML.  Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.  Areas covered: This review aims to highlight the agents furthest along in their development.  It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.  Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML.  The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTT7YoH9KV7Vg90H21EOLACvtfcHk0lhPLVy-iEe4Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D&md5=b624124fc07e406fe1c802b2e6f6a94c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.911839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.911839%26sid%3Dliteratum%253Aachs%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DInvestigational%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520in%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D943%26epage%3D954%26doi%3D10.1517%2F13543784.2014.911839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5929</span>– <span class="NLM_lpage">5941</span>, <span class="refDoi"> DOI: 10.1021/jm1001869</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1001869" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1WhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5929-5941&author=C.+C.+Chiangauthor=Y.+H.+Linauthor=S.+F.+Linauthor=C.+L.+Laiauthor=C.+Liuauthor=W.+Y.+Weiauthor=S.+C.+Yangauthor=R.+W.+Wangauthor=L.+W.+Tengauthor=S.+H.+Chuangauthor=J.+M.+Changauthor=T.+T.+Yuanauthor=Y.+S.+Leeauthor=P.+Chenauthor=W.+K.+Chiauthor=J.+Y.+Yangauthor=H.+J.+Huangauthor=C.+B.+Liaoauthor=J.+J.+Huang&title=Discovery+of+pyrrole-indoline-2-ones+as+Aurora+kinase+inhibitors+with+a+different+inhibition+profile&doi=10.1021%2Fjm1001869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrrole-Indolin-2-ones as Aurora Kinase Inhibitors with a Different Inhibition Profile</span></div><div class="casAuthors">Chiang, Chao-Cheng; Lin, Yu-Hsiang; Lin, Shu Fu; Lai, Chun-Liang; Liu, Chiawei; Wei, Win-Yin; Yang, Sheng-chuan; Wang, Ru-Wen; Teng, Li-Wei; Chuang, Shih-Hsien; Chang, Jia-Ming; Yuan, Ta-Tung; Lee, Ying-Shuen; Chen, Paonien; Chi, Wei-Kuang; Yang, Ju-Ying; Huang, Hung-Jyun; Liao, Chu-Bin; Huang, Jiann-Jyh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5929-5941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrrole-indolin-2-ones were synthesized; and their inhibition profile for Aurora kinases was studied.  The potent compd. I (R1 = COOH)(II) with phenylsulfonamido at the C-5 position and a carboxyethyl group at the C-3' position selectively inhibited Aurora A over Aurora B with IC50 values of 12 and 156 nM, resp.  Replacement of the carboxyl group with an amino group led to compd. I (R1 = Me2NCH2)(III), which retained the activity for Aurora B and lost activity for Aurora A (IC50 = 2.19 μM).  Computation modeling was used to address the different inhibition profiles of II and III.  Compds. III and I (R1 = COOEt) inhibited the proliferation of HCT-116 and HT-29 cells and suppressed levels of the phosphorylated substrates of Aurora A and Aurora B in the Western blots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfVXFbZCr6bVg90H21EOLACvtfcHk0ljADgqGzCJm5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1WhsLg%253D&md5=00ae36d58067c40a693253f7d7121b9f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm1001869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1001869%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DS.%2BF.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DW.%2BY.%26aulast%3DYang%26aufirst%3DS.%2BC.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DTeng%26aufirst%3DL.%2BW.%26aulast%3DChuang%26aufirst%3DS.%2BH.%26aulast%3DChang%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DT.%2BT.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DChi%26aufirst%3DW.%2BK.%26aulast%3DYang%26aufirst%3DJ.%2BY.%26aulast%3DHuang%26aufirst%3DH.%2BJ.%26aulast%3DLiao%26aufirst%3DC.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520pyrrole-indoline-2-ones%2520as%2520Aurora%2520kinase%2520inhibitors%2520with%2520a%2520different%2520inhibition%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5929%26epage%3D5941%26doi%3D10.1021%2Fjm1001869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaba, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhavale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagchi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Avignon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakerdge, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacskai, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotzbauer, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and characterization of 3-(benzylidene)indolin-2-one derivatives as ligands for α-synuclein fibrils</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6002</span>– <span class="NLM_lpage">6017</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00571</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00571" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOlsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6002-6017&author=W.+Chuauthor=D.+Zhouauthor=V.+Gabaauthor=J.+Liuauthor=S.+Liauthor=X.+Pengauthor=J.+Xuauthor=D.+Dhavaleauthor=D.+P.+Bagchiauthor=A.+d%E2%80%99Avignonauthor=N.+B.+Shakerdgeauthor=B.+J.+Bacskaiauthor=Z.+Tuauthor=P.+T.+Kotzbauerauthor=R.+H.+Mach&title=Design%2C+synthesis%2C+and+characterization+of+3-%28benzylidene%29indolin-2-one+derivatives+as+ligands+for+%CE%B1-synuclein+fibrils&doi=10.1021%2Facs.jmedchem.5b00571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils</span></div><div class="casAuthors">Chu, Wenhua; Zhou, Dong; Gaba, Vrinda; Liu, Jialu; Li, Shihong; Peng, Xin; Xu, Jinbin; Dhavale, Dhruva; Bagchi, Devika P.; d'Avignon, Andre; Shakerdge, Naomi B.; Bacskai, Brian J.; Tu, Zhude; Kotzbauer, Paul T.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6002-6017</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(benzylidine)indolin-2-one derivs. were synthesized and evaluated for their in vitro binding to alpha synuclein (α-syn), beta amyloid (Aβ), and tau fibrils.  Compds. with a single double bond in the 3-position had only a modest affinity for α-syn and no selectivity for α-syn vs. Aβ or tau fibrils.  Homologation to the corresponding diene analogs yielded a mixt. of Z,E and E,E isomers; substitution of the indoline nitrogen with an N-benzyl group resulted in increased binding to α-syn and reasonable selectivity for α-syn vs. Aβ and tau.  Introduction of a para-nitro group into the benzene ring of the diene enabled sepn. of the Z,E and E,E isomers and led to the identification of the Z,E configuration as the more active regioisomer I.  The data described here provide key structural information in the design of probes which bind preferentially to α-syn vs. Aβ or tau fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQNEJSQjpIC7Vg90H21EOLACvtfcHk0ljADgqGzCJm5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOlsL3I&md5=10515999b1fff6aa4079fcd8340546ac</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00571%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DGaba%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDhavale%26aufirst%3DD.%26aulast%3DBagchi%26aufirst%3DD.%2BP.%26aulast%3Dd%25E2%2580%2599Avignon%26aufirst%3DA.%26aulast%3DShakerdge%26aufirst%3DN.%2BB.%26aulast%3DBacskai%26aufirst%3DB.%2BJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DKotzbauer%26aufirst%3DP.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520characterization%2520of%25203-%2528benzylidene%2529indolin-2-one%2520derivatives%2520as%2520ligands%2520for%2520%25CE%25B1-synuclein%2520fibrils%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6002%26epage%3D6017%26doi%3D10.1021%2Facs.jmedchem.5b00571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, S.</span></span> <span> </span><span class="NLM_article-title">Indolinones as promising scaffold as kinase inhibitors: a review</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.2174/138955712798995039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2174%2F138955712798995039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22372601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFSqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=98-119&author=C.+R.+Prakashauthor=S.+Raja&title=Indolinones+as+promising+scaffold+as+kinase+inhibitors%3A+a+review&doi=10.2174%2F138955712798995039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Indolinones as promising scaffold as kinase inhibitors: a review</span></div><div class="casAuthors">Prakash, C. R.; Raja, S.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-119</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases are probably the most important signaling enzymes, which represent about 20% of the druggable genome.  Currently, more than 150 kinases are known.  So, kinase inhibition therapy has become a very important area of drug research since most of our diseases are related to intra or intercellular signaling by kinases.  Indole alkaloids are extensively studied for their biol. activities in several pharmaceutical areas, including, for example, antitumor.  Among this chem. family, indolinone displays very promising antitumor properties by inhibiting various kinase families.  These small mols. have a low mol. wt. and most of them bind to protein kinases competing with ATP for the ATP-binding site.  This review focuses on the indolinone based drugs approved for the treatment of cancer, drugs under clin. trial and then chem. diversity of various synthetic analogs of indolinone and their metabolites as various kinase inhibitors.  This review also focused on structural activity relationship (SAR), mechanisms of action and biol. targets through which indolinone and its derivs. display their antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBE65_guK-XrVg90H21EOLACvtfcHk0ljADgqGzCJm5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFSqtbY%253D&md5=0cdd80efd45309dc2e5a9f2370d6385e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.2174%2F138955712798995039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955712798995039%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DC.%2BR.%26aulast%3DRaja%26aufirst%3DS.%26atitle%3DIndolinones%2520as%2520promising%2520scaffold%2520as%2520kinase%2520inhibitors%253A%2520a%2520review%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D98%26epage%3D119%26doi%3D10.2174%2F138955712798995039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-08-523035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-08-523035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24408321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlOnsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=1525-1534&author=H.+Maauthor=B.+Nguyenauthor=L.+Liauthor=S.+Greenblattauthor=A.+Williamsauthor=M.+Zhaoauthor=M.+Levisauthor=M.+Rudekauthor=A.+Duffieldauthor=D.+Small&title=TTT-3002+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+activity+against+FLT3-associated+leukemias+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2013-08-523035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo</span></div><div class="casAuthors">Ma, Hayley; Nguyen, Bao; Li, Li; Greenblatt, Sarah; Williams, Allen; Zhao, Ming; Levis, Mark; Rudek, Michelle; Duffield, Amy; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1525-1534</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">More than 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating mutation in FMS-like tyrosine kinase-3 (FLT3).  The most common type, internal tandem duplication (ITD), confers poor prognosis.  We report for the first time on TTT-3002, a tyrosine kinase inhibitor (TKI) that is one of the most potent FLT3 inhibitors discovered to date.  Studies using human FLT3/ITD mutant leukemia cell lines revealed the half maximal inhibitory concn. (IC50) for inhibiting FLT3 autophosphorylation is from 100 to 250 pM.  The proliferation IC50 for TTT-3002 in these same cells was from 490 to 920 pM.  TTT-3002 also showed potent activity when tested against the most frequently occurring FLT3-activating point mutation, FLT3/D835Y, against which many current TKIs are ineffective.  These findings were validated in vivo by using mouse models of FLT3-assocd. AML.  Survival and tumor burden of mice in several FLT3/ITD transplantation models is significantly improved by administration of TTT-3002 via oral dosing.  Finally, we demonstrated that TTT-3002 is cytotoxic to leukemic blasts isolated from FLT3/ITD-expressing AML patients, while displaying minimal toxicity to normal hematopoietic stem/progenitor cells from healthy blood and bone marrow donors.  Therefore, TTT-3002 has demonstrated preclin. potential as a promising new FLT3 TKI in the treatment of FLT3-mutant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry55X4DcrgWbVg90H21EOLACvtfcHk0lj61izaD7G3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlOnsLo%253D&md5=b04f0416b03ffccfc35bdb5134d7cd52</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-08-523035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-08-523035%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGreenblatt%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DRudek%26aufirst%3DM.%26aulast%3DDuffield%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DTTT-3002%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520activity%2520against%2520FLT3-associated%2520leukemias%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D1525%26epage%3D1534%26doi%3D10.1182%2Fblood-2013-08-523035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5206</span>– <span class="NLM_lpage">5217</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F0008-5472.CAN-14-1028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25060518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFChur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5206-5217&author=H.+S.+Maauthor=B.+Nguyenauthor=A.+S.+Duffieldauthor=L.+Liauthor=A.+Galanisauthor=A.+B.+Williamsauthor=P.+A.+Brownauthor=M.+J.+Levisauthor=D.+J.+Leahyauthor=D.+Small&title=FLT3+kinase+inhibitor+TTT-3002+overcomes+both+activating+and+drug+resistance+mutations+in+FLT3+in+acute+myeloid+leukemia&doi=10.1158%2F0008-5472.CAN-14-1028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia</span></div><div class="casAuthors">Ma, Hayley S.; Nguyen, Bao; Duffield, Amy S.; Li, Li; Galanis, Allison; Williams, Allen B.; Brown, Patrick A.; Levis, Mark J.; Leahy, Daniel J.; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5206-5217</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There have been a no. of clin. trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors (TBC1) in patients with acute myeloid leukemia (AML) harboring a constitutively activating mutation in FLT3.  However, there has been limited efficacy, most often because of inadequate achievement of FLT3 inhibition through a variety of mechanisms.  In a previous study, TTT-3002 was identified as a novel FLT3 inhibitor with the most potent activity to date against FLT3 internal tandem duplication (FLT3/1TD) mutations.  Here, the activity of TTT-3002 is demonstrated against a broad spectrum of FLT3-activating point mutations, including the most frequently occurring D835 mutations.  The compd. is also active against a no. of point mutations selected for in FLT3/1TD alleles that confer resistance to other TBC1s, including the F691L gatekeeper mutation.  TTT-3002 maintains activity against patients with relapsed AML samples that are resistant to sorafenib and AC220.  Studies utilizing human plasma samples from healthy donors and patients with AML indicate that TTT-3002 is only moderately protein bound compared with several other TBQs currently in clin. trials.  Tumor burden of mice in a FLT3 TBQ-resistant transplant model is significantly improved by oral dosing of TTT-3002.  Therefore, TTT-3002 has demonstrated preclin. potential as a promising new FLT3 TK1 that may overcome some of the limitations of other TK1s in the treatment of FLT3-mutant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrixEzcXb7up7Vg90H21EOLACvtfcHk0lj61izaD7G3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFChur7K&md5=cad8c94b1222156359a4b70b596b4150</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1028%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DH.%2BS.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DDuffield%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGalanis%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DA.%2BB.%26aulast%3DBrown%26aufirst%3DP.%2BA.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520kinase%2520inhibitor%2520TTT-3002%2520overcomes%2520both%2520activating%2520and%2520drug%2520resistance%2520mutations%2520in%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5206%26epage%3D5217%26doi%3D10.1158%2F0008-5472.CAN-14-1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ookura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zokumasu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span> <span> </span><span class="NLM_article-title">Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2014.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bcp.2014.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24735609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslahtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2014&pages=16-24&author=A.+Yoshidaauthor=M.+Ookuraauthor=K.+Zokumasuauthor=T.+Ueda&title=G%C3%B66976%2C+a+FLT3+kinase+inhibitor%2C+exerts+potent+cytotoxic+activity+against+acute+leukemia+via+inhibition+of+survivin+and+MCL-1&doi=10.1016%2Fj.bcp.2014.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Go6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1</span></div><div class="casAuthors">Yoshida, Akira; Ookura, Miyuki; Zokumasu, Kouichi; Ueda, Takanori</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mutations of the FMS-like tyrosine kinase 3 (FLT3) have been reported in about a third of patients with acute myeloid leukemia (AML).  The presence of FLT3 mutations confers a poor prognosis.  Thus, pharmacol. inhibitors of FLT3 are of therapeutic interest for AML.  Go6976 is an indolocarbazole with a similar structural backbone to staurosporine.  In the present study, the authors demonstrated that Go6976 displays a potent inhibitory activity against recombinant FLT3 using an in vitro kinase assay, with an IC50 value of 0.7 nM.  Go6976 markedly inhibited the proliferation of human leukemia cells having FLT3-ITD such as MV4-11 and MOLM13.  The authors also obsd. that Go6976 showed minimal toxicity for human normal CD34(+) cells.  Go6976 suppressed the phosphorylation of FLT3 and downstream signaling mols. such as STAT3/5, Erk1/2, and Akt in MV4-11 and MOLM13 cells.  Interestingly, induction of apoptosis by Go6976 was assocd. with rapid and pronounced down-regulation of the anti-apoptotic protein survivin and MCL-1.  Suppression of survivin protein expression by Go6976 was due to the inhibition of transcription via the suppression of STAT3/5.  Go6976 induced proteasome-mediated degrdn. of MCL-1.  Previously described FLT3 inhibitors such as PKC412 are bound by the human plasma protein, α1-acid glycoprotein, resulting in diminished inhibitory activity against FLT3.  In contrast, the authors found that Go6976 potently inhibited phosphorylation of FLT3 and exerted cytotoxicity in the presence of human serum.  In conclusion, Go6976 is a potent FLT3 inhibitor that displays a significant antiproliferative activity against leukemia cells with FLT3-ITD through the profound down-regulation of survivin and MCL-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUNQ6_U3s_SLVg90H21EOLACvtfcHk0lj61izaD7G3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslahtL0%253D&md5=3b3c80c72aa3ecf5a80214d05dc83028</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DA.%26aulast%3DOokura%26aufirst%3DM.%26aulast%3DZokumasu%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DT.%26atitle%3DG%25C3%25B66976%252C%2520a%2520FLT3%2520kinase%2520inhibitor%252C%2520exerts%2520potent%2520cytotoxic%2520activity%2520against%2520acute%2520leukemia%2520via%2520inhibition%2520of%2520survivin%2520and%2520MCL-1%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D90%26spage%3D16%26epage%3D24%26doi%3D10.1016%2Fj.bcp.2014.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puente-Moncada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antolín, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermosilla, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Escuredo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ríos-Lombardía, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Sanchez, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luño, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morís, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-17-0530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29339551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslKks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=614-624&author=N.+Puente-Moncadaauthor=P.+Costalesauthor=I.+Antol%C3%ADnauthor=L.+E.+N%C3%BA%C3%B1ezauthor=P.+Oroauthor=M.+A.+Hermosillaauthor=J.+P%C3%A9rez-Escuredoauthor=N.+R%C3%ADos-Lombard%C3%ADaauthor=A.+M.+Sanchez-Sanchezauthor=E.+Lu%C3%B1oauthor=C.+Rodr%C3%ADguezauthor=V.+Mart%C3%ADnauthor=F.+Mor%C3%ADs&title=Inhibition+of+FLT3+and+PIM+kinases+by+EC-70124+exerts+potent+activity+in+preclinical+models+of+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-17-0530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia</span></div><div class="casAuthors">Puente-Moncada, Noelia; Costales, Paula; Antolin, Isaac; Nunez, Luz-Elena; Oro, Patricia; Hermosilla, Maria Ana; Perez-Escuredo, Jhudit; Rios-Lombardia, Nicolas; Sanchez-Sanchez, Ana M.; Luno, Elisa; Rodriguez, Carmen; Martin, Vanesa; Moris, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">614-624</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) or tyrosine kinase domain mutations of FLT3 is the most frequent genetic alteration in acute myelogenous leukemia (AML) and are assocd. with poor disease outcome.  Despite considerable efforts to develop single-target FLT3 drugs, so far, the most promising clin. response has been achieved using the multikinase inhibitor midostaurin.  Here, we explore the activity of the indolocarbazole EC-70124, from the same chem. space as midostaurin, in preclin. models of AML, focusing on those bearing FLT3-ITD mutations.  EC-70124 potently inhibits wild-type and mutant FLT3, and also other important kinases such as PIM kinases.  EC-70124 inhibits proliferation of AML cell lines, inducing cell-cycle arrest and apoptosis.  EC-70124 is orally bioavailable and displays higher metabolic stability and lower human protein plasma binding compared with midostaurin.  Both in vitro and in vivo pharmacodynamic analyses demonstrate inhibition of FLT3-STAT5, Akt-mTOR-S6, and PIM-BAD pathways.  Oral administration of EC-70124 in FLT3-ITD xenograft models demonstrates high efficacy, reaching complete tumor regression.  Ex vivo, EC-70124 impaired cell viability in leukemic blasts, esp. from FLT3-ITD patients.  Our results demonstrate the ability of EC-70124 to reduce proliferation and induce cell death in AML cell lines, patient-derived leukemic blast and xenograft animal models, reaching best results in FLT3 mutants that carry other mol. pathways' alterations.  Thus, its unique inhibition profile warrants EC-70124 as a promising agent for AML treatment based on its ability to interfere the complex oncogenic events activated in AML at several levels.  Mol Cancer Ther; 17(3); 614-24. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQ9fNZW2JAbVg90H21EOLACvtfcHk0liO4_35ApBdIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslKks78%253D&md5=a344bc7ff7f94e8897e140e9947fc1fb</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0530%26sid%3Dliteratum%253Aachs%26aulast%3DPuente-Moncada%26aufirst%3DN.%26aulast%3DCostales%26aufirst%3DP.%26aulast%3DAntol%25C3%25ADn%26aufirst%3DI.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DL.%2BE.%26aulast%3DOro%26aufirst%3DP.%26aulast%3DHermosilla%26aufirst%3DM.%2BA.%26aulast%3DP%25C3%25A9rez-Escuredo%26aufirst%3DJ.%26aulast%3DR%25C3%25ADos-Lombard%25C3%25ADa%26aufirst%3DN.%26aulast%3DSanchez-Sanchez%26aufirst%3DA.%2BM.%26aulast%3DLu%25C3%25B1o%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DC.%26aulast%3DMart%25C3%25ADn%26aufirst%3DV.%26aulast%3DMor%25C3%25ADs%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520FLT3%2520and%2520PIM%2520kinases%2520by%2520EC-70124%2520exerts%2520potent%2520activity%2520in%2520preclinical%2520models%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D614%26epage%3D624%26doi%3D10.1158%2F1535-7163.MCT-17-0530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Civenni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longoni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García Inclán, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morís, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span> <span> </span><span class="NLM_article-title">EC-70124, a novel glycosylated indolocarbazole multikinase inhibitor, reverts tumorigenic and stem cell properties in prostate cancer by inhibiting STAT3 and NF-κB</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-15-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26826115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt12kurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=806-818&author=G.+Civenniauthor=N.+Longoniauthor=P.+Costalesauthor=C.+Dallavalleauthor=C.+Garc%C3%ADa+Incl%C3%A1nauthor=D.+Albinoauthor=L.+E.+Nu%C3%B1ezauthor=F.+Mor%C3%ADsauthor=G.+M.+Carboneauthor=C.+V.+Catapano&title=EC-70124%2C+a+novel+glycosylated+indolocarbazole+multikinase+inhibitor%2C+reverts+tumorigenic+and+stem+cell+properties+in+prostate+cancer+by+inhibiting+STAT3+and+NF-%CE%BAB&doi=10.1158%2F1535-7163.MCT-15-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB</span></div><div class="casAuthors">Civenni, Gianluca; Longoni, Nicole; Costales, Paula; Dallavalle, Cecilia; Garcia Inclian, Cristina; Albino, Domenico; Nuianez, Luz Elena; Morianis, Francisco; Carbone, Giuseppina M.; Catapano, Carlo V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">806-818</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer stem cells (CSC) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance to current therapies.  The transcription factors NF-κB and STAT3 are frequently activated in advanced prostate cancer and sustain expansion of prostate CSCs.  EC-70124 is a novel chimeric indolocarbazole compd. generated by metabolic engineering of the biosynthetic pathways of glycosylated indolocarbazoles, such as staurosporine and rebeccamycin.  In vitro kinome analyses revealed that EC-70124 acted as a multikinase inhibitor with potent activity against IKKβ and JAK2.  In this study, we show that EC-70124 blocked concomitantly NF-κB and STAT3 in prostate cancer cells and particularly prostate CSCs, which exhibited overactivation of these transcription factors.  Phosphorylation of IkB and STAT3 (Tyr705), the immediate targets of IKKβ and JAK2, resp., was rapidly inhibited in vitro by EC-70124 at concns. that were well below plasma levels in mice.  Furthermore, the drug blocked activation of NF-κB and STAT3 reporters and suppressed transcription of their target genes.  Treatment with EC-70124 impaired proliferation and colony formation in vitro and delayed development of prostate tumor xenografts.  Notably, EC-70124 had profound effects on the prostate CSC subpopulation both in vitro and in vivo.  Thus, EC-70124 is a potent inhibitor of the NF-κB and STAT3 signaling pathways and blocked tumor growth and maintenance of prostate CSCs.  EC-70124 may provide the basis for developing new therapeutic strategies that combine agents directed to the CSC component and the bulk tumor cell population for treatment of advanced prostate cancer.  Mol Cancer Ther; 15(5); 806-18. cpr2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBpNvOhVgoyLVg90H21EOLACvtfcHk0liO4_35ApBdIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt12kurs%253D&md5=aa370ca82631a8ba1bb4015a27fbd17f</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0791%26sid%3Dliteratum%253Aachs%26aulast%3DCivenni%26aufirst%3DG.%26aulast%3DLongoni%26aufirst%3DN.%26aulast%3DCostales%26aufirst%3DP.%26aulast%3DDallavalle%26aufirst%3DC.%26aulast%3DGarc%25C3%25ADa%2BIncl%25C3%25A1n%26aufirst%3DC.%26aulast%3DAlbino%26aufirst%3DD.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DL.%2BE.%26aulast%3DMor%25C3%25ADs%26aufirst%3DF.%26aulast%3DCarbone%26aufirst%3DG.%2BM.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26atitle%3DEC-70124%252C%2520a%2520novel%2520glycosylated%2520indolocarbazole%2520multikinase%2520inhibitor%252C%2520reverts%2520tumorigenic%2520and%2520stem%2520cell%2520properties%2520in%2520prostate%2520cancer%2520by%2520inhibiting%2520STAT3%2520and%2520NF-%25CE%25BAB%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D806%26epage%3D818%26doi%3D10.1158%2F1535-7163.MCT-15-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2019.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31207462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1SrsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=468-483&author=T.+Yuanauthor=B.+Qiauthor=Z.+Jiangauthor=W.+Dongauthor=L.+Zhongauthor=L.+Baiauthor=R.+Tongauthor=J.+Yuauthor=J.+Shi&title=Dual+FLT3+inhibitors%3A+against+the+drug+resistance+of+acute+myeloid+leukemia+in+recent+decade&doi=10.1016%2Fj.ejmech.2019.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade</span></div><div class="casAuthors">Yuan, Ting; Qi, Baowen; Jiang, Zhongliang; Dong, Wenjuan; Zhong, Lei; Bai, Lan; Tong, Rongsheng; Yu, Jiying; Shi, Jianyou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">468-483</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth and differentiation of hematopoietic stem cells.  Although the pathogenesis has not been fully elucidated, many specific gene mutations have been found in AML.  Fms-like tyrosine kinase 3 (FLT3) is recognized as a drug target for the treatment of AML, and the activation mutations of FLT3 were found in about 30% of AML patients.  Targeted inhibition of FLT3 receptor tyrosine kinase has shown promising results in the treatment of FLT3 mutation AML.  Unfortunately, the therapeutic effects of FLT3 tyrosine kinase inhibitors used as AML monotherapy are usually accompanied by the high risk of resistance development within a few months after treatment.  FLT3 dual inhibitors were generated with the co-inhibition of FLT3 and another target, such as CDK4, JAK2, MEK, Mer, Pim, etc., to solve the problems mentioned above.  As a result, the therapeutic effect of the drug is significantly improved, while the toxic and side effects are reduced.  Besides, the life quality of AML patients with FLT3 mutation has been effectively improved.  In this paper, we reviewed the studies of dual FLT3 inhibitors that have been discovered in recent years for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom3VPbgD-eHbVg90H21EOLACvtfcHk0ljDt7G4BhXKFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1SrsbrO&md5=3d22e4e96fcaee23470677de454bf557</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DTong%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DDual%2520FLT3%2520inhibitors%253A%2520against%2520the%2520drug%2520resistance%2520of%2520acute%2520myeloid%2520leukemia%2520in%2520recent%2520decade%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D468%26epage%3D483%26doi%3D10.1016%2Fj.ejmech.2019.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondekar, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.07.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2014.07.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25089810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GqsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=268-288&author=A.+D.+Jagtapauthor=P.+T.+Changauthor=J.+R.+Liuauthor=H.+C.+Wangauthor=N.+B.+Kondekarauthor=L.+J.+Shenauthor=H.+W.+Tsengauthor=G.+S.+Chenauthor=J.+W.+Chern&title=Novel+acylureidoindolin-2-one+derivatives+as+dual+Aurora+B%2FFLT3+inhibitors+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1016%2Fj.ejmech.2014.07.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Jagtap, Ajit Dhananjay; Chang, Pei-Teh; Liu, Jia-Rong; Wang, Hsiao-Chun; Kondekar, Nagendra B.; Shen, Li-Jiuan; Tseng, Hsiang-Wen; Chen, Grace Shiahuy; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">268-288</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 6-acylureido derivs. contg. a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide I was identified as a dual Aurora B/FLT3 inhibitor (IC50 = 0.4 nM and 0.5 nM, resp.).  Compd. I also exhibited potent cytotoxicity with single-digit nanomolar IC50 values against the FLT3 mutant-assocd. human acute myeloid leukemia (AML) cell lines MV4-11 (FLT3-ITD) and MOLM-13 (FLT3-ITD).  Compd. I also specifically induced extrinsic apoptosis by inhibiting the phosphorylation of the Aurora B and FLT3 pathways in MOLM-13 cells.  Compd. I had a moderate pharmacokinetic profile.  The mesylate salt of I efficiently inhibited tumor growth and reduced the mortality of BALB/c nude mice (s.c. xenograft model) that had been implanted with AML MOLM-13 cells.  Compd. 54 is more potent than sunitinib not only against FLT3-WT AML cells but also active against sunitinib-resistant FLT3-ITD AML cells.  This study demonstrates the significance of dual Aurora B/FLT3 inhibitors for the development of potential agents to treat AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpsREAI85CULVg90H21EOLACvtfcHk0ljDt7G4BhXKFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GqsrfJ&md5=402a36cc073d35716a90b33f2011eb9a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.07.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.07.108%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DA.%2BD.%26aulast%3DChang%26aufirst%3DP.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DH.%2BC.%26aulast%3DKondekar%26aufirst%3DN.%2BB.%26aulast%3DShen%26aufirst%3DL.%2BJ.%26aulast%3DTseng%26aufirst%3DH.%2BW.%26aulast%3DChen%26aufirst%3DG.%2BS.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DNovel%2520acylureidoindolin-2-one%2520derivatives%2520as%2520dual%2520Aurora%2520B%252FFLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D85%26spage%3D268%26epage%3D288%26doi%3D10.1016%2Fj.ejmech.2014.07.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2016.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28038328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=72-86&author=F.+Maauthor=P.+Liuauthor=M.+Leiauthor=J.+Liuauthor=H.+Wangauthor=S.+Zhaoauthor=L.+Hu&title=Design%2C+synthesis+and+biological+evaluation+of+indolin-2-one-based+derivatives+as+potent%2C+selective+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase3+%28FLT3%29&doi=10.1016%2Fj.ejmech.2016.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)</span></div><div class="casAuthors">Ma, Fei; Liu, Peng; Lei, Min; Liu, Jian; Wang, Hongtao; Zhao, Shaohua; Hu, Lihong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-86</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approx. one third of acute myeloid leukemia (AML) patients, which has been proposed as a promising drug target for AML therapy.  A series of indolin-2-one derivs. bearing different groups at the solvent interface position based on sunitinib as FLT3 inhibitors were designed, synthesized and evaluated in FLT3-dependent human AML cell line MV4-11.  Structure-activity relationship (SAR)anal. showed that heterocyclic alkane at the solvent interface position could significantly increase the potency for the inhibition of proliferation of MV4-11 cell line.  Compd. I and II exhibited better efficacy (MV4-11, IC50: 14.7 nM for 10a and 24.8 nM for 10d) than pos. control sunitinib (MV4-11, IC50: 38.5 nM).  The kinase and cellular inhibition assay exhibited that II (FLT3, IC50: 5.3 nM) was a potent and selective FLT3 inhibitor.  Furthermore, the pharmacokinetic expts. showed that II had good properties of oral bioavailability, Cmax, Tmax, T1/2 and AUC in mice, resp.  The in vivo study indicated that 10d could significantly suppress tumor growth in MV4-11 xenografts nude mice model and occupied with a commendable therapeutic window compared to sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGombpAwcRUoKLVg90H21EOLACvtfcHk0ljDt7G4BhXKFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSksw%253D%253D&md5=02b3a5a36defa999945f359774c15fbc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520indolin-2-one-based%2520derivatives%2520as%2520potent%252C%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase3%2520%2528FLT3%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D72%26epage%3D86%26doi%3D10.1016%2Fj.ejmech.2016.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quast, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolanus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trebicka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D.</span></span> <span> </span><span class="NLM_article-title">The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2123</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2016.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27220666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2ksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=2119-2123&author=J.+Rudolphauthor=A.+Heineauthor=T.+Quastauthor=W.+Kolanusauthor=J.+Trebickaauthor=P.+Brossartauthor=D.+Wolf&title=The+JAK+inhibitor+ruxolitinib+impairs+dendritic+cell+migration+via+off-target+inhibition+of+ROCK&doi=10.1038%2Fleu.2016.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK</span></div><div class="casAuthors">Rudolph, J.; Heine, A.; Quast, T.; Kolanus, W.; Trebicka, J.; Brossart, P.; Wolf, D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2119-2123</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative neoplasms (MPNs) are clonal neoplastic disorders of hematopoiesis, leading to a hypercellular bone marrow and eventually to severe fibrosis, termed myelofibrosis (MF).1 Particularly advanced stage MF patients suffer from splenomegaly, anemia and constitutional symptoms due to elevated levels of proinflammatory cytokines.  A gain-of-function V617F mutation in the JAK2 kinase causes the constitutive activation of the JAK/STAT pathway and is supposed to be at least in part responsible for the disease phenotype of MPN.  As the mutation is present in 65% of primary MF patients, 95% of polycythemia vera (PV) patients and 55% of essential thrombocythemia (ET) patients, various JAK inhibitors are currently tested as targeted therapeutics in MPN.2.  Ruxolitinib is an oral JAK inhibitor recently approved for treatment of primary and secondary MF that shows impressive symptom control by suppression of inflammation irresp. of the JAK mutational status.  Moreover, ruxolitinib is also a promising drug for acute and chronic GvHD treatment.3, 4 We recently described various aspects of immune modulation by ruxolitinib5, 6 including impaired DC function.7.  DCs are important antigen-presenting cells maturing and migrating via afferent lymphatic vessels from peripheral organs into T-cell areas of draining lymph nodes (LNs) upon antigen contact.8.  This process is guided by chemokine gradients and requires cytoskeletal rearrangement promoting cell movement.  CCR7 is expressed on DCs upon antigen contact and senses chemokine gradients of CCL19 and CCL21.  CCL19 is essential for guiding DCs into draining LNs.9, 10.  Notably, recent work suggested that activation of JAKs is involved in lymphocyte migration.11.  The aim of this study was a detailed anal. of the impact of ruxolitinib on DC migration with a particular focus on short-term effects of the drug and the identification of potential target mols. mediating these effects.  We recently already described that in vivo DC migration under conditions of inflammation is impaired after long-term exposure with ruxolitinib.7 We now extended our previous findings by evaluating the effects of ruxolitinib on DC migration.  Using a set-up of an ex vivo crawl-in assay within explanted ear dermis, we could visualize DCs migrating towards and entering afferent lymphatic vessels.  Vehicle-treated bmDCs (green) appropriately migrate to and localize around lymphatics (stained for laminin in red), while ruxolitinib-exposed bmDCs cannot be detected around lymphatic vessels (Figure 1a).  We then analyzed the effect of ruxolitinib on chemokine-induced migration of LPS-matured human moDCs in vitro using three-dimensional (3D) collagen matrixes.  After collagen polymn., cells are embedded in a complex network of fibrils, mimicking the extracellular matrix.  Again, the JAK inhibitor ruxolitinib was added directly to the assay, limiting the max. exposure of the cells to 4 h.  Thus, the obsd. effects are unlikely due to dedifferentiation or dematuration of DCs, which are usually seen as early as 48 h after drug exposure.7.  Ruxolitinib dose-dependently impairs directional migration of moDCs towards a CCL19 gradient, as mirrored by reduced velocity and accumulated distance (Figures 1b and c).  Toxicity of the drug was excluded by annexin V/7-AAD staining (data not shown).  Importantly, ruxolitinib-exposed moDCs are still able to sense the chemokine gradient as they form lamellipodia at the leading edge of the cell, whereas retraction of the uropod is clearly inhibited, resulting in an elongated cell body of the cells (Supplementary Videos 1 and 2).  According to proper chemokine sensing, ruxolitinib does not alter the expression of the CCL19-sensing chemokine receptor CCR7 (data not shown).  Anal. of the cell cytoskeleton by fluorescent labeling of the actin and tubulin network also revealed no overt structural alterations after ruxolitinib exposure (Figure 1d).  To investigate if the obsd. defects in DC migration after ruxolitinib treatment are based on an imbalance of adhesion, migration of talin1-deficient moDCs in 3D collagen matrixes, static adhesion analyses on different two-dimensional (2D) substrates and flow cytometry-based characterization of integrin subsets was performed.  As talin is of crit. importance for integrin activation and the coupling of integrins to the actin cytoskeleton,12 talin1-deficient moDCs were evaluated for their migratory capacity within complex collagen networks.  In accordance with the previous reports, the absence of talin had no impact on the migratory ability, as DCs are able to switch between integrin-dependent and -independent migration modes (Figure 1e).  Knockdown efficiency of talin1 was proven by western blot anal. (Figure 1f).  Of note, the migratory defects seen in ruxolitinib-treated control cells could be induced irresp. of the presence or absence of talin (Figure 1e).  In line with these observations, we could not detect any changes of adhesion of mature moDCs to fibronectin or collagen (Figure 1g) as a potential reason for decreased migration due to increased 'stickiness' of the moDCs.  As expected, in contrast to the migration within 3D environments, adhesion of talin1-deficient moDCs to both substrates was markedly impaired.  Ruxolitinib treatment did not further reduce adhesion in the 2D setting.  Similarly, no alteration of integrin expression levels could be detected in ruxolitinib-exposed DC (Figure 1h).  Due to the highly conserved structure of the catalytic sites of protein kinases, ATP-competitive inhibitors like ruxolitinib often show side effects due to unspecific binding to different target kinases.  It is known that ruxolitinib impairs the function of other kinases in addn. to JAKs.13 Therefore, we first tested whether siRNAs targeting either JAK1, JAK2 or JAK1 and 2 affect moDC migration towards CCL19 in the 3D migration assay.  Interestingly, CCL19-induced chemotaxis is not significantly altered in the absence of JAK1 and/or JAK2 expression (Figure 2a), highlighting that the inhibitory effects of ruxolitinib are independent of JAK1 and/or JAK2, the main targets of the drug.  Knockdown efficiency was verified by western blot anal. of the resp. JAKs (Figure 2b).  This data is in contrast to recent publications reporting a functional involvement of JAKs in lymphocyte migration,11 as JAK1/JAK2-deficient lymphocytes do not properly migrate in vitro and their homing to LNs in vivo is also reduced.  However, in these reports intranodal localization and motility of lymphocytes were not affected by JAK deficiency.  The study performed by Stein et al. also applied relatively high concns. of AG490, a JAK inhibitor currently not used/tested in clin. praxis.  We confirmed our pharmacol. data by using momelotinib, another clin. tested JAK inhibitor, mimicking the redn. of the migratory capacity induced by ruxolitinib (data not shown) and the discrepancy may also at least in part be explained by the different cell types (lymphocytes vs. DCs) examd.  On the basis of literature findings describing 33 kinases inhibited more than 50% in the presence of 1 μM of ruxolitinib, we next aimed to identify the target of the drug mediating the migration defects.  Interestingly, the screen revealed two kinases, Rho-assocd. coiled-coil kinase 1 and 2 (ROCK1 and ROCK2), with a functional impairment of 71 and 65% after ruxolitinib treatment.13 The serine-threonine kinase ROCK controls non-muscle myosin II activity, thereby regulating reorganization and contraction of cellular actin-myosin filaments14 and is of crit. importance in DC migration as it mediates the deadhesion of cells from ICAM-1 and propels the rigid nucleus through narrow gaps of the extracellular matrix.12, 15.  To evaluate the data from the kinase screen in our cellular setup, we analyzed various target proteins known to be regulated by ROCK.  Therapeutic doses of ruxolitinib clearly inhibit ROCK activity as phosphorylation of myosin phosphatase targeting subunit 1 (pMYPT1), a downstream target of ROCK (Figure 2c), was clearly reduced.  As a consequence, the phosphorylation of moesin in LPS-matured moDCs was also affected (Figure 2d) and more of the phosphorylated inactive form of cofilin could be detected (Figure 2e).  To compare the effect of ROCK inhibition on migration behavior obsd. in ruxolitinib-treated moDCs, Y-27632 an ATP-competitive ROCK inhibitor was added to the migration assays.  Similar to ruxolitinib, Y-27632 potently inhibited moDC migration (Figure 2f) and induced a morphol. phenotype showing conserved chemokine sensing but impaired uropod retraction (Supplementary Video 3).  In contrast to ruxolitinib,7 sole inhibition of ROCK by Y-27632 did not induce any phenotypic changes of bona fide DC markers or the in vitro differentiation from monocytes (data not shown).  Hence, while inhibition of DC migration is independent of JAK, the effects on DC differentiation and maturation cannot be explained by the here-described off-target inhibition of ROCK.  Consequently, the immunosuppressive effects induced by ruxolitinib are most likely a consequence of a combined targeting of several kinases involved in the regulation of immune cell functions.  In summary, we here provide the mol. basis for a deeper understanding of ruxolitinib-mediated inhibition of DC migration, as we identified ROCK as ruxolitinib target.  Thus via interference with ROCK activation, ruxolitinib profoundly impairs DC migration.  Subsequently, the loss of trafficking DCs may lead to reduced activation of T cells in draining LNs and might therefore explain the abundance of these proinflammatory cells from the blood of MPN patients after ruxolitinib treatment.5.  Our data may be of importance to better understand the immune-modulatory effects of ruxolitinib in vivo and add further pieces to the puzzle how pleiotropic ruxolitinib-mediated immune-suppressive effects in mice and men may be.  The data also complement recent reports on the immune-suppressive role of this compd. class for the treatment of immune-mediated diseases, such as GvHD.3, 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ2L03q1y7yLVg90H21EOLACvtfcHk0ljnSya1ZccyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2ksb8%253D&md5=29121a00b0afd89b9d005912c8e1c204</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.155%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DQuast%26aufirst%3DT.%26aulast%3DKolanus%26aufirst%3DW.%26aulast%3DTrebicka%26aufirst%3DJ.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DWolf%26aufirst%3DD.%26atitle%3DThe%2520JAK%2520inhibitor%2520ruxolitinib%2520impairs%2520dendritic%2520cell%2520migration%2520via%2520off-target%2520inhibition%2520of%2520ROCK%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D2119%26epage%3D2123%26doi%3D10.1038%2Fleu.2016.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fancher, K. M.</span></span> <span> </span><span class="NLM_article-title">Off-target effects of BCR-ABL and JAK2 inhibitors</span>. <i>Am. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1097/COC.0000000000000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1097%2FCOC.0000000000000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24351780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=76-84&author=M.+R.+Greenauthor=M.+D.+Newtonauthor=K.+M.+Fancher&title=Off-target+effects+of+BCR-ABL+and+JAK2+inhibitors&doi=10.1097%2FCOC.0000000000000023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Off-Target Effects of BCR-ABL and JAK2 Inhibitors</span></div><div class="casAuthors">Green, Myke R.; Newton, Michael D.; Fancher, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-84</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The advent of targeted oncolytic agents has created a revolution in the treatment of malignancies.  Perhaps best exemplified in myeloproliferative neoplasms (MPN), the tyrosine kinase inhibitors, including inhibitors of BCR-ABL tyrosine kinase and JAK2, have dramatically changed outcomes in persons with MPN.  However, clin. relevant dosing of these ATP-mimetic agents in humans leads to inhibition of numerous tyrosine kinases beyond those touted by drug manufacturers and studied in landmark clin. trials.  These so-called off-target effects have been linked to both clin. efficacy and toxicity.  Rational drug development and serendipitous discovery of drug mols. allows the clinician to select targeted oncolytic agents to treat a specific clin. diagnosis and/or avoid exacerbation of concomitant disease states due to effects upon signaling pathways.  Understanding the off-target binding and effects upon signaling pathway of the agents approved for the treatment of MPN will empower the clinician to adroitly select pharmacotherapy, predict toxicities, and utilize these agents in clin. practice for indications beyond MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj0y3czkLgvrVg90H21EOLACvtfcHk0ljnSya1ZccyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGru70%253D&md5=cad05d4b8798b00ea8a4c9b370075d87</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1097%2FCOC.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0000000000000023%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DM.%2BR.%26aulast%3DNewton%26aufirst%3DM.%2BD.%26aulast%3DFancher%26aufirst%3DK.%2BM.%26atitle%3DOff-target%2520effects%2520of%2520BCR-ABL%2520and%2520JAK2%2520inhibitors%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D39%26spage%3D76%26epage%3D84%26doi%3D10.1097%2FCOC.0000000000000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornace, A. J.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, H. J.</span></span> <span> </span><span class="NLM_article-title">Off-target response of a Wip1 chemical inhibitor in skin keratinocytes</span>. <i>J. Dermatol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.jdermsci.2013.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.jdermsci.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24126074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Wit7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=125-134&author=J.+S.+Leeauthor=J.+R.+Parkauthor=O.+S.+Kwonauthor=H.+Kimauthor=A.+J.+Fornaceauthor=H.+J.+Cha&title=Off-target+response+of+a+Wip1+chemical+inhibitor+in+skin+keratinocytes&doi=10.1016%2Fj.jdermsci.2013.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Off-target response of a Wip1 chemical inhibitor in skin keratinocytes</span></div><div class="casAuthors">Lee, Ji-Seon; Park, Jeong-Rak; Kwon, Ok-Seon; Kim, Hyongbum; Fornace, Albert J.; Cha, Hyuk-Jin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">JDSCEI</span>;
        ISSN:<span class="NLM_cas:issn">0923-1811</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The wild type p53 inducible phosphatase (Wip1) plays an important role in modulating not only stress responses by various environmental stresses, but when overexpressed it also impairs the intrinsic tumor surveillance networks that are frequently found in a no. of cancers including skin cancers.  As a result, using a pharmacol. inhibitor of Wip1 has been suggested to be a novel chemotherapeutic approach to recover the innate tumor surveillance in a variety of cancers.  We studied the effect of a pharmacol. inhibitor of Wip1 in skin keratinocytes, under a ultra-violet (UV) stress condition.  A human keratinocyte cell line or human epidermal keratinocytes were exposed to UV, with or without the sole com. available chem. inhibitor of Wip1, CCT007093; subsequently, we detd. the diverse stress responses, including apoptosis and the activation of stress signaling.  We demonstrate that the Wip1 inhibitor unexpectedly attenuated the UV-mediated apoptotic response in skin keratinocytes, as a consequence of attenuated JNK activation and reduced H2AX phosphorylation in both, skin keratinocytes and a Wip1-null cell model.  On the other hand, the loss of Wip1 expression, either by knockout or knockdown in mice or human keratinocytes resp., promoted apoptosis and potentiated H2AX phosphorylation following UV treatment.  Of note, CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression.  Thus, our studies suggest that the development of a more potent and specific Wip1 inhibitor is necessary to achieve the desired chemotherapeutic potential and to avoid off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqAM70hic0irVg90H21EOLACvtfcHk0ljnSya1ZccyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Wit7%252FI&md5=9d385da3dc9d4ff237d9f70427de5ffa</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.jdermsci.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdermsci.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DJ.%2BR.%26aulast%3DKwon%26aufirst%3DO.%2BS.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DFornace%26aufirst%3DA.%2BJ.%26aulast%3DCha%26aufirst%3DH.%2BJ.%26atitle%3DOff-target%2520response%2520of%2520a%2520Wip1%2520chemical%2520inhibitor%2520in%2520skin%2520keratinocytes%26jtitle%3DJ.%2520Dermatol.%2520Sci.%26date%3D2014%26volume%3D73%26spage%3D125%26epage%3D134%26doi%3D10.1016%2Fj.jdermsci.2013.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takács-Novák, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Völgyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horváth, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szokol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breza, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szántai-Kis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illyés, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Őrfi, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2018.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29935772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2qsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2391-2398&author=Z.+Nemesauthor=K.+Tak%C3%A1cs-Nov%C3%A1kauthor=G.+V%C3%B6lgyiauthor=K.+Valkoauthor=S.+B%C3%A9niauthor=Z.+Horv%C3%A1thauthor=B.+Szokolauthor=N.+Brezaauthor=J.+Dobosauthor=C.+Sz%C3%A1ntai-Kisauthor=E.+Illy%C3%A9sauthor=S.+Borosauthor=R.+J.+Kokauthor=L.+%C5%90rfi&title=Synthesis+and+characterization+of+amino+acid+substituted+sunitinib+analogues+for+the+treatment+of+AML&doi=10.1016%2Fj.bmcl.2018.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML</span></div><div class="casAuthors">Nemes, Zoltan; Takacs-Novak, Krisztina; Volgyi, Gergely; Valko, Klara; Beni, Szabolcs; Horvath, Zoltan; Szokol, Balint; Breza, Nora; Dobos, Judit; Szantai-Kis, Csaba; Illyes, Eszter; Boros, Sandor; Kok, Robbert Jan; Orfi, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2391-2398</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common type of leukemia in adults.  Sunitinib, a multikinase inhibitor, was the first Fms-like tyrosine kinase 3 (FLT3) inhibitor clin. used against AML.  Off-target effects are a major concern for multikinase inhibitors.  As targeted delivery may reduce such undesired side effects, our goal was to develop novel amino acid substituted derivs. of sunitinib which are potent candidates to be used conjugated with antibodies and peptides.  In the current paper we present the synthesis, physicochem. and in vitro characterization of sixty two Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutant kinase inhibitors, bearing amino acid moieties, fit to be conjugated with peptide-based delivery systems via their carboxyl group.  We detd. the soly., pKa, CHI and LogP values of the compds. along with their inhibition potential against FLT3-ITD mutant kinase and on MV4-11 cell line.  The ester derivs. of the compds. inhibit the growth of the MV4-11 leukemia cell line at submicromolar concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrebu-EoBV6bVg90H21EOLACvtfcHk0ljwuNS3yk34eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2qsbvL&md5=a4c6c132752aaf839729a8f31e57e2db</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DNemes%26aufirst%3DZ.%26aulast%3DTak%25C3%25A1cs-Nov%25C3%25A1k%26aufirst%3DK.%26aulast%3DV%25C3%25B6lgyi%26aufirst%3DG.%26aulast%3DValko%26aufirst%3DK.%26aulast%3DB%25C3%25A9ni%26aufirst%3DS.%26aulast%3DHorv%25C3%25A1th%26aufirst%3DZ.%26aulast%3DSzokol%26aufirst%3DB.%26aulast%3DBreza%26aufirst%3DN.%26aulast%3DDobos%26aufirst%3DJ.%26aulast%3DSz%25C3%25A1ntai-Kis%26aufirst%3DC.%26aulast%3DIlly%25C3%25A9s%26aufirst%3DE.%26aulast%3DBoros%26aufirst%3DS.%26aulast%3DKok%26aufirst%3DR.%2BJ.%26aulast%3D%25C5%2590rfi%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520amino%2520acid%2520substituted%2520sunitinib%2520analogues%2520for%2520the%2520treatment%2520of%2520AML%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2391%26epage%3D2398%26doi%3D10.1016%2Fj.bmcl.2018.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovelman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, K. J.</span></span> <span> </span><span class="NLM_article-title">A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>451</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1042/BJ20121418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1042%2FBJ20121418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23398362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvFOgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=451&publication_year=2013&pages=313-328&author=Y.+Gaoauthor=S.+P.+Daviesauthor=M.+Augustinauthor=A.+Woodwardauthor=U.+A.+Patelauthor=R.+Kovelmanauthor=K.+J.+Harvey&title=A+broad+activity+screen+in+support+of+a+chemogenomic+map+for+kinase+signalling+research+and+drug+discovery&doi=10.1042%2FBJ20121418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery</span></div><div class="casAuthors">Gao, Yinghong; Davies, Stephen P.; Augustin, Martin; Woodward, Anna; Patel, Umesh A.; Kovelman, Robert; Harvey, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">451</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-328</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Despite the development of a no. of efficacious kinase inhibitors, the strategies for rational design of these compds. have been limited by target promiscuity.  In an effort to better understand the nature of kinase inhibition across the kinome, esp. as it relates to off-target effects, we screened a well-defined collection of kinase inhibitors using biochem. assays for inhibitory activity against 234 active human kinases and kinase complexes, representing all branches of the kinome tree.  For our study we employed 158 small mols. initially identified in the literature as potent and specific inhibitors of kinases important as therapeutic targets and/or signal transduction regulators.  Hierarchical clustering of these benchmark kinase inhibitors on the basis of their kinome activity profiles illustrates how they relate to chem. structure similarities and provides new insights into inhibitor specificity and potential applications for probing new targets.  Using this broad dataset, we provide a framework for assessing polypharmacol.  We not only discover likely off-target inhibitor activities and recommend specific inhibitors for existing targets, but also identify potential new uses for known small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNLU0ONM4SALVg90H21EOLACvtfcHk0ljwuNS3yk34eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvFOgs7g%253D&md5=9e0f17ec5cac10198fe28b27e70b4966</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1042%2FBJ20121418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121418%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DWoodward%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DU.%2BA.%26aulast%3DKovelman%26aufirst%3DR.%26aulast%3DHarvey%26aufirst%3DK.%2BJ.%26atitle%3DA%2520broad%2520activity%2520screen%2520in%2520support%2520of%2520a%2520chemogenomic%2520map%2520for%2520kinase%2520signalling%2520research%2520and%2520drug%2520discovery%26jtitle%3DBiochem.%2520J.%26date%3D2013%26volume%3D451%26spage%3D313%26epage%3D328%26doi%3D10.1042%2FBJ20121418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lochner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moolman, J. A.</span></span> <span> </span><span class="NLM_article-title">The many faces of H89: a review</span>. <i>Cardiovasc. Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3466.2006.00261.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1111%2Fj.1527-3466.2006.00261.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=17214602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWisLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=261-274&author=A.+Lochnerauthor=J.+A.+Moolman&title=The+many+faces+of+H89%3A+a+review&doi=10.1111%2Fj.1527-3466.2006.00261.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">The many faces of H89: a review</span></div><div class="casAuthors">Lochner, A.; Moolman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">261-274</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  H89 is marketed as a selective and potent inhibitor of protein kinase A (PKA).  Since its discovery, it has been used extensively for evaluation of the role of PKA in the heart, osteoblasts, hepatocytes, smooth muscle cells, neuronal tissue, epithelial cells, etc.  Despite the frequent use of H89, its mode of specific inhibition of PKA is still not completely understood.  It has also been shown that H89 inhibits at least 8 other kinases, while having a relatively large no. of PKA-independent effects which may seriously compromise interpretation of data.  Thus, while recognizing its kinase inhibiting properties, it is advised that H89 should not be used as the single source of evidence of PKA involvement.  H-89 should be used in conjunction with other PKA inhibitors, such as Rp-cAMPS or PKA analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgjvr_RF9KrVg90H21EOLACvtfcHk0ljwuNS3yk34eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWisLfJ&md5=d1a07a95a053662b725fcfe19fd1378a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.2006.00261.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.2006.00261.x%26sid%3Dliteratum%253Aachs%26aulast%3DLochner%26aufirst%3DA.%26aulast%3DMoolman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520many%2520faces%2520of%2520H89%253A%2520a%2520review%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D2006%26volume%3D24%26spage%3D261%26epage%3D274%26doi%3D10.1111%2Fj.1527-3466.2006.00261.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagestein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keijzer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijdeven, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenselink, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuin, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Westen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2019.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30661740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVehu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=692-699&author=S.+H.+Grimmauthor=B.+Gagesteinauthor=J.+F.+Keijzerauthor=N.+Liuauthor=R.+H.+Wijdevenauthor=E.+B.+Lenselinkauthor=A.+W.+Tuinauthor=A.+van+den+Nieuwendijkauthor=G.+van+Westenauthor=C.+van+Boeckelauthor=H.+S.+Overkleeftauthor=J.+Neefjesauthor=M.+van+der%0AStelt&title=Comprehensive+structure-activity-relationship+of+azaindoles+as+highly+potent+FLT3+inhibitors&doi=10.1016%2Fj.bmc.2019.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors</span></div><div class="casAuthors">Grimm, Sebastian H.; Gagestein, Berend; Keijzer, Jordi F.; Liu, Nora; Wijdeven, Ruud H.; Lenselink, Eelke B.; Tuin, Adriaan W.; van den Nieuwendijk, Adrianus M. C. H.; van Westen, Gerard J. P.; van Boeckel, Constant A. A.; Overkleeft, Herman S.; Neefjes, Jacques; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">692-699</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is characterized by fast progression and low survival rates, in which Fms-like tyrosine kinase 3 (FLT3) receptor mutations have been identified as a driver mutation in cancer progression in a subgroup of AML patients.  Clin. trials have shown emergence of drug resistant mutants, emphasizing the ongoing need for new chem. matter to enable the treatment of this disease.  Here, we present the discovery and topol. structure-activity relationship (SAR) study of analogs of isoquinolinesulfonamide H-89, a well-known PKA inhibitor, as FLT3 inhibitors.  Surprisingly, we found that the SAR was not consistent with the obsd. binding mode of H-89 in PKA.  Matched mol. pair anal. resulted in the identification of highly active sub-nanomolar azaindoles as novel FLT3-inhibitors.  Structure based modeling using the FLT3 crystal structure suggested an alternative, flipped binding orientation of the new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT5rwrdjbivbVg90H21EOLACvtfcHk0lgcSuFoE59Gkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVehu7o%253D&md5=20e2230d003c1f058f5d675dcdfbb544</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DS.%2BH.%26aulast%3DGagestein%26aufirst%3DB.%26aulast%3DKeijzer%26aufirst%3DJ.%2BF.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DWijdeven%26aufirst%3DR.%2BH.%26aulast%3DLenselink%26aufirst%3DE.%2BB.%26aulast%3DTuin%26aufirst%3DA.%2BW.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%26aulast%3Dvan%2BWesten%26aufirst%3DG.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DNeefjes%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DComprehensive%2520structure-activity-relationship%2520of%2520azaindoles%2520as%2520highly%2520potent%2520FLT3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D692%26epage%3D699%26doi%3D10.1016%2Fj.bmc.2019.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scarpino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span> <span> </span><span class="NLM_article-title">Comparative evaluation of covalent docking tools</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1441</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00228</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00228" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSmsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=1441-1458&author=A.+Scarpinoauthor=G.+G.+Ferenczyauthor=G.+M.+Keser%C5%B1&title=Comparative+evaluation+of+covalent+docking+tools&doi=10.1021%2Facs.jcim.8b00228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Evaluation of Covalent Docking Tools</span></div><div class="casAuthors">Scarpino, Andrea; Ferenczy, Gyorgy G.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1441-1458</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Increased interest in covalent drug discovery led to the development of computer programs predicting binding mode and affinity of covalent inhibitors.  Here we compare the performance of six covalent docking tools, AutoDock4, CovDock, FITTED, GOLD, ICM-Pro, and MOE, for reproducing exptl. binding modes in an unprecedently large and diverse set of covalent complexes.  It was found that 40-60% of the top scoring ligand poses are within 2.0 Å RMSD from the exptl. binding mode.  This rate showed program dependent increase and achieved 50-90% when the best RMSD among the top ten scoring poses was considered.  This performance is comparable to that of noncovalent docking tools and therefore suggests that anchoring the ligand does not necessarily improve the accuracy of the prediction.  The effect of various ligand and protein features on the docking performance was investigated.  At the level of warhead chem., higher success rate was found for Michael addns., nucleophilic addns. and nucleophilic substitutions than for ring opening reactions and disulfide formation.  Increasing ligand size and flexibility generally affects pose predictions unfavorably, although AutoDock4, FITTED, and ICM-Pro were found to be less sensitive up to 35 heavy atoms.  Increasing the accessibility of the target cysteine tends to result in improved binding mode predictions.  Docking programs show protein dependent performance suggesting a target-dependent choice of the optimal docking tool.  It was found that noncovalent docking into Cys/Ala mutated proteins by ICM-Pro and Glide reproduced exptl. binding modes with only slightly lower performance and at a significantly lower computational expense than covalent docking did.  Overall, our results highlight the key factors influencing the docking performance of the investigated tools and they give guidelines for selecting the optimal combination of warheads, ligands, and tools for the system investigated.  Results also identify the most important aspects to be considered for developing improved protocols for docking and virtual screening of covalent ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozylYIfr8i8rVg90H21EOLACvtfcHk0lgcSuFoE59Gkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSmsLzE&md5=d74695be1f047ac840527161c510692d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00228%26sid%3Dliteratum%253Aachs%26aulast%3DScarpino%26aufirst%3DA.%26aulast%3DFerenczy%26aufirst%3DG.%2BG.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DComparative%2520evaluation%2520of%2520covalent%2520docking%2520tools%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D1441%26epage%3D1458%26doi%3D10.1021%2Facs.jcim.8b00228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waßmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engemann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identifies irreversible FMS-like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2446</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01714</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01714" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2428-2446&author=D.+Bensingerauthor=D.+Stubbaauthor=A.+Cremerauthor=V.+Kohlauthor=T.+Wa%C3%9Fmerauthor=J.+Stuckertauthor=V.+Engemannauthor=K.+Stegmaierauthor=K.+Schmitzauthor=B.+Schmidt&title=Virtual+screening+identifies+irreversible+FMS-like+tyrosine+kinase+3+inhibitors+with+activity+toward+resistance-conferring+mutations&doi=10.1021%2Facs.jmedchem.8b01714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations</span></div><div class="casAuthors">Bensinger, Dennis; Stubba, Daniel; Cremer, Anjali; Kohl, Vanessa; Wassmer, Theresa; Stuckert, Johanna; Engemann, Victoria; Stegmaier, Kimberly; Schmitz, Katja; Schmidt, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2428-2446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of covalent irreversible binding inhibitors is an established concept for drug development.  Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed.  Herein, the authors report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia.  A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chem. reactive groups.  Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds.  Lead compd. I (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compds. in recent clin. trials and overcomes drug-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquy_8BkIpJILVg90H21EOLACvtfcHk0lgcSuFoE59Gkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D&md5=336bed5b86809d78cfaf8b74d934ef68</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01714%26sid%3Dliteratum%253Aachs%26aulast%3DBensinger%26aufirst%3DD.%26aulast%3DStubba%26aufirst%3DD.%26aulast%3DCremer%26aufirst%3DA.%26aulast%3DKohl%26aufirst%3DV.%26aulast%3DWa%25C3%259Fmer%26aufirst%3DT.%26aulast%3DStuckert%26aufirst%3DJ.%26aulast%3DEngemann%26aufirst%3DV.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DSchmitz%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DVirtual%2520screening%2520identifies%2520irreversible%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520with%2520activity%2520toward%2520resistance-conferring%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2428%26epage%3D2446%26doi%3D10.1021%2Facs.jmedchem.8b01714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondekar, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Ureas: applications in drug design</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.2174/0929867323666161129124915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.2174%2F0929867323666161129124915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27897114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVChurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=622-651&author=A.+D.+Jagtapauthor=N.+B.+Kondekarauthor=A.+A.+Sadaniauthor=J.+W.+Chern&title=Ureas%3A+applications+in+drug+design&doi=10.2174%2F0929867323666161129124915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Ureas: Applications in Drug Design</span></div><div class="casAuthors">Jagtap, Ajit Dhananjay; Kondekar, Nagendra Bharatrao; Sadani, Amit A.; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">622-651</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The unique hydrogen binding capabilities of ureas make them an important functional group to make drug-target interactions and thus incorporated in small mols. displaying broad range of bioactivities.  The related research and numerous excellent achievements of ureas applicability in drug design for the modulation of selectivity, stability, toxicity and pharmacokinetic profile of lead mols. have become active topic.  This review aims to provide insights in to the significance of urea in drug design by summarizing successful studies of various urea derivs. as modulators biol. targets (viz. kinases, NAMPT, sol. epoxide hydrolases, mTOR, proteases, gyrB/parE, and epigenetic enzymes such as HDAC, PRMT or DOT1L etc.).  The findings of this review confirm the importance of urea moiety in medicinal chem. and stimulate its use as a structural motif with rational decision making approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql4bGowxpMbbVg90H21EOLACvtfcHk0li6w6Cgj23v0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVChurg%253D&md5=a3b883c65d950d7e698b40bb71a7f938</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.2174%2F0929867323666161129124915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666161129124915%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DA.%2BD.%26aulast%3DKondekar%26aufirst%3DN.%2BB.%26aulast%3DSadani%26aufirst%3DA.%2BA.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DUreas%253A%2520applications%2520in%2520drug%2520design%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D622%26epage%3D651%26doi%3D10.2174%2F0929867323666161129124915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang
Hsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H. P.</span></span> <span> </span><span class="NLM_article-title">Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1002%2Fcmdc.201300571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24665000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks1Omsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=953-961&author=Y.+Chang%0AHsuauthor=Y.+Y.+Keauthor=H.+Y.+Shiaoauthor=C.+C.+Leeauthor=W.+H.+Linauthor=C.+H.+Chenauthor=K.+J.+Yenauthor=J.+T.+Hsuauthor=C.+Changauthor=H.+P.+Hsieh&title=Facile+identification+of+dual+FLT3-Aurora+A+inhibitors%3A+a+computer-guided+drug+design+approach&doi=10.1002%2Fcmdc.201300571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer-Guided Drug Design Approach</span></div><div class="casAuthors">Chang Hsu, Yung; Ke, Yi-Yu; Shiao, Hui-Yi; Lee, Chieh-Chien; Lin, Wen-Hsing; Chen, Chun-Hwa; Yen, Kuei-Jung; Hsu, John T.-A.; Chang, Chungming; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">953-961</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Computer-guided drug design is a powerful tool for drug discovery.  Herein we disclose the use of this approach for the discovery of dual FMS-like receptor tyrosine kinase-3 (FLT3)-Aurora A inhibitors against cancer.  An Aurora hit compd. was selected as a starting point, from which 288 virtual mols. were screened.  Subsequently, some of these were synthesized and evaluated for their capacity to inhibit FLT3 and Aurora kinase A.  To further enhance FLT3 inhibition, structure-activity relationship studies of the lead compd. were conducted through a simplification strategy and bioisosteric replacement, followed by the use of computer-guided drug design to prioritize mols. bearing a variety of different terminal groups in terms of favorable binding energy.  Selected compds. were then synthesized, and their bioactivity was evaluated.  Of these, one novel inhibitor was found to exhibit excellent inhibition of FLT3 and Aurora kinase A and exert a dramatic antiproliferative effect on MOLM-13 and MV4-11 cells, with an IC50 value of 7 nM.  Accordingly, it is considered a highly promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ni1CGTzIErVg90H21EOLACvtfcHk0li6w6Cgj23v0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks1Omsb0%253D&md5=122eecc6e0497fd90f7e0acc9a3dc94c</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300571%26sid%3Dliteratum%253Aachs%26aulast%3DChang%2BHsu%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DY.%2BY.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DFacile%2520identification%2520of%2520dual%2520FLT3-Aurora%2520A%2520inhibitors%253A%2520a%2520computer-guided%2520drug%2520design%2520approach%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D953%26epage%3D961%26doi%3D10.1002%2Fcmdc.201300571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Göring, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumann, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span> <span> </span><span class="NLM_article-title">Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1002%2Fcmdc.201402477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25677073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BC2MrltVOjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=511-522&author=S.+G%C3%B6ringauthor=D.+Bensingerauthor=E.+C.+Naumannauthor=B.+Schmidt&title=Computer-guided+design%2C+synthesis%2C+and+biological+evaluation+of+quinoxalinebisarylureas+as+FLT3+inhibitors&doi=10.1002%2Fcmdc.201402477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors</span></div><div class="casAuthors">Goring Stefan; Bensinger Dennis; Naumann Eva C; Schmidt Boris</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">511-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in ∼30 % of patients with acute myeloid leukemia (AML) and are associated with poor prognosis.  Point mutations in the tyrosine kinase domain (TKD) are observed as primary mutations or are acquired as secondary mutations in FLT3 with internal tandem duplications (ITDs) after treatment with tyrosine kinase inhibitors (TKIs).  Although dozens of potent inhibitors against FLT3 ITD have been reported, activating TKD point mutations, especially at residues F691 and D835, remain the leading cause for therapy resistance, highlighting the consistent need for new potent inhibitors.  Herein we report the identification and characterization of novel quinoxaline-based FLT3 inhibitors.  We used the pharmacophore features of diverse known inhibitors as a starting point for a new optimization algorithm for type II TKIs, starting from an in silico library pharmacophore search and induced-fit docking in the known FLT3 structure.  This led to the design of a set of diverse quinoxalinebisarylureas, which were profiled in an FLT3 kinase activity assay.  The most promising compounds were further evaluated in a zebrafish embryo phenotype assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_wpMj6Vi8LZggzHGM8X5CfW6udTcc2eaCcVLFWWQXq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrltVOjsA%253D%253D&md5=cb23aedbe8ad7d196e784f0f4d1ff4cd</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402477%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6ring%26aufirst%3DS.%26aulast%3DBensinger%26aufirst%3DD.%26aulast%3DNaumann%26aufirst%3DE.%2BC.%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DComputer-guided%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520quinoxalinebisarylureas%2520as%2520FLT3%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D511%26epage%3D522%26doi%3D10.1002%2Fcmdc.201402477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W. T.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26081023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=151-161&author=C.+T.+Chenauthor=J.+T.+Hsuauthor=W.+H.+Linauthor=C.+T.+Luauthor=S.+C.+Yenauthor=T.+Hsuauthor=Y.+L.+Huangauthor=J.+S.+Songauthor=C.+H.+Chenauthor=L.+H.+Chouauthor=K.+J.+Yenauthor=C.+P.+Chenauthor=P.+C.+Kuoauthor=C.+L.+Huangauthor=H.+E.+Liuauthor=Y.+S.+Chaoauthor=T.+K.+Yehauthor=W.+T.+Jiaang&title=Identification+of+a+potent+5-phenyl-thiazol-2-ylamine-based+inhibitor+of+FLT3+with+activity+against+drug+resistance-conferring+point+mutations&doi=10.1016%2Fj.ejmech.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span></div><div class="casAuthors">Chen, Chiung-Tong; Hsu, John T.-A.; Lin, Wen-Hsing; Lu, Cheng-Tai; Yen, Shih-Chieh; Hsu, Tsu; Huang, Yu-Ling; Song, Jen-Shin; Chen, Chun-Hwa; Chou, Ling-Hui; Yen, Kuei-Jung; Chen, Ching-Ping; Kuo, Po-Chu; Huang, Chen-Lung; Liu, H. Eugene; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML).  However, clin. data have been not encouraging due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated with these older agents.  The authors previously developed a series of 3-phenyl-1H-5-pyrazolylamine derivs. as highly potent and selective FLT3 inhibitors with good in vivo efficacy using an i.v. (IV) route.  However, the poor bioavailability of these pyrazole compds. limits the development of these promising antileukemic compds. for clin. use.  Herein, the authors describe a novel class of 5-phenyl-thiazol-2-ylamine compds. that are multitargeted FLT3 inhibitors.  From this class of compds., compd. I was very potent against AML cell lines and exhibited excellent oral efficacy in AML xenograft models.  In addn., further studies demonstrated that compd. I exhibited potent in vitro and in vivo activities against clin. relevant AC220 (3)-resistant kinase domain mutants of FLT3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KrlNgs-LL7Vg90H21EOLACvtfcHk0lggAbLsw0Q2TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI&md5=d51f2152965d841a378c3c38dbcde6c7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DKuo%26aufirst%3DP.%2BC.%26aulast%3DHuang%26aufirst%3DC.%2BL.%26aulast%3DLiu%26aufirst%3DH.%2BE.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3DIdentification%2520of%2520a%2520potent%25205-phenyl-thiazol-2-ylamine-based%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520drug%2520resistance-conferring%2520point%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D100%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.ejmech.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N’-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4333</span>– <span class="NLM_lpage">4343</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2015.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26142317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2it73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4333-4343&author=Y.+Xuauthor=N.+Y.+Wangauthor=X.+J.+Songauthor=Q.+Leiauthor=T.+H.+Yeauthor=X.+Y.+Youauthor=W.+Q.+Zuoauthor=Y.+Xiaauthor=L.+D.+Zhangauthor=L.+T.+Yu&title=Discovery+of+novel+N-%285-%28tert-butyl%29isoxazol-3-yl%29-N%E2%80%99-phenylurea+analogs+as+potent+FLT3+inhibitors+and+evaluation+of+their+activity+against+acute+myeloid+leukemia+in+vitro+and+in+vivo&doi=10.1016%2Fj.bmc.2015.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo</span></div><div class="casAuthors">Xu, Ying; Wang, Ning-Yu; Song, Xue-Jiao; Lei, Qian; Ye, Ting-Hong; You, Xin-Yu; Zuo, Wei-Qiong; Xia, Yong; Zhang, Li-Dan; Yu, Luo-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4333-4343</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">FLT3 inhibitors have been explored as a viable therapy for acute myeloid leukemia (AML).  However, the clin. outcomes of these FLT3 inhibitors were underwhelming except AC220.  Therefore, the development of novel FLT3 inhibitors with high potency against both FLT3-WT and FLT3-ITD mutants are strongly demanded at the present time.  In this study, we designed and synthesized a series of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea derivs. as FLT3 inhibitors.  SAR studies focused on the fused rings led to the discovery of a series of compds. with high potency against FLT3-ITD-bearing MV4-11 cells and significantly inhibitory activity toward FLT3.  Among these compds., N-(5-(tert-butyl)isoxazol-3-yl)-N'-(4-(7-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl)urea (16i), displayed acceptable aq. soly., desirable pharmacokinetic profile and high cytotoxicity selectivity against MV4-11 cells.  This compd. can inhibit phosphorylation of FLT3 and induce apoptosis in a concn.-dependent manner.  Further in vivo antitumor studies showed that 16i led to complete tumor regression in the MV4-11 xenograft model at a dose of 60 mg/kg/d while without observable body wt. loss.  This study had provided us a new chemotype of FLT3 inhibitors as novel therapeutic candidates for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqCNY34V2V7Vg90H21EOLACvtfcHk0lg5kB6hcbCvFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2it73F&md5=6cb879cc03de46bc7761063fb35195b7</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DN.%2BY.%26aulast%3DSong%26aufirst%3DX.%2BJ.%26aulast%3DLei%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DT.%2BH.%26aulast%3DYou%26aufirst%3DX.%2BY.%26aulast%3DZuo%26aufirst%3DW.%2BQ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%2BD.%26aulast%3DYu%26aufirst%3DL.%2BT.%26atitle%3DDiscovery%2520of%2520novel%2520N-%25285-%2528tert-butyl%2529isoxazol-3-yl%2529-N%25E2%2580%2599-phenylurea%2520analogs%2520as%2520potent%2520FLT3%2520inhibitors%2520and%2520evaluation%2520of%2520their%2520activity%2520against%2520acute%2520myeloid%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4333%26epage%3D4343%26doi%3D10.1016%2Fj.bmc.2015.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4534</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2015.08.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26342867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4534-4538&author=X.+D.+Linauthor=H.+W.+Yangauthor=S.+Maauthor=W.+W.+Liauthor=C.+H.+Zhangauthor=W.+J.+Wangauthor=R.+Xiangauthor=L.+L.+Liauthor=S.+Y.+Yang&title=Discovery+of+6-phenylimidazo%5B2%2C1-b%5Dthiazole+derivatives+as+a+new+type+of+FLT3+inhibitors&doi=10.1016%2Fj.bmcl.2015.08.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors</span></div><div class="casAuthors">Lin, Xing-Dong; Yang, Hui-Wen; Ma, Shuang; Li, Wei-Wei; Zhang, Chun-Hui; Wang, Wen-Jing; Xiang, Rong; Li, Lin-Li; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4534-4538</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this investigation, a series of 6-phenylimidazo[2,1-b]thiazole derivs. were synthesized.  Structure-activity relationship (SAR) anal. of these compds. based on cellular assays led to the discovery of a no. of compds. that showed potent activity against FLT3-dependent human acute myeloid leukemia (AML) cell line MV4-11, but very weak or no activity against FLT3-independent human cervical cancer cell line HeLa.  FLT3 kinase inhibition assays were then performed on the three most active compds.  Among these compds., 6-(4-(3-(5-(tert-butyl)isoxazol-3-yl)ureido)phenyl)-N-(3-(dimethylamino)propyl)imidazo[2,1-b]thiazole-3-carboxamide (I) exhibited the highest potency in both cellular (MV4-11, IC50: 0.002 μM) and enzymic (FLT3, IC50: 0.022 μM) assays.  Further in-depth in vitro anti-AML activity and mechanism of action studies were carried out on compd. I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdn7IogHRnRrVg90H21EOLACvtfcHk0lg5kB6hcbCvFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmsrbI&md5=ccb7f2021e9e20cde5cbc01ead16e273</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.068%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DYang%26aufirst%3DH.%2BW.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DW.%2BJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%25206-phenylimidazo%255B2%252C1-b%255Dthiazole%2520derivatives%2520as%2520a%2520new%2520type%2520of%2520FLT3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4534%26epage%3D4538%26doi%3D10.1016%2Fj.bmcl.2015.08.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.</span></span> <span> </span><span class="NLM_article-title">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2016.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27773927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=913-921&author=B.+Xuauthor=Y.+Zhaoauthor=X.+Wangauthor=P.+Gongauthor=W.+Ge&title=MZH29+is+a+novel+potent+inhibitor+that+overcomes+drug+resistance+FLT3+mutations+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2016.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span></div><div class="casAuthors">Xu, B.; Zhao, Y.; Wang, X.; Gong, P.; Ge, W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">913-921</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant mutations in Fms-like tyrosine kinase 3 (FLT3).  Among them, the internal tandem duplication (ITD) mutation predicts poor prognosis.  MZH29 is a novel FLT3 inhibitor synthesized in our lab. that showed that cellular and kinase assays sustained inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants.  More importantly, MZH29 retained its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220.  MZH29 is a type II FLT3 inhibitor that tolerated the F691L mutation in mol. docking studies.  Oral administration of 10 mg/kg MZH29 caused complete tumor regression and extended survival in a mouse model of AML with less toxicity.  Subsequent proteomics study revealed less proteome perturbation in the MZH29-treated group than in the AC220-treated group.  MZH29 demonstrates potential and potent novel FLT3 inhibitory effects for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypie-S2V6M7Vg90H21EOLACvtfcHk0lg5kB6hcbCvFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI&md5=76a4ff225ff13fc14e810826e75572fc</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.297%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DGe%26aufirst%3DW.%26atitle%3DMZH29%2520is%2520a%2520novel%2520potent%2520inhibitor%2520that%2520overcomes%2520drug%2520resistance%2520FLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D913%26epage%3D921%26doi%3D10.1038%2Fleu.2016.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4735</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30121211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFeqtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4735-4744&author=Z.+H.+Shiauthor=F.+T.+Liuauthor=H.+Z.+Tianauthor=Y.+M.+Zhangauthor=N.+G.+Liauthor=T.+Lu&title=Design%2C+synthesis+and+structure-activity+relationship+of+diaryl-ureas+with+novel+isoxazol%5B3%2C4-b%5Dpyridine-3-amino-structure+as+multi-target+inhibitors+against+receptor+tyrosine+kinase&doi=10.1016%2Fj.bmc.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase</span></div><div class="casAuthors">Shi, Zhi-Hao; Liu, Feng-Tao; Tian, Hao-Zhong; Zhang, Yan-Min; Li, Nian-Guang; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4735-4744</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inspired by that the multi-target inhibitors against receptor tyrosine kinases (RTKs) have significantly improved the effect of clin. treatment for cancer, and based on the chem. structure of Linifanib (ABT-869, Abbott), two series of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure were designed and synthesized as multi-target inhibitors against RTKs.  The preliminary biol. evaluation showed that several compds. exhibited comparable potency with Linifanib.  Compd. S21 was identified as the most potent inhibitor against Fms-like tyrosine kinase 3 (FLT-3), kinase insert domain contg. receptor (KDR) and platelet-derived growth factor receptor β (PDGFR-β) with its IC50 values were 4 nM, 3 nM and 8 nM resp., it also showed potent inhibitory activities against several cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAmdxzd3Mv5bVg90H21EOLACvtfcHk0lhqOfPabEphJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFeqtLnF&md5=f171dd14fc3b5d924be73439fd6cec24</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%2BH.%26aulast%3DLiu%26aufirst%3DF.%2BT.%26aulast%3DTian%26aufirst%3DH.%2BZ.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DN.%2BG.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520of%2520diaryl-ureas%2520with%2520novel%2520isoxazol%255B3%252C4-b%255Dpyridine-3-amino-structure%2520as%2520multi-target%2520inhibitors%2520against%2520receptor%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4735%26epage%3D4744%26doi%3D10.1016%2Fj.bmc.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lhqOfPabEphJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2019.03.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30940564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=2127-2139&author=B.+Qiauthor=X.+Xuauthor=Y.+Yangauthor=Y.+Zhouauthor=T.+Chenauthor=G.+Gongauthor=X.+Yueauthor=X.+Xuauthor=L.+Huauthor=H.+He&title=Discovery+of+thiazolidin-4-one+urea+analogues+as+novel+multikinase+inhibitors+that+potently+inhibit+FLT3+and+VEGFR2&doi=10.1016%2Fj.bmc.2019.03.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2</span></div><div class="casAuthors">Qi, Baohui; Xu, Xingwei; Yang, Ying; Zhou, Yuting; Chen, Tao; Gong, Guowei; Yue, Xupeng; Xu, Xin; Hu, Liping; He, Huan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2127-2139</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel thiazolidine-4-one urea analogs were designed, synthesized and biol. evaluated.  The structure-activity relationship (SAR) at several positions of the scaffolds was investigated and its binding mode was analyzed by mol. modeling studies.  Compd. 17b proved to be the most potent one, and IC50 values against A549 and HT-29 cancer cell lines were 0.65 μM and 0.11 μM, resp.  The results of kinase profile demonstrated that compd. 17b is a multikinase inhibitor that potently inhibits FLT3 (IC50 = 8.6 nM) and VEGFR2 (IC50 = 18.7 nM).  The results of real-time live-cell imaging indicated that compd. 17b showed excellent cytotoxicity and anti-proliferative activity against HT-29 cancer cells in a time- and dose-dependent manner, which was significantly potent than that of Cabozantinib.  In addn., in vitro antitumor activity was assocd. with inducing cancer cell apoptosis and suppression of cancer cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYiQyPetitWrVg90H21EOLACvtfcHk0lhqOfPabEphJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOqsr4%253D&md5=63e95dbef3a82115f1c94a93ff6dc9ac</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.049%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DYue%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520thiazolidin-4-one%2520urea%2520analogues%2520as%2520novel%2520multikinase%2520inhibitors%2520that%2520potently%2520inhibit%2520FLT3%2520and%2520VEGFR2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D2127%26epage%3D2139%26doi%3D10.1016%2Fj.bmc.2019.03.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter-Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintim, H. O.</span></span> <span> </span><span class="NLM_article-title">Identification of new FLT3 inhibitors that potently inhibit AML cell lines via an azo click-it/staple-it approach</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=492-497&author=X.+Maauthor=J.+Zhouauthor=C.+Wangauthor=B.+Carter-Cooperauthor=F.+Yangauthor=E.+Larocqueauthor=J.+Fineauthor=G.+Tsujiauthor=G.+Chopraauthor=R.+G.+Lapidusauthor=H.+O.+Sintim&title=Identification+of+new+FLT3+inhibitors+that+potently+inhibit+AML+cell+lines+via+an+azo+click-it%2Fstaple-it+approach&doi=10.1021%2Facsmedchemlett.6b00468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach</span></div><div class="casAuthors">Ma, Xiaochu; Zhou, Jie; Wang, Changhao; Carter-Cooper, Brandon; Yang, Fan; Larocque, Elizabeth; Fine, Jonathan; Tsuji, Genichiro; Chopra, Gaurav; Lapidus, Rena G.; Sintim, Herman O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">492-497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is an aggressive malignancy with only a handful of therapeutic options.  About 30% of AML patients harbor mutated FLT3 kinase and thus this cancer-driver has become a hotly pursued AML target.  Herein we report a new class of FLT3 inhibitors, which potently inhibit the of acute myeloid leukemia (AML) cells at nanomolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-9N0byp2-K7Vg90H21EOLACvtfcHk0limWhp-psnXeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyjs7g%253D&md5=1e325dddb25a1a93a48e7cfa05fed6ac</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00468%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DCarter-Cooper%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLarocque%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DJ.%26aulast%3DTsuji%26aufirst%3DG.%26aulast%3DChopra%26aufirst%3DG.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DSintim%26aufirst%3DH.%2BO.%26atitle%3DIdentification%2520of%2520new%2520FLT3%2520inhibitors%2520that%2520potently%2520inhibit%2520AML%2520cell%2520lines%2520via%2520an%2520azo%2520click-it%252Fstaple-it%2520approach%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D492%26epage%3D497%26doi%3D10.1021%2Facsmedchemlett.6b00468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamli, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of quinolinone derivatives as potent FLT3 inhibitors</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>445</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bbrc.2014.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24530392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVWqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2014&pages=561-565&author=H.+J.+Chungauthor=M.+R.+Kamliauthor=H.+J.+Leeauthor=J.+D.+Haauthor=S.+Y.+Choauthor=J.+Leeauthor=J.+Y.+Kongauthor=S.+Y.+Han&title=Discovery+of+quinolinone+derivatives+as+potent+FLT3+inhibitors&doi=10.1016%2Fj.bbrc.2014.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of quinolinone derivatives as potent FLT3 inhibitors</span></div><div class="casAuthors">Chung, Hye Jin; Kamli, Majid Rasool; Lee, Hyo Jeong; Ha, Jae Du; Cho, Sung Yun; Lee, Jongkook; Kong, Jae Yang; Han, Sun-Young</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">561-565</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently some fms-like tyrosine kinase 3 (FLT3) inhibitors have shown good efficacy in acute myeloid leukemia (AML) patients.  In an effort to develop anti-leukemic drugs, we investigated quinolinone derivs. as novel FLT3 inhibitors.  Two substituted quinolinones, KR65367 and KR65370 were subjected to FLT3 kinase activity assay and showed potent inhibition against FLT3 kinase activity in vitro, with IC50 of 2.7 and 0.57 nM, resp.  As a measure of selectivity, effects on the activity of other kinases were also tested.  Both compds. have negligible activity against Met, Ron, epidermal growth factor receptor, Aurora A, Janus kinase 2, and insulin receptor; with IC50 greater than 10 μM.  KR compds. showed strong growth inhibition in MV4;11 AML cells and increased the apoptotic cell death in flow cytometric analyses.  A decrease in STAT5 phosphorylation by KR compds. was obsd. in MV4;11 cells.  Furthermore, in vitro evaluation of compds. structurally related to KR65367 and KR65370 showed a good structure-activity relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-JuYaVQVxE7Vg90H21EOLACvtfcHk0limWhp-psnXeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVWqtbk%253D&md5=d7453c5b158262c372eef20a0978bc9d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DH.%2BJ.%26aulast%3DKamli%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DJ.%2BY.%26aulast%3DHan%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520quinolinone%2520derivatives%2520as%2520potent%2520FLT3%2520inhibitors%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D445%26spage%3D561%26epage%3D565%26doi%3D10.1016%2Fj.bbrc.2014.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku-Temeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter-Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintim, H. O.</span></span> <span> </span><span class="NLM_article-title">Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.4155/fmc-2017-0067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.4155%2Ffmc-2017-0067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28490193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2qsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1213-1225&author=E.+Larocqueauthor=N.+Nagannaauthor=X.+Maauthor=C.+Opoku-Temengauthor=B.+Carter-Cooperauthor=G.+Chopraauthor=R.+G.+Lapidusauthor=H.+O.+Sintim&title=Aminoisoquinoline+benzamides%2C+FLT3+and+Src-family+kinase+inhibitors%2C+potently+inhibit+proliferation+of+acute+myeloid+leukemia+cell+lines&doi=10.4155%2Ffmc-2017-0067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoisoquinoline benzamides, flt3 and src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines</span></div><div class="casAuthors">Larocque, Elizabeth; Naganna, N.; Ma, Xiaochu; Opoku-Temeng, Clement; Carter-Cooper, Brandon; Chopra, Gaurav; Lapidus, Rena G.; Sintim, Herman O.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1213-1225</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Aim: Mutated or overexpressed FLT3 drives about 30% of reported acute myeloid leukemia (AML).  Currently, FLT3 inhibitors have shown durable clin. responses but a complete remission of AML with FLT3 inhibitors remains elusive due to mutation-driven resistance mechanisms.  The development of FLT3 inhibitors that also target other downstream oncogenic kinases may combat the resistance mechanism.  Results: 4-substituted aminoisoquinoline benzamides potently inhibit Src-family kinases and FLT3, including secondary mutations, such as FLT3D835.  Modifications of aminoisoquinoline benzamide to aminoquinoline or aminoquinazoline abrogated FLT3 and Src-family kinase binding.  Conclusion: The lead aminoisoquinolines potently inhibited FLT3-driven AML cell lines, MV4-11 and MOLM-14.  These aminoisoquinoline benzamides represent new kinase scaffolds with high potential to be translated into anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvu4O-4pq_3bVg90H21EOLACvtfcHk0lgbeThj0rEdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2qsLbJ&md5=9363dc08a85ef1adf7daa661c6f7ae46</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2017-0067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2017-0067%26sid%3Dliteratum%253Aachs%26aulast%3DLarocque%26aufirst%3DE.%26aulast%3DNaganna%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DOpoku-Temeng%26aufirst%3DC.%26aulast%3DCarter-Cooper%26aufirst%3DB.%26aulast%3DChopra%26aufirst%3DG.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DSintim%26aufirst%3DH.%2BO.%26atitle%3DAminoisoquinoline%2520benzamides%252C%2520FLT3%2520and%2520Src-family%2520kinase%2520inhibitors%252C%2520potently%2520inhibit%2520proliferation%2520of%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D1213%26epage%3D1225%26doi%3D10.4155%2Ffmc-2017-0067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naganna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku-Temeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter-Cooper, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torregrosa-Allen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintim, H. O.</span></span> <span> </span><span class="NLM_article-title">Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice</span>. <i>EBioMedicine.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2019.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ebiom.2019.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30686755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3cjlslKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=231-239&author=N.+Nagannaauthor=C.+Opoku-Temengauthor=E.+Y.+Choiauthor=E.+Larocqueauthor=E.+T.+Changauthor=B.+A.+Carter-Cooperauthor=M.+Wangauthor=S.+E.+Torregrosa-Allenauthor=B.+D.+Elzeyauthor=R.+G.+Lapidusauthor=H.+O.+Sintim&title=Amino+alkynylisoquinoline+and+alkynylnaphthyridine+compounds+potently+inhibit+acute+myeloid+leukemia+proliferation+in+mice&doi=10.1016%2Fj.ebiom.2019.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice</span></div><div class="casAuthors">Naganna N; Larocque Elizabeth; Wang Modi; Opoku-Temeng Clement; Choi Eun Yong; Chang Elizabeth T; Carter-Cooper Brandon A; Lapidus Rena G; Torregrosa-Allen Sandra E; Elzey Bennett D; Sintim Herman O</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-239</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics.  Currently, the 5-year survival of AML patients is about 30% and for elderly patients, the rate drops to <10%.  About 30% of AML patients harbor an activating mutation in the tyrosine kinase domain (TKD) of Fms-Like Tyrosine kinase 3 (FLT3) or a FLT3 internal tandem duplication (FLT3-ITD).  Inhibitors of FLT3, such as Rydapt that was recently approved by the FDA, have shown good initial response but patients often relapse due to secondary mutations in the FLT3 TKD, like D835Y and F691 L mutations.  METHODS:  Alkynyl aminoisoquinoline and naphthyridine compounds were synthesized via Sonogashira coupling.  The compounds were evaluated for their in vitro and in vivo effects on leukemia growth.  FINDINGS:  The compounds inhibited FLT3 kinase activity at low nanomolar concentrations.  The lead compound, HSN431, also inhibited Src kinase activity.  The compounds potently inhibited the viability of MV4-11 and MOLM-14 AML cells with IC50 values <1 nM.  Furthermore, the viability of drug-resistant AML cells harboring the D835Y and F691 L mutations were potently inhibited.  In vivo efficacy studies in mice demonstrated that the compounds could drastically reduce AML proliferation in mice.  INTERPRETATION:  Compounds that inhibit FLT3 and downstream targets like Src (for example HSN431) are good leads for development as anti-AML agents.  FUND: Purdue University, Purdue Institute for Drug Discovery (PIDD), Purdue University Center for Cancer Research, Elks Foundation and NIH P30 CA023168.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbXsDtlq8R1ZagfuraLLzSfW6udTcc2ebA0fwccvlcP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjlslKnsw%253D%253D&md5=9ddc0c74c5b1f1998bc427084f13f0a3</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2019.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2019.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DNaganna%26aufirst%3DN.%26aulast%3DOpoku-Temeng%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DE.%2BY.%26aulast%3DLarocque%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DE.%2BT.%26aulast%3DCarter-Cooper%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DTorregrosa-Allen%26aufirst%3DS.%2BE.%26aulast%3DElzey%26aufirst%3DB.%2BD.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DSintim%26aufirst%3DH.%2BO.%26atitle%3DAmino%2520alkynylisoquinoline%2520and%2520alkynylnaphthyridine%2520compounds%2520potently%2520inhibit%2520acute%2520myeloid%2520leukemia%2520proliferation%2520in%2520mice%26jtitle%3DEBioMedicine.%26date%3D2019%26volume%3D40%26spage%3D231%26epage%3D239%26doi%3D10.1016%2Fj.ebiom.2019.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126630</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2019.126630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31466809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yhu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126630&author=Q.+Xuauthor=B.+Daiauthor=Z.+Liauthor=L.+Xuauthor=D.+Yangauthor=P.+Gongauthor=Y.+Houauthor=Y.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+4-%28%286%2C7-dimethoxyquinoline-4-yl%29oxy%29aniline+derivatives+as+FLT3+inhibitors+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1016%2Fj.bmcl.2019.126630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Xu, Qiaoling; Dai, Baozhu; Li, Zhiwei; Xu, Le; Yang, Di; Gong, Ping; Hou, Yunlei; Liu, Yajing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">126630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) was an important therapeutic target in acute myeloid leukemia (AML).  We synthesized two series of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivs. possessing the semicarbazide moiety and 2,2,2-trifluoro-N,N'-dimethylacetamide moiety as the linker.  The cell proliferation assay in vitro against HL-60 and MV4-11 cell lines demonstrated that most series I compds. contg. semicarbazide moiety had more potent than Cabozantinib.  Furthermore, the enzyme assay showed that compd. I and II were potent FLT3 inhibitors with IC50 values of 312 nM and 384 nM, resp.  Following that, mol. docking anal. was also performed to det. possible binding mode between FLT3 and the target compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKiKqqRR0A27Vg90H21EOLACvtfcHk0lgUbBuA8qeiQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yhu7zE&md5=bb50806ab6a53173b899a2ae6fb60ae2</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126630%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25204-%2528%25286%252C7-dimethoxyquinoline-4-yl%2529oxy%2529aniline%2520derivatives%2520as%2520FLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126630%26doi%3D10.1016%2Fj.bmcl.2019.126630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2655</span>– <span class="NLM_lpage">2660</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2014.04.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24813730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2655-2660&author=C.+H.+Parkauthor=C.+Leeauthor=J.+S.+Yangauthor=B.+Y.+Joeauthor=K.+Chunauthor=H.+Kimauthor=H.+Y.+Kimauthor=J.+S.+Kangauthor=J.+I.+Leeauthor=M.+H.+Kimauthor=G.+Han&title=Discovery+of+thienopyrimidine-based+FLT3+inhibitors+from+the+structural+modification+of+known+IKK%CE%B2+inhibitors&doi=10.1016%2Fj.bmcl.2014.04.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors</span></div><div class="casAuthors">Park, Chun-Ho; Lee, Chulho; Yang, Jee Sun; Joe, Bo-Young; Chun, Kwangwoo; Kim, Hyuntae; Kim, Hye Yun; Kang, Jong Soon; Lee, Jangik I.; Kim, Myung-Hwa; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2655-2660</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inactivation of the NF-κB signaling pathway by inhibition of IKKβ is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer.  Thienopyrimidine-based analogs were designed through modification of the known IKKβ inhibitor, SPC-839, and then biol. evaluated.  The resulting analogs had good inhibitory activity against both nitric oxide and TNF-α, which are well-known inflammatory responses generated by activated NF-κB.  However, no inhibitory activity against IKKβ was obsd. with these compds.  The thienopyrimidine-based analogs were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified.  Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 μM.  Overall, these compds. represent a promising family of inhibitors for future development of a treatment for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSn5PgGCIn17Vg90H21EOLACvtfcHk0lgUbBuA8qeiQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSnt7Y%253D&md5=75b4124026a81eae8d8670ed06d3c463</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.058%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DJoe%26aufirst%3DB.%2BY.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520thienopyrimidine-based%2520FLT3%2520inhibitors%2520from%2520the%2520structural%2520modification%2520of%2520known%2520IKK%25CE%25B2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2655%26epage%3D2660%26doi%3D10.1016%2Fj.bmcl.2014.04.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2014.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25108079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KjsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=399-407&author=J.+S.+Yangauthor=C.+H.+Parkauthor=C.+Leeauthor=H.+Kimauthor=C.+Ohauthor=Y.+Choiauthor=J.+S.+Kangauthor=J.+Yunauthor=J.+H.+Jeongauthor=M.+H.+Kimauthor=G.+Han&title=Synthesis+and+biological+evaluation+of+novel+thieno%5B2%2C3-d%5Dpyrimidine-based+FLT3+inhibitors+as+anti-leukemic+agents&doi=10.1016%2Fj.ejmech.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents</span></div><div class="casAuthors">Yang, Jee Sun; Park, Chun-Ho; Lee, Chulho; Kim, Hwan; Oh, Changmok; Choi, Yejoo; Kang, Jong Soon; Yun, Jieun; Jeong, Jin-Hyun; Kim, Myung-Hwa; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">399-407</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3).  Therefore, FLT3 is regarded as a potential target for the treatment of AML.  A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors.  All synthesized compds. were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60).  Among these compds., compd. 1-[6-Methoxy-5-methyl-2-(thiophen-2-yl)thieno[2,3-d]pyrimidin-4-ylamino]-3-methyl-1H-pyrrole-2,5-dione, which possesses relatively short and simple substituents at the C6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent.  Compd. 1-[6-Methoxy-5-methyl-2-(thiophen-2-yl)thieno[2,3-d]pyrimidin-4-ylamino]-3-methyl-1H-pyrrole-2,5-dione exhibited potent inhibition of FLT3-pos. leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML.  The data supports the further study of this class of compds. as potential anti-leukemic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquZGzLnO11GbVg90H21EOLACvtfcHk0lgUbBuA8qeiQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KjsrnJ&md5=1f0389e4cda56e486ed0bec48ae143b9</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520thieno%255B2%252C3-d%255Dpyrimidine-based%2520FLT3%2520inhibitors%2520as%2520anti-leukemic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D85%26spage%3D399%26epage%3D407%26doi%3D10.1016%2Fj.ejmech.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2016.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=27187860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2016&pages=74-85&author=H.+Kimauthor=C.+Leeauthor=J.+S.+Yangauthor=S.+Choiauthor=C.+H.+Parkauthor=J.+S.+Kangauthor=S.+J.+Ohauthor=J.+Yunauthor=M.+H.+Kimauthor=G.+Han&title=Structural+modifications+at+the+6-position+of+thieno%5B2%2C3-d%5Dpyrimidines+and+their+effects+on+potency+at+FLT3+for+treatment+of+acute+myeloid+leukemia&doi=10.1016%2Fj.ejmech.2016.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia</span></div><div class="casAuthors">Kim, Hyuntae; Lee, Chulho; Yang, Jee Sun; Choi, Seonghwi; Park, Chun-Ho; Kang, Jong Soon; Oh, Soo Jin; Yun, Jieun; Kim, Myung-Hwa; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-85</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of thieno[2,3-d]pyrimidines I (R1 = Me, CH2OH, 4-MeOC6H4, etc.; R2 = H, Me) modified at the 6-position were synthesized to identify effective FLT3 inhibitors.  Previously synthesized thieno[2,3-d]pyrimidine derivs. emerged as promising FLT3 inhibitors among the synthesized compds., but these compds. exhibited poor metabolic stability in human and rat liver microsomes.  Hence, further optimization was required for the discovery of FLT3 inhibitors, with a focus on improving metabolic stability.  The compd. I [R1 = 4-(MeNHCH2CH2O)C6H4; R2 = Me; (II)] exhibited good inhibitory activity against FLT3 and showed effective antiproliferative activity against four leukemia cell lines, including MV4-11 and also displayed enhanced metabolic stability.  The results of this study indicated that the compd. II could be a promising compd. for further optimization and development as a potent FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozXOKzSI0MqLVg90H21EOLACvtfcHk0li7FkXFfmoXuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wqtb8%253D&md5=7a373e4072b799e89366133745503967</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DOh%26aufirst%3DS.%2BJ.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DStructural%2520modifications%2520at%2520the%25206-position%2520of%2520thieno%255B2%252C3-d%255Dpyrimidines%2520and%2520their%2520effects%2520on%2520potency%2520at%2520FLT3%2520for%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D120%26spage%3D74%26epage%3D85%26doi%3D10.1016%2Fj.ejmech.2016.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C<sub>2</sub> and C<sub>6</sub> positions</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.12.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2016.12.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28043794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=496-500&author=C.+Ohauthor=H.+Kimauthor=J.+S.+Kangauthor=J.+Yunauthor=J.+Simauthor=H.+M.+Kimauthor=G.+Han&title=Synthetic+strategy+for+increasing+solubility+of+potential+FLT3+inhibitor+thieno%5B2%2C3-d%5Dpyrimidine+derivatives+through+structural+modifications+at+the+C2+and+C6+positions&doi=10.1016%2Fj.bmcl.2016.12.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C2 and C6 positions</span></div><div class="casAuthors">Oh, Changmok; Kim, Hyuntae; Kang, Jong Soon; Yun, Jieun; Sim, Jaejun; Kim, Hwan-Mook; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">496-500</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cell.  In AML, a mutation in FLT3 is commonly occurs and is assocd. with poor prognosis.  The authors have previously reported that thieno[2,3-d]pyrimidine deriv. compd. (I) exhibited better antiproliferative activity against MV4-11 cells which harbor mutant FLT3 than AC220, which is a well-known FLT3 inhibitor, and has good microsomal stability.  However, compd. (I) had poor soly.  The authors then carried out further structural modification at the C2 and the C6 positions of thieno[2,3-d]pyrimidine scaffold.  Compd. 13b (II), which possesses a thiazole moiety at the C2 position, exhibited better antiproliferative activity than compd. (I) and showed increased soly. and moderate microsomal stability.  These results indicate that compd. 13b could be a promising potential FLT inhibitor for AML chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlu-ZWgtlWurVg90H21EOLACvtfcHk0li7FkXFfmoXuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVylug%253D%253D&md5=33d2f34fd8d1a267dc4396f7e726fd5c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.034%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DSynthetic%2520strategy%2520for%2520increasing%2520solubility%2520of%2520potential%2520FLT3%2520inhibitor%2520thieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520through%2520structural%2520modifications%2520at%2520the%2520C2%2520and%2520C6%2520positions%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D496%26epage%3D500%26doi%3D10.1016%2Fj.bmcl.2016.12.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Cesco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittermaier, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitessier, N.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors design and discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2017.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28651155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=96-114&author=S.+De+Cescoauthor=J.+Kurianauthor=C.+Dufresneauthor=A.+K.+Mittermaierauthor=N.+Moitessier&title=Covalent+inhibitors+design+and+discovery&doi=10.1016%2Fj.ejmech.2017.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors design and discovery</span></div><div class="casAuthors">De Cesco, Stephane; Kurian, Jerry; Dufresne, Caroline; Mittermaier, Anthony K.; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-114</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the history of therapeutics, covalent drugs occupy a very distinct category.  While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biol. target.  In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.  All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods.  The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLNDmLtBdB7Vg90H21EOLACvtfcHk0liuvLInj0wvQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI&md5=551c9a9c4bd69d4ad4d9156c315d5a94</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DJ.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DMittermaier%26aufirst%3DA.%2BK.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DCovalent%2520inhibitors%2520design%2520and%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114%26doi%3D10.1016%2Fj.ejmech.2017.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. J.</span></span> <span> </span><span class="NLM_article-title">G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">2209</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-04-493916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2013-04-493916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24532805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVOju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=2209-2219&author=H.+K.+Leeauthor=H.+W.+Kimauthor=I.+Y.+Leeauthor=J.+Leeauthor=J.+Leeauthor=D.+S.+Jungauthor=S.+Y.+Leeauthor=S.+H.+Parkauthor=H.+Hwangauthor=J.+S.+Choiauthor=J.+H.+Kimauthor=S.+W.+Kimauthor=J.+K.+Kimauthor=J.+Coolsauthor=J.+S.+Kohauthor=H.+J.+Song&title=G-749%2C+a+novel+FLT3+kinase+inhibitor%2C+can+overcome+drug+resistance+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-04-493916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Lee, Hee Kyu; Kim, Hong Woo; Lee, In Yong; Lee, Jungmi; Lee, Jaekyoo; Jung, Dong Sik; Lee, Sang Yeop; Park, Sung Ho; Hwang, Haejun; Choi, Jang-Sik; Kim, Jung-Ho; Kim, Se Won; Kim, Jung Keun; Cools, Jan; Koh, Jong Sung; Song, Ho-Juhn</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Aberrant activations of Fms-like tyrosine receptor kinase (FLT) 3 are implicated in the pathogenesis of 20% to 30% of patients with acute myeloid leukemia (AML).  G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants including FLT3-ITD, FLT3-D835Y, FLT3-ITD/N676D, and FLT3-ITD/F691L in cellular assays.  G-749 retained its inhibitory potency in various drug-resistance milieus such as patient plasma, FLT3 ligand surge, and stromal protection.  Furthermore, it displayed potent antileukemic activity in bone marrow blasts from AML patients regardless of FLT3 mutation status, including those with little or only minor responses to AC220 or PKC412.  Oral administration of G-749 yielded complete tumor regression and increased life span in animal models.  Thus, G-749 appears to be a promising next-generation drug candidate for the treatment of relapsed and refractory AML patients with various FLT3-ITD/FLT3-TKD mutants and further shows the ability to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1dwuSRK6JrVg90H21EOLACvtfcHk0liuvLInj0wvQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVOju74%253D&md5=07b23569d047a3a16789d673fe904c6b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-04-493916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-04-493916%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DD.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DHwang%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DKoh%26aufirst%3DJ.%2BS.%26aulast%3DSong%26aufirst%3DH.%2BJ.%26atitle%3DG-749%252C%2520a%2520novel%2520FLT3%2520kinase%2520inhibitor%252C%2520can%2520overcome%2520drug%2520resistance%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D2209%26epage%3D2219%26doi%3D10.1182%2Fblood-2013-04-493916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.+M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lh2N0lhTUUYWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.%2BM.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lh2N0lhTUUYWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenback, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quéva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1535-7163.MCT-13-0858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24526162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=880-889&author=K.+Keeganauthor=C.+Liauthor=Z.+Liauthor=J.+Maauthor=M.+Ragainsauthor=S.+Coberlyauthor=D.+Hollenbackauthor=J.+Eksterowiczauthor=L.+Liangauthor=M.+Weidnerauthor=J.+Huardauthor=X.+Wangauthor=G.+Albaauthor=J.+Orfauthor=M.+C.+Loauthor=S.+Zhaoauthor=R.+Ngoauthor=A.+Chenauthor=L.+Liuauthor=T.+Carlsonauthor=C.+Qu%C3%A9vaauthor=L.+R.+McGeeauthor=J.+Medinaauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=Preclinical+evaluation+of+AMG+925%2C+a+FLT3%2FCDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-13-0858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia</span></div><div class="casAuthors">Keegan, Kathleen; Li, Cong; Li, Zhihong; Ma, Ji; Ragains, Mark; Coberly, Suzanne; Hollenback, David; Eksterowicz, John; Liang, Lingming; Weidner, Margaret; Huard, Justin; Wang, Xianghong; Alba, Grace; Orf, Jessica; Lo, Mei-Chu; Zhao, Sharon; Ngo, Rachel; Chen, Ada; Liu, Lily; Carlson, Timothy; Queva, Christophe; McGee, Lawrence R.; Medina, Julio; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a serious unmet medical need.  Despite high remission rates with chemotherapy std.-of-care treatment, the disease eventually relapses in a major proportion of patients.  Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approx. 30% of patients with AML.  Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML.  Responses, however, are not sustained and acquired resistance has been a clin. challenge.  Treatment options to overcome resistance are currently the focus of research.  We report here the preclin. evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.  AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body wt. loss.  The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, resp.  In addn., AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib).  CDK4 is a cyclin D-dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals.  A crit. role of the CDK4-RB pathway in cancer development has been well established.  CDK4-specific inhibitors are being developed for treating RB-pos. cancer.  AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clin. responses.  Mol Cancer Ther; 13(4); 880-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4p2uOyF0ObVg90H21EOLACvtfcHk0lh7PU-CqepyyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D&md5=7343fdb82e66c9115c8b018a260aadde</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0858%26sid%3Dliteratum%253Aachs%26aulast%3DKeegan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRagains%26aufirst%3DM.%26aulast%3DCoberly%26aufirst%3DS.%26aulast%3DHollenback%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DWeidner%26aufirst%3DM.%26aulast%3DHuard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlba%26aufirst%3DG.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DQu%25C3%25A9va%26aufirst%3DC.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520AMG%2520925%252C%2520a%2520FLT3%252FCDK4%2520dual%2520kinase%2520inhibitor%2520for%2520treating%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D880%26epage%3D889%26doi%3D10.1158%2F1535-7163.MCT-13-0858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase inhibitor with potentially high efficiency against acute myelocytic leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1499-1518&author=Y.+Wangauthor=Y.+Zhiauthor=Q.+Jinauthor=S.+Luauthor=G.+Linauthor=H.+Yuanauthor=T.+Yangauthor=Z.+Wangauthor=C.+Yaoauthor=J.+Lingauthor=H.+Guoauthor=T.+Liauthor=J.+Jinauthor=B.+Liauthor=L.+Zhangauthor=Y.+Chenauthor=T.+Lu&title=Discovery+of+4-%28%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29-N-%284-%28%284-methylpiperazin-1-yl%29methyl%29phenyl%29-1H-pyrazole-3-carboxamide+%28FN-1501%29%2C+an+FLT3-+and+CDK-Kinase+inhibitor+with+potentially+high+efficiency+against+acute+myelocytic+leukemia&doi=10.1021%2Facs.jmedchem.7b01261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></div><div class="casAuthors">Wang, Yue; Zhi, Yanle; Jin, Qiaomei; Lu, Shuai; Lin, Guowu; Yuan, Haoliang; Yang, Taotao; Wang, Zhanwei; Yao, Chao; Ling, Jun; Guo, Hao; Li, Tonghui; Jin, Jianlin; Li, Baoquan; Zhang, Li; Chen, Yadong; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1499-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1-H-pyrazole-3-carboxamide derivs. have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities.  A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is crit. for FLT3 and CDK inhibition.  Compd. 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis.  Acute-toxicity studies in mice show that compd. I (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg).  In MV4-11 xenografts in a nude-mouse model, compd. I can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg).  Taken together, these results demonstrate the potential of this unique compd. for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfX9S4QkGccbVg90H21EOLACvtfcHk0lh7PU-CqepyyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D&md5=2757ad7559e655c5d96f0a8af8c74aa5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25204-%2528%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2520%2528FN-1501%2529%252C%2520an%2520FLT3-%2520and%2520CDK-Kinase%2520inhibitor%2520with%2520potentially%2520high%2520efficiency%2520against%2520acute%2520myelocytic%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1499%26epage%3D1518%26doi%3D10.1021%2Facs.jmedchem.7b01261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee-Sherick, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGranahan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armistead, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGary, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsucker, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span> <span> </span><span class="NLM_article-title">Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5368</span>, <span class="refDoi"> DOI: 10.1038/onc.2013.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fonc.2013.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23474756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslKmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=5359-5368&author=A.+B.+Lee-Sherickauthor=K.+M.+Eisenmanauthor=S.+Satherauthor=A.+McGranahanauthor=P.+M.+Armisteadauthor=C.+S.+McGaryauthor=S.+A.+Hunsuckerauthor=J.+Schlegelauthor=H.+Martinsonauthor=C.+Cannonauthor=A.+K.+Keatingauthor=H.+S.+Earpauthor=X.+Liangauthor=D.+DeRyckereauthor=D.+K.+Graham&title=Aberrant+Mer+receptor+tyrosine+kinase+expression+contributes+to+leukemogenesis+in+acute+myeloid+leukemia&doi=10.1038%2Fonc.2013.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia</span></div><div class="casAuthors">Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; McGranahan, A.; Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">5359-5368</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clin. response to conventional therapy.  Abnormal tyrosine kinase activation in AML has been assocd. with poor prognosis and provides strategic targets for novel therapy development.  We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult (10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse.  Mer was also found to be expressed in 12 of 14 AML cell lines (86%).  In contrast, normal bone marrow myeloid precursors expressed little to no Mer.  Following AML cell line stimulation with Gas6, a Mer ligand, we obsd. activation of prosurvival and proliferative signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6.  To assess the phenotypic role of Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines Nomo-1 and Kasumi-1.  Redn. of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in response to serum starvation.  Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation by 67-87%, relative to control cell lines (P<0.01).  NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines (median survival 17 days in parental and control cell lines, vs. 32-36 days in Mer knockdown cell lines, P<0.0001).  These data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective therapeutic strategy in pediatric and adult AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSaqXGJx3YcbVg90H21EOLACvtfcHk0lh7PU-CqepyyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslKmtL0%253D&md5=9dcd6e614aa7ff40c38eeebe26950db9</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.40%26sid%3Dliteratum%253Aachs%26aulast%3DLee-Sherick%26aufirst%3DA.%2BB.%26aulast%3DEisenman%26aufirst%3DK.%2BM.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMcGranahan%26aufirst%3DA.%26aulast%3DArmistead%26aufirst%3DP.%2BM.%26aulast%3DMcGary%26aufirst%3DC.%2BS.%26aulast%3DHunsucker%26aufirst%3DS.%2BA.%26aulast%3DSchlegel%26aufirst%3DJ.%26aulast%3DMartinson%26aufirst%3DH.%26aulast%3DCannon%26aufirst%3DC.%26aulast%3DKeating%26aufirst%3DA.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DAberrant%2520Mer%2520receptor%2520tyrosine%2520kinase%2520expression%2520contributes%2520to%2520leukemogenesis%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D5359%26epage%3D5368%26doi%3D10.1038%2Fonc.2013.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaros, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7031</span>– <span class="NLM_lpage">7041</span>, <span class="refDoi"> DOI: 10.1021/jm500749d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500749d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7031-7041&author=W.+Zhangauthor=D.+DeRyckereauthor=D.+Hunterauthor=J.+Liuauthor=M.+A.+Stashkoauthor=K.+A.+Minsonauthor=C.+T.+Cummingsauthor=M.+Leeauthor=T.+G.+Glarosauthor=D.+L.+Newtonauthor=S.+Satherauthor=D.+Zhangauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC2025%2C+a+potent+and+orally+bioavailable+MER%2FFLT3+dual+inhibitor&doi=10.1021%2Fjm500749d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor</span></div><div class="casAuthors">Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra; Liu, Jing; Stashko, Michael A.; Minson, Katherine A.; Cummings, Christopher T.; Lee, Minjung; Glaros, Trevor G.; Newton, Dianne L.; Sather, Susan; Zhang, Dehui; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7031-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported a potent small mol. Mer tyrosine kinase inhibitor UNC1062.  However, its poor PK properties prevented further assessment in vivo.  We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examg. phospho-Mer in leukemic blasts from mouse bone marrow.  Kinome profiling vs. more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an addnl. important target in acute myelogenous leukemia (AML), with pharmacol. useful selectivity vs. other kinases examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIu8sRwBmPqrVg90H21EOLACvtfcHk0lh5tPDuS3NRrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN&md5=b3be89f194e6f5ea853d82aa67aea939</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm500749d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500749d%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMinson%26aufirst%3DK.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DGlaros%26aufirst%3DT.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC2025%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520MER%252FFLT3%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7031%26epage%3D7041%26doi%3D10.1021%2Fjm500749d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deryckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayakody, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">UNC1062, a new and potent Mer inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2013.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=23693152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=83-93&author=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=D.+Deryckereauthor=C.+T.+Cummingsauthor=D.+Hunterauthor=C.+Yangauthor=C.+N.+Jayakodyauthor=N.+Chengauthor=C.+Simpsonauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC1062%2C+a+new+and+potent+Mer+inhibitor&doi=10.1016%2Fj.ejmech.2013.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">UNC1062, a new and potent Mer inhibitor</span></div><div class="casAuthors">Liu, Jing; Zhang, Weihe; Stashko, Michael A.; DeRyckere, Deborah; Cummings, Christopher T.; Hunter, Debra; Yang, Chao; Jayakody, Chatura N.; Cheng, Nancy; Simpson, Catherine; Norris-Drouin, Jacqueline; Sather, Susan; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma.  The authors have discovered a new family of small mol. Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer.  Importantly, these compds. do not demonstrate significant hERG activity in the PatchXpress assay.  Through structure-activity relationship studies, UNC1062 was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor.  When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar.  Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrAMT5879KW7Vg90H21EOLACvtfcHk0lh5tPDuS3NRrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE&md5=fde1dd50f35af93a0e671932fb7c579d</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DJayakody%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC1062%252C%2520a%2520new%2520and%2520potent%2520Mer%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D83%26epage%3D93%26doi%3D10.1016%2Fj.ejmech.2013.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fleu.2015.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26139428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1emu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=754-757&author=H.+Wuauthor=C.+Huauthor=A.+Wangauthor=E.+L.+Weisbergauthor=W.+Wangauthor=C.+Chenauthor=Z.+Zhaoauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=A.+Nonamiauthor=L.+Wangauthor=B.+Wangauthor=R.+M.+Stoneauthor=S.+Liuauthor=J.+D.+Griffinauthor=J.+Liuauthor=Q.+Liu&title=Ibrutinib+selectively+targets+FLT3-ITD+in+mutant+FLT3-positive+AML&doi=10.1038%2Fleu.2015.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML</span></div><div class="casAuthors">Wu, H.; Hu, C.; Wang, A.; Weisberg, E. L.; Wang, W.; Chen, C.; Zhao, Z.; Yu, K.; Liu, J.; Wu, J.; Nonami, A.; Wang, L.; Wang, B.; Stone, R. M.; Liu, S.; Griffin, J. D.; Liu, J.; Liu, Q.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">754-757</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that has been extensively used as a tool compd. to validate the role of BTK kinase in B cell related malignances.1, 2.  Ibrutinib has been shown in preclin. studies to inhibit the proliferation of diffuse large B-cell lymphoma cells, mantle cell lymphoma cells, chronic lymphocytic leukemia cells and multiple myeloma cells by blocking BTK kinase activity; ibrutinib was recently approved for the clin. application on mantle cell lymphoma and chronic lymphocytic leukemia cells.3, 4, 5, 6, 7.  Ibrutinib has also exhibited anti-inflammatory effects in preclin. models.8, 9.  Recently, it has been reported that ibrutinib is also effective against epidermal growth factor receptor mutant-pos. non-small cell lung cancers through inhibition of epidermal growth factor receptor kinase activities.10.  In addn., there is evidence showing that BTK is also an important target for Acute Myeloid Leukemia (AML).11.  Despite the evidence that BTK knockdown impaired AML cancer cell growth, which suggested that BTK was important for AML cell proliferation, BTK kinase inhibition through use of a small mol. inhibitor like ibrutinib led only to moderate inhibition of proliferation of U937 cells with no apparent activity against other AML cell lines such as HL-60, TF-1 and THP-1.11.  To further investigate the potency and Interestingly, we found that only FLT3-internal tandem duplication (ITD) mutant AML cell lines (MOLM13, MOLM14 and MV4-11) were sensitive to ibrutinib (Figure 1a and Supplementary Table 1).  This is similar to what has been obsd. with the highly potent and selective FLT3 inhibitor, AC220, but differs from that obsd. for the targeted BTK kinase inhibitor, CGI-1746.12, 13 The selective antiproliferative activity was further confirmed in the clonogenic assay (GI50: 170-478 nM) (Supplementary Figure 1).  This suggests that ibrutinib might target FLT3 kinase in addn. to BTK kinase.  We then investigated the effect of ibrutinib on FLT3-ITD mediated signaling in drug-sensitive cell lines.  (Figure 1b) Ibrutinib potently inhibited FLT3-ITD auto-phosphorylation (EC50: 318, 39 and 356 nM resp. for MOLM13, MOLM14 and MV4-11) (Supplementary Figure 2A).  Phosphorylation of STAT5, a well-established downstream target, also was significantly inhibited with an EC50 between 100 and 200 nM (Supplementary Figure 2B).  In addn., c-Myc expression was inhibited with an EC50 between 185 and 315 nM.  (Supplementary Figure 2C) However, in FLT3 wt-expressing cell lines such as NOMO-1, HL-60, OCI-AML-3 and U937 cells, FLT3 signaling was not affected by ibrutinib upon FLT3 ligand stimulation (Supplementary Figure 2D).  Interestingly, despite the expression of the FLT3 wt kinase in all four cell lines, the induction of FLT3 auto-phosphorylation upon FLT3 ligand treatment was not obsd. in NOMO-1 and HL-60 cells like what was obsd. in the OCI-AML-3 and U937 cells, which might be due to the different genetic background and require further detailed mechanistic study.  The FLT3 inhibitor AC220 demonstrated similar inhibitory activity to ibrutinib in FLT3-mediated signaling pathways in the FLT3-ITD pos. cell lines.  However, the BTK inhibitors, CGI-1746 and AVL-292, did not exhibit any effect on the signaling14 (Figure 2b and Supplementary Figure 2D).  As all of these cell lines express BTK kinase, we then studied the effect of ibrutinib on BTK signaling.  Upon anti-IgM (IgM) stimulation of B-cell receptor to active the BTK kinase signaling pathway, we found that only in the FLT3 wild-type (wt)-expressing cell lines (U937 and OCI-AML3), downstream mediators of BTK kinase were affected despite BTK phosphorylation having been inhibited in both FLT3 wt and FLT3-ITD cell lines.9 This suggests that FLT3-ITD mutant cell lines might not rely on BTK signaling for growth (Supplementary Figure 3A).  Interestingly, except NOMO-1 and U937 cells, the phosphorylation of BTKY223 of MOLM14, MOLM13, MV4-11, OCI-AML-3 and HL-60 cells did not respond to anti-IgM stimulation apparently, which might be due to the basal-level expression of the IgM in these AML cells (Supplementary Figure 3B).  AC220 did not affect BTK kinase activity and its direct downstream target PLCγ but instead inhibited phosphorylation of protein kinase B and extracellular-signal-regulated kinase.  The BTK inhibitors, CGI-1746 and AVL-292, were effective against BTK kinase and PLCγ kinase phosphorylation, but had no effect on the phosphorylation of protein kinase B and extracellular-signal-regulated kinase.  These results suggest that ibrutinib may mainly exert its inhibitory activity through FLT3 kinase but not BTK kinase in the FLT3-ITD pos. cells.  To further confirm this, we knocked down BTK kinase in MOLM14 (FLT3-ITD), MOLM13 (FLT3-ITD), human erythroleukemia cell (HEL) (FLT3 wt) and NB4 (FLT3 wt) cells and found that the growth of MOLM14 and MOLM13 was only minimally affected; however NB4 cells were significantly inhibited and HEL cells were moderately inhibited (Figures 2a and b).  The fact that BTK knockdown in HEL cells did not lead to suppressed growth may be due to the fact that mutant JAK2 is the oncogenic driver in this cell line.15 In addn., the finding that ibrutinib still significantly blocked the growth of BTK-knockdown MOLM14 and MOLM13 cells further validated that the growth inhibitory effect of ibrutinib is likely dependent mainly on FLT3-ITD inhibition.  However, BTK kinase inhibition may also exert a combinatorial effect (Figure 2c).  It has recently been reported that BTK kinase is activated by FLT3-ITD in FLT3-ITD pos. cell lines and dual inhibition of BTK and FLT3 kinase demonstrates combinatorial effects; these findings further confirm this observation.16 Previous kinase selectivity profiling revealed that FLT3 wt might be an addnl. target of ibrutinib.9 The biochem. ADP-Glo assay confirmed that ibrutinib has an IC50 of 205.8 nM/65.65 nM against FLT3 wt and FLT3-ITD, resp. (Supplementary Figure 4A).  In the FLT3-ITD-dependent isogenic BaF3 cell line, ibrutinib demonstrated a GI50 of 120 nM; this inhibitory effect could be completely rescued by interleukin-3 treatment (Supplementary Figure 4B).  Interestingly, it also potently inhibited the FLT3-D835H-BaF3 isogenic cell (GI50: 0.063 μM) and moderately inhibited FLT3-D835Y-BaF3 as well as TEL-FLT3-wt-BaF3 isogenic cells (GI50: 0.5 μ/0.46 μ), however was less active against ITD-D835Y, ITD-F691L and FLT3-K663Q mutations.  (Supplementary Figure 5A) In addn., ibrutinib did not affect the growth of other oncogene-expressing Ba/F3 cells, such as c-Kit, PDGFRα, BCR-ABL and NRAS (Supplementary Figure 5B).  Although there are cysteine residues in the ATP-binding pocket, binding mode examn. with mol. modeling demonstrates that unlike the mode of inhibition against BTK kinase, ibrutinib inhibits FLT3 kinase through reversible binding and this is further confirmed by the washing-out expt. (Supplementary Figure 4C and D).  Ibrutinib induced apoptotic cell death in a concn.- and time-dependent manner in FLT3-ITD cell lines but not FLT3 wt-expressing cell lines (Supplementary Figure 6).  Cell cycle anal. revealed that ibrutinib, but not the highly selective BTK kinase inhibitor, CGI-1746, could induce a concn.-dependent manner-arrest cells in G0/G1 phase (Supplementary Figure 7).  In addn., ibrutinib exhibited dose-dependent anti-proliferation activity against FLT3-ITD mutant-expressing primary patient cells but not FLT3 wt-expressing and multiple mutants such as FLT3-ITD/FLT3-D835Y and FLT3-D835Y/E mutants expressing samples, which further confirms that ibrutinib is FLT3-ITD selective (Figure 2d).  AML still remains a serious unmet medical need and the FLT3-ITD mutant has been found in ∼30% of AML patients.  Besides std. chemotherapy, there is no targeted therapy approved in the clinic to date despite several inhibitors that are presently under clin. investigation.17 Currently, ibrutinib is under extensive clin. investigation against a variety of different B-cell malignancies.  Given the fact that the safety profile of ibrutinib is tolerated in the patients, our results might help to expand the application of this drug to AML patients harboring the FLT3-ITD mutant.  Interestingly, despite the fact that the effective concn. of ibrutinib in the in vitro studies in the FLT3-ITD pos. cell lines falls within the range of the peak plasma concn. used in human clin. trials (around 150 ng/mL at 560 mg/day dosage), the concn. required for the induction of apoptosis and cell cycle arrest for ibrutinib is higher, which suggests that an alternative formulation might be needed such as nano technol., to allow the increase of the plasma concns. in the human patients while simultaneously retaining the safety profile for the potential clin. application.18.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9uujF_Uu1FbVg90H21EOLACvtfcHk0lhYVRFF0ZeZFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1emu7vO&md5=cc08960c1d1db9a9f83c9c67bac15f85</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.175%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520targets%2520FLT3-ITD%2520in%2520mutant%2520FLT3-positive%2520AML%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D754%26epage%3D757%26doi%3D10.1038%2Fleu.2015.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3–122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9625</span>– <span class="NLM_lpage">9638</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9625-9638&author=X.+Liauthor=A.+Wangauthor=K.+Yuauthor=Z.+Qiauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=H.+Wuauthor=J.+Wuauthor=Z.+Zhaoauthor=J.+Liuauthor=F.+Zouauthor=L.+Wangauthor=B.+Wangauthor=W.+Wangauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-amino-3-%284-phenoxyphenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-1-yl%29-2-%28dimethylamino%29ethanone+%28CHMFL-FLT3%E2%80%93122%29+as+a+potent+and+orally+available+FLT3+kinase+inhibitor+for+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia</span></div><div class="casAuthors">Li, Xixiang; Wang, Aoli; Yu, Kailin; Qi, Ziping; Chen, Cheng; Wang, Wenchao; Hu, Chen; Wu, Hong; Wu, Jiaxin; Zhao, Zheng; Liu, Juan; Zou, Fengming; Wang, Li; Wang, Beilei; Wang, Wei; Zhang, Shanchun; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9625-9638</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, the authors have discovered compd. 18 (CHMFL-FLT3-122, I), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold).  It significantly inhibited the proliferation of FLT3-ITD pos. AML cancer cell lines MV4-11 (GIC50 = 22 nM), MOLM13/14 (GIC50 = 21 nM/42 nM).  More importantly, compd. 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GIC50 = 11 nM vs. 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity.  In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase.  In the in vivo studies compd. 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity.  Compd. 18 might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotxBPmnbEZ17Vg90H21EOLACvtfcHk0lhYVRFF0ZeZFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ&md5=f0d6f5f767f35c4aed3b20c02de06e86</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529-2-%2528dimethylamino%2529ethanone%2520%2528CHMFL-FLT3%25E2%2580%2593122%2529%2520as%2520a%2520potent%2520and%2520orally%2520available%2520FLT3%2520kinase%2520inhibitor%2520for%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9625%26epage%3D9638%26doi%3D10.1021%2Facs.jmedchem.5b01611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a highly potent type II FLT3 kinase inhibitor capable of overcoming a variety of FLT3 kinase mutants in FLT3-ITD positive AML</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8407</span>– <span class="NLM_lpage">8424</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8407-8424&author=A.+Wangauthor=X.+Liauthor=C.+Chenauthor=H.+Wuauthor=Z.+Qiauthor=C.+Huauthor=K.+Yuauthor=J.+Wuauthor=J.+Liuauthor=X.+Liuauthor=Z.+Huauthor=W.+Wangauthor=W.+Wangauthor=W.+Wangauthor=L.+Wangauthor=B.+Wangauthor=Q.+Liuauthor=L.+Liauthor=J.+Geauthor=T.+Renauthor=S.+Zhangauthor=R.+Xiaauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+1-%284-%284-amino-3-%284-%282-morpholinoethoxy%29phenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29phenyl%29-3-%285-%28tert-butyl%29isoxazol-3-yl%29urea+%28CHMFL-FLT3-213%29+as+a+highly+potent+type+II+FLT3+kinase+inhibitor+capable+of+overcoming+a+variety+of+FLT3+kinase+mutants+in+FLT3-ITD+positive+AML&doi=10.1021%2Facs.jmedchem.7b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML</span></div><div class="casAuthors">Wang, Aoli; Li, Xixiang; Chen, Cheng; Wu, Hong; Qi, Ziping; Hu, Chen; Yu, Kailin; Wu, Jiaxin; Liu, Juan; Liu, Xiaochuan; Hu, Zhenquan; Wang, Wei; Wang, Wenliang; Wang, Wenchao; Wang, Li; Wang, Beilei; Liu, Qingwang; Li, Lili; Ge, Jian; Ren, Tao; Zhang, Shanchun; Xia, Ruixiang; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8407-8424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of our previous study that ibrutinib exhibited selective and moderate inhibitory activity against FLT3-ITD pos. AML cells, through a structure-guided drug design approach, we have discovered a new type II FLT3 kinase inhibitor, compd. I (CHMFL-FLT3-213), which exhibited highly potent inhibitory effects against FLT3-ITD mutant and assocd. oncogenic mutations (including FLT3-D835Y/H/V, FLT3-ITD-D835Y/I/N/A/G/Del, and FLT3-ITD-F691L).  In the cellular context I strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting cell cycle into G0/G1 phase.  In the in vivo studies I demonstrated an acceptable bioavailability (F = 19%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (15 mg kg-1 day-1, TGI = 97%) without exhibiting obvious toxicity.  Compd. I might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1tbOp_Bxu-LVg90H21EOLACvtfcHk0lgEPvnw7zGqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN&md5=e4f3a47069f8ea615a3e1543b24a19b9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00840%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%25201-%25284-%25284-amino-3-%25284-%25282-morpholinoethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529phenyl%2529-3-%25285-%2528tert-butyl%2529isoxazol-3-yl%2529urea%2520%2528CHMFL-FLT3-213%2529%2520as%2520a%2520highly%2520potent%2520type%2520II%2520FLT3%2520kinase%2520inhibitor%2520capable%2520of%2520overcoming%2520a%2520variety%2520of%2520FLT3%2520kinase%2520mutants%2520in%2520FLT3-ITD%2520positive%2520AML%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8407%26epage%3D8424%26doi%3D10.1021%2Facs.jmedchem.7b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrrolo[2,3-d]pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4158</span>– <span class="NLM_lpage">4173</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4158-4173&author=X.+Yuanauthor=Y.+Chenauthor=W.+Zhangauthor=J.+Heauthor=L.+Leiauthor=M.+Tangauthor=J.+Liuauthor=M.+Liauthor=C.+Douauthor=T.+Yangauthor=L.+Yangauthor=S.+Yangauthor=Y.+Weiauthor=A.+Pengauthor=T.+Niuauthor=M.+Xiangauthor=H.+Yeauthor=L.+Chen&title=Identification+of+pyrrolo%5B2%2C3-d%5Dpyrimidine-based+derivatives+as+potent+and+orally+effective+Fms-like+tyrosine+receptor+kinase+3+%28FLT3%29+inhibitors+for+treating+acute+myelogenous+leukemia&doi=10.1021%2Facs.jmedchem.9b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia</span></div><div class="casAuthors">Yuan, Xue; Chen, Yong; Zhang, Wanhua; He, Jun; Lei, Lei; Tang, Minghai; Liu, Jiang; Li, Muzhou; Dou, Caixia; Yang, Tao; Yang, Linyu; Yang, Shengyong; Wei, Yuquan; Peng, Aihua; Niu, Ting; Xiang, Mingli; Ye, Haoyu; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4158-4173</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrrolo[2,3-d]pyrimidine derivs. were prepd. and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells.  Among them, compd. I possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13 cells.  It also showed excellent inhibitory activities in FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to quizartinib.  Furthermore, I exhibited over 40-fold selectivity toward FLT3 relative to c-Kit kinase, which might reduce myelosuppression toxicity.  Cellular assays demonstrated that I inhibited phosphorylated FLT3 and downstream signaling factors and also induced cell cycle arrest in the G0/G1 stage and apoptosis in MV4-11 and Molm-13 cells.  Oral administration of I at 10 mg/kg could achieve rapid tumor extinction in the MV4-11 xenograft model and significantly inhibit the tumor growth in the MOLM-13 xenograft model with a tumor growth inhibitory rate of 96% without obvious toxicity.  Addnl., I demonstrated high bioavailability (F = 59.5%) and suitable eliminated half-life time (T1/2 = 2.06 h), suggesting that I may be a potent candidate for treating acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc5FKDBj_PA7Vg90H21EOLACvtfcHk0lgEPvnw7zGqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D&md5=37666941adb79cb2a5d8a4115ddd2519</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDou%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DA.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520pyrrolo%255B2%252C3-d%255Dpyrimidine-based%2520derivatives%2520as%2520potent%2520and%2520orally%2520effective%2520Fms-like%2520tyrosine%2520receptor%2520kinase%25203%2520%2528FLT3%2529%2520inhibitors%2520for%2520treating%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4158%26epage%3D4173%26doi%3D10.1021%2Facs.jmedchem.9b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and rational design of pteridin-7(8H)-one-based inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6187</span>– <span class="NLM_lpage">6200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVCltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6187-6200&author=D.+Sunauthor=Y.+Yangauthor=J.+Lyuauthor=W.+Zhouauthor=W.+Songauthor=Z.+Zhaoauthor=Z.+Chenauthor=Y.+Xuauthor=H.+Li&title=Discovery+and+rational+design+of+pteridin-7%288H%29-one-based+inhibitors+targeting+FMS-like+tyrosine+kinase+3+%28FLT3%29+and+its+mutants&doi=10.1021%2Facs.jmedchem.6b00374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants</span></div><div class="casAuthors">Sun, Deheng; Yang, Yu; Lyu, Jiankun; Zhou, Wei; Song, Wenlin; Zhao, Zhenjiang; Chen, Zhuo; Xu, Yufang; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6187-6200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML).  In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 inhibitors derived from structural optimizations on irreversible EGFR inhibitors.  The representative inhibitor (31) demonstrates single-digit nanomolar inhibition against FLT3 and subnanomolar KD for drug-resistance FLT3 mutants.  In profiling of the in vitro tumor cell lines, it shows good selectivity against AML cells harboring FLT3-ITD mutations over other leukemia and solid tumor cell lines.  The mechanism of action study illustrates that pteridin-7(8H)-one derivs. suppress the phosphorylation of FLT3 and its downstream pathways, thereby inducing G0/G1 cell cycle arrest and apoptosis in AML cells.  In in vivo studies, 31 significantly suppresses the tumor growth in MV4-11 xenograft model.  Overall, we provide a structurally distinct chem. scaffold with which to develop FLT3 mutants-selective inhibitors for AML treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOmpGYdXfHlbVg90H21EOLACvtfcHk0lgEPvnw7zGqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVCltrc%253D&md5=b672eb968645a0ca88f0af371c67629d</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00374%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520rational%2520design%2520of%2520pteridin-7%25288H%2529-one-based%2520inhibitors%2520targeting%2520FMS-like%2520tyrosine%2520kinase%25203%2520%2528FLT3%2529%2520and%2520its%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6187%26epage%3D6200%26doi%3D10.1021%2Facs.jmedchem.6b00374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarusiewicz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of a diaminopyrimidine FLT3 inhibitor active against acute myeloid leukemia</span>. <i>ACS Omega.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1985</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/acsomega.7b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.7b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVegu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=1985-2009&author=J.+A.+Jarusiewiczauthor=J.+Y.+Jeonauthor=M.+C.+Connellyauthor=Y.+Chenauthor=L.+Yangauthor=S.+D.+Bakerauthor=R.+K.+Guy&title=Discovery+of+a+diaminopyrimidine+FLT3+inhibitor+active+against+acute+myeloid+leukemia&doi=10.1021%2Facsomega.7b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia</span></div><div class="casAuthors">Jarusiewicz, Jamie A.; Jeon, Jae Yoon; Connelly, Michele C.; Chen, Yizhe; Yang, Lei; Baker, Sharyn D.; Guy, R. Kiplin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1985-2009</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Profiling of the kinase-binding capabilities of an aminopyrimidine analog detected in a cellular screen of the St.  Jude small-mol. collection led to the identification of a novel series of FMS-like tyrosine kinase 3 (FLT3) inhibitors.  Structure-activity relationship studies led to the development of compds. exhibiting good potency against MV4-11 and MOLM13 acute myelogenous leukemia cells driven by FLT3, regardless of their FLT3 mutation status.  In vitro pharmacol. profiling demonstrated that compd. 5e shows characteristics suitable for further preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG8D0TrL7uCbVg90H21EOLACvtfcHk0lh9sh37yafGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVegu7w%253D&md5=653dacc5371930c67aa79246e1a35846</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facsomega.7b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.7b00144%26sid%3Dliteratum%253Aachs%26aulast%3DJarusiewicz%26aufirst%3DJ.%2BA.%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DConnelly%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3DDiscovery%2520of%2520a%2520diaminopyrimidine%2520FLT3%2520inhibitor%2520active%2520against%2520acute%2520myeloid%2520leukemia%26jtitle%3DACS%2520Omega.%26date%3D2017%26volume%3D2%26spage%3D1985%26epage%3D2009%26doi%3D10.1021%2Facsomega.7b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelaziz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=28863357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaht73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=762-772&author=S.+Diabauthor=A.+M.+Abdelazizauthor=P.+Liauthor=T.+Teoauthor=S.+Basnetauthor=B.+Nollauthor=M.+H.+Rahamanauthor=J.+Luauthor=J.+Houauthor=M.+Yuauthor=B.+T.+Leauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+Wang&title=Dual+inhibition+of+Mnk2+and+FLT3+for+potential+treatment+of+acute+myeloid+leukaemia&doi=10.1016%2Fj.ejmech.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia</span></div><div class="casAuthors">Diab, Sarah; Abdelaziz, Ahmad M.; Li, Peng; Teo, Theodosia; Basnet, Sunita K. C.; Noll, Ben; Rahaman, Muhammed H.; Lu, Jingfeng; Hou, Jinqiang; Yu, Mingfeng; Le, Bich T.; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">762-772</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The discovery of novel anti-AML therapeutic agents is urgently needed, but the complex heterogeneity of the disease has so far hampered the development of a curative treatment.  FLT3 inhibitors have shown therapeutic potential in clin. trials; but a monotherapy regimen has been assocd. with resistance mediated by the activation of parallel signaling circuitry, including MAPK and mTOR.  Therefore, inhibiting a nexus of the two signaling pathways along with inhibition of FLT3 might be advantageous.  Herein, the authors propose that a dual inhibition of FLT3 and Mnk would provide a better clin. option for AML patients compared to targeting FLT3 alone.  Thus, a series of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amines and 4-(indol-3-yl)-N-phenylpyrimidin-2-amines were prepd.  Potent Mnk2 inhibitors, FLT3 inhibitors, and dual inhibitors of Mnk2 and FLT3 were identified and their antiproliferative activities assessed against MV4-11 AML cell lines.  Dual inhibition of FLT3 and Mnk2 caused the increased apoptotic cell death of MV4-11 cells compared to inhibition of FLT3 or Mnk2 alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeSmNto09qL7Vg90H21EOLACvtfcHk0lh9sh37yafGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaht73F&md5=439b0e509af9800c168beb69c9d2b1a0</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DAbdelaziz%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DBasnet%26aufirst%3DS.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDual%2520inhibition%2520of%2520Mnk2%2520and%2520FLT3%2520for%2520potential%2520treatment%2520of%2520acute%2520myeloid%2520leukaemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D762%26epage%3D772%26doi%3D10.1016%2Fj.ejmech.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radošová Muchová, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klejová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malínková, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepšík, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divoký, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of N<sup>2</sup>-(4-amino-cyclohexyl)-9-cyclopentyl- N<sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3855-3869&author=T.+Guck%C3%BDauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+Rado%C5%A1ov%C3%A1+Muchov%C3%A1author=R.+Jordaauthor=Z.+Klejov%C3%A1author=V.+Mal%C3%ADnkov%C3%A1author=K.+Berkaauthor=V.+Bazgierauthor=H.+Ajaniauthor=M.+Lep%C5%A1%C3%ADkauthor=V.+Divok%C3%BDauthor=V.+Kry%C5%A1tof&title=Discovery+of+N2-%284-amino-cyclohexyl%29-9-cyclopentyl-+N6-%284-morpholin-4-ylmethyl-phenyl%29-9H-purine-2%2C6-diamine+as+a+potent+FLT3+kinase+inhibitor+for+acute+myeloid+leukemia+with+FLT3+mutations&doi=10.1021%2Facs.jmedchem.7b01529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></div><div class="casAuthors">Gucky, Tomas; Reznickova, Eva; Radosova Muchova, Tereza; Jorda, Radek; Klejova, Zuzana; Malinkova, Veronika; Berka, Karel; Bazgier, Vaclav; Ajani, Haresh; Lepsik, Martin; Divoky, Vladimir; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3.  We present novel 2,6,9-trisubstituted purine derivs. with potent FLT3 inhibitory activity.  The lead compd. 7d displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive.  The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis.  Addnl., a single dose of 7d in mice with s.c. MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ88Wx0YxwWLVg90H21EOLACvtfcHk0lh9sh37yafGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D&md5=cbc982a08f1905840e273e23c825a134</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DRado%25C5%25A1ov%25C3%25A1%2BMuchov%25C3%25A1%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKlejov%25C3%25A1%26aufirst%3DZ.%26aulast%3DMal%25C3%25ADnkov%25C3%25A1%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DLep%25C5%25A1%25C3%25ADk%26aufirst%3DM.%26aulast%3DDivok%25C3%25BD%26aufirst%3DV.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520N2-%25284-amino-cyclohexyl%2529-9-cyclopentyl-%2520N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2520as%2520a%2520potent%2520FLT3%2520kinase%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3855%26epage%3D3869%26doi%3D10.1021%2Facs.jmedchem.7b01529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111590</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2019.111590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31408808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111590&author=Y.+Liauthor=T.+Yeauthor=L.+Xuauthor=Y.+Dongauthor=Y.+Luoauthor=C.+Wangauthor=Y.+Hanauthor=K.+Chenauthor=M.+Qinauthor=Y.+Liuauthor=Y.+Zhao&title=Discovery+of+4-piperazinyl-2-aminopyrimidine+derivatives+as+dual+inhibitors+of+JAK2+and+FLT3&doi=10.1016%2Fj.ejmech.2019.111590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span></div><div class="casAuthors">Li, Yingxiu; Ye, Tianyu; Xu, Le; Dong, Yuhong; Luo, Yong; Wang, Chu; Han, Yufei; Chen, Ke; Qin, Mingze; Liu, Yajing; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111590</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design.  In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivs.  All compds. were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compds. with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60).  The structure-activity relationship studies were conducted through variations in two regions, the "A" Ph ring and "B" Ph ring.  Compd. 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines.  In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs61BoDk0-lbVg90H21EOLACvtfcHk0lj4LBEqhFVRBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO&md5=787f97231f5494a8f85f581521486b25</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111590%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25204-piperazinyl-2-aminopyrimidine%2520derivatives%2520as%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520FLT3%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111590%26doi%3D10.1016%2Fj.ejmech.2019.111590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally effective dual Janus Kinase 2/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10305</span>– <span class="NLM_lpage">10320</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10305-10320&author=T.+Yangauthor=M.+Huauthor=W.+Qiauthor=Z.+Yangauthor=M.+Tangauthor=J.+Heauthor=Y.+Chenauthor=P.+Baiauthor=X.+Yuanauthor=C.+Zhangauthor=K.+Liuauthor=Y.+Luauthor=M.+Xiangauthor=L.+Chen&title=Discovery+of+potent+and+orally+effective+dual+Janus+Kinase+2%2FFLT3+inhibitors+for+the+treatment+of+acute+myelogenous+leukemia+and+myeloproliferative+neoplasms&doi=10.1021%2Facs.jmedchem.9b01348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></div><div class="casAuthors">Yang, Tao; Hu, Mengshi; Qi, Wenyan; Yang, Zhuang; Tang, Minghai; He, Jun; Chen, Yong; Bai, Peng; Yuan, Xue; Zhang, Chufeng; Liu, Kongjun; Lu, Yulin; Xiang, Mingli; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10305-10320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivs. that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases is described.  These screening cascades revealed that I was a preferred compd. with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, resp.  Moreover, I was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, resp., and possessed an excellent selectivity profile over the other 100 representative kinases.  In a series of cytokine-stimulated cell-based assays, I exhibited a higher JAK2 selectivity over other JAK isoforms.  The oral administration of 60 mg/kg of I could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, resp.  Addnl., I showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that I might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHnNcuajGNcLVg90H21EOLACvtfcHk0lj4LBEqhFVRBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE&md5=86c811cf77a95a7250996456cd29e6dc</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520effective%2520dual%2520Janus%2520Kinase%25202%252FFLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10305%26epage%3D10320%26doi%3D10.1021%2Facs.jmedchem.9b01348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1066</span>– <span class="NLM_lpage">1076</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2017.11.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29232583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1066-1076&author=H.+Daiauthor=S.+Geauthor=J.+Guoauthor=S.+Chenauthor=M.+Huangauthor=J.+Yangauthor=S.+Sunauthor=Y.+Lingauthor=Y.+Shi&title=Development+of+novel+bis-pyrazole+derivatives+as+antitumor+agents+with+potent+apoptosis+induction+effects+and+DNA+damage&doi=10.1016%2Fj.ejmech.2017.11.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage</span></div><div class="casAuthors">Dai, Hong; Ge, Shushan; Guo, Jing; Chen, Shi; Huang, Meiling; Yang, Jiaying; Sun, Siyu; Ling, Yong; Shi, Yujun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1066-1076</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of bis-pyrazole derivs. I (R1 = Et, 4-fluorophenyl, 4-chlorophenyl; R2 = 2-F, 3-Me, 4-OCF3, etc.) was designed and synthesized, and their antitumor effects in vitro and in vivo were investigated.  Several compds. displayed good antiproliferative activity with IC50 values in low-micromolar range against three human cancer cell lines in vitro, superior to 5-FU.  The most potent compd. I (R1 = 4-chlorophenyl; R2 = 4-OCH3) selectively inhibited human hepatocellular carcinoma cells but not non-tumor liver cell proliferation in vitro, and significantly triggered SMMC-7721 cell apoptosis by cleavage of both PARP and caspase-3 in a concn.-dependent manner.  Further study revealed that the potent activity in the cell growth inhibition and apoptosis induction effects of compd. I (R1 = 4-chlorophenyl; R2 = 4-OCH3) were related to DNA damage and activation of the p53 signaling pathway.  Moreover, compd. I (R1 = 4-chlorophenyl; R2 = 4-OCH3) showed low acute toxicity to mice and significant growth inhibition of the hepatoma tumor in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2FnwsxrlS67Vg90H21EOLACvtfcHk0lj4LBEqhFVRBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3K&md5=ecbc99d1c9ad62e443791b4f0a1b28c0</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.098%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520novel%2520bis-pyrazole%2520derivatives%2520as%2520antitumor%2520agents%2520with%2520potent%2520apoptosis%2520induction%2520effects%2520and%2520DNA%2520damage%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1066%26epage%3D1076%26doi%3D10.1016%2Fj.ejmech.2017.11.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span> <span> </span><span class="NLM_article-title">Pyrazole scaffold: a remarkable tool in the development of anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2013.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=24161702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOqurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=248-258&author=H.+Kumarauthor=D.+Sainiauthor=S.+Jainauthor=N.+Jain&title=Pyrazole+scaffold%3A+a+remarkable+tool+in+the+development+of+anticancer+agents&doi=10.1016%2Fj.ejmech.2013.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole scaffold: A remarkable tool in the development of anticancer agents</span></div><div class="casAuthors">Kumar, Harish; Saini, Deepika; Jain, Sandeep; Jain, Neelam</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">248-258</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Pyrazole has been the topic of interest for thousands of researchers across the world because of its wide spectrum pharmacol. activities.  Various structural modifications of the pyrazole nucleus have been made to explore its characteristics and biol. potential.  The present work aims to review the use of mol. modeling in the designing of novel pyrazole analogs that may target various receptors such as protein kinase inhibitor, tyrosine kinase, Aurora-A kinase, tumor growth factor (TGF), cyclin dependent kinase (CDK) and fibroblast growth factor (FGF), which are significant for the management of cancer.  An insight has been given in this article for the importance of pyrazoles in the treatment of cancer and the perspectives that they hold for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf4c2cE6IwfrVg90H21EOLACvtfcHk0lhwbG0X-RQ57Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOqurjE&md5=a1c1f41aa2949d40a8f6adc57ee4fc4e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DH.%26aulast%3DSaini%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DN.%26atitle%3DPyrazole%2520scaffold%253A%2520a%2520remarkable%2520tool%2520in%2520the%2520development%2520of%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D70%26spage%3D248%26epage%3D258%26doi%3D10.1016%2Fj.ejmech.2013.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Qudah, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbuTayeh, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, S. A.</span></span> <span> </span><span class="NLM_article-title">Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.02.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.canlet.2016.02.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26916980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=199-208&author=A.+M.+Salehauthor=M.+O.+Tahaauthor=M.+A.+Azizauthor=M.+A.+Al-Qudahauthor=R.+F.+AbuTayehauthor=S.+A.+Rizvi&title=Novel+anticancer+compound+%5Btrifluoromethyl-substituted+pyrazole+N-nucleoside%5D+inhibits+FLT3+activity+to+induce+differentiation+in+acute+myeloid+leukemia+cells&doi=10.1016%2Fj.canlet.2016.02.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells</span></div><div class="casAuthors">Saleh, Ayman M.; Taha, Mutasem O.; Aziz, Mohammad A.; Al-Qudah, Mahmoud A.; AbuTayeh, Reem F.; Rizvi, Syed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-208</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anticancer properties of chem. synthesized compds. have continuously been optimized for better efficacy and selectivity.  Derivs. of heterocyclic compds. are well known to have selective antiproliferative effect against many types of cancer.  In this study, we investigated the ability of an indigenously synthesized anticancer mol., G-11 [1-(2",3",4",6"-Tetra-O-acetyl-β-D-glucopyranosyl)-4-(3'-trifluoromethylphenylhydrazono)-3-trifluoromethyl-1,4-dihydropyrazol-5-one], to cause selective cytotoxicity and induce differentiation in the acute myeloid leukemia HL-60 cells.  G-11 was able to exert cytotoxic effect on hematol. (Jurkat, U937, K562, HL-60, CCRF-SB) and solid tumor (MCF-7, HepG2, HeLa, Caco-2) cell lines, with IC50 values significantly lower than noncancerous cells (HEK-293, BJ and Vero) and normal peripheral blood mononuclear cells.  G-11 induced differentiation of HL-60 cells to granulocytes and monocytes/macrophages by inhibiting the activation of FLT3 (CD135 tyrosine kinase).  ITD-FLT3 mutation found in many acute myeloid leukemia patients could also be targeted by G-11 as exhibited by its inhibitory effect on MOLM-13 and MV4-11 cell lines.  Mol. docking studies suggest the involvement of Leu616, Asp698, Cys694 and Cys828 residues in binding of G-11 to FLT3.  The ability of G-11 to cause selective cytotoxicity and induce differentiation in cancer cells could be clin. relevant for therapeutic gains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG___Toist2rVg90H21EOLACvtfcHk0li-PkrJQjoetw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCntr0%253D&md5=ca9f0c932e024759b69245c983a1ea81</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.02.028%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DA.%2BM.%26aulast%3DTaha%26aufirst%3DM.%2BO.%26aulast%3DAziz%26aufirst%3DM.%2BA.%26aulast%3DAl-Qudah%26aufirst%3DM.%2BA.%26aulast%3DAbuTayeh%26aufirst%3DR.%2BF.%26aulast%3DRizvi%26aufirst%3DS.%2BA.%26atitle%3DNovel%2520anticancer%2520compound%2520%255Btrifluoromethyl-substituted%2520pyrazole%2520N-nucleoside%255D%2520inhibits%2520FLT3%2520activity%2520to%2520induce%2520differentiation%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D375%26spage%3D199%26epage%3D208%26doi%3D10.1016%2Fj.canlet.2016.02.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagano, T.</span></span> <span> </span><span class="NLM_article-title">Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2370</span>– <span class="NLM_lpage">2374</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2016.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26995531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2370-2374&author=H.+Nakanoauthor=T.+Hasegawaauthor=R.+Imamuraauthor=N.+Saitoauthor=H.+Kojimaauthor=T.+Okabeauthor=T.+Nagano&title=Development+of+a+potent+and+selective+FLT3+kinase+inhibitor+by+systematic+expansion+of+a+non-selective+fragment-screening+hit&doi=10.1016%2Fj.bmcl.2016.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit</span></div><div class="casAuthors">Nakano, Hirofumi; Hasegawa, Tsukasa; Imamura, Riyo; Saito, Nae; Kojima, Hirotatsu; Okabe, Takayoshi; Nagano, Tetsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2370-2374</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A nonselective inhibitor (1) of FMS-like tyrosine kinase-3 (FLT3) was identified by fragment screening and systematically modified to afford a potent and selective inhibitor I.  The authors confirmed that I inhibited the growth of FLT-3-activated human acute myeloid leukemia cell line MV4-11.  The design strategy enabled rapid development of a novel type of FLT3 inhibitor from the hit fragment in the absence of target-structural information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSnyMZHnQnP7Vg90H21EOLACvtfcHk0li-PkrJQjoetw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGhs70%253D&md5=76f8dcdcaa318db08018378135dafb13</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DNakano%26aufirst%3DH.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DImamura%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DN.%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DT.%26aulast%3DNagano%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520a%2520potent%2520and%2520selective%2520FLT3%2520kinase%2520inhibitor%2520by%2520systematic%2520expansion%2520of%2520a%2520non-selective%2520fragment-screening%2520hit%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2370%26epage%3D2374%26doi%3D10.1016%2Fj.bmcl.2016.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2018.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=29894944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=303-315&author=Y.+Zhiauthor=B.+Liauthor=C.+Yaoauthor=H.+Liauthor=P.+Chenauthor=J.+Baoauthor=T.+Qinauthor=Y.+Wangauthor=T.+Luauthor=S.+Lu&title=Discovery+of+the+selective+and+efficacious+inhibitors+of+FLT3+mutations&doi=10.1016%2Fj.ejmech.2018.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span></div><div class="casAuthors">Zhi, Yanle; Li, Baoquan; Yao, Chao; Li, Hongmei; Chen, Puzhou; Bao, Jiyin; Qin, Tianren; Wang, Yue; Lu, Tao; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">303-315</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy.  Starting from the lead compd. LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivs. were synthesized to improve the FLT3 inhibitory potency and selectivity.  Among them, compd. 50 (4-((2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide) was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib.  Compd. 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants.  Inversely, compd. 50 displayed no cytotoxicity to FLT3-independent cells, and the biochem. analyses showed that its effects were related to the inhibition of FLT3 signal pathways.  Addnl., compd. 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry.  Moreover, compd. 50 showed enhanced metabolic stability.  Altogether, it was concluded that compd. 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUFIlbd1kxabVg90H21EOLACvtfcHk0li-PkrJQjoetw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ&md5=8b82ebdbf00f4693a7e7b94b32c9f1b7</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FLT3%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D303%26epage%3D315%26doi%3D10.1016%2Fj.ejmech.2018.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2018.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=30508668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWksbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=195-206&author=H.+Hengauthor=Y.+Zhiauthor=H.+Yuanauthor=Z.+Wangauthor=H.+Liauthor=S.+Wangauthor=J.+Tianauthor=H.+Liuauthor=Y.+Chenauthor=T.+Luauthor=T.+Ranauthor=S.+Lu&title=Discovery+of+a+highly+selective+FLT3+inhibitor+with+specific+proliferation+inhibition+against+AML+cells+harboring+FLT3-ITD+mutation&doi=10.1016%2Fj.ejmech.2018.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation</span></div><div class="casAuthors">Heng, Hao; Zhi, Yanle; Yuan, Haoliang; Wang, Zhijie; Li, Hongmei; Wang, Shuxian; Tian, Jieyi; Liu, Haichun; Chen, Yadong; Lu, Tao; Ran, Ting; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">FLT3 is often over-expressed in AML, and FLT3 mutants, esp. FLT-ITD, are closely related to the poor prognosis in AML patients.  Thus, FLT3 has become an attractive target for AML therapy.  A series of FLT3 inhibitors have been evaluated in various clin. trials, one of which was approved for AML.  However, current FLT3 inhibitors still faced the challenges of kinase selectivity and drug resistance due to concurrent FLT3-ITD-TKD mutations.  In this work, a new FLT3 inhibitor (compd. 1) with simple structure was discovered through virtually screening an inhouse mol. database which contains numerous compds. with kinase-inhibition activity.  Compd. 1(I) was identified with potent inhibitory activity against several FLT3 mutants and high FLT3 selectivity over other kinases.  Moreover, its anti-growth effects on tumor cells in vitro were dependent on the expression of FLT3-ITD, and it showed little cytotoxicity to MV4-11 and human normal cells.  Mechanism studies illustrated that compd. 1 blocked FLT3 pathway, caused cell cycle arrest and induced apoptosis in MV4-11 cells.  Finally, the binding mode of compd. 1 was studied by mol. dynamics simulations, which provides insights into key residues involved in intermol. binding and further structural optimization strategy.  Compd. 1 can thus serve as a good starting point for the research on FLT3 inhibitors towards the kinase selectivity and potential to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolUgNd6f7RQ7Vg90H21EOLACvtfcHk0lhDvMrjqjTllg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWksbvL&md5=065281d4737ba15abd098930ae7de6e0</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DHeng%26aufirst%3DH.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520selective%2520FLT3%2520inhibitor%2520with%2520specific%2520proliferation%2520inhibition%2520against%2520AML%2520cells%2520harboring%2520FLT3-ITD%2520mutation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2018.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2019.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31103903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=248-267&author=H.+Hengauthor=Z.+Wangauthor=H.+Liauthor=Y.+Huangauthor=Q.+Lanauthor=X.+Guoauthor=L.+Zhangauthor=Y.+Zhiauthor=J.+Caiauthor=T.+Qinauthor=L.+Xiangauthor=S.+Wangauthor=Y.+Chenauthor=T.+Luauthor=S.+Lu&title=Combining+structure-+and+property-based+optimization+to+identify+selective+FLT3-ITD+inhibitors+with+good+antitumor+efficacy+in+AML+cell+inoculated+mouse+xenograft+model&doi=10.1016%2Fj.ejmech.2019.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model</span></div><div class="casAuthors">Heng, Hao; Wang, Zhijie; Li, Hongmei; Huang, Yatian; Lan, Qingyuan; Guo, Xiaoxing; Zhang, Liang; Zhi, Yanle; Cai, Jiongheng; Qin, Tianren; Xiang, Li; Wang, Shuxian; Chen, Yadong; Lu, Tao; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">248-267</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients.  Recently, FLT3 inhibitors have been approved for AML therapy.  Herein, a series of new compds. with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD.  Compd. 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line.  Furthermore, the apoptosis and down regulation of P-STAT5 were also obsd. in tumor cells extd. from the MV4-11 cell xenografts model upon compd. 46 treatment.  Compd. 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo.  Compd. 46 showed no toxicity to the viscera of mice and caused no decrease in body wt. of mice.  In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compd. 46 was worthy of further development as potential drug candidate to treat AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIoN2WJhKLwrVg90H21EOLACvtfcHk0lhDvMrjqjTllg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsLc%253D&md5=cfd4e6fc9b38b1a4272199267102a31d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DHeng%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DCombining%2520structure-%2520and%2520property-based%2520optimization%2520to%2520identify%2520selective%2520FLT3-ITD%2520inhibitors%2520with%2520good%2520antitumor%2520efficacy%2520in%2520AML%2520cell%2520inoculated%2520mouse%2520xenograft%2520model%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D176%26spage%3D248%26epage%3D267%26doi%3D10.1016%2Fj.ejmech.2019.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, C. L. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6625</span>– <span class="NLM_lpage">6637</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmc.2014.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25456387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGgu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=6625-6637&author=J.+Xuauthor=E.+H.+Q.+Ongauthor=J.+Hillauthor=A.+Chenauthor=C.+L.+L.+Chai&title=Design%2C+synthesis+and+biological+evaluation+of+FLT3+covalent+inhibitors+with+a+resorcylic+acid+core&doi=10.1016%2Fj.bmc.2014.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core</span></div><div class="casAuthors">Xu, Jin; Ong, Esther H. Q.; Hill, Jeffrey; Chen, Anqi; Chai, Christina L. L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6625-6637</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of simplified ring-opened resorcylic acid lactones were conveniently synthesized to target FLT3 and its mutants either irreversibly or reversibly.  The design of covalent FLT3 inhibitors is based on cis-enone lactones (e.g., L-783,277) that have a β-resorcylic acid as the core structure.  The designed compds. contain three types of Michael acceptors (acrylamide, vinylsulfonamide and maleimide) as potential covalent traps of a cysteine residue at the binding site of kinases.  A variety of functional substitutions were also introduced to maximize the binding interactions.  Biol. evaluations revealed that compd. I, despite the presence of a highly reactive maleimide Michael acceptor, is a potent covalent FLT3 inhibitor which shows some specificity in cellular assays.  On the other hand, compds. II [R1 = 3-morpholinopropyl, R2 = iso-Pr, R3 = acryl] and II [R1 = Me, R2 = iso-Pr, R3 = vinylsulfonyl] contg. acrylamide or vinylsulfonamide groups are reversible towards FLT3 binding, and are potent and selective inhibitors of mutant FLT3-ITD vs. wt-FLT3.  They also inhibit cell proliferation in FLT3-ITD expressing cell line MV-4-11 as compared to wt-FLT3 expressing cell line THP-1 and non-FLT3 cell lines (K562, HL60 and Hek-293T).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5eFfzrhOk6rVg90H21EOLACvtfcHk0lhDvMrjqjTllg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGgu7fL&md5=9a2bbc42d3af387ed5a0051a25dd4e75</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DE.%2BH.%2BQ.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChai%26aufirst%3DC.%2BL.%2BL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520FLT3%2520covalent%2520inhibitors%2520with%2520a%2520resorcylic%2520acid%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D6625%26epage%3D6637%26doi%3D10.1016%2Fj.bmc.2014.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e69</span> <span class="refDoi"> DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=22829971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.+C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+oral+HDAC+inhibitor+pracinostat+%28SB939%29+is+efficacious+and+synergistic+with+the+JAK2+inhibitor+pacritinib+%28SB1518%29+in+preclinical+models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520oral%2520HDAC%2520inhibitor%2520pracinostat%2520%2528SB939%2529%2520is%2520efficacious%2520and%2520synergistic%2520with%2520the%2520JAK2%2520inhibitor%2520pacritinib%2520%2528SB1518%2529%2520in%2520preclinical%2520models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N. F.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.ejmech.2015.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25800646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=104-115&author=C.+Q.+Ningauthor=C.+Luauthor=L.+Huauthor=Y.+J.+Biauthor=L.+Yaoauthor=Y.+J.+Heauthor=L.+F.+Liuauthor=X.+Y.+Liuauthor=N.+F.+Yu&title=Macrocyclic+compounds+as+anti-cancer+agents%3A+design+and+synthesis+of+multi-acting+inhibitors+against+HDAC%2C+FLT3+and+JAK2&doi=10.1016%2Fj.ejmech.2015.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span></div><div class="casAuthors">Ning, Cheng-Qing; Lu, Cheng; Hu, Liang; Bi, Yan-Jing; Yao, Lei; He, Yu-Jun; Liu, Li-Fei; Liu, Xiao-Yu; Yu, Nie-Fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of macrocyclic compds. I [X = O, CH2O; Y = CH2, CO; n = 1, 2; m = 1-5] were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2.  Some of these compds. exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions.  In vitro antiproliferative assay indicated that these compds. were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2V617F mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvwiDjzqtazLVg90H21EOLACvtfcHk0lj8kOUVFvwL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D&md5=fc2b93fcbce2998ecd2d6de46a01811d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DY.%2BJ.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DYu%26aufirst%3DN.%2BF.%26atitle%3DMacrocyclic%2520compounds%2520as%2520anti-cancer%2520agents%253A%2520design%2520and%2520synthesis%2520of%2520multi-acting%2520inhibitors%2520against%2520HDAC%252C%2520FLT3%2520and%2520JAK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2015.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holladay, M. W.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3441</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bmcl.2015.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26208887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3436-3441&author=G.+Liuauthor=S.+Abrahamauthor=X.+Liuauthor=S.+Xuauthor=A.+M.+Rooksauthor=R.+Nepomucenoauthor=A.+Daoauthor=D.+Brighamauthor=D.+Gitnickauthor=D.+E.+Inskoauthor=M.+F.+Gardnerauthor=P.+P.+Zarrinkarauthor=R.+Christopherauthor=B.+Belliauthor=R.+C.+Armstrongauthor=M.+W.+Holladay&title=Discovery+and+optimization+of+a+highly+efficacious+class+of+5-aryl-2-aminopyridines+as+FMS-like+tyrosine+kinase+3+%28FLT3%29+inhibitors&doi=10.1016%2Fj.bmcl.2015.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors</span></div><div class="casAuthors">Liu, Gang; Abraham, Sunny; Liu, Xing; Xu, Shimin; Rooks, Allison M.; Nepomuceno, Ron; Dao, Alan; Brigham, Daniel; Gitnick, Dana; Insko, Darren E.; Gardner, Michael F.; Zarrinkar, Patrick P.; Christopher, Ron; Belli, Barbara; Armstrong, Robert C.; Holladay, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3436-3441</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on a putative binding mode of quizartinib, a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor in Phase III clin. development, the authors have designed de novo a simpler aminopyridine-based hinge binding motif.  Further optimization focusing on maximizing in vivo efficacy and minimizing CYP3A4 time-dependent inhibition resulted in a highly efficacious compd. I in tumor xenograft model for further preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOVKXkqpRELbVg90H21EOLACvtfcHk0lj8kOUVFvwL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7I&md5=e0af0933baacfafe789ab3f49aa26f55</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DRooks%26aufirst%3DA.%2BM.%26aulast%3DNepomuceno%26aufirst%3DR.%26aulast%3DDao%26aufirst%3DA.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DChristopher%26aufirst%3DR.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520highly%2520efficacious%2520class%2520of%25205-aryl-2-aminopyridines%2520as%2520FMS-like%2520tyrosine%2520kinase%25203%2520%2528FLT3%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3436%26epage%3D3441%26doi%3D10.1016%2Fj.bmcl.2015.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103248</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.bioorg.2019.103248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31548092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCnu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103248&author=J.+Baoauthor=H.+Liuauthor=Y.+Zhiauthor=W.+Yangauthor=J.+Zhangauthor=T.+Luauthor=Y.+Wangauthor=S.+Lu&title=Discovery+of+benzo%5Bd%5Doxazole+derivatives+as+the+potent+type-I+FLT3-ITD+inhibitors&doi=10.1016%2Fj.bioorg.2019.103248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors</span></div><div class="casAuthors">Bao, Jiyin; Liu, Haichun; Zhi, Yanle; Yang, Wenqianzi; Zhang, Jiawei; Lu, Tao; Wang, Yue; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103248</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of compds. I [R1 = H, Me, F, MeO; R2 = diethylamino, piperidinyl, piperazin-1-yl, etc.; R3 = Ph, pyridin-3-yl, pyridin-4-yl, etc.] were designed and synthesized based on benzo[d]oxazole-2-amine scaffold to discover new potent Fms-like tyrosine kinase 3 inhibitors.  During the medicinal chem. works, flexible mol. docking was used to provide design rationale and study the binding modes of the target compds.  Through the mixed SAR exploration based on the enzymic and cellular activities, compd. I [R1 = MeO; R2 = piperazin-1-yl; R3 = 3-carbamoylphenyl] was identified with potent FLT3-ITD inhibitory (IC50: 0.41 nM) and anti-proliferative (IC50: 0.037μM against MV4-11 cells) activities.  And the binding mode of I [R1 = MeO; R2 = piperazin-1-yl; R3 = 3-carbamoylphenyl] with ''DFG-in'' FLT3 was simulated by a 20-ns mol. dynamics run, providing some insights into further medicinal chem. efforts toward novel FLT3 inhibitors in AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojrKPWJTNcubVg90H21EOLACvtfcHk0lgGSqAVKypycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCnu7nK&md5=a29ee98c55772848cb822c604a5048ba</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103248%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520benzo%255Bd%255Doxazole%2520derivatives%2520as%2520the%2520potent%2520type-I%2520FLT3-ITD%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103248%26doi%3D10.1016%2Fj.bioorg.2019.103248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salk, J. J.</span></span> <span> </span><span class="NLM_article-title">The influence of subclonal resistance mutations on targeted cancer therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fnrclinonc.2015.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26483300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslaksLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=335-347&author=M.+W.+Schmittauthor=L.+A.+Loebauthor=J.+J.+Salk&title=The+influence+of+subclonal+resistance+mutations+on+targeted+cancer+therapy&doi=10.1038%2Fnrclinonc.2015.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of subclonal resistance mutations on targeted cancer therapy</span></div><div class="casAuthors">Schmitt, Michael W.; Loeb, Lawrence A.; Salk, Jesse J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-347</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Clin. oncol. is being revolutionized by the increasing use of molecularly targeted therapies.  This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge.  Evidence continues to emerge that cancers are characterized by extensive intratumor genetic heterogeneity, and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a minority of cells.  Indeed, multiple examples of pre-existing subclonal resistance mutations to various molecularly targeted agents have been described, which we review herein.  Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective.  We consider how monitoring of drug resistance could be incorporated into clin. practice to optimize the use of targeted therapies in individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxT2q0nGx_PbVg90H21EOLACvtfcHk0lgGSqAVKypycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslaksLrF&md5=b20adb7d5dc96fedd40c8905840c3aa1</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.175%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DM.%2BW.%26aulast%3DLoeb%26aufirst%3DL.%2BA.%26aulast%3DSalk%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520influence%2520of%2520subclonal%2520resistance%2520mutations%2520on%2520targeted%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D13%26spage%3D335%26epage%3D347%26doi%3D10.1038%2Fnrclinonc.2015.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F2159-8290.CD-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskisauthor=R.+Shellooeauthor=G.+Tsangauthor=H.+Cariasauthor=B.+Powellauthor=E.+A.+Burtonauthor=B.+Matusowauthor=J.+Zhangauthor=W.+Spevakauthor=P.+N.+Ibrahimauthor=M.+H.+Leauthor=H.+H.+Hsuauthor=G.+Habetsauthor=B.+L.+Westauthor=G.+Bollagauthor=N.+P.+Shah&title=Characterizing+and+overriding+the+structural+mechanism+of+the+quizartinib-resistant+FLT3+%E2%80%9Cgatekeeper%E2%80%9D+F691L+mutation+with+PLX3397&doi=10.1158%2F2159-8290.CD-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0lgGSqAVKypycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DLe%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCharacterizing%2520and%2520overriding%2520the%2520structural%2520mechanism%2520of%2520the%2520quizartinib-resistant%2520FLT3%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520F691L%2520mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.CD-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodcock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrman, R. E.</span></span> <span> </span><span class="NLM_article-title">Development of novel combination therapies</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1101548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1056%2FNEJMp1101548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=21323535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtlSlsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=985-987&author=J.+Woodcockauthor=J.+P.+Griffinauthor=R.+E.+Behrman&title=Development+of+novel+combination+therapies&doi=10.1056%2FNEJMp1101548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: development of novel combination therapies</span></div><div class="casAuthors">Woodcock, Janet; Griffin, Joseph P.; Behrman, Rachel E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">985-987</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8vvzDTmHJzbVg90H21EOLACvtfcHk0lgWMTU1_17QlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtlSlsLc%253D&md5=980327e1a25278595653a6546e76ccea</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1101548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1101548%26sid%3Dliteratum%253Aachs%26aulast%3DWoodcock%26aufirst%3DJ.%26aulast%3DGriffin%26aufirst%3DJ.%2BP.%26aulast%3DBehrman%26aufirst%3DR.%2BE.%26atitle%3DDevelopment%2520of%2520novel%2520combination%2520therapies%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D985%26epage%3D987%26doi%3D10.1056%2FNEJMp1101548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of drug combinations: interaction and network perspectives</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1038/nrd2683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1038%2Fnrd2683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=19180105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=111-128&author=J.+Jiaauthor=F.+Zhuauthor=X.+Maauthor=Z.+W.+Caoauthor=Y.+X.+Liauthor=Y.+Z.+Chen&title=Mechanisms+of+drug+combinations%3A+interaction+and+network+perspectives&doi=10.1038%2Fnrd2683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug combinations: interaction and network perspectives</span></div><div class="casAuthors">Jia, Jia; Zhu, Feng; Ma, Xiaohua; Cao, Zhiwei W.; Li, Yixue X.; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-128</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Understanding the mol. mechanisms underlying synergistic, potentiative and antagonistic effects of drug combinations could facilitate the discovery of novel efficacious combinations and multi-targeted agents.  In this article, we describe an extensive investigation of the published literature on drug combinations for which the combination effect has been evaluated by rigorous anal. methods and for which relevant mol. interaction profiles of the drugs involved are available.  Anal. of the 117 drug combinations identified reveals general and specific modes of action, and highlights the potential value of mol. interaction profiles in the discovery of novel multicomponent therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwawbpKWy27Vg90H21EOLACvtfcHk0lgWMTU1_17QlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7w%253D&md5=87ab00309751229f6f91b83448c82daf</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnrd2683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2683%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DZ.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BX.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DMechanisms%2520of%2520drug%2520combinations%253A%2520interaction%2520and%2520network%2520perspectives%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D111%26epage%3D128%26doi%3D10.1038%2Fnrd2683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+a+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lgWMTU1_17QlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia</span>. <i>Biomark Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/s40364-019-0170-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1186%2Fs40364-019-0170-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31528345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A280%3ADC%252BB3MrpsFSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=19&author=J.+Zhaoauthor=Y.+Songauthor=D.+Liu&title=Gilteritinib%3A+a+novel+FLT3+inhibitor+for+acute+myeloid+leukemia&doi=10.1186%2Fs40364-019-0170-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia</span></div><div class="casAuthors">Zhao Juanjuan; Song Yongping; Liu Delong; Liu Delong</div><div class="citationInfo"><span class="NLM_cas:title">Biomarker research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn">2050-7771</span>.
    </div><div class="casAbstract">FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics.  The FLT3-ITD and FLT3-TKD (tyrosine kinase domain) mutations are biomarkers for high risk AML and are associated with drug resistance and high risk of relapse.  Multiple FLT3 inhibitors are in clinical development, including lestaurtinib, tandutinib, quizartinib, midostaurin, gilteritinib, and crenolanib.  Midostaurin and gilteritinib have been approved by FDA for Flt3 mutated AML.  Gilteritinib (ASP2215, Xospata) is a small molecule dual inhibitor of FLT3/AXL.  The ADMIRAL study showed that longer overall survival and higher response rate are associated with gilteritinib in comparison with salvage chemotherapy for relapse /refractory (R/R) AML.  These data from the ADMIRAL study may lead to the therapy paradigm shift and establish gilteritinib as the new standard therapy for R/R FLT3-mutated AML.  Currently, multiple clinical trials are ongoing to evaluate the combination of gilteritinib with other agents and regimens.  This study summarized clinical trials of gilteritinib for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx25RB8hEeSGgRQsDqrjW_fW6udTcc2ebzse6kPUDU57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrpsFSjtw%253D%253D&md5=f0e2376879c61e28d9eec81dd4efbff6</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1186%2Fs40364-019-0170-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40364-019-0170-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DGilteritinib%253A%2520a%2520novel%2520FLT3%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DBiomark%2520Res.%26date%3D2019%26volume%3D7%26spage%3D19%26doi%3D10.1186%2Fs40364-019-0170-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostic, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in selective and irreversible covalent ligand development and validation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1486</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1016%2Fj.chembiol.2019.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=31631011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1486-1500&author=T.+Zhangauthor=J.+M.+Hatcherauthor=M.+Tengauthor=N.+S.+Grayauthor=M.+Kostic&title=Recent+advances+in+selective+and+irreversible+covalent+ligand+development+and+validation&doi=10.1016%2Fj.chembiol.2019.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation</span></div><div class="casAuthors">Zhang, Tinghu; Hatcher, John M.; Teng, Mingxing; Gray, Nathanael S.; Kostic, Milka</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1486-1500</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Some of the most widely used drugs, such as aspirin and penicillin, are covalent drugs.  Covalent binding can improve potency, selectivity, and duration of the effects, but the intrinsic reactivity represents a potential liability and may result in idiosyncratic toxicity.  For decades, the cons were believed to outweigh the pros, and covalent targeting was deprioritized in drug discovery.  Recently, several covalent inhibitors have been approved for cancer treatment, thus rebooting the field.  In this review, we briefly reflect on the history of selective covalent targeting, and provide a comprehensive overview of emerging developments from a chem. biol. stand-point.  Our discussion will reflect on efforts to validate irreversible covalent ligands, expand the scope of targets, and discover new ligands and warheads.  We conclude with a brief commentary of remaining limitations and emerging opportunities in selective covalent targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc9UIuWjfX97Vg90H21EOLACvtfcHk0lhIubS-o1twgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVSlsrzO&md5=ce957a868ca27f545243d28e60dc5868</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKostic%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520selective%2520and%2520irreversible%2520covalent%2520ligand%2520development%2520and%2520validation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D1486%26epage%3D1500%26doi%3D10.1016%2Fj.chembiol.2019.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Claro, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfuma, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hakim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3586</span>– <span class="NLM_lpage">3590</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=10.1158%2F1078-0432.CCR-14-2225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=26275952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKltr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3586-3590&author=R.+A.+de+Claroauthor=K.+M.+McGinnauthor=N.+Verdunauthor=S.+L.+Leeauthor=H.+J.+Chiuauthor=H.+Saberauthor=M.+E.+Browerauthor=C.+J.+Changauthor=E.+Pfumaauthor=B.+Habtemariamauthor=J.+Bullockauthor=Y.+Wangauthor=L.+Nieauthor=X.+H.+Chenauthor=D.+R.+Luauthor=A.+Al-Hakimauthor=R.+C.+Kaneauthor=E.+Kaminskasauthor=R.+Justiceauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval%3A+ibrutinib+for+patients+with+previously+treated+mantle+cell+lymphoma+and+previously+treated+chronic+lymphocytic+leukemia&doi=10.1158%2F1078-0432.CCR-14-2225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia</span></div><div class="casAuthors">de Claro, R. Angelo; McGinn, Karen M.; Verdun, Nicole; Lee, Shwu-Luan; Chiu, Haw-Jyh; Saber, Haleh; Brower, Margaret E.; Chang, C. J. George; Pfuma, Elimika; Habtemariam, Bahru; Bullock, Julie; Wang, Yun; Nie, Lei; Chen, Xiao-Hong; Lu, Donghao; Al-Hakim, Ali; Kane, Robert C.; Kaminskas, Edvardas; Justice, Robert; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3586-3590</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Nov. 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.  On Feb. 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.  Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval.  Both approvals were based on overall response rate (ORR) and duration of response (DOR) in single-arm clin. trials in patients with prior treatment.  In MCL (N = 111), the complete and partial response rates were 17.1% and 48.6%, resp., for an ORR of 65.8% [95% confidence interval (CI), 56.2%-74.5%].  The median DOR was 17.5 mo (95% CI, 15.8-not reached).  In CLL (N = 48), the ORR was 58.3% (95% CI, 43.2%-72.4%), and the DOR ranged from 5.6 to 24.2 mo.  The most common adverse reactions (≥30% in either trial) were thrombocytopenia, diarrhea, neutropenia, bruising, upper respiratory tract infection, anemia, fatigue, musculoskeletal pain, peripheral edema, and nausea.  Clin Cancer Res; 21(16); 3586-90. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn3L2XMvoW6LVg90H21EOLACvtfcHk0lhIubS-o1twgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKltr%252FE&md5=75a4f6ffb6a20a0cd08413c79d020f88</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2225%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DMcGinn%26aufirst%3DK.%2BM.%26aulast%3DVerdun%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DS.%2BL.%26aulast%3DChiu%26aufirst%3DH.%2BJ.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DBrower%26aufirst%3DM.%2BE.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DPfuma%26aufirst%3DE.%26aulast%3DHabtemariam%26aufirst%3DB.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DLu%26aufirst%3DD.%2BR.%26aulast%3DAl-Hakim%26aufirst%3DA.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%253A%2520ibrutinib%2520for%2520patients%2520with%2520previously%2520treated%2520mantle%2520cell%2520lymphoma%2520and%2520previously%2520treated%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3586%26epage%3D3590%26doi%3D10.1158%2F1078-0432.CCR-14-2225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITQ','PDB','2ITQ'); return false;">PDB: 2ITQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7','PDB','4RT7'); return false;">PDB: 4RT7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG','PDB','1PKG'); return false;">PDB: 1PKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF','PDB','4XUF'); return false;">PDB: 4XUF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3','PDB','2VU3'); return false;">PDB: 2VU3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46','PDB','1T46'); return false;">PDB: 1T46</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4','PDB','2XA4'); return false;">PDB: 2XA4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P2H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P2H','PDB','2P2H'); return false;">PDB: 2P2H</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UX0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UX0','PDB','4UX0'); return false;">PDB: 4UX0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHX','PDB','3RHX'); return false;">PDB: 3RHX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FGK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FGK','PDB','1FGK'); return false;">PDB: 1FGK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WUN','PDB','4WUN'); return false;">PDB: 4WUN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JS2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3JS2','PDB','3JS2'); return false;">PDB: 3JS2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R7H','PDB','4R7H'); return false;">PDB: 4R7H</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00696%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00696" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                13MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ade714f773d06","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
